AUTHOR INDEX* Volume 52

Alfieri, A. A., 4620 Arimura, Y., 737 Bahler, D. W., 5547s Alfthan, H., 4628 Arita, Y., 4514 Bahnson, R. R., 851 Aakvaag, A., 4719 Ali, I. U., 4550, 6716 Ariyoshi, Y., 734 Bailey, H. H., 5115 Aalders, T. W., 5104, 6182 Ali, R. B., 6423 Armand, J-P., 974 Bailey, S. K., 746 Aaltonen, L., 4530 Alitalo, K., 746, 5738 Armstrong, D. K., 1416, 3418 Bailey-Wilson, J. E., 2694s Aamdal, S., 6088 Alitalo, R., 746, 2004, 5738 Armstrong, E., 746, 2004 Baird, A., 227 Aaronson, S. A., 4550 Armstrong, N., 5610 Baird, S. M., 2468, 5552s Abbruzzese, J. L., 2180 Allegra, C. J., 36, 4306, 6860 Allen, T. M., 2431, 4817, 6638 Arndt, C., 521 Bajorin, D. F., 5775 Abdul-Aziz, Z., 2108s Arnold, A., 5541s Baker, M. A., 5244 Abe, M., 2563 Aller, P., 1245 Arnon, R., 4448 Baker, P. D., 5893 Abe, M., 6522 Allinson, E. T., 3103 Aronson, L., 521 Balaschak, M. S., 2791 Abe, O., 1187 Allred, D. C., 483 Aim, P., 2991 Arredondo, M. A., 5900 Balboni, G., 3726 Abe, R., 3914 Alnemri, E. S., 491 Arrick, B. A., 6949 Baldwin, G. S., 2261 Abe, S., 1481 Alter, H., 5364 Arron, R. J., 3796 Bale, A. E., 6804 Abe, T., 1481, 6083 Arthur, G., 2806, 2813 Balfe, J. W., 6125 Abel, G., 822, 1710, 3857, 6188 Altschuler, E., 209 Arvelo, F., 4872 Balis, F. M., 521, 3503 Aberg, B., 6244 Alvarez Sotomayor, E., 6702 Alvord, W. G., 3005 Asakawa, E., 1675 Balitrand, N., 3329 Aberle, S., 3056 Asano, Y., 2197 Balkissoon, J., 6561 Abney, D. L., 3425 Amanuma, H., 6463 Asao, T., 6254 Ballejo, G., 1704 Abrahams, P. J., 53 Amato, T., 1222 Aschele, C., 1855 Balmain, A., 680 Abrams, S., 6917 Ames, M. M., 2830 Amfo, K., 6646 Ashida, Y., 5313 Bambara, R. A., 1073 Ackerman, J. J. H., 1259 Amin, S. G., 3875 Ashizawa, T., 2818 Banavali, S. D., 409'0 Acs, G., 202 Amos, B., 4878 Ashwell, J. D., 2394 Bander, N. H., 6229 Adachi, I., 301 l Aslakson, C. J., 1399 Bandyopadhyay, G. K., 6531 Adachi, K., 121 Amstad, P. A., 3952 Ananthaswamy, H. N., 3946 Aslo, A., 1695 Banerjee, A., 6297 Adachi, M., 737 Anastasi, J., 4678 Atema, A., 6209 Banerjee, S., 4824 Adami, F., 5223 Atherton, M., 5516s Banki, K., 4391 Adams, E. G., 5687 Andersen C., 726 Andersen T. I., 3234 Atkins, M. B., 2545 Banks, P. M., 5453s Adams, E. R., 6931 Atkins, R. C., 4356 Bannasch, P., 3220 Adamson, P. C., 521, 3503 Anderson C. H., 5076 Anderson G. R., 4372 Atlas, I., 3335 Banner, B., 851 Adamson, R. H., 2099s, 2124s Atsumi, R., 4396 Bao, L., 1737 Adelman, L. S., 4672 Anderson L. M., 1463 Anderson M. J., 6956 Attal, M., 1352 Bao, S., 3067 Adler, V., 2143 Attali, S., 3317 Barbanti-Brodano, G., 1297 Adler-Storthz, K., 4706 Anderson M. W., 3164 Anderson R. L., 2854 Auberger, P., 3622 Barbat, A., 4655 Adluri, S., 5663 Auersperg, N., 4269 Barbier, N., 6976 Agarwal, R., 3582, 4050, 6890 Anderson S. K., 1916, 2907 Anderson W. B., 3750 Aurbach, G. D., 6804 Barbier-Piraux, N., 3234 Agarwal, S., 2557 Ausmus, P. L., 4965 Barca, S., 2880 Aggarwal, B. B., 2557, 3787 Ando, H., 6696 Ando, K., 978 Ausserer, W. A., 5219 Bard, J-M., 3629 Agostini, C., 5223 Autry, S., 1235 Bare, J. W., 1494 Aguayo, S. M., 2727s Andreeff, M., 4587 Avdalovic, N. M., 6761 Barker, E. A., 2597 Aguzzi, A., 3760 Andrejauskas-Buchdunger, E., Averboukh, L., 6966 Barnard, G. F., 3067 Ahmad, I., 4817 5353 Andrews, P. A., 1895, 1902 Avis, I., 2743s Barone, L., 4433 Ahmed, N., 4121 Avril, M-F., 4649 Ahn, C. W., 2408 Andrews, P. E., 1525 Barr, F. G., 3391 Ang, K. K., 6348 Avvisati, G., 3687 Barranco, S. C., 4608 Ahr6n, B., 5794 Ayi, T. C., 6423 Aida, Y., 6463 Angeli, A., 1791 Barrera, G., 4866 Anglard, P., 348 Azar, C. G., 1364 Barrett, J. C., 2624, 3486 Aigner, K., 108 Azocar, J., 4649 Airoldi, L., 6699 Anichini, A., 4499 Barrett, S. K., 1386 Anolik, S. L., 1101 Azuma, A., 4890 Barron, R., 6898 Aisner, S., 5100 Azuma, C., 6823 Akao, Y., 6083 Anselmi, C., 623 Bar-Shavit, R., 5656 Ansher, S. S., 262 Azzam, H. S., 4540 Bartolom6, M., 4885 Akashi, K., 3052 Azzarone, B., 5963 Akatsu, T., 444 Antoine, E., 4872 Bartsch, H., 6248 Antoniades, H. N., 3453 Baselga, J., 3335 Akedo, H., 1422, 5313 B Akeli, M-G., 3241 Anwar, K., 5991 Baserga, R., 4522, 6447 Akiyama, F., 3914 Anzai, H., 2180 Baas, F., 4361 Bast, R. C., Jr., 1622 Akiyama, M., 1369 Aoki, D., 1205 Baba, H., 3306 Basu, A., 3119 Akiyama, S., 6258 Aoki, T., 4055 Baba, S., 4055 Basu, H. S., 6782 Akiyama, S-i., 3655 Apelgren, L. D., 3838 Baban, D., 1737 Batist, G., 6254 Akman, S. A., 2408 Appelbaum, F. R., 89, 1228 Back, T., 4082 Batova, A., 187 Alas, L. G., 4227 Aprelikova, O., 746, 5738 Bacon, T. A., 6741 Batra, J. K., 181, 3189 Alberg, A. J., 1 Aquilina, G., 6471 Bacus, S. S., 2580 Batra, S. K., 1144 Albertini, R., 3558 Araujo, D., 1297, 6297 Bader, H., 2148 Battey, J., 2732s Albini, A., 2353 Arbeit, J. M., 71 Badger, B., 5720 Battula, N., 1796 Albino, A. P., 5775 Archer, M. C., 5037 Badger, C. C., 89, 1228 Baubet, D., 3194 Albright, K. D., 1895, 6790 Arcidiacono, A., 1891 Baer, M., 3811 Bauer, H. C., 6969 Aldaz, C. M., 4791 " Ardelt, B., 470, 6200 Baggetto, L. G., 4935 Bauer, S. L., 6237 Alderton, P. M., 194 Argil6s, A., 4356 Baggs, R. B., 2304 Bauluz, C., 680 Alexander, I. E., 2236 Arguello, F., 2304 Bagnati, R., 6699 Baum, M., 4261 Alexandrov, K., 6248 Arima, M., 1364 Baguley, B. C., 209 Baxter, L. T., 5838

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 6999

Baylin, S. B., 770, 2764s Best, K. L., 4663 Bonifer, R., 3353 Broker, T. R., 1561 Bayona, W., 1427, 3791 Bethke, K. P., 548 Bonnet, J., 301 Bronstein, S. M., 2008, 3851, Bear, H. D., 548, 1386 Bethwaite, P., 5496s Bontenbal, M., 6101 6984 Beardsley, G. P., 2148 Beveridge, J. M., 2394, 3005 Boobis, A. R., 6216 Broskie, E. N., 2349 Beattie, C. W., 5076 Bhatia, K. G., 1032, 4273 Bookland, E. A., 1606, 1615 Bross, K. J., 1026 Beauchamp, R. L., 6194 Bhavani, K., 2823 Boone, C. W., 1651 Brother, M. B., 770 Beaune, P. H., 6567 Bhorjee, J. S., 6129 Boone, T. C., 701 Brown, J. M., 4473 Beaupain, R., 843 Bhuyan, B. K., 5687 Bootsma, G., 3131 Brown, L. M., 2447 Beausang, L. A., 422 Bianchi, A. B., 3432 Borden, E. C., 3528 Brown, P. H., 2658s Becher, R., 2590 Biard, D. S. F., 5213 Bordier, C., 1352 Brown, R., 6375 Bechtel, D. H., 662, 2049s Bickers, D. R., 6106 Borek, C., 154 Brown, V. L., 741 Beck, H., 1666 Bicknell, R., 275 Borg, A., 2991 Brown-Shimer, S., 478 Beck, W. T., 4248, 5701 Bidart, J-M., 3901 B6rmer, O., 2329 Broxterman, H. J., 17 Beckett, M., 1451, 4832, 5299 Bidoli, E., 3589 Bornkamm, G. W., 6547 Bruckner, A., 3043, 3661 Beckwith, M., 101 Biedermann, K. A., 4473 Borochovitz, D., 6371 Bruland, O. S., 6088 Beerman, T. A., 4372 Biegel, J. A., 3391 Borrelli, M. J., 5780 Brunetto, V., 3768 Begg, A. C., 6653 Bigbee, W. L., 3558 Bcrresen, A-L., 3234 Bruno, S., 470, 3491, 6200 Behrens, D. L., 3521 Bignami, G. S., 5759 Bosch, D. A., 1568 Bruns, C., 4973 Beidler, D. R., 4280 Bignami, M., 6471 Bosl, G. J., 2285, 3558, 5775, Bruskin, A. M., 478 Beitz, J. G., 227 Bigner, D. D., 1144, 5054, 5373, 6229 Bruzzi, P., 1791 Belardelli, F., 2880 5590 Bosnie, N., 6653 Bryan, G. T., 3528 Belfiore, A., 3924 Bigner, S. H., 1144 Botta, E., 6690 Bryce, W. H., 5853 Belinsky, S. A., 3164 Bigotti, A., 6139 Bouchard, H-L., 2325 Brynes, R., 5482s Boucher, Y., 3237, 5110, 6371, Bell, C., 1717 Binder, B. R., 1717, 3043 Bu, D., 5985 Bell, J., 5264 Bingham, J. P., 4190 6553 Bucchi, L., 1791 Bell, R. H., Jr., 3295, 6905 Biondo, R., 6471 Bourgain, C., 6646 Buchanan, M. R., 2202 Bellet, D., 3901 Biquard, J-M., 6329 Boven, E., 2257, 5940 Belliveau, D. J., 4208 Birckbichler, P. J., 4779 Bowden, P. E., 5865 Buchegger, F., 2329 Bellomo, G., 1342 Bird, R. P., 4291 Bowman, E. D., 1499 Buchmann, A., 3220 Bell6n, T., 1245 Birrer, M. J., 2658s Bowman, M., 6407 Buchsbaum, D. J., 637, 6476 Belser, P., 121 Birt, D. F., 2035s Boyce, B., 5395 Buckmeier, J. A., 5024 Belury, M. A., 662, 2049s Biser, N., 5720 Boyd, M. R., 2791, 3029 Budach, W., 6292 Bement, W. J., 3615 Bissett, D., 2894 Boyd, R. A., 6746 Budman, D. R., 3818 Benati, C., 5223 Bitonti, A. J., 1195 Boyer, M. J., 4441 Buetler, T. M., 314 BenCheikh, M., 3918 Black, S. D., 3035 Boynton, R. F., 6525 Buettner, G. R., 6045 Bendele, R. A., 6931 Blacklock, J. B., 1123 Braakhuis, B. J. M., 5940 Buijs, F., 2318 Bender, H., 121 Blaese, R. M., 6020 Brach, M. A., 1026, 2197, 3353 Bulian, P., 5223 Benedetti, M. S., 5933 Blair, A., 2447, 5485s, 5501s Brachman, D. G., 4832 Bull, J. M. C., 4096 Benedict, W. F., 4587, 6297 Blair, O., 3340 Bradley, G., 5154 Bull, M. K., 6761 Benezra, M., 5656 Blaney, S. M., 3503 Bradley, M. O., 1580, 3347, Bullock, N., 5373 Benfield, J. R., 2687s Blankenship, L. J., 1304 5171 Bulovas, K., 1457 Bengmark, S., 5794 Bl/ittler, W. A., 127, 4200 Brady, J., 5516s Bumol, T. F., 3838 Benjamin, H., 1754 Blay, J-Y., 3194, 3317 Brandes, L. J., 3796 Bunin, G. R., 782 Benjamin, W. H., Jr., 2143 Block, N. L., 5821 Brandt, S., 6020 Bunn, P. A., Jr., 24, 4752 Bennati, S., 4979 Bloemena, E., 2440 Brant, L. J., 3323 Burak, E. S., 1463 Benner, S. E., 2758s Bloemers, H. P. J., 129 l Braquet, P., 2509 Burgess, W. M., 2108s Bennett, W. P., 218, 2610, 6092 Bloomfield, C. D., 3768, 381 l Braslawsky, G. R., 5693 Burk, C. D., 3391 Benoni, G., 623 Blot, W. J., 254, 2119s Brathwaite, O., 3791 Burmeister, L. F., 2447, 5501s Ben-Sasson, S., 5656 Blount, P. L., 6525 Brattain, M., 428 Burns, C. P., 6045, 6263 Benson, A. M., 58 Blumberg, P. M., 202 Brautigan, D. L., 4027 Burrows, F. J., 5954 Benson, L. M., 2830 Blumenthal, R. D., 6036 Brazy, P. C., 6953 Busch, H., 428, 5681 Bentvelzen, P. A. J., 3073 Boarman, D. M., 36 Brechbiel, M. W., 5818 Busch, R. K., 428, 5681 Benzil, D. L., 2951 Bobo, H., 719 Br6chot, C., 5089 Bush, T. L., 1 Beppu, T., 6926 Bodensteiner, D., 4458 Breistr K., I347 Bushel, P., 6877 Beran, M., 4130, 4587 Boer, H. H., 963 Bren, G. D., 1974 Bussemakers, M. J. G., 2916 Berchuck, A., 1622 Boersma, W., 3552 Brennan, M. F., 1434, 3845 Bussolati, G., 1553 Brent, T. P., 1144, 6052, 6404 Berdel, W. E., 1865, 3498 Boffa, L. C., 5906 Butel, J. S., 1635 Berenbaum, M. C., 4558 Bogdanovic, R. P., 3796 Bresnick, E., 32, 1804 Butler, W. B., 6164 Berger, D. P., 5940 Bogden, A., 843 Briand, P., 1210 Butta, A., 4261 Bergeron, R. J., 2424, 5359 Boggan, J. E., 1235 Briggs, A. A., 6956 Bermudez, E., 301, 6113 Bohr, V. A., 4183, 6853 Briggs, S. L., 3838 Butterworth, B. E., 5617 Bernabeu, C., 1245 Bohuon, C., 3901 Bril, H., 2440 Butti, G., 4348 Bernacki, R. J., 2424 Boice, J. D., Jr., 5489s Briles, D. E., 2143 Buttyan, R., 4313 Bernal, M. L., 4885 Boisvert, D. P. J., 3831 Brill, A. B., 1961 Buys, C. H. C. M., 1536, 1695, Bernhard, S. L., 3056 Bokari, S. A. J., 4090 Brinton, L. A., 3865 6705 Berns, E. M. J. J., 1036, 1107 Boland, C. R., 1744 Brisbay, S. M., 6940 Buzzi, G., 1791 Bernstein, I. D., 89, 1228 Bols, B. L. M. C., 2253 Brock, W. A., 6348 Buzzi, M., 4027 Bernstein, L., 5482s, 5510s Bonadonna, G., 2127 Brockmeyer, D., 674 Byers, H. R., 4036 Bertino, J. R., 1434, 1855, 3908, Bonavida, B., 6630 Brodeur, G. M., 770, 1364, 1780 Byers, S. W., 5190 6866 Bond, J. A., 2938 Brodt, P., 4613, 6254 Byrd, J. C., 4655 Bertram, J. S., 5707 Bonfatti, A., 1297 Broeksma, C., 5364 Bystryn, J-C., 5948

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7000

C Casero, R. A., Jr., 5359 Chen, Z., 6113 Clendeninn, N. J., 521 Casey, G., 5997 Chen, Z. H., 1729 Clinton, S. K., 857 Cabalas, C., 1245 Casey, M. L., 554 Chenevix-Trench, G., 285 Cabrera, T., 4009 Clottes, E., 4935 Cass, C. E., 5879 Cheng, J., 222 Cficeres-Cort6s, J. R., 5208 Clugston, C. K., 6375 Cassatella, M., 2530, 5223 Cheng, J. Q., 1322 Caderni, G., 4292 Co, M. S., 6761 Cassidy, J., 2894 Caenazzo, C., 4548 Cheng, K. H., 6066 Coale, M. M., 6020 Castagnoli, A., 1297 Caffrey, P. B., 4812 Cheng, R. C., 6413 Coccia, M. A., 3746 Cai, R., 2346 Castegnaro, M., 6248 Cheng, Y-C., 4280 Cochran, C., 2624 Cairns-Smith, S., 5257 Castelijns, J. A., 2569 Chern, J-W., 4484 Coe, F. L., 1573 Cajot, J-F., 6956 Castonguay, A., 2641s, 3273 Chernajovsky, Y., 1087 Coene, M-C., 2841 Calabresi, P., 227, 4069 Castronovo, V., 2966 Chervenak, R., 4149 Coffey, R. J., Jr., 3224 Calabretta, B., 4221 Cats, A., 3552 Chetty, U., 5291 Cohen, A., 5663 Calderon~ C., 6385 Cavaliere, R., 1222 Chew, K. E., 6603 Cohen, B. L., 654 Calderwood, S. K., 3814 Cavenee, W. K., 1780 Chiba, J., 4987 Cohen, G. M., 4190 Callen, D. F., 3094, 6117 Cavener, D. R., 77 Chien, K-Y., 4696 Cohen, H. J., 2304 Callender, D. L., 6348 Cawthon, R. M., 674 Chignola, R., 623 Cohen, I., 6746 Callens, M. J. L., 1240 Cay, O., 5794 Chin, D., 2580 Cohen, L. A., 2402 Calm/~s, J-M., 3705 Cazin, J-C., 3629 Chin, T., 1182 Cohen, S. M., 3577 Calorini, L., 4036 Cazin, M., 3629 Chin, Y. C., 2431 Colburn, N. H., 1907 Calvert, A. H., 603, 1137 Celano, P., 5359 Chirivi, R. G. S., 2628 Colcher, D., 1067 Calvert, L., 4587 Celli, G., 6144 Chiton, M., 1352 Cole, D. E., 3503 Calvo, F., 6380 Center, M. S., 3157 Chisari, F. V., 2549, 2823 Cole, S. P. C., 5244 Calvo, J. C., 4113 Ceppi, M., 5906 Chlebowski, R. T., 5386 Coleman, W. B., 2349, 3807 Cameron, R., 173 Cerniglia, G. J., 3988 Cho-Chung, Y. S., 2504 Coles, C., 5291 Campbell, I. G., 5416 Cerny, W. L., 4507 Chodak, G. W., 571 Collart, F. R., 5826 Campbell, K., 5013 Cerrito, P. B., 4914 Choe, M., 2035s Colletta, A. A., 4261 Campbell, M. J., 4117 Cerutti, P. A., 3952 Choi, B. C. K., 3131 Collins, D. C., 5073 Campbell, M. L., 6940 Ceska, M., 4297 Choi, P., 4787 Collins, J. A., 1961 Campo, S. M., 6898 Chabot, G. G., 6567 Chomienne, C., 3329 Collins, J. L., 866 Camus, A-M., 6248 Chadwick, G. A., 2894 Chou, C-K., 385 Collins, T. J., IV, 341 Canaani, E., 3811 Chae, Y-H., 2402 Chou, H-C., 6098 Collins, V. P., 5334 Canaani, O., 3811 Chaganti, R. S. K., 2285 Chow, D. A., 5235 Colofiore, J. R., 4074 Candiani, C., 623 Chagnaud, J. L., 2862 Chow, L. T., 1561 Colombatti, M., 623 Cano, A., 680 Chakravarthy, B., 6329 Chrispeels, J., 5364 Colombel, M., 4313 Cano, G., 4672 Champoux, J. J., 525 Christa, L., 5089 Colombo, M. P., 4853 Cantell, K., 4571 Chan, C-L., 32, 1804 Christen, R., 6790 Colvin, M. O., 1770 Cantor, A. B., 1780 Chan, D. C., 24, 4752 Christensen, H., 3131 Colvin, O. M., 1416, 5373, 5590, Cantor, K. P., 2447, 5501s Chan, D. W., 3323 Christensson, P. I., 3022 6168 Cao, Y., 4766 Chan, L-N. L., 2384 Christoffersen, T., 3598 Combaret, V., 3194, 3317 Capizzi, R. L., 3886 Chan, T. C. K., 3566 Chu, E., 1729 Comora, S., 3931 Caporaso, N. E., 1499, 6712 Chan, T-s., 2384 Chu, M. Y., 1729 Comstock, G. W., 1 Capranico, G., 1666 Chanda, E. R., 5244 Chu, S. H., 1729 Condie, A., 5291 Caravatti, G., 4712 Chang, A. E., 1129 Chubb, C. B., 5826 Coney, L. R., 3396, 6708 Carbone, D. P., 1996, 2340, Chang, C., 571 Chubb, S., 533 Coni, P., 2078s 4168 Chang, C., 1329 Chung, C. K., 3453 Conney, A. H., 1162, 1943, Carbone, R., 4960 Chang, K., 181 Chung, F-L., 2719s, 3875 2124s, 6657 Cariani, C. T., 6079 Chang, L., 2957 Chung, J-C., 6098 Connolly, J. G., 3131 Cariello, N. F., 2866 Chang, M., 5656 Chung, K. H., 4779 Connolly, J. M., 5386 Carlini, M., 1222 Chang, R., 6657 Chung, L. W. K., 1598, 3174, Conry, R. M., 6979 Carlsson, J., 1587 Chapelon, J. Y., 6353 6940 Conti, C. J., 662, 3432 Carmella, S. G., 2698s Charak, B. S., 6482 Chung, R. Y., 2987 Conway, K., 6487 Caron, P. C., 6761 Chari, R. V. J., 127 Chung, T. D. Y., 231 Cook, J. A., 719 Carpenter, G., 4526 Chassoux, D., 2880 Cianfriglia, M., 2880 Cook, P. P., 5604 Carpenter, H. A., 1974 Chatelain, P., 1352, 6440 Ciardiello, F., 3467 Cook, P. W., 3224 Carpenter, R. N., 4385 Chatterton, R. T., 578 Cigel, F. K., 5610 Cook, S. B., 127 Carra, G., 5223 Chaudhry, A., 1006 Cimino, G., 3811 Cools, W., 2841 Carrasquillo, J., 2743s Chauffert, B., 2797 Ciocca, D. R., 3648 Coombes, R. C., 5933 Carritt, B., 1536 Chavez-Kappel, C., 2243, 6871 Citron, M., 4227 Cooney, R. V., 5707 Carroll, A. J., 3811 Chazinski, T., 6237 Claessen, A. M. E., 2440 Copeland, E. S., 4058 Carson, B. S., 6168 Chen, A., 4791 Claesson-Welsh, L., 3213 Coppes, M. J., 6125 Carson, L. F., 2248 Chen, A., 5971 Clark, G. C., 3436 Coppock, D. L., 5244 Carta, M., 4979 Chen, D~ 6098 Clark, J. C., 5342 Corallini, A., 1297 Carter, B. S., 5104 Chen, F-S., 5647 Clark, J. W., 227 Corbett, A. H., 2156 Carter, G. L., 2000 Chen, H-C., 3534 Clark, W. C., 4550, 6716 Corey, T. S., 3425 Carter, H. A., 4779 Chen, J-C., 5100 Clarke, C. L., 2236 Cork, L. C., 6168 Carter, H. B., 3323 Chen, L., 3474 Clarke-Pearson, D. L., 1622 Cork, M. A., 4587 Cartwright, R. A., 5441s Chen, L. B., 3067 Clausen, H., 5030 Cornaglia-Ferraris, P., 931, 4960 Casalaro, A., 931 Chen, S-F., 3521 Clavey, V., 3629 Cornelisse, C. J., 5229 Casale, V., 1222 Chen, S-H., 1329 Clawson, G. A., 1304 Cornett, L. E., 2516 Case, D. C., Jr., 3871 Chen, T. T., 5547s Cleary, K. R., 2603 Cornford, E. M., 138 Case, L. D., 5198 Chen, Y., 1968 Cleaver, J. E., 4053, 5126 Cornic, M., 3329

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7001

Correa, P., 5431s, 5574s, 6735 Davidoff, A. M., 1622 DeSombre, E. R., 5752 Dropcho, E., 4342 Corry, P. M., 5780 Davidson, A. G., 4828 De Sutter, P., 6646 Droz, J-P., 3901 Cory, A. H., 2000 Davidson, N. E., 1278, 1416, de Tribolet, N., 4297 Drucker, D. J., 3103 Cory, J. G., 2000 2984, 3418 Dev, I. K., 4895 Druker, B., 566 Cosimelli, M., 1222 Davies, D. S., 6216 Devereux, D. F., 829 Dubbelman, T. M. A. R., 117 Costantini, M., 1791 Davies, P., 2931 Devereux, T. R., 3164 Dubinett, S. M., 3931 Cotter, T. G., 997 Davies, R., 2938 Devesa, S. S., 5432s, 5566s Duch, D. S., 4895 Coudray, A-M., 6827 Davis, M. A., 3698 DeVeyra, E., 3048 Duchamp, O., 2797 Coulter, D. M., 3255 Davis, M. B., 1536 Devilee, P., 5229 Dufour, J-M., 610 Courtenay-Luck, N. S., 904 Davis, R., 6871 Devitt, M. L., 4620 Duggan-Keen, M., 4009 Cowan, J., 1451 Davis, S., 5492s DeVote, R. F., 2156 Duhig, T., 1954 Cowan, J. M., 2523 Davol, P., 227 de Vos, S., 2197, 3498 Dumont, J. A., 1195 Cowan, K. H., 6175 Da Volio, J., 4600 de Vries, E. G. E., 17, 3552, Dumont, M. P., 5940 Cowburn, D., 4620 Dawson, T., 2938 6885 Dungworth, D. L., 4724 Cowen, A., 285 Day, R., 851 de Waziers, I., 6567 Dunn, J. A., 990 Cowen, M. E., 2923 Dayal, Y., 5002 Dewhirst, M. W., 4265 Dunn, M., 5250 Cowlen, M. S., 6912 Dayton, S. H., 6194 de Witte, T., 5921 Dunn, R. S., 3094 Craft, N. E., 2060s Debinski, W., 5379 DeYarman, M. T., 2148 Dunphy, E., 4832 Craven, P. A., 2216 Debruyne, F. M. J., 2916, 5104, Dianzani, M. U., 4866 Dupont, W. D., 77 Cravo, M. L., 5002 6182 Dias, P., 6431 Dur~in, G. E., 4379 Crawford, J., 2456, 3871 DeClerck, Y. A., 701 Diaz, M. O., 2523, 2999 Duriez, P., 3629 Creek, K. E., 187 DeCosse, J. J., 3449 Diaz-Guerra, M., 680 Durkin, J. P., 6329 Creekmore, S. P., 2394, 3005 De Coster, R., 1240, 2841 DiBenedetto, C., 4948 D'Urso, C. M., 4766 Cremer, T., 2590 Dedrick, R. L., 357, 377, 2464 Dick, F. R., 2447 Duvillard, P., 3901 Crist, W. M., 3811 Degos, L., 3329 Dienhart, D. G., 24 Dvorak, H. F., 357, 367, 377 Croce, C. M., 491, 3811, 6110, DeGrazia, F., 2138 Diez-ltza, I., 95 Dy, D. Y., 917 6547 De Gr6ve, J., 6646 Di Fiore, P. P., 2771 Dykes, D. J., 3604, 4752 Crommelin, D. J. A., 646 de Groot, N., 3713 Di Francesco, C., 4548 Crooke, S. T., 231 De Guzman, M. F., 3048 Dillen, A., 2841 E Cross, F. T., 5126 de Harven, E., 3131 Dimanche-Boitrel, M. T., 2797 Eary, J. F., 89 Crossley, P. H., 1137 Deisseroth, A. B., 4587 Dinney, C. P. N., 1155 Crouch, G. D., 2243 Eastman, A., 32, 1804, 6790 De Jong, W. H., 646 DiPaolo, J. A., 456, 5865 Eaton, A. M., 6832 Crowe, J. P., 1477 DeKoning, T. F., 4904 Di Salle, E., 5933 Crowley, N. J., 394 Eaton, D. L., 314 de la Chapelle, A., 4530 Diwan, B. A., 4747 Eaton, W. D., 6496 Cuadrado, M. A., 5979 de la M. Hall, P., 2108s Dixon, K. H., 6175 Cuddy, M., 2802 Eberle, G., 5307 DeLaney, T. F., 719 Dixon, P., 4342 Ebert, K., 4642 Culine, S., 3083 De La Rosa, J., 3361 Djakiew, D., 5403 Cullis, P. M., 4190 Eccles, M. R., 3094 Delbart, C., 3629 Djuric, Z., 1515 Ecochard, R., 6353 Cunningham, J., 1974 Del Bino, G., 1530 Dockter, M. E., 3409 Curetty, L., 5780 Economos, K., 554 deLeon, C., 3539 Dodge, R. K., 1622, 4265 Curley, T., 64 Economou, J. S., 3931 Delgado, M. D., 5979 Dogliotti, E., 6471 Cuttitta, F., 2743s Edwards, M. J., 3425 del Giglio, A., 4587 Cuzi, T. J., 4478 Dogliotti, L., 1791 Effenberger, F., 4297 Delisio, J., 1451 Dohi, K., 1369, 1948 Czerski, L., 5299 Egami, H., 4046 Della Porta, G., 6079 Doi, S., 1628 Eggensperger, D., 1067, 6917 Dellian, M., 487 Dolan, M. E., 1171 D Egorin, M. J., 64 Dellinger, M., 6385 Dolara, P., 4292 Ehrke, M. J., 3572, 3880 Daghighian, F., 2743s Del Maestro, R. F., 4208 Doll, S. R., 2024s Eibl, R. H., 2987, 3760 Dahiya, R., 4655 Delque-Bayer, P., 3622 Dolnick, B. J., 558 Eid, P., 2880 Dahlstrand, J., 5334 Del Rio-Tsonis, K., 4858 Domach, M. M., 6010 Eisenbach, L., 3679, 6507 Daino, L., 4979 De Luca, L. M., 2966, 6144 Donahoe, P. K., 1182 Eisinger, D. P., 4242 D'Alessandri, J., 5244 Delva, L., 3329 Donahue, P. R., 45, 267 Eklind, K. I., 2719s D'Alessio, G., 4582 Demant, E. J. F., 2874 Donato, N. J., 4758 El Atiq, F., 3182 Dalton, W. S., 5013 De Marco, L., 6804 Donehower, R. C., 2268 EI-Bayoumy, K., 1176, 2402, Damante, G., 3924 Demard, F., 2899 Dong, J., 3486 5635 Damg6, C., 3726 Demers, L., 5720 Donghi, R., 6079 Eldar-Geva, T., 3713 Damia, G., 4082 Demeter, L. M., 1561 Doniger, J., 5865 Eldridge, S. R., 5617 D'Amico, D., 1996 Demetriou, A., 6603 Donovan, K., 6224 Elger, B., 2167 Damon, L. E., 3819 Dempke, W. C. M., 3110 Dorman, T. E., 231 Elgjo, K., 1218 Damsky, C. H., 6001 Demple, B., 4058 Doroshow, J. H., 2408 Elia, M. C., 1580 Damstrup, L., 3089 Demura, H., 444 Dorssers, L. C. J., 5082 Eliason, J. F., 3705 Danenberg, K. D., 108, 797 Denda, A., 5042 Dosanjh, M. K., 1377 Eling, T. E., 6912 Danenberg, P. V., 108, 797 den Engelse, L., 1252 Doshi, H. M., 4828 Elisevich, K., 4208 Danks, M. K., 4248, 5701 Deng, G., 3378 Doualin, G., 3629 Elledge, R. M., 483 Danner, D., 1643 Deng, N., 3661 Dougherty, G. J., 3931 Ellis, T. M., 6318 Dan0, K., 1336 Den Otter, W., 6516 Douglass, E. C., 6117 Ellison, B. J., 667 Darnowski, J. W., 1729, 4069 DePriest, P. D., 4106 Dowsett, M., 1411, 4261 Elmets, C. A., 6106 D'Arpa, P., 1823 De Rosa, C. M., 4571 Doyle, L. A., 1322 Elmhorn-Rosenborg, A., 3281 Darwiche, N., 6144 DeRubertis, F. R., 2216 Drake, J. C., 4306 Elston, R. C., 2694s Darzynkiewicz, Z., 470, 1530, De Santes, K., 1916 Draoui, M., 2732s Emanuel, B. S., 3391 3491, 6200 Desbaillets, I., 4297 Drexler, H-G., 1026, 3353 Emerson, S. G., 4701 Datta, R., 1445 Descomps, R., 3622 Dritschilo, A., 3478, 6390 Emi, M., 5368

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7002

Emonard, H. P., 5845 Fennell, T. R., 4320, 4328 Forssen, E. A., 3255 Fultz, E., 2103s Endo, M., 1875 Fenton, R., 2394 Fort, D. W., 3396 Fumagalli, R., 4348 Engel, T., 2167 Feo, F., 4979 Foshag, L. J., 6059 Funa, K., 1006, 3213 English, H., 5720 Fernandes, T. F., 491 Foster, B. J., 603 Fuqua, S. A. W., 483, 3648 Enomoto, K., 6945 Fernandez, C., 437 Foster, T. H., 3443 Furlanetto, R. W., 2304 Enomoto, T., 5323 Ferradini, L., 4649 Foulkes, W., 5416 Furlong, I. J., 4000 Ensminger, W. D., 3698 Ferrara, J. A., 515 Fox, M. E., 4000 Furmanski, P., 6129 Entwistle, M. L., 2545 Ferrari, S., 11 Fozard, J. L., 3323 Furukawa, T., 3655 Epand, R. F., 4121 Ferrario, A., 2890 Frackelton, A. R., Jr., 227, 4027 Futami, H., 4082 Epand, R. M., 4121 Ferraro, T., 1162, 6657 Fradet, Y., 3131 Futreal, P. A., 2624 Epenetos, A. A., 904 Ferrone, S., 1309, 2497, 3201, Fragu, P., 974 Futscher, B. W., 5013 Epstein, E. H., Jr., 1494 4766 Franceschi, A., 623 Epstein, J., 1182 Feuerstein, B. G., 6782 Franceschi, S., 3589 G Epstein, J. H., 4053 Feyh, J., 1993 Frankel, R. H., 1427 Epstein, M. H., 2951 Fichtinger-Schepman, A. M., Frankel, S. R., 2138 Gabbert, H. E., 474 Eriksson, L. C., 3281 3110 Franko, A. J., 3831 Gabizon, A. A., 891 Ermler, D., 1717 Ficsor-Jacobs, R., 5183 Frantz, C. E., 4682 Gaetano, C., 4402 Ernstoff, M. S., 851 Fidler, I. J., 1155, 5808 Frantz, C. N., 2304 Gagliardi, A., 5073 Ershler, W. B., 5412 Fiebig, H. H., 5940 Frasca, V., 3396 Gaide, A-C., 3705 Esaki, T., 6501 Filderman, A. E., 3043, 3661 Frati, L., 4866 Gaillard, C., 6380 Gajl-Peczalska, K., 3768 Escudier, B., 3901 Filipovich, A. H., 5465s Fraumeni, J. F., Jr., 254, 3865, Galivan, J., 2148 Eskey, C. J., 6010 Finardi, G., 1342 5571s Gallagher, G. T., 389 Essex, M., 5430s, 5573s Finch, P. W., 2951 Frazier, D. L., 4965 Galli, A., 6699 Estey, E., 4587 Fine, R. L., 2456 Frebourg, T., 6976 Gallic, B. L., 654 Esumi, H., 2092s Fingar, V. H., 4914 Freeman, J., 6292 Gallion, H. H., 4106 Etheredge, J. L., 4779 Freeman, J. W., 5250 Finke, D., 4090 Gamarra, F., 487 Etienne, M-C., 2899 Finkelstein, S. D., 2951 Freemantle, S. E., 1137 Etou, T., 3052 Gamliel, H., 1056 Finkenzeller, G., 4821 Freemont, P. S., 5416 Gams, R. A., 3871 Evans, A. S., 5479s, 5557s Finlay, G. J., 138 Frei, K., 4297 Evans, C. H., 456, 5893 Gandhi, V., 897 Finley, G. G., 5853 Freidlos, F., 1710 Gandia, D., 974 Evans, H. J., 5291 Finn, O. J., 5985 Freireich, E., 4130 Evans, T. R. J., 5933 Gannett, P., 2279 Finstad, C. L., 6229 Freisheim, J. H., 2148 Gansbacher, B., 6229 Evelhoch, J. L., 1259 Fischer, K. J., 5759 Frenkel, G. D., 4812, 5803 Everett, C. K., 1515 Gansow, O. A., 5818 Fischer, R., 6110 Frenkel, K., 2298, 4969 Gao, Y-T., 3865 Everett, G., 2447, 5501s Fischer, S. M., 662, 2049s, 3432 Friche, E., 2874, 5701 Everitt, J., 301 Gapany, M., 2597 Fishbaugh, P. M., 5119 Friedman, E., 6804 Gapany, S., 2597 Ewel, C. H., 2394, 3005 Fisher, B., 2371 Friedman, H. S., 1144, 5373, Eyfj6rd, J., 3234 Garaud, J-C., 3726 Fisher, B., 2854 5590 Garber, J., 3234 Fisher, D. R., 1228 Friedmann, T., 222 F Garbisa, S., 4548 Fisher, R. I., 6318 Friend, D. S., 5135 Garcia, M., 6531 Faderan, M. A., 1855 Fisher, S. J., 6001 Friend, S. H., 3234, 6976 Garcia-Arenas, R., 4600 Fady, C., 764 Fishwild, D. M., 3056 Friesel, R. E., 1040 Garcia de Palazzo, I., 5713 Fagot, D., 6827 Fisk, D., 2957 Fr6sing, R., 108 Gardner, A. M., 764 Faiderbe, S., 2862 FitzGerald, D. J., 3189 Frost, P., 2180 Garg, P. K., 5054 Fair, W. R., 3335 Fitzgerald, S. D., 483 Fruchart, J-C., 3629 Garg, S., 5054 Faletto, M. B., 990 Fivash, M., 1451 Frucht, H., 1114 Garland, E. M., 3577 Falk, M. H., 6547 Flanders, K. C., 4261 Fu, P. P., 1176 Garland, W. A., 2138 Falls, K. M., 231 Flannery, D. J., 3515 Fuchs, J., 5622 Garofalo, A., 2628 Fanelli, R., 6699 Fleming, R. A., 2899 Fujii, K., 3642 Garrett, C. T., 2777 Fang, W., 3796 Fleming, T. P., 4550 Fujii, T., 3610 Garris, T. O., 5604 Fang, X-J., 173 Fletcher, J. A., 6224 Fujimoto, K., 1393 Garrouste, F. L., 3182 Fanning, P., 1457 Fl#renes, V. A., 6088 Fujimoto, S., 5641 Garte, S. J., 1047 Farace, M. G., 4866 Florkiewicz, R. Z., 5024 Fujimoto, Y., 1044 Gastl, G., 6229 Faras, A. J., 5872 Flowers, M., 173 Fujishima, A., 2346 Gattoni-Celli, S., 1201, 4036, Farrell, N., 5065 Fodstad, O., 1347, 5940, 6088 Fujita, M., 5323, 6823 4942 Fast, L. D., 4027 Foekens, J. A., 1036, 1107, Fujita, S., 4046 Gaumont, Y., 2228 Faust, J. B., 2460 5082, 6101 Fujita, S., 5770 Gaver, R. C., 1406 Fausto, N., 5162, 5171 Foidart, J-M., 5845 Fujiwara, H., 5641 Gazdar, A. F., 1114, 1666, Favre, G., 3629 Foiles, P. G., 2698s Fujiwara, T., 4954 2732s, 3340, 3534, 4168, 4752 Favrot, M. C., 3194, 3317 Foley, J. F., 3164 Fujiwara, Y., 328 Gazitt, Y., 2957 Fazio, V. M., 4866 Fonagy, A., 5250 Fujiwara, Y., 5368 Geara, F. B., 6348 Fears, T., 5432s, 5516s Fong, C-J., 5887 Fukayama, M., 3965 Geard, C. R., 3495 Feinberg, A. P., 3094 Fong, C-T., 770, 1780 Fuks, A., 2329 Gearing, A. J. H., 2628 Fekete, I., 5590 Fontana, A., 4297, 6121 Fukuda, A., 5061 Gebhard, I., 4904 Feldman, M., 3679, 6507 Fontana, J. A., 3938, 5100, 6164 Fukuhara, K., 1542 Geertsen, P. F., 726 Felix, C. A., 2243 Fordyce, W. A., 6413 Fukuhara, S., 1481 Geffard, M., 2862 Feller, N., 17 Forgue-Latitte, M-E., 6827 Fukui, Y., 6926 Geiger, P. G., 5282 Felton, J. S., 2103s Forkert, P. G., 6797 Fukunari, H., 3801, 3965 Geiser, C. F., 6117 Fendl, K. C., 235 Forni, G., 4853 Fukushima, S., 400 Geissler, F., 2907 Fendly, B., 1916 Forrest, A., 64 Fukushima, S., 1675 Geissler, J. F., 4492 Feng, P., 5100 Forrest, G. L., 4752 Fults, D., 674 Gejman, P. V., 6804

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7003

Gelber, C., 6507 6983 Grem, J., 3503 Habif, D. V., 4571 Gelboin, H. V., 6237 Goldschmidt, M. H., 5391 Gresser, I., 2880 Habig, W. H., 262 Gelet, A., 6353 Goldstein, J. A., 3436 Gridley, G., 5516s Habuchi, T., 1881 Geller, A. M., 3361 Goldstein, M. F., 3449 Gries, C. L., 6931 Hadd, H., 5073 Gelmann, E. P., 5190 Gollahon, L. S., 4791 Griffin, C. A., 3486 Haddow, S., 680 Gendler, S. J., 1954 Gollan, J. L., 3067 Griffin, J. D., 566 Hadziyannis, S., 5364 Geneste, O., 6248 Golomb, H. M., 1056 Griffin, T. W., 1961 Hagerty, M., 5516s Genieser, H-G., 2504 Goltzman, D., 4613 Griffith, O. W., 5373 Haggitt, R. C., 2946 Genne, P., 2797 Gombar, C. T., 1463 Griffiths, S., 4534 Haglund, C., 4628 Gera, J. F., 764 Gomella, L. G., 4286, 6110 Grignani, F., 3687 Hahn, G. M., 2854, 6815 Gerber, M. C., 3871 Gomer, C. J., 2890 Grimaud, J-A., 5845 Hahn, S. M., 1750 Gerbes, A. L., 1520 Gomez-Casares, M. T., 5979 Grimm, E. A., 1123, 4954 Hajri, A., 3726 Gercel-Taylor, C., 829, 5713 Gong, Y., 1704 Grindey, G. B., 533 Hakkak, R., 2516 Gerharz, C-D., 474 Gonzaga, P. E., 6052 Grochow, L. B., 2268, 6168 Hakomori, S-i., 3739 Gerlach, J. H., 5244 Gonzalez, F. J., 1757, 6237 Groebe, K., 474 Hakura, A., 4420 Gervasoni, J. E., Jr., 5244 Gonzalez, W., 843 Groffen, J., 4534 Halatsch, M-E., 2616 Gerwin, B. I., 2610 Gonzalez-Zulueta, M., 4787 Groner, B., 6310 Hald, T., 726 Gewirtz, D. A., 6270 Goode, R. L., 4663 Groopman, J. D., 45, 267, 5668 Haldar, S., 491 Ghai, J., 5872 Gooden, C. S., 904 Groot, K., 4545 Halko, N., 6200 Ghiabi, M., 389 Goodenow, R. S., 6507 Groothuis, D. R., 5590 Hall, E. J., 3495 Ghillani, P., 3901 Gooderham, N. J., 6216 Gross, E. A., 6113 Hall, K., 4719 Ghosh, B., 2743s Gooding, W., 851 Gross, J., 194 Hall, K. S., 1218 Ghosh, L., 4824 Goodman, G. E., 2752s Gross, J. L., 127 Hall, P., 2143 Giaccone, G., 1666, 2732s Goodrich, D. W., 1968 Gross, M. A., 1770 Hall, R. E., 2236 Giandomenico, C. M., 822 Goodrow, T., 5171 Grossbard, M. L., 4200 Halpern, S., 974 Giavazzi, R., 2628 Gopal, V., 4090 Grossberg, S. E., 5096 Haluska, F. G., 6547 Gibbins, J. R., 6603 Gorczyca, W., 3491 Grothaus, P. G., 5759 Hamaoka, T., 5641 Gibson, N. W., 108, 797 Gordon, A. W., 341 Grouzmann, E., 4297 Hameister, H., 6547 Gibson, R., 2447, 5501s Gordon, C. M., 4948 Grover, A., 2966 Hamel, E., 3892 Giga-Hama, Y., 1422 Gordon, G. B., 1, 1416 Gruenstein, E., 144 Hamilton, S. R., 4530 Giglioni, B., 4866 Gorman, N., 3615 Grundel, R., 1049 Hammarstr6m, M-L., 2329 Gilani, S., 6774 Gorry, F., 6353 Grundy, P. E., 3094 Hammarstr6m, S., 2329 Gilboa, E., 6229 Gorsch, S. M., 6949 Grunert, F., 2329 Hammermeister, C., 5171 Gilchrist, K. W., 688, 1606 Goto, I., 1192 Grusell, E., 1587 Hammond, W. G., 2687s Gilleran, S., 5244 Gotoh, M., 5770 Gruss, H-J., 1026, 2197, 3353 Hampsch, K., 1451 Gillespie, A., 521 Gottesman, M. M., 4427 Gruys, M. E., 4082 Hampton, L. L., 1044 Gillet, D., 6380 Gould, J., 3871 Gu, Y., 3811 Han, C., 3875 Gimenez-Conti, I. B., 3432 Gould, M. N., 4021, 4102, 5617 Guadagni, F., 1222 Han, K-A., 749 Gioioso, D., 6292 Goulette, F. A., 4069 Gualandi, F., 1297 Han, X., 1360 Giorda, R., 5913 Gouyette, A., 6567 Guarini, A., 6229 Handa, N., 1875 Giorgino, F., 3924 Graham, M. A., 603, 2894 Guengerich, F. P., 1757, 1868 Handa, S., 1875, 4805 Giovanella, B. C., 3980 Graham, M. J., 5024 Guernsey, D. L., 2186 Handa, S., 3011 Gugliotta, P., 1553 Gipp, J. J., 5115 Graham, M. L., II, 593 Handschumacher, R. E., 1660 Guidez, F., 3329 Giroldi, L. A., 2916 Graham-Pole, J., 2957 Handt, S., 2329 Guimaraes, M. A., 5900 Girotti, A. W., 5282 Grande, A., 11 Hanisch, F-G., 3138 Gulati, K., 1536 Gismondi, A., 4499 Grant, D. M., 3961 Hanna, M. G., Jr., 2603, 3460 Gullick, W. J., 3467 Giunta, C., 1297 Hanna, W., 3131 Grant, M. D., 578 Gum, J. R., Jr., 3378 Giuntini, C., 6248 Grant, S., 6270 Hansen, C., 2431 Gumbrell, L. A., 603 Hanski, C., 3138 Givel, J-C., 3705 Granzen, B., 4248 Gumerlock, P. H., 4724 Hanson, R. N., 5752 Glass, J., 719, 1750 Gratas, C., 2835 Gunji, H., 878, 1445 Hao, X-Y., 3281 Glatstein, E., 719, 1750 Graubard, B. I., 2060s Guo, Z., 1757 Haq, M., 4613 Gleave, M. E., 1598 Graves, B. T., 2304 Gupta, J. W., 2530 Glenn, G., 145 I Graves, D., 4832 Gupta, P. K., 271 ls Harada, M., 3052 Glenn, S. D., 637 Graves-Deal, R., 3224 Gupta-Burt, S., 149 Harada, N., 3052 Glew, S. S., 4009 Gray, J., 3474 Gurnani, M., 3733 Haraf, D., 4832 Glick, A., 3145 Graziano, S. L., 1322 Gurtoo, H. L., 990 Harbury, P., 4467 Gloudemans, T., 6516 Greaves, B. R., 4608 Gustafson, D. L., 6936 Hard, G. C., 2995 Glfisenkamp, K-H., 6209 Greaves, M. F., 4534 Gustavsson, B., 108 Hardonk, M. J., 3552 Glynn, J. M., 997 Greco, W. R., 2228, 4561 Gutierrez, G., 2797 Harling, O. K., 4672 Godwin, T. A., 3449 Green, D. R., 997 Gutierrez, M. I., 1032, 4273 Harlow, E., 2362 Goeminne, N. K. G., 1240 Green, E. D., 2590 Gutmann, R., 1993 Harmon, J. M., 6612 Goetz, A. E., 487, 1993, 6553 Green, M. D., 194 Guttenberger, R., 6348 Harpaz, N., 741 Goffman, T. E., 719 Greenberg, A. S., 4113 Gutterman, J. U., 1087 Harrap, K. R., 822, 1710, 3857, Goillot, E., 3194, 3317 Greene, G. L., 483 Guy, Z., 6576 6188 Goji, J., 4214 Greenfeld, R. S., 5693 Guzman, R. C., 4413, 5732 Harrington, G. W., 1463 Gold, A. M., 2497 Greenhalgh, D., 3145 Harris, A. L., 275 Harris, C. C., 218, 2610, 4837, Gold, L. I., 6949 Greenhouse, S., 2777 H Goldenberg, D. M., 835, 6036 Greenwald, B. D., 741 6092, 6712 Goldfarb, S., 280 Gregory, R. R., 2482 Haag, J. D., 4021 Harris, L. C., 6404 Goldfine, I. D., 3924 Greig, N. H., 2191 Haag, M., 5926 Harrison, J. S., 2408 Goldmacher, V. S., 127, 4200, Greiner, J. W., 1222, 6917 Haas, M., 222 Harrison, S. D., Jr., 4752

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7004

Hart, A. A. M., 2344 Henderson, K. W., 791 Hoffman, W. P., 6931 Huber, K., 1717 Hart, G. W., 2222 Henderson, M. M., 2030s Hofstra, R. M. W., 1536 Huberman, E., 2580, 5826 Hart, R. W., 2124s Hendrick, M. J., 5391 Hogg, G. R., 3796 Hudes, G. R., 6746 Hartford, A., 6292 Hendricks, C. B., 2268 Hogge, D., 3931 Hudson, P. L., 1182 Hartge, P., 5566s Hendry, W. J., III, 2516 H6hne, M. W., 2616 Huebner, K., 746 Hartley, J. A., 4190 Henglein, B., 6547 Holbrook, N. J., 5 Huff, V., 6117 Hartley-Asp, B., 3022 Hengstler, J. G., 5622 Holford, T. R., 5443s Hug, H., 4821 Hartman, L., 2530 Henn, M., 5948 Holley, J. L., 4190 Hughes, A., 5752 Hartman, M., 3213 Henning, D., 5681 Hollstein, M. C., 6092 Huh, N-h., 5307 Hartmann, A., 1445 Hennings, H., 1439, 3145 Holm, P., 6244 Huhtala, P., 1336 Harvey, B. E., 1775 Hennipman, A., 4773 Holm, R., 2329 Hui, E. K-W., 3593 Harwell, S. E., 2304 Henrar, R., 2894 Holmes, M., 5713 Hui, T. E., 1228 Harwerth, I-M., 6310 Henslee, J. G., 4175 Holte, H., 5007 Hukku, B., 6612 Hasan, T., 924 Heo, D. S., 5963 Holwerda, U., 2257 Hulsebos, T. J. M., 1568 Hasegawa, A., 3138 Heppner, G. H., 2209 Hong, J-Y., 1943 Humphrey, P. A., 1622 Hasegawa, T., 6583 Herberman, R. B., 5913, 5963 Hong, K., 5135 Humphreys, T., 5759 Hashida, M., 4396 Hercend, T., 4649 Hong, R., 5610 Huneke, R. B., 5818 Hashimoto, K., 2346 Herlyn, D., 121,815 Hong, W. K., 2707s, 2758s Hung, M-C., 6624 Hasler, C. M., 202 Hermann, G. G., 726 Honma, Y., 4017 Huot, J., 2325 Hasler, J. A., 267 Hermanson, M., 3213 HonorS, N., 3083 Huppi, K., 1032, 4273 Haspel, M. V., 2603 Hermens, A. F., 3073 Hoon, D. S. B., 6059 Hurskainen, T., 1336 Hass, R., 1445 Hernandez, L., 3300 Hooth, M. J., 3851 Hurwitz, E., 2580 Hassanein, R. S., 4458 Hernandez, M., 6066 Hoover, D. M., 4663 Huselton, C., 2138 Hastings, A., 1681 Herndon, J. E., II, 2456 Hoover, R. N., 5477s, 5516s, Hutchinson, M., 5002 Hatada, I., 3642 Herrera, G. E., 6194 6712 Hutchinson, P., 4356 Hatch, M. C., 3865 Herrmann, F., 1026, 2197, 3353, Hoover, S. K., 1386 Hutchison, G. B., 5503s Hatcher, J. F., 3528 3498 Hopman, A. H. N., 4929 Hwang, J-Y., 6848 Hatton, J. D., 1933, 1938 Herrmann, R., 1865 Hori, K., 912 Hwang, S-I., 5732 Hattori, N., 1875 Hertel, L. W., 533 Hori, S., 3011 Hwang, Y. C., 1259 Hattori, Y., 3367 Heseltine, E., 2357 Horiguchi, K., 5042 Hynes, N. E., 6310 Hatzakis, A., 5364 Heslin, M. J., 3845 Horii, A., 643, 3231, 4055, 6696 Haugen, A., 218, 1510 Hewer, A., 1510 Horikawa, K., 3201 I Hawkins, A. L., 3486 Hibi, K., 3506 Horikoshi, T., 108, 797 latropoulos, M., 1162 Hayashi, H., 6671 Hibshoosh, H., 6840 Horinouchi, S., 6926 Ichii, S., 3231, 6696 Hayashi, J., 4242 Hida, T., 2340 Hornung, R. L., 101 Ichikawa, T., 2916, 3022, 3486 Hayashi, K., 4799 Hider, R. C., 4591 Horton, J., 6175 Ichikawa, Y., 3486 Hayashi, S., 1542 Higano, C. S., 3871 Horwitz, K. B., 593 lglehart, J. D., 1622, 2624 Hayashi, S., 3310 Higgins, R. J., 1235 Hosking, L. K., 3110 lhde, D. C., 2767s Hayashi, T., 1369 Higinbotham, K. G., 4747 Hosoe, S., 3310 lida, S., 6083 Hayashi, Y., 400 Higuchi, M., 6125 Hosomi, J., 2818 lino, H., 3965 Hayashi, Y., 1369 Hildesheim, A., 3048 Hotchkiss, J. H., 4139 Ikeda, H., 566 Hayashizaki, Y., 3642 Hilf, R., 1073 Hotz, M. A., 1530 Ikeda, T., 5641 Hayes, D. F., 2563, 6365 Hilkens, J., 2318 Hou, Z-Z., 5780 lkejiri, B., 6716 Hayostek, C. J., 3228 Hill, B. T., 3110 Houchens, D., 1067 Ikematsu, W., 3052 Haywood, L., 6036 Hill, D. E., 478 Houghton, J. A., 558 lliakis, G., 508 He, A., 6092 Hilton, J., 1416, 6168 Houghton, P. J., 558, 6431 Ilson, D. H., 2285 He, S., 3131 Himmelmann, A., 6121 Houssaini, H. S., 3629 llvesmaki, V., 5204 He, X., 1144 Hindenburg, A. A., 5244 Houweling, A., 53 Imagawa, W., 6531 He, Y. J., 2957 Hinds, M., 209 Hovig, E., 3234 Imai, J., 3048 He, Z. Y., 6305 Hinkle, G., 1067 Howard, P. C., 6237 lmai, K., 737 Hecht, S. S., 2698s Hino, O., 978, 6810 Howard, R. B., 2923 lmaida, K., 1542 Heckford, S. E., 5190 Hinoda, Y., 737 Howell, S. B., 3566, 6790 lmamura, Y., 2620 Hedlund, T. E., 515 Hinuma, Y., 3048 Hoyes, K. P., 4591 Imaoka, S., 6594 Hefta, L. J. F., 5647 Hinz, H. R., 3980 Hozumi, M., 4017 Imoto, H., 4396 Hefta, S., 5647 Hirai, S., 3201 Hsieh, C-c., 5364 Imrey, P. B., 857 Hegmann, E. J., 6969 Hirano, J., 400 Hsieh, J-T., 1598, 6940 Imura, H., 3972 Hei, T. K., 6305 Hiraoka, M., 6522 Hsieh-Ma, S. T., 6832 Inaba, N., 1205 Heiman, M. L., 4663 Hirohashi, S., 1504, 3099, 3674, Hsing, A. W., 254 Inada, K., 4046 Heimans, J. J., 3994 4837, 5368, 5770, 6358 Hu, C-p., 1329 Inagaki, H., 1187 Heinemann, V., 533 Hirose, M., 787 Hu, L., 3378 Inagaki, N., 3972 Heisterkamp, N., 4534 Hirota, M., 163 Hu, S-X., 4587, 6297 Inaji, H., 6594 Held, W. A., 2549 Hirota, N., 2995 Huang, B-S., 4696 Inazawa, J., 6083 Heldin, C-H., 1006, 3213 Hirotsune, S., 3642 Huang, D. P., 4787 Incognito, L. S., 5997 Helfrich, B. A., 6318 Hitomi, S., 2292 Huang, G-T., 6098 Inge, T. H., 548, 1386 Hellstr6m, I., 3262 Hittelman, W. N., 2707s, 4758 Huang, J., 1631 Inoue, H., 3483 Hellstr6m, K. E., 3262 Ho, C-T., 3875, 6657 Huang, L., 6287 Inoue, H., 4420 Helman, L. J., 1830, 2243 Ho, R. L. X., 3572 Huang, M-T., 1162, 1943, 6657 lnoue, H., 5313 Helzlsouer, K. J., 1, 2984 Hoang, T., 5208 Huang, Q., 3547 Inoue, M., 4420, 5323, 6823 Hemingway, I., 2628 Hochberg, A., 3713 Huang, S. K., 5135, 6774 Inoue, T., 2903 Henderson, A. J., 5693 Hodam, J. R., 187 Huang, Y., 741, 6525 Inuzuka, M., 5991 Henderson, B. R., 2489 Hoermann, R., 1520 Huang, Z. D., 6702 lrie, R. F., 1681

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7005

Irvine, K., 6917 Jardillier, J-C., 3241 Kajigaya, S., 4017 Kawara, T., 3642 Irwin, S. E., 1639 Jarrett, W. F. H., 6898 Kajumo, F., 3267 Kawasaki, C., 3052 Isaacs, J. T., 2538, 2916, 3022, JS.rvinen, H., 4530 Kakehi, Y., 1881 Kawase, I., 3310 3418, 3486 Jarvis, W. D., 6270 Kakizoe, T., 1393 Kaye, S. B., 2894 Isaacs, W. B., 3486, 5104 Jastorff, B., 2504 Kaklamani, E., 5364 Keating, A., 173 Ishida, T., 775, 2903 Jaszcz, W. B., 406, 1314, 3768 Kalbfleish, J. H., 1699 Keating, M. J., 897 Ishihara, H., 4408 Jeanteur, P., 3918 Kallioniemi, A., 3474 Keeble, W. W., 3224 Ishikawa, H., 3483 Jekunen, A., 3566 Kallioniemi, O., 3474 Kefford, R. F., 2489, 6603 Ishikawa, S., 3011 Jeng, M-H., 6539 Kamada, M., 5178 Keimig, S., 1463 Ishikawa, T., 2575 Jenis, L. G., 829 Kamada, N., 1481 Kelland, L. R., 822, 1710, 3857, Ishizaki, K., 2419, 6194, 6588 Jenkins, G. R., 187 Kamat, D., 5465s 5065, 5674, 6188 Isoai, A., 1422 Jenkins, R. B., 2523 Kamataki, T., 758 Kelleher, M. B., 4254 Isoda, Y., 400 Jennings, D. S., 6708 Kamen, B. A., 3396, 6708 Keller, J. R., 4082 Isom, H. C., 940 Jenns, K. E., 603 Kameya, T., 307 Kelley, D., 3931 Isono, K., 6671 Jensen, P. B., 2874 Kaminska, B., 1891 Kelley, E. E., 6263 Israel, M., 3409 Jensen, R. H., 3558 Kaminski, M. S., 637, 6476 Kelley, K., 6175 Israel, M. A., 6871 Jensen, R. T., 1114, 3295 Kamiya, H., 1836, 3483 Kelley, P. Y., 1938 Isselbacher, K. J., 1201, 4036 Jeppsson, B., 5794 Kanakura, Y., 566 Kelloff, G. J., 1651 Itai, S., 5744 Jerome, K. R., 5985 Kanayama, Y., 566 Kelly, R. C., 4904 Itakura, M., 5061 Jetten, A. M., 3687, 3938 Kanda, S., 1681 Kemena, A., 897 Ito, A., 1948 Jewett, P. B., 24, 593 Kane, M. A., 2727s Kemeny, N., 5663 Ito, H., 295 Jhiang, S. M., 428 Kaneko, Y., 1481, 2419, 6945 Kemp, J. D., 4144 Ito, H., 3739 Jiang, M-s., 2222 Kang, H-i., 5307 Kenady, D. E., 4106 Ito, H., 4214 Jiang, W., 2980, 6840 Kannagi, R., 2292, 5744 Kennan, W. S., 4102 Ito, M., 295 Jiaqi, Z., 45 Kantarjian, H., 1087, 4130 Kennedy, M. J., 1278 Ito, M., 6961 Jimbow, K., 6638 Kantor, J., 6917 Kennel, S. J., 1284, 6036 Ito, N., 787, 4837 Jimenez, J. J., 413, 5123 Kao, C., 688 Kenney, N., 3467 Ito, S., 3965 Jodrell, D. I., 64 Kao, M-S., 866 Kenny, M. K., 6375 Ito, T., 1369 Joenje, H., 4361 Kappel, C. C., 2243, 6871 Kent, M. L., 6496 Ito, T., 1961 Johnson, B. E., 1996, 3534, Karaszkiewicz, J. W., 3750 Kerbel, R. S., 6969 Itoh, F., 737 4168 Karbach, U., 474 Kerckaert, G., 144 Itoh, Y., 5278 Johnson, C. E., 2000 Karczmar, G. S., 71 Kere, J., 4530 Itoyama, S., 4408 Johnson, G. R., 341, 3467 Karpatkin, S., 3267 Kerley, S. E., 4672 Itzkowitz, S. H., 4741, 5971 Johnson, J. T., 5963 Karran, P., 5257 Kern, S. E., 1780 Iversen, J. M., 64, 5775 Johnson, K. A., 478 Karthaus, H. F. M., 5104 Kerr, D. J., 2894 Iwahana, H., 5061 Johnston, D., 4130 Kasai, K., 307 Kersey, J. H., 406, 1314 lwama, T., 3965 Johnston, M. R., 2923 Kasai, Y., 815 Kerwar, S. S., 2148 Iwamori, M., 416, 803 Johnston, P. G., 4306, 6860 Kasama, T., 4805 Kessel, D., 2890 Iwamoto, S., 5323 Jones, C., 3048 Kaspar, L. V., 1469 Keyomarsi, K., 6966 Iwamura, A., 5178 Jones, J. A., 6790 Kaspar, L. V., 1469 Khan, S. G., 4050 Iwasaki, R., 6583 Jones, L. A., 5386 Kasper, S. J., 990 Kharbanda, S., 878, 1445 Iwashima, A., 6583 Jones, M. J., 3005 Kasprzak, K. S., 4747 Khazaeli, M. B., 4342, 6979 Izawa, M., 1628 Jones, M. O., 5853 Kasprzyk, P. G., 2771 Khin, S., 5720 Jones, P. A., 3821, 4787 Kassel, J., 6976 Khodadadian, M., 5271 J Jones, T., 1592 Kastenbauer, E., 1993 Khokhar, A. R., 4096, 6341 Jones, W. D., Jr., 1195 Jablons, D., 4113 Kasuga, M., 4335 Khoo, N. K. S., 6452 Jongenelen, C. A. M., 3994 Kasukabe, T., 4017 Kibitel, J. T., 4227 Jackman, A. L., 1137 Joos, S., 6547 Jackson, B. C., 1938 Kasumi, F., 1643, 3914 Kido, J-i., 5313 Jorcano, J. L., 680 Kaszkin, M., 5627 Kiguchi, K., 416, 803 Jackson, C. L., 341 Jordan, V. C., 6539 Jackson, D., 5264 Katiyar, S. K., 3582, 4050, 6890 Kikuchi, H., 3972 Jorquera, R., 3273 Kikuchi-Yanoshita, R., 3801, Jacob, J. R., 4139 Josephy, P. D., 3961 Kato, J., 227 3965 Jacrot, M., 4872 Jostes, R., 5126 Kato, K., 464 Killion, J. J., 1155 Jaffe, E. S., 5447s Jouishomme, H., 6329 Kato, S., 6712 Kim, S-G., 1259 Jaffey, P., 2384 Joyce, A. D., 1457 Kato, Y., 3231, 6696 Kim, S. Y., 2707s Jaffr6zou, J-P., 1352, 6440 Joyce, M. A., 4672 Katoh, O., 3367 J~ihde, E., 6209 Jung, M., 6390 Katsuki, M., 978, 1628 Kim, Y. S., 3378, 4655 Jahn, U-R., 3220 Jiingst, D., 1520 Katz, A., 3679 Kimler, B. F., 4458 Jain, R. K., 487, 1993, 3237, Jun-shi, C., 45 Katz, D., 149 Kimoto, A., 1013 4157, 5110, 5838, 6010, 6371, Jurado, A., 3048 Kauffman, F. C., 1639 Kimura, E., 1205 6553 Juweid, M., 5144 Kaufman, D. G., 3807 Kimura, G., 775 Jameson, B. A., 6447 Kaufman, E. N., 4157 Kimura, M., 978, 1628 Kaufman, H., 6917 Kimura, N., 6598 Jani, J. P., 709, 2931 K J~inicke, F., 6101 Kaufmann, S. H., 2268, 2847, Kimura, T., 3201 Janik, J., 2394 Kacinski, B. M., 3661 4895, 5373 King, C. R., 2771 Jankowski, S. A., 3746 Kaczmarek, L., 1891 Kaur, G., 3340 King, D., 5693 Jankun, J., 5829 Kadam, S., 4735 Kawabata, Y., 4408 King, K. M., 5879 Jannatipour, M., 4467 Kagawa, M., 1675 Kawaguchi, N., 2419 King, T. E., Jr., 2727s Janot, F., 6567 Kageshita, T., 3201 Kawaguchi, T., 400 Kinlen, L., 5474s Janowska-Wieczorek, A., 5879 Kahl, G. F., 2616 Kawaguchi, T., 1013 Kino, I., 3372 Jansen, B., 406, 1314 Kahn, S. M., 2980, 6840 Kawakita, M., 464 Kinoshita, F., 5313 Janssens, B. L. E., 1240 Kaipainen, A., 5738 Kawakubo, K., 6598 Kinsella, T. J., 1687

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7006

Kinzel, V., 5627 Koprowski, H., 815 Kumble, K. D., 163 Lassota, P., 1530 Kinzler, K. W., 643, 4530 Koretsky, A. P., 6010 Kung, A. H. C., 3056 Lassus, M., 5933 Kipps, T. J., 2468, 5552s Korhonen, J., 2004, 5738 Kuranami, M., 3011 Latham, K. M., 616 Kirchheimer, J. C., 1717, 3043 Kornblau, S. M., 4587 Kuriu, A., 566 Latif, F., 348, 1451 Kirkwood, J. M., 851 Kornblith, A. B., 4620 Kuroishi, T., 734 Lattime, E. C., 4286 Kirsch, I. R., 5545s Kosano, H., 1187 Kuroiwa, Y., 4634 Lau, C. C., 5119 Kirsch, K., 1201 Koseniauskas, R., 1463 Kuroki, T., 5307 Lau, D. H. M., 4379 Kirven, M., 2468, 4678 Koshiba, M., 1881 Kuroki-Migita, M., 6501 Laurent, G., 1352, 6440 Kishimoto, S., 400 Koshikawa, N., 5046 Kurzrock, R., 1087 Laursen, I., 1210 Kishimoto, Y., 4799 Koski, R. A., 5853 Kushnaryov, V. M., 5096 La Vecchia, C., 3589 Kisliuk, R. L., 2228 Koslow, M., 1427 Kusters, I., 6092 Law, D. J., 3094 Kitada, M., 758 Kosmas, C., 904 Kusuhara, M., 3011 Lawrence, T. S., 3698 Kitagawa, H., 4408 Kotani, T., 6323 Kusumoto, T., 3306 Lawson, S., 4342 Kitagawa, T., 2478, 6810 Kotb, M., 3361 Kusumoto, Y., 2620 Lazo, J. S., 709, 2931, 3119 Kitamura, K., 6323 Kotoura, Y., 2419, 6194 Kute, T. E., 5100, 5198 Leach, M. W., 1235 Kitano, H., 6583 Koutcher, J. A., 4074, 4620 Kuznicki, J., 1291 Leander, K. R., 3347 Kittrell, F. S., 1924, 2482 Koutsoukos, A. D., 3029 Kvols, L., 6074 Le Beau, M. M., 4678 Kiyohara, H., 4046 Kovach, J. S., 1974 Kwak, K-S., 4655 LeBlanc, G. A., 540 Kjcnniksen, I., 1347 Koval, T. M., 3228 Kwak, L. W., 4117 Lebo, R. V., 1494 Klann, R~ C., 1372 Kovatch, R., 450 Kwei, G. Y., 1639 LeBoeuf, R. A., 144 Kleibeuker, J. H., 3552 Kowal, C., 6746 Kwon, H. J., 6926 Lebovics, R., 719 Kleihues, P., 2987, 2995, 3760 Koyama, H., 6594 Kyo, E., 295 Lechtman, A. N., 1933 Klein, S., 1801 Koza, S., 2957 Kyriakos, R. J., 835 Ledwith, B. J., 3347 Klijanienko, J., 974 Kozielski, A. J., 3980 Lee, C., 5887 Klijn, J. G. M., 1036, 1107, Kozlowski, J. M., 5887 L Lee, F. Y. F., 3515 Kozu, T., 6945 Lee, G-H., 5162 6101 LaBella, F. S., 3796 Kraegel, S. A., 4724 Lee, H-S., 6098 Klinge, C. M., 1073 Laborda, J., 3340 Lee, I., 3237 Klingelhutz, A. J., 1631 Kraemer, K. H., 5668 LaBresh, K., 5872 Lee, J. S., 2707s Klitzman, B., 4265 Kraft, A. S., 2143 Labrie, C., 610 Lee, K-D., 5135 Klopman, G., 4121 Kraft, N. E., 4356 Labrie, F., 610 Klostergaard, J., 4096, 5271 Kraft, P., 2854 Lacasse, B., 2325 Lee, K. W., 4036 Kluge, M., 2167 Krauer, K. G., 132 Laccetti, P., 4582 Lee, M. L., 662, 2049s Klurfeld, D. M., 2055s Kraynak, A. R., 3347 LaCreta, F., 6746 Lee, P-H., 6098 Knapp, R. C., 5119 Kreider, J., 940 Ladenstein, R., 3194 Lee, S. A., 3750 Knize, M. G., 2103s, 6216 Kreis, W., 3818 Ladisch, S., 810 Lee, S-J., 1235 Knoll, R. H., 3782 Kreisle, R. A., 5412 Lafrenie, R. M., 2202 Lee, W-H., 1968 Knuppen, R., 4642 Kress, S., 3220, 6400 Lagac6, R., 2325 Lee, Y. J., 5780 Kobayakawa, K., 3642 Kreuser, E. D., 3498 Lai, M-Y., 6098 Leenstra, S., 1568 Kobayashi, H., 3610 Krewson, J., 1754 Lala, P. K., 6452 LeGros, H. L., Jr., 3361 Kobayashi, M., 3099 Kripke, M. L., 3946 Lalani, E-N., 1954 Legros, Y., 6380 Kobayashi, R., 2468, 5552s Kris, E. S., 2035s Lamb, J. C., 3022 Lehman, T. A., 2610, 6956 Kobayashi, T., 1205 Kris, M. G., 6619 Lambert, J. M., 4200 Lehnert, E., 4478 Koch, C. J., 3831 Krishna, C. M., 1750 Lambrecht, L. K., 3615 Leichman, L., 108 Kodama, H., 4017 Krishna, S., 5244 Lamerz, R., 2329 Leith, J. T., 2162 Koeffler, H. P., 1695 Kroeger-Koepke, M. B., 3300 Lammertsma, A. A., 1592 Lendahl, U., 5334 Koenig, M., 3726 Krohn, K. A., 89 Lampidis, T. J., 6385 Lengauer, C., 2590 Koepke, S. R., 3300 Krsmanovic, V., 6329 Lampson, L. A., 1018 Lennon, S. V., 997 Kohler, M. F., 1622 Krueger, W. C., 4904 Lancillotti, F., 6144 Lenoir, G., 6117 Kohn, E. C., 3208 Krupitza, G., 3952 Lanciotti, M., 931 Lentz, S. K., 1660 Kohn, K. W., 3125 Kubin, M., 2530 Landry, J., 2325 Le6n, J., 5979 Koi, S., 5815 Kubota, T., 1187 Lane, D. P., 6092, 6380 Leong, L. A., 2408 Koier, I., 2894 Kubota, Y., 2346 Langdon, S., 2737s, 4554, 5940 Lepak, N. M., 4242 Koike, M., 3965 Kubushiro, K., 803 Langenberg, P., 578 Leppert, M., 6117 Koike, T., 696 Kucera, G. L., 3886 Langeveid, C. H., 3994 Lerman, M. I., 348, 1451 Koizumi, K., 168 Kuchan, M. J., 1091 Langkilde, N. C., 5030 LeRoith, D., 5100 Kok, K., 1536, 1695 Kudo, R., 2777, 5815 Langley, K. E., 701 Leroux, E., 5271 Kolonias, D., 6385 Kufe, D. W., 878, 1445, 2563, Langmuir, V. K., 4728 Lesieur, D., 3629 Kolossvary, I., 4121 6365 Lankelma, J., 17 Lesieur, I., 3629 Komatsubara, H., 3642 Kuffel, M. J., 2830 Lanson, M., 843 Less, J. R., 6371 Komschlies, K. L., 4082 Kuhlmann, E. T., 3295 Lanuza, J., 4885 Lestavel-Delattre, S., 3629 Konda, Y., 4335 Kuijten, R. R., 782 Lapenson, D. P., 5797 Lesuffleur, T., 4655 Kondo, S., 3052 Kuiper, C. M., 17 Lappi, D. A., 227 Leteurtre, F., 4478 Kondoh, N., 791 Kuipers, F., 3552 Lark, R. H., 3396 Leung, M-F., 949, 3063 Konecki, D., 2590 Kuivanen, P. C., 5752 Laroye, G., 5037 Leunig, M., 487, 1993, 6553 Konishi, C., 5307 Kulesz-Martin, M. F., 749, 4058 Larson, R. G., 428 Levade, T., 1352, 6440 Konishi, M., 3801, 3965 Kulkarni, N., 5635 Larson, S. M., 2743s Leverstein, H., 2569 Konishi, Y., 5042 Kuma, K., 3642 Larsson, O., 6244 L6vesque, C., 610 Konno, T., 1013 Kumagai, H., 1422 Larsson, P., 1267 Levin, B., 2603 Koops, H. S., 6705 Kumagai, Y., 4987 Lasch, S. J., 5693 Levine, A. M., 5482s Kopp, W. C., 2394, 3005 Kumar, C. C., 6877 Lasic, D. D., 6774 Levine, D. S., 2946 Koppel, G. A., 3838 Kumar, R., 3335 Lasserre, C., 5089 Levine, P. H., 5516s, 5518s,

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7007

5561s, 5562s Little, J. B., 5788, 6194, 6394 Lupton, J. R., 5906 Manjeshwar, S., 2078s Levine, P. M., 5482s Litwack, G., 491 Lust, J. A., 1974 Mank, A. R., 5359 Levy, A. T., 6020 Liu, E. T., 5018 Lutze, L. H., 5126 Mann, K., 1520 Levy, D. D., 5668 Liu, G., 3378 Lutzky, J., 5244 Mann, R. A., 1840 Levy, R., 4117, 5547s Liu, H-S., 983 Luu-The, V., 4269 Mannervik, B., 3281 Lewis, A. D., 4379 Liu, L. F., 1823 Lydon, N. B., 4492 Manni, A., 5720 Leyton, J., 662, 2049s Liu, R., 4973 Lyerly, D. M., 5096 Manzari, V., 4866 Lhomm6, C., 3901 Liu, R. H., 4139 Lykkesfeldt, A. E., 1210 Mao, J-i., 231 Li, A., 571 Liu, R. Y., 3667 Lynch, A. M., 6216 Maratrat, M., 5213 Li, B. F. L., 6423 Liu, S., 348 Lynch, C. F., 254 Marcillac, I., 3901 Li, B-Y., 2248 Liu, T., 4342 Lynch, J. H., 5403 Margison, G. P., 6052 Li, F. P., 6117 Liu, W., 1754 Lynch, M. J., 4995 Margolin, K. A., 2408 Li, G. C., 3667 Liu, Y-X., 4467 Lynch, S. R., 4458 Margonari, J., 6353 Li, J., 3498 Livingston, D., 3246 Lyng, H., 584 Mariani, M. R., 5906 Li, J., 5948 Livingston, P. O., 5663 Marincola, F. M., 6561 Li, L., 3667 Lloyd, K. O., 4948, 5663, 5725 M Markaverich, B. M., 2482 Li, L. H., 4904 Lo, K-W., 4787 Markowitz, D. D., 3838 Li, W-W,, 1434, 3908, 6866 LoBuglio, A. F., 4342, 6979 Ma, W., 6657 Marks, J. R., 1622, 2624 Li, X., 3667 Lock, R. B., 1817 Mabry, M., 2764s, 4752 Marm6, D., 4821 Maccubbin, D. L., 3572, 3880 Li, X-F., 5641 Lock-Lim, S., 3648 Marnett, L. J., 5575 MacDonald, P. C., 554 Li, Y. P., 6522 Locniskar, M., 662, 2049s Maronde, E., 2504 Macdonald, T., 4478 Maronpot, R. R., 3164 Liang, P., 6966 Lo Coco, F., 3687 Mace, K. F., 3572 Liang, S., 121 Loeb, L. A., 1082 Marozzi, A., 4036 Mach, J-P., 2329 Marquardt, D., 3157 Libertino, J. A., 1457 Loeffler, D. A., 2209 Machinami, R., 6810 Lichtenstein, A., 764 Logan, S. K., 6001 Marras, V., 4979 Mackensen, D. G., 1810 Martel, C., 610 Lichti, U., 456 Logothetis, C., 6940 Mackey, M. A., 1101 Lidgard, G. P., 422 Loh, K. C., 6423 Martel, J., 5720 MacLennan, K., 4261 Martell, B. A., 127 Lie, S. O., 5007 Loh, S. Y., 1710, 3857, 6188 MacManus, J. P., 3718 Lieberman, M. A., 983 Lohman, P. H. M., 2253 Martens, H. J. M., 2569 MacNeela, J. P., 4320 Martin, D. S., 4074 Liefers, G. J., 6125 Lokeshwar, B. L., 5821 Madalengoitia, J., 4478 Martin, F., 2797 Liehr, J. G., 1360 Lolli, M., 6699 Madden, K. R., 525 Martin, F. J., 6774 Lien, E. A., 4719 Lombardi, A. J., Jr., 4027 Madewell, B. R., 4724 Ligtenberg, M. J. L., 2318 Long, R. T., 5198 Madoc-Jones, H., 4672 Martin, P. J., 1228 Lim, J. S., 4969 Long, S. D., 2000 Madri, J. A., 4995 Martinez, C. A., 5979 Lim, S. E., 5668 Longnecker, D. S., 3295, 6905 Madsen, M. W., 1210 Martin-Nizard, F., 3629 Lin, B-Y., 6848 Longo, D. L., 101, 2394, 3005, Maeda, H., 1013 Martinotti, S., 4866 Lin, C. M., 3892 4082 Maeda, Y., 3965, 5368 Marton, L. J., 6782 Lin, F., 5282 Longtine, J., 6224 Maehara, Y., 3306 Marry, M., 6380 Lin, J-K., 385 LOnning, P. E., 4719 Maehle, L., 218 Marvaldi, J. L., 3182 Lin, J. T., 1434, 3908 Look, A. T., 1780 Maekawa, A., 2995 Marvin, J., 578 Lin, K., 357, 367 Lopaczynska, J., 6692 Maelandsmo, G. M., 6088 Marx, S. J., 6804 Lin, M-F., 4600 Lopez, M. E., 5997 Mafune, K-i., 3067 Masahito, P., 2575 Lin, P., 144 L6pez-Otin, C., 95 Magagnotti, C., 6699 Maseki, N., 6945 Lin, P-S., 6270 Lord, H. L., 3961 Magee, P. N., 1463 Masiero, L., 4548 Lin, R. T., 6059 Lorico, A., 2782 Maggi, M., 1830 Mason, J. B., 5002 Lin, T-P., 4413 Los, G., 1252 Magrath, I. T., 1032, 4273, Massaad, L., 6567 Lin, T. S., 3063 Lotan, R., 2707s, 4878 5529s Massarelli, G., 4979 Lin, W-c., 5963 Lothstein, L., 3409 Mahmood, U., 4620 Mastronicola, M. R., 4582 Lindstrom, M. J., 1606, 1615, Lottering, M-L., 5926 Mahterian, S., 5482s Masuda, A., 787 4021, 4102 Lotze, M. T., 6561 Maimonis, P. J., 2563, 4741 Masui, H., 3335 Linehan, W. M., 348 Lou, Y-R., 1162 Majors, A., 5299 Masuno, T., 3310 Linet, M. S., 5468s Loudon, W. G., 1123 Makino, M., 4096 Mata, F., 1245 Ling, V., 5154 Louis, D. N., 2987, 4277 Malaguarnera, L., 1891 Mather, A., 4190 Link, E. M., 4385 Louison, C., 5775 Malaise, E. P., 6348 Mathew, S., 2285 Linker, C. A., 3819 Lowenstein, J. M., 154 Malarska, A., 3241 Mathiesen, D. A., 2830 Linnainmaa, K., 2610 Lower, E. E., 2597 Malassagne, B., 3901 Mathur, A., 5465s Linnenbach, A. J., 815 Lu, L., 4027 Maldve, R. E., 662, 2049s Matias, M. S., 4175 Linnoila, I., 2340 Lu, S-H., 2980 Malik, K., 2523 Matozaki, T., 4335 Linnoila, R. I., 450, 5342 Lu, S-J., 5037 Malipiero, U., 6121 Matrisian, L. M., 4942 Linos, A., 5501s Lu, X., 2806, 2813 Malkin, D., 3234 Matsuda, H., 4890 Liotta, L. A., 3208, 4548, 6020 Lu, X., 3718 Malkinson, A. M., 2670s, 4752, Matsuda, K., 4335 Lipkin, M., 2067s, 5906 Lucia, M. S., 515 6797 Matsui, M., 1309 Lipkowitz, S., 5545s Lucier, G. W., 3436 Malkovska, V., 5610 Matsui, T., 6961 Lippitz, B. E., 5590 Ludeman, S. M., 5373 Malspeis, L., 3604, 3892 Matsumoto, K., 4402 Lippman, S. M., 2707s, 2758s, Ludlum, D. B., 6052 Manam, S., 3347 Matsumoto, T., 3655 2767s Ludwig, W-D., 2197, 3498 Manchester, D. K., 1499 Matsumura, I., 566 Lips, C. J. M., 6516 Luethy, J. D., 5 Maneval, D., 1916 Matsumura, K., 3474 Lisheng, Z., 45 Lugagne, P-M., 3901 Manfredini, R., l 1 Matsumura, Y., 2174 Lissens, W., 6646 Lunec, J., l 137 Mangian, H. J., 857 Matsunashi, M., 3310 List, J., I 123 Luo, K. J., 3593 Mangold, G. L., 3636 Matsuno, T., 1192 Litterst, C. L., 149 Luo, L-d., 1044 Mangold, K. A., 4507 Matsuo, S., 4046

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7008

Matsuzaki, H., 464 Melcion, C., 5213 4168 Moore, M. A. S., 6576 Matsuzawa, A., 6531 Melder, D., 2835 Minnick, D. T., 4688 Moorer-van Delft, C. M., 963 Mattano, L. A., Jr., 4701 Meldgaard, P., 3739 Minniti, C. P., 1830 Moradi, M., 2248 Matter, A., 4712 Melhem, M. F., 5853 Miozzo, M., 6079 Moreb, J., 1770 Mattes, M. J., 835 Meltzer, P. S., 3746 Mirabelli, C. K., 231 Moreno, J. G., 6110 Matthews, D. C., 89, 1228 Meltzer, S. J., 741, 1996, 6525 Mirabelli, F., 1342 Morgan, D., 3145, 6487 Mattson, K., 2610 Memoli, V. A., 6949 Mirkin, B. L., 5826 Morgan, K., 6113 Maunoury, M-T., 2880 Mendelsohn, J., 3335, 5887 Mirvish, S. S., 3547 Morgan, R. J., 2408 Maurel, P., 6237 Mendonca, H. L., 4728 Misawa, S., 6588 Mori, T., 3965 Maurer, J., 3498 Mendoza, J. T., 3980 Miser, J., 521 Mori, T., 5744 Maury, C., 2880 Meng, Y., 940 Mistry, J. S., 709, 2931 Morimoto, M., 2818 Maus, M., 4735 Mengel, L., 940 Mistry, P., 822, 1710, 3857, Morisaki, T., 6059 Mauvernay, R. Y., 2797 Menger, M. D., 6553 5674, 6188 Morita, T., 3367 Maw, M. A., 3094 Mentzer, S., 6224 Mitamura, K., 4987 Morizet, J., 6567 May, W. S., 1278 M6rand, Y., 610 Mitchell, B. S., 2389 Moroson, B. A., 2148 Maybaum, J., 3698 Mercatello, A., 3317 Mitchell, D., 4227 Morrell, C. H., 3323 Mayes, J., 209 Merchant, T. E., 4620 Mitchell, J. B., 719, 1750 Morris, D. L., 917 Mayhew, E., 6774 Merino, M. J., 348 Mitchell, M. J., 209 Morris, G., 709, 2931 Mayne, S. T., 5443s Merlino, G., 5162, 5171 Mitchell, R. B., 1171 Morris, J. H., 1018 Mazars, R., 3918 Merrick, M. A., 5997 Mitra, S., 1144 Morrison, G. H., 5219 Mazumder, A., 6482 Merriman, R. L., 4663 Mitsudomi, T., 2243 Morrison, L. D., 3961 McAlpine, J., 4735 Merrouche, Y., 3317 Mitsugi, K., 6501 Morrison, P. F., 377, 2464 McBride, W. H., 3931 Mertelsmann, R. H., 2197, 3353 Mitsui, H., 566 Morrison, S. L., 1681 McCabe, R. P., 2603 Merwin, J. R., 4995 Mitsui, H., 4232 Morrow, C., 6175 McCall, M. J., 904 Meschter, C., 2402 Miura, H., 1836 Morse, M. A., 2719s McClay, E. F., 6790 Messer, B. R., 5604 Miura, I., 1322 Mortarini, R., 4499 McCoy, Z., 3436 Messina, A., 1891 Miura, K., 3483 Morton, D. L., 6059 McCrady, C. W., 548 Messina, L., 1891 Miura, Y., 4017 Morton, D. M., 6931 McCue, P. A., 4286 Messmer, K., 487, 1993, 6553 Mivechi, N. F., 6815 Moschel, R. C., 1171 McDaniel, T. K., 741, 6525 Mester, J., 6827 Miyagaki, T., 6323 Moser, G. J., 631 McDonnell, D. P., 483 Metcalf, R. A., 218, 2610, 6092 Miyagi, M., 3914 Moser, R. P., 1123 McDonnell, T. J., 6940 Mett, H., 4712 Miyake, M., 2292 Mosier, D. E., 2468, 4678, McDougall, C. J., 3449 Metter, E. J., 3323 Miyaki, M., 3801, 3965, 5368 5552s McGlennen, R. C., 5872 Meuth, M., 6471 Miyakoshi, J., 6522 Moskal, T. J., 1463 McGovren, J. P., 4904, 5687 Meyer, S. A., 631 Miyamoto, K., 1481 Moskovtchenko, J-F., 3317 McGregor, D., 2357 Meyer, T., 4492 Miyamoto, S., 5732 Moss, T. J., 4701 McGroarty, R., 3131 Meyskens, F. L., Jr., 5024 Miyashita, T., 5407 Motomura, K., 6594 McGuire, W. L., 483, 3539, Micela, M., 4548 Miyata, N., 1542 Motzer, R. J., 3558, 5775 3648 Michaels, E., 1573 Miyauchi, Y., 1013 Mueller, B. M., 3838 Mclntosh, J., 4113 Michalides, J. A. M., 5229 Miyazaki, K., 5046 Mueller, M., 6310 McKay, L. A., 5443s Michalopoulos, G., 2078s Miyoshi, H., 6945 Mueller, N. E., 5479s, 5557s, McKeever, P. E., 3698 Michejda, C. J., 3300 Miyoshi, Y., 643, 3231, 4055, 5571s McKenzie, C. G., 1592 Michels, A. A., 4773 6696 Mueller-Klieser, W., 474 McKenzie, I. F. C., 132, 2310 Michelson, S., 2162 Mizumoto, Y., 5042 Muench, M. O., 6576 McKenzie, R. S., 6318 Michna, H., 4642 Mizuno, T., 1369 Muindi, J. R. F., 2138 McKenzie, S. J., 127 Mick, R., 4832 Mizushima, S., 464 Muir, M., 4554 McKinna, A., 4261 Mickisch, G. H., 4427 Mizuuchi, H., 2777 Mujumdar, R. B., 709 McKinnon, R. A., 2108s Mihich, E., 3246, 3572, 3880 Mochizuki, H., 1205 Mukai, M., 1422 McLaughlin, J. K., 254 Mikami, M., 803 Modest, E. J., 2835, 6263 Mukai, T., 3642 McLaughlin, K., 6375 Miketic, L. M., 851 Modesti, A., 4853 Mukhopadhyay, S. K., 3698 McMahon, J., 746 Miki, Y., 643, 1643 Moffett, B. F., 1737 Mukhtar, H., 3582, 4050, 6106, McManus, M. E., 2108s, 6237 Milano, G., 2899 Mohan-Peterson, S., 6877 6400, 6890 McNamee, F. L., 5516s Milazzo, G., 3924 Mohauraj, D., 2248 Mulcahy, R. T., 5115 McNitt, K. L., 3005 Milenic, D. E., 3402, 6413 Mohar, A., 5479s Mulder, N. H., 3552, 6885 McVie, J. G., 1252 Miller, C. W., 1695 Mohler, J. L., 2349 Mulholland, S. G., 6110 Meadows, A. T., 782, 6117 Miller, D. M., 4342 Mok, C-H., 5119 Mullen, C. A., 6020 Meares, C. F., 904 Miller, E. M., 1687 Moley, J. F., 770 Mullendore, L. A., 3029 Mecklin, J-P., 4530 Miller, F. N., 3425 Molinolo, A., 1067 Miiller, L. J., 963 Medeiros, L. J., 5447s Miller, F. R., 1399 Molloy, C. J., 301 Miiller, M., 4712 Medina, D., 1924, 2482 Miller, G. J., 515 Molnar, P., 5590 Mulshine, J. L., 2639s, 271 ls, Medina, M., 227 Miller, L. S., 1067 Momose, H., 5329 2743s, 2766s Meeker, T. C., 2460 Miller, T., 940 Moncharmont, B., 290 Muncaster, M. M., 654 Meersma, G. J., 6885 Miller, T. E., 422 Monks, A., 3029 Mundy, G. R., 3636, 5395 Mehra, T., 2431 Miller, W. M., 3782 Monne, M., 61 l0 Murakami, Y., 4799 Mehta, K., 437 Miller, Y. E., 2727s Montag, A., 4832 Murakoshi, M., 6583 Meijer, C., 6885 Millow, L. J., 3094 Montaldo, P. G., 931, 4960 Murata, M., 775 Meijer, C. J. L. M., 2440, 2569 Mills, G. B., 2580 Montafio, J. T., 5879 Murata, M., 873 Meisler, A. I., 5853 Milner, J. A., 1091 Montgomery, B. T., 1525 Murphy, J. R., 2545 Meisner, L., 955 Milovanovic, S., 2538 Moody, T. W., 2732s, 2764s Murphy, L. C., 1704 Melamed, M. R., 3491 Miniou, P., 815 Mooi, W. J., 5229 Murphy, L. J., 1704 Melchiori, A., 2353 Minna, J. D., 1996, 2340, 3340, Moon, H., 3011 Murphy, M. J., Jr., 2012

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7009

Murphy, S. E., 2698s Natazuka, T., 9607 Nitiss, J. L., 4467 Ohtake, K., 6810 Murray, J. H., 2603 Nathwani, B., 5482s Niu, T-q., 6052 Ohtaki, S., 4987 Murray, J. L., 2603 Natsumeda, Y., 258 Niwa, K., 3655 Ohtani, H., 307 Murray, S., 6216 Nau, M. M., 2243, 2340 Nobori, T., 2523 Ohtsuka, E., 1836, 3483 Murrer, B. A., 822, 3857, 5674, Naumann, P. W., 4144 Noda, K., 5815 Ohtsuka, M., 6463 6188 Naus, C. C. G., 4208 Noel, A. C., 5845 Ohyashiki, J. H., 6598 Mushinski, J. F., 1032 Nawaz, Z., 483 Noguchi, A., 6323 Ohyashiki, K., 6598 Mutch, D. G., 866 Neckers, L. M., 1721 Noguchi, M., 3099 Oie, H. K., l 114, 2732s, 4752 Myklebost, O., 6088 Neda, H., 5278 Noguchi, S., 6594 Oikawa, S., 5647 Negishi, Y., 1205 Nomoto, K., 775 Okabe, H., 6583 N Negri, E., 3589 Nord, L. D., 4074 Okabe-Kado, J., 4017 Negrier, S., 3317 Nordan, R. P., 4113 Okada, K., 6463 Naaktgeboren, J. M., 2253 Negrini, M., 1297 Nordling, S., 4530 Okajima, E., 1393 Nadler, L. M., 4200 Negroni, A., 4221 Normanno, N., 3467 Okamoto, N., 2575 Naeem, R., 6224 Neilson, E. G., 6129 Normolle, D. P., 637, 3698, Okamoto, T., 5278, 6258 Nagafuchi, A., 5770 Neiman, R. S., 5503s 6476 Okamura, S., 3052 Nagahara, A., 1754 Nelkin, B., 770 Norton, J. A., 6804 Okamura, T., 3052 Nagai, H., 3642 Nelson, A. C., 6279 Norton, T. R., 4779 Okamura, T., 3577 Nagai, M., 258 Nelson, K., 4106 Norwood, T., 2946 Okano, J. H., 5178 Nagai, Y., 416, 803 Nervi, C., 3687, 3938' Notario, V., 6390 Okazaki, S., 787 Nagao, M., 2092s Nett, L. M., 2727s Nourigat, C., 1228 Okuma, M., 2620 Nagao, M., 4335 Netzer, M. F., 1573 Nouso, K., 1796 Okumura, K., 4890 Nagasawa, H., 6394 Neubauer, B. L., 4663 Novosad, E., 4735 Okuzumi, J., 6583 Nagase, H., 3231, 4055, 6696 Novy, M. B., 1573 Old, L. J., 5663 Nagata, J., 6945 Neumann, R., 5144 Newcom, S. R., 6768 Nowell, P. C., 3811 Oldfield, E. H., 719, 4550, 6716 Nagata, N., 1187 Nozawa, S., 416, 803, 1205, Olifant, A., 1643 Nagy, J. A., 357, 367 Newcomb, E. W., 1427, 3791 Newell, D. R., 603 6153, 6158 Olofsson, B., 3083 Naiki, H., 5991 Numata, M., 400 Olopade, O. I., 2523 Nair, S., 851 Newkirk, C., 741, 6525 Newman, B. M., 1406 Numata, M., 6690 Olsen, R., 6917 Nakae, D., 5042 Nunnink, B., 5229 Olson, M. C., 2248 Nakagawa, K., 328 Newman, E., 3845 Newman, E. M., 2408 Nyce, J. W., 1372 Olson, M. V., 2590 Nakagawa, K., 2478 Nyman, T., 5204 Nakagawa, M., 6175 Newman, R. A., 1406, 3306, Olsson, C. A., 4313 4758 Olsson, H., 2991 Nakagawa, Y., 1573 O Nakagawara, A., 1364 Newmark, H. L., 2067s, 5906 O'Malley, B. W., 483 Nakagawara, A., 3642 Ng, J. C., 4484 Oberberg, D., 3498 O'Moore, P., 5775 Nakai, H., 6588 Ng, P-Y., 4313 Oberg, K., 1006 O'Neil, B. W., 6898 Nakai, M., 5395 Ng, T. C., 5299 Oberyszyn, A., 4227 O'Neill, C. F., 3857 Nakajima, T., 5368 Ng, Y-S., 6976 Oborn, C. J., 1924 O'Neill, P., 3558 Nakakuki, K., 5991 Nguyen, D., 1314 O'Boyle, K. P., 5663 Ong, A., 154 Nakakuma, H., 3201 Nguyen, K., 4130 Obrams, I., 5570s Ong, G. L., 835 Nakamoto, T., 571 Nicholls, J. E., 1411 O'Brien, K., 5516s Onisto, M., 4548 Nakamura, H., 4214 Nichols, P. H., 5765 O'Brien, P. J., 3015 Ono, T., 3201 Nakamura, M., 6501 Nichols, W. W., 3347 O'Brien, S., 4130 Ono, Y., 444 Nakamura, N., 1369 Nickols, J., 3547 O'Connor, B. M., 1137, 2148 Onoda, M., 5403 Nakamura, T., 3811 Nicola, N. A., 2012 O'Conor, G., 5570s Oosterhuis, J. W., 6705 Nakamura, Y., 643, 873, 1643, Nicotera, P., 1342 Oda, T., 1504, 3674, 6358 Ootaka, T., 4356 2419, 2478, 3231, 3914, 4055, Nicotra, M. R., 6139 Oda, Y., 3972 Orazem, J. P., 6619 5368, 5815, 6696 Nieborowska-Skorska, M., 4221 Odagiri, H., 3367 Orcutt, M. L., 1451 Nakanishi, T., 1309 Niedzwiecki, D., 3908 Odartchenko, N., 3705 Ordonez, J. V., 5100 Nakano, H., 2818 Niehans, G. A., 3768 O'Driscoll, K. R., 4514 Oreffo, V. I. C., 4724 Nakano, M., 400 Nielsen, L. L., 3733 O'Dwyer, P. J., 6746 Ornati, G., 5933 Nakano, O., 4335 Nierodzik, M. L. R., 3267 Oesch, F., 1801, 5622 Orntoft, T. F., 3739, 5030 Nakano, S., 6501 Nieuwint, A. W. M., 4361 Oettgen, H. F., 5663 Orr, A., 3125, 4478 Nakao, Y., 6961 Niho, Y., 3052, 6501 Ogasawara, H., 1542 Orr, F. W., 2202 Nakatsuru, S., 3231, 6696 Niimi, S., 328 Ogata, M., 5641 Orrenius, S., 1342 Nakaya, K., 4634 Niitani, H., 4890 Ogata, S., 4741,5971 Osaki, T., 3310 Nakayama, H., 295 Niitsu, Y., 5278, 6258 Ogawa, M., 4046, 4055 Osborn, R. C., 4413, 5732 Nakazato, H., 5647 Nikaido, T., 6676 Ogawa, O., 1881 Osborne, C. K., 3636 Nakazawa, S., 6083, 6598 Nisen, P. D., 2243 Ogiso, Y., 450 Osborne, M. P., 1477 Naldoni, C., 1791 Nishikata, J., 5744 Oguma, S., 2620 Osheroff, N., 2156 Nandi, S., 4413, 5732, 6531 Nishikawa, K., 4758 O'Hara, C., 2563 Oshimura, M., 3486 Nandkumar, S., 857 Nishimura, S., 1628, 1836, 3483 Ohgaki, H., 2987, 2995 Osinga, J., 1536 Nanus, D. M., 5775 Nishimura, Y., 2620 Ohi, H., 758 Ossowski, L., 6754 Nap, M., 2329 Nishino, H., 6583 Ohi, H., 3610 Osteaux, M., 6025 Narimatsu, H., 6153, 6158 Nishino, M., 5313 Ohki, M., 6945 Ostrow, R. S., 5872 Nasim, S., 2777 Nishio, K., 328 Ohkouchi, K., 4396 Ostrowski, L. E., 1144 Nason-Burchenal, K., 5317 Nishioka, T., 3972 Ohkura, H., 1205 Ottaviano, Y. L., 3418 Nass, C. C., 782 Nishisaki, H., 4335 Ohno, S., 4096 Ottenhoff-Kalff, A. E., 4773 N~issander, U. K., 646 Nishisho, I., 643 Ohno, T., 5178 Ottestad, L., 3234 Natale, A. M., 6036 Nishiwaki, S., 1875 Ohsaki, Y., 3534 Ouding, R. J., 4904 Natali, P. G., 6139 Nist6r, M., 3213 Ohsawa, N., 1187 Ouyang, H., 6815

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7010

Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1992 American Association for Cancer Research. AUTHOR INDEX TO VOLUME 52* llDvrebr S., 1510 Paull, K. D., 3029, 3892 Phillips, J. A., 437 Potter, J. D., 2694s Owada, M. K., 4232 Paulsen, J. E., 1218 Phillips, J. M., 1463 Potter, M., 5522s, 5572s Owens, J. K., 2389 Pavan, J. V., 1297 Phillips, K. K., 6487 Potter, P. M., 6052, 6404 Oyasu, R., 688, 1606, 5329 Pavelic, L., 2597 Phillips, P. C., 6168 Pottern, L. M., 5468s Ozzello, L., 4571 Pavelic, Z. P., 2597 Phillips, R. A., 654 Poulsen, H. S., 3089 Pavlik, E. J., 4106 Phillips, S. M., 2489 Poupon, M. F., 4872 P Paxton, J. W., 138 Pianezzola, E., 5933 Pour, P. M., 163 Paxton, R. J., 4175 Piao, C. Q., 6305 Poustis-Delpont, C., 3622 Padarathsingh, M., 6129 Payne, H. S., 319 Picchio, G. R., 2468, 4678, Poutanen, M., 290 Padbury, G. E., 4904 Peale, F. V., Jr., 1073 5552s Pouzet, M. T., 1096 Padfield, G., 2162 Pearce, N., 5496s Piccoli, R., 4582 Povoski, S. P., 6905 Pagliarini, P., 4348 Pearson, J. D., 3323 Pichiri-Coni, G., 2078s Powell, C. B., 866 Pai, L. H., 181, 3189, 4427 Pearson, J. W., 101 Pierceail, W. E., 3946 PoweU, D. E., 4106 Paik, C., 5144 Peat, N., 1954 Pierotti, M. A., 6079 Powell, D. M., 1182 Paine, M. L., 6603 Pederson, N. V., 3782 Pietersz, G. A., 132 Powers, R. H., 1699 Pajusola, K., 746, 5738 Pediaditakis, P., 2078s Pietrzkowski, Z., 6447 Powis, G., 2835 Palmer, L. A., 6612 Pedone, C. A., 674 Pigott, R., 2628 Poynard, T., 3901 Pan, B. C., I729 Peifley, K. A., 1040 Pikul, A., 45, 267 Pozzatti, R. O., 4942 Pan, J., 4269 Pekonen, F., 5204 Pilotti, S., 6079 Prade, M., 3901 Pandita, T. K., 4758 Pelicci, P. G., 3687 Pilz, A., 1536 Prahalada, S., 3347 Pandolfi, P. P., 3687 Pelin, K., 2610 Pinedo, H. M., 17, 1252, 2257, Prairie, M. D., 4904 Panella, T. J., 2456 Pelle, B., 3460 4922 Prasad, D. D. K., 5833 Pantazis, P., 3980 PeUing, J. C., 2035s Pinkel, D., 3474 Prasad, R., 3811 Paoletti, P., 4348 Peltom~iki, P., 4530 Pratt, C. I., 688 Paoletti, R., 4348 Pinkoski, M. J., 5244 Penning, L. C., 117 Pinkus, G. S., 6224 Prehn, R. T., 501 Papahadjopoulos, D., 5135, Preijers, F. W. M. B., 5921 6774 Penno, M. B., 2222 Pinkus, J. L., 6224 Penta, J. S., 521 Pinna, G., 4979 Preisler, H. D., 2597, 4090 Papanicolaou, V., 1006 Prenzoska, J., 2310 Papas, T. S., 791 Pepe, S., 2504 Pinski, J., 4545 Perantoni, A. O., 4747 Pinsky, C. M., 3005 Press, O. W., 89, 1916, 2907 Papotti, M., 1553 Pressman, B. C., 6385 Papp, L. M., 3521 Perera, F. P., 3558 Pipas, J. M., 5853 Perey, L., 2563, 6365 Pippin, C. G., 5818 Pressman, N. J., 271 ls Paquette, B., 5788 Prestigiacomo, L. J., 1278, 2984 Parchment, R. E., 4858 P6rez, J., 4885 Pirisi, L., 187 Perez, N., 701 Pir~el, M., 6853 Preston, G. A., 319 Pardee, A. B., 6966 Preston, R. J., 319 Pardridge, W. M., 138 Perez-Bacete, M. J., 5144 Pisters, P. W. T., 3845 Perez-Soler, R., 6341 Pitot, H. C., 955, 4837 Pretlow, T. P., 4291 Parham, D. M., 6431 Pr6vost, G., 843 Paris, E. M., 2603 Perl, A., 4391 Pittelkow, M. R., 3224 Perlaky, L., 428, 5681 Pizzolo, G., 5223 Prevost, V., 4328 Pariza, M. W., 1754 Prewett, M., 121 Park, C. H., 4458 Perotti, M., 1342 Pizzorno, G., 1660 Perrella, F. W., 3521 Plaisance, S., 5963 Price, B. D., 3814 Park, J-A., 1114 Primrose, J. N., 5765 Parker, C. J., 6539 Perri, P., 1222 Plato, C. C., 3323 Perri, R. T., 3768 Plattner, J., 4735 Principe, P., 2509 Parker, N. B., 1499 Prinsze, C., 117 Parker, P. J., 5604 Perry, R. R., 4608 Plowman, J., 3604 Persky, V. W., 578 Plunkett, W., 533, 897, 3819 Pritsos, C. A., 6936 Parker, R., 3558 Proffitt, R. T., 3255 Pertovaara, L., 5738 Pluta, L., 6113 Parkinson, A., 6797 Propst, F., 450 Peters, G. J., 4922 Poddig, J., 4735 Parkinson, D. R., 6561 Prosser, J., 5291 Peters, H. A., 6101 Parl, F. F., 77 Poddighe, P. J., 4929 Pruitt, B. T., 3871 Parmiani, G., 4499, 4853 Peters, L. J., 6348 Podor, T. J., 2202 Przetakiewicz, M., 154 Peters, W. H. M., 1886 Parry, R. L., 1182 Poels, L. G., 646 Pucci, S., 4221 Parsons, J. C., 2228 Peterse, H. L., 2344 Poindexter, E. C., 3687 Pugh, T. D., 280 Partanen, J., 746, 2004 Peterse, J. L., 5229 Poirier, L. A., 2071 s Purdon, D., 2191 Partanen, S., 5204 Petersen, E. S., 6263 Poirier, M. C., 149 Puri, R. K., 262, 3787 Pascale, R. M., 4979 Petersen, G., 4530 Pollack, S. B., 6279 Pyke, C., 1336 Pasquinelli, C., 2823 Petersen, I., 2987, 4277 Pomato, N., 2603 Pylkk~nen, L., 4530 Pass, H., 719 Peterson, C., 6244 Pommier, G. J., 3182 Pyysalo, H., 2279 Passaniti, A., 2222 Peterson, D., 5516s Pommier, Y., 1848, 1907, 3125, Pastan, I., 181, 3189, 4427, Peterson, K., 1780 4478 Q 4995, 5379 Peterson, L. A., 2698s Pomykala, H., 2523 Qi, C-F., 3467 Pasti, M., 623 Petit, J-M., 2797 Ponzoni, M., 931, 4960 Qin, W., 5604 Pastorino, U., 6079 Petruzzelli, S., 6248 Poore, C. M., 6692 Qin, Y., 6025 Patel, K., 835 Pettersson, O-A., 1587 Poplack, D. G., 521, 3503 Qiu, Z-H., 1377 Patel, K. V., 334, 1786 Pettijohn, D. E., 2923 Poppe, H., 646 Quak, J. J., 2569 Patel, U., 4824 Pettit, G. R., 548, 2143, 6270 Porcu, P., 6447 Quaranto, L., 2162 Pater, A., 4254 Petty, T. L., 2727s Porgador, A., 3679 Queen, C., 6761 Pater, M. M., 4254 Petzold, G. L., 4904, 5687 Portella, G., 4582 Quelch, K., 2310 Paterson, M. C., 3094 Pfenninger, O., 2923 Portengen, H., 1036, 1107, 5082 Quincoces, A. F., 5979 Patil, K., 2279 Pfister, S., 515 Porter, C. W., 2424, 4712 Quinlan, D. C., 4828 Pattengale, P. K., 4534 Pflug, B. R., 5403 Porter, J. B., 4591 Quintanilla, M., 680 Patterson, B. H., 2060s Phang, J. M., 6692 Portier, C. J., 3436 Paul, C., 3281 Philip, T., 3194, 3317 Posner, M. C., 6371 R Paules, R. S., 450 Phillips, A. W., 5412 Posner, M. R., 4027 Rabbitts, P. H., 1536 Pauley, R., 5183 Phillips, D. H., 1510 Pospiech, I., 6516 Raber, M. N., 1406

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7011

Rabinovitch, P. S., 2946 Remacle-Bonnet, M. M., 3182 Rokukawa, C., 4805 Sacks, P. G., 4706 Rachmilewitz, J., 3713 Remold, H. G., 3043, 3661 Roloff, B., 955 Sadamori, N., 1481 Rademaker, A., 5329 Renaud, C. A., 4069 Roman, S. D., 2236 Sadowski, R. M., 6482 Radinsky, R., 5808 Ren6e, N., 2899 Roman, V. A., 1018 Saeki, T., 3467 Radnell, M., 5794 Resau, J. H., 741, 3547, 6092, Roman-Roman, S., 4649 S:ienz, M. A., 4885 Radulovic, S., 2538 6525 Romeo, A., 4221 Safrit, J. T., 6630 Rady, P., 3804 Reubi, J-C., 6074 Romero, P., 6976 Sagae, S., 5815 Raffeld, M., 5447s Reuhl, K. R., 1162, 1943, 6657 Rondinone, C. M., 6860 Sager, R., 6966 Rafferty, J. A., 6052 Reuter, V., 2285, 5775 Ronk, M., 5647 Saijo, N., 328 Rago, R. P., 6953 Reuvekamp, P. T. W., 6705 Rookus, M. A., 2344 Saijo, Y., 5681 Rahman, A., 558 Revel, M., 3679 Roos, J. C., 2569 Saini, K. S., 1457 Rajalakshmi, S., 2078s, 5154 Reynolds, I. J., 709 Roper, M., 2103s Saito, H., 1643, 5815 Rajewsky, M. F., 5307, 6209 Reynolds, J. C., 2743s Rosado, M., 5244 Saito, H., 3506 Ralfkiaer, E., 1336 Reznikoff, C. A., 688, 1606, Rose, D. P., 5386 Saito, J., 5815 Ramaekers, F. C. S., 4929, 6182 1615, 1631, 3286 Roselli, M., 1222 Saito, S., 912 Ramakrishnan, S., 2248 Rhame, J. G., 1304 Rosen, P. P., 1477 Saito, S., 3310 Rambaldi, A., 2628 Rhee, J. G., 4620 Rosenberg, C. L., 5541s Saito, S., 5061 Ramirez, F., 6877 Rhim, J. S., 3478 Rosenberg, I. H., 5002 Saito, S., 5815 Ramsden, C. W., 5765 Riboni, R., 6690 Rosenberg, M. P., 450 Saito, T., 3099 Ramshaw, I. A., 2489 Ribrag, V., 3901, 6567 Rosenberg, S. A., 6561 Saitoh, A., 978 Randall, C., 3558 Rice, J. M., 1463, 4747 Rosenblum, M., 6871 Saji, F., 6823 Ranparia, D. J., 2349 Rich, S. S., 2694s Rosenblum, M. G., 4758 Sakaguchi, T., 6153 Ransom, D. T., 2523 Richard, C., 5979 Rosenstein, R., 4227 Sakaguchi, Y., 3306 Ransom, J. H., 3460 Richard, F., 3901 Roskelley, C. D., 4269 Sakai, H., 2346 Rao, D. N. R., 3015 Richards, J., 5627 Rosowsky, A., 2148 Sakamoto, C., 4335 Rao, M. S., 2977 Richards, R. I., 3094 Ross, D., 797, 4752 Sakamoto, G., 3914 Rao, P. M., 2078s Rideout, W. M., III, 4787 Ross, R. K., 254, 5510s Sakamoto, H., 3367 Rao, V. N., 5833 Rieber, M., 6397 Rossi, B., 3622 Sakamoto, M., 1504, 3674, 6358 Rapoport, S. I., 2191 Rieber, M. S., 6397 Rossi, E., 11 Sakamoto, T., 1643 Rappa, G., 2782 Riebow, J., 2835 Rossio, J. L., 2394, 3005 Sakamura, Y., 4396 Rasberry, U., 4608 Riethman, H. C., 2590 Roth, J. A., 2652s Sakata, K., 464 Raschell~, G., 4221 Rigas, B., 84, 3449 Rothschild, H., 2694s Sakiyama, S., 873 Raschko, J. W., 2408 Rigas, J. R., 6619 Roti Roti, J. L., 1101 Sakthivel, R., 5732 Rasheed, A., 1144 Rijksen, G., 4773 Roubos, E. W., 963 Sakuraba, H., 3965 Rasheed, S., 5482s Riley, C. L., 5482s Rougier, P., 3901 Sakurai, M., 1481 Raskind, W. H., 2946 Rimessi, P., 1297 Rouse, B. T., 6287 Sala, A., 2880 Rasmussen, R., 4735 Rinderle, S. J., 3035 Rowinsky, E. K., 2268 Salant, T., 3713 Rausch, G., 2984 Ring, D. B., 6832 Rowley, J. D., 2523, 2999, 4678 Saleh, M. N., 4342 Ravault, A., 3317 Ringer, D. P., 4779 Roy, A. K., 1176 Salomon, D. S., 3467 Ravech6, E. S., 437 Riou, J-F., 3125 Rozengurt, E., 2737s, 4554, Samid, D., 1988 Ray, J. M., 2353 Ripple, M., 5115 6031 Samuni, A., 1750 Ray, M., 108 Ritchie, A., 4554 Ruan, S., 5725 Sanada, 1., 1481 Raz, A., 4878 Ritchie, B., 6194 Rubin, E., 878 Sfinchez, L. M., 95 Rubin, H., 667, 1049 Recio, L., 6113 Rittenhouse, H. G., 4175 Sandeen, M. A., 3208 Rubin, J. T., 6561 Redding, T. W., 2538 Rittmann-Grauer, L. S., 1810 Sanders, V., 1810 Rubinstein, L. V., 3029 Reddy, B. S., 2402, 5635 Sanfilippo, B., 1553 Rius, C., 1245 Rugstad, H. E., 1218 Sanga, R., 3566 Reddy, E. S. P., 5833 Rivenson, A., 5635 Ruiter, D. J., 1291 Reddy, J. K., 2977 Rizza, E., 1974 Ruperto, J. F., 1477 Sano, K., 4214 Sano, T., 5061 Reddy, K. B., 3636 Ro, J. Y., 2707s Ruscetti, F. W., 4082 Sansone, E. B., 1463 Redlich, P. N., 5096 Roberts, C. T., Jr., 5100 Rusello, O., 2148 Reed, C. D., 4747 Roberts, J. D., 5065 Russell, C. H., 4342 Santella, R., 3558 Reed, E., 149, 3558 Roberts, J. J., 1710 Russell, G. B., 5198 Santodonato, L., 2880 Reed, J. C., 2802, 5407 Roberts, P., 4628 Russell, K. S., 6624 Santoni, A., 4499 Reese, M. R., 5235 Roberts, V., 6407 Russo, A., 1750 Santoro, E., 1222, 6139 Reeve, A. E., 3094, 6117 Roberts, W. G., 924 Russo, A., 4582 Sapienza, C., 1780 Reeves, M. E., 1546 Robertson, D. W., 4663 Russo, C. A., 4372 Sapino, A., 1553 Reeves, S. A., 6871 Robertson, J. T., 4550, 6716 Russo, J., 4791 Sarasin, A., 5213 Refsnes, M., 3598 Roccabianca, M., 3182 Rustum, Y., 2549 Sargent, L. M., 955 Regan, J., 5656 Rodeck, U., 121 Rustum, Y. M., 4561, 5900 Sarid, J. A., 1018 Regenass, U., 4712, 5353 Rodenhuis, S., 2665s Ryberg, D., 218 Sarin, V., 5647 Reichelt, K. L., 1218 Rodriguez, E., 2285 Rydberg, B., 1377 Saris, S. C., 4672 Reichlin, S., 2545 Roe, C. R., 5590 Ryde, C. M., 1411 Sarma, D. S. R., 2078s Reid, B. J., 2946, 6525 Roelofs, H. M. J., 1886 Rygaard, K., 3089 Sarosdy, M. F., 4663 Reid, J. M., 2830 Roesel, J. L., 4492 Sartorelli, A. C., 949, 2782, Reid, T. M., 1082 3063 Roffler, S. R., 4484 S Reiners, J. J., Jr., 3432 Rofstad, E. K., 584, 1764, 4453 Sasagawa, T., 4420 Reisfeld, R. A., 3838 Rogers, B., 6746 Saarloos, M. N., 6452 Sasaki, H., 1393, 3372 Reiss, K., 4522 Rogers, M. P., 2456 Sabbath, M., 5244 Sasaki, H., 6258 Reiter, M. J., 3528 Rogler, C. E., 2549 Sabbioni, S., 1297 Sasaki, M. S., 2419, 6194 Remack, J. S., 6404 Rojas, M., 6248 Sacchi, M., 5963 Sasazuki, T., 2903, 4055 Remacle, A. G., 5845 Rojiani, M., 4269 Sacks, N. P. M., 4261 Sata, T., 4987

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7012

Satitpunwaycha, P., 209 Schuman, L., 2447, 5501s Sharma, R., 5154 Sikic, B. I., 4379 Sato, H., 1205 Schuschke, D. A., 3425 Sharp, R., 5171 Sikora, K., 1592 Sato, J., 5144 Schut, H. A. J., 2099s Shea, L. C. C., 108 Siler, K., 1067 Sato, K., 444 Schuuring, E., 5229 Sheikh, A., 2078s Silva, J. M., 3015 Sato, T., 1643, 3914 Schwab, G., 1721 Sheikh, M. S., 5100 Silverberg, S. G., 2777 Satoh, T., 444 Schwartsmann, G., 2894 Shellard, S. A., 3110 Silverman, D. T., 254 Satomi, Y., 6583 Schwarz, L. R., 1149 Shelton, B., 2984 Silvers, K. J., 6237 Sattler, C. A., 955 Schwarz, M., 3220, 6400 Shen, N. H., 2103s, 4682 Silvers, W., 2727s Sattler, G. L., 955 Schweinfest, C. W., 791 Sheng, K., 1754 Siiverstein, R. J., 6525 Saunders, G. F., 6117 Schweitzer, B. I., 3908 Shepard, M., 1916 Simile, M. M., 4979 Sausville, E. A., 3340 Schweizer, J., 6400 Sherman, L. T., 1988 Simms, P. E., 6318 Sauter, S. L., 5647 Scinicariello, F., 3804 Sherman, M., 173 Simon, K., 1695 Savaraj, N., 6385 Scorsone, K. A., 1635 Sherritt, K. M., 2727s Simon, M-T., 5089 Saxena, A., 4550, 6716 Scow, R. O., 4113 Sherwood, E. R., 5887 Simon-Cereijido, G., 3558 Saxton, R. E., 1681 Scrable, H., 983 Sheu, J-C., 6098 Simonis, T. B., 6561 Scagliotti, G., 4548 Scudiero, D. A., 3029 Shewach, D. S., 2389 Simons, J. W. I. M., 2253 Scalmati, A., 5906 Scully, P., 1968 Shi, T., 6832 Simony-Lafontaine, J., 3918 Scanlon, K. J., 3110 Searle, J., 285 Shibata, D., 5482s Simpson, R. U., 2413 Scarpa, A., 3674, 6358 Sebti, S. M., 709, 2931 Shibata, H. R., 6254 Simpson, S., 456 Scarpelli, D. G., 4507 Seddaiu, M. A., 4979 Shibusawa, M., 696 Simpson-Morgan, M. W., 5400 Scavarda, N. J., 1364 Seddon, M. B., 2610 Shibuya, T., 3052 Sims, D. E., 3425 Schaafsma, H. E., 5104, 6182 Sedgwick, B., 3693 Shields, P. G., 6712 Sinclair, J. F., 3615 Schacter, L. P., 1406 Sedmak, J. J., 5096 Shifrin, S. D., 1721 Sinclair, P. R., 3615 Schaefer, C., 2167 Sedman, P. C., 5765 Shigedo, Y., 3310 Singer, B., 1377 Schaeffer, B. K., 3615 Sedwick, W. D., 4688 Shigemoto, R., 3972 Singh, A. B., 1840 Schaid, D. J., 1974 Seed, T. M., 1469 Shih, L. B., 835 Singh, M., 1840 Schalken, J. A., 2916, 5104, Seega, J., 2167 Shih, L-N., 6098 Singh, S. V., 6666 6182 Seegers, J. C., 5926 Shillitoe, E. J., 4706 Singhal, A. K., 3739 Schally, A. V., 2538, 4545, 6025 Seewald, M. J., 2835 Shimada, H., 701 Sing-Shang, N., 3449 Schauweker, T. H., 2482 Seguin, P., 2329 Shimada, T., 1868 Sinu6s, B., 4885 Schechter, B., 4448 Sehested, M., 2874 Shimakura, S., 1744 Sirivongs, D., 1573 Schechter, G. L., 5997 Seidman, M. M., 5668 Shimazu, H., 3655 Sisk, S., 6113 Scheffer, H., 6705 Seigler, H. F., 394 Shimizu, K., 6945 Sistonen, P., 4530 Scheinberg, D. A., 6761 Seino, Y., 3972 Shimoda, K., 3052 Sivon, S. S., 6348 Scheper, R. J., 2440 Seizinger, B. R., 2987, 4277 Shimotohno, K., 3367 Siwarski, D., 1032, 4273 Scher, H. I., 64, 5775 Seki, M., 3965 Shimotsuma, M., 5400 Skerker, J. M., 5190 Scherr, P. A., 5503s Sekiya, M., 737 Shimoyama, M., 1481 Skibba, J. L., 1699 Scheuplein, R. J., 2124s Sekiya, T., 4799 Shimoyama, Y., 5770 Skierski, J. S., 470 Schiff, P. B., 3495 Sela, M., 2580 Shindo-Okada, N., 1628 Skolnick, M., 1643 Schilder, R., 6746 Selhub, J., 5002 Shinkai, K., 1422, 5313 Skopek, T. R., 2008, 2866, 3851, Schirmacher, P., 2549 Seligy, V. L., 3718 Shinohara, H., 3610 4328, 6984 Schlageter, K. E., 5590 Sell, C., 4522 Shinozaki, M., 912 Skorski, T., 4221 Schlichtholz, B., 6380 Sellberg, G., 2991 Shipley, G. D., 3224 Skretting, A., 584 Schlom, J., 1067, 1222, 3402, Sellers, T. A., 2694s Shirai, T., 1675 Slaga, T. J., 662, 2049s, 3432 6413, 6917 Semenzato, G., 5223 Shiraishi, M., 4799 Slagle, B. L., 1635 Schmidt, S., 4735 Sen, A., 533 Shiraishi, T., 5991 Slamon, D., 1916 Schmitt, M., 6101 Seng, B. A., 815 Shiraishi, Y., 1481 Slebos, R. J. C., 2665s Schmitz, S., 6638 Sensi, A., 1297 Shiraiwa, K., 5042 Slovak, M., 5482s Schnaper, L., 5100 Senter, P. D., 5759 Shively, J. E., 4175, 5647 Sluiter, W. J., 3552, 6885 Schneemann, M., 3760 Serrero, G., 4242 Shizume, K., 444 Smals, O. A. G., 1252 Schneid, H., 6516 Setanoians, A., 2894 Shockley, T. R., 357, 367, 377 Smart, R. C., 631 Schneider, E., 6175 Sethi, T., 2737s, 4554, 6031 Shoemaker, R. H., 2791, 3029 Smeets, A. W. G. B., 4929 Schneider, J. F., 5872 Seto, K., 3655 Shofer, F. S., 5391 Smeland, E. B., 5007 Schneider, M., 2899 Seto, M., 6083 Shroba, S., 5948 Smets L. A., 6209 Schneider, P., 4712 Seyama, T., 1369 Shu, S., 1129 Smid K., 4922 Schneider, T., 3713 Sezaki, H., 4396 Shu, X. O., 3865 Smith D., 5002 Schneider-Schaulies, J., 2384 Shaar, C. J., 4663 Shudo, N., 3655 Smith D. C., 2456 Schoenberg, J. B., 254 Shack, S., 1988 Shuin, T., 2346 Smith E. L., 3615 Schold, S. C., 2456 Shafii, B., 5752 Shuke, N., 2743s Smith G. J., 2349, 3807 Schonfeld, S., 1372 Shah, S. A., 127 Shuker, D. E. G., 4328 Smith G. K., 4895 Schott, M. E., 6413 Shao, J., 2384 Shung, B., 6522 Smith H. S., 3474 Schrappe, M., 121, 3838 Shao, Z-M., 3938, 5198 Siddik, Z. H., 4096, 5271 Smith I., 4261 Schreiber, E., 6121 Shao, Z-M., 5100 Sidky, Y. A., 3528 Smith J., 5359 Schreiber, G. J., 3262 Shapiro, D. N., 6431 Sidoti, C., 2509 Smith J. A., 593 Schrey, M. P., 334, 1786 Shapiro, H., 6956 Sidransky, D., 2984 Smith J. W., II, 2394, 3005 Schreyer, M., 2329 Shapiro, R. S., 5465s Siegall, C. B., 4995 Smith K. M., 1235 Schroeder, J. K., 3498 Sharfman, W., 2394 Siegel, D., 4752 Smith K. S., 5687 Schiiller, H. M., 2723s, 3273 Sharief, Y., 2349 Siegel, J. A., 6036 Smith K. T., 6898 Schultz, R. M., 6682 Sharkey, R. M., 6036 Siegfried, J. M., 2702s Smith P.J., 3094 Schulz, N., 450 Sharma, P. K., 3035 Siemann, D. W., 3515 Smith P. J., 4000 Schulz, S., 1372 Sharma, P. M., 6407 Sikes, R. A., 3174 Smith, Q. R., 2191

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7013

Smith, R. A., 3577 Stearns, M. E., 3776 Siihnel, J., 4560 Takamizawa, H., 1205 Smith, S. H., 3746 Steel, C. M., 5291 Suit, H. D., 6292 Takao, S., 3655 Smith, T. J., 1757 Steele, C., 4706 Sukumar, S., 6407 Takatsuki, K., 464, 2620, 3201 Smith, T. J., 2545 Steele, G. D., Jr., 1775, 3067 Sullivan-Halley, J., 5482s Takayama, S., 1628 Smith, T. L., 4587 Steele, V. E., 1651 Summerhayes, I. C., 1457 Takayasu, J., 6583 Smithson, G., 4149 Steen, H. B., 5007 Summers, C. L., 4828 Takebe, H., 6522 Smith-Sorensen, B., 3234 Steerenberg, P. A., 646 Sun, Q., 4254 Takeichi, M., 2916, 5770 Smolders, I. J. H., 6653 Stefanini, M., 6690 Sun, W. H., 5412 Takekawa, M., 737 Smyth, J., 2737s, 4554 Stehlin, J. S., Jr., 3980 Sun, Y., 1907 Takeshita, K., 1875 Smythe, A. M., 2791, 3029 Steis, R. G., 2394, 3005 Sunday, M. E., 2677s Takeya, M., 464 Snook, D., 904 Stemhagen, A., 254 Sundseth, S. S., 540, 5797 Taki, T., 1875, 4805 Snow, G. B., 2569 Stenman, U-H., 4628 Sung, C., 357, 377 Taki, T., 2292 Snoy, P., 6917 Stephens, L. C., 4096 Sung, C., 3924 Takita, K-i., 1643, 3914 Snyder, L., 4678 Stern, P. L., 4009 Sures, I., 6139 Takiuchi, H., 5641 Snyderwine, E. G., 2099s, 4183 Stessman, C., 2279 Surmaez, E., 4522 Talamini, R., 3589 Sobel, M. E., 1561, 2966 Stetler-Stevenson, M., 5447s Sussenbach, J. S., 6516 Talpaz, M., 1087 Sobrero, A., 1855 Stetler-Stevenson, W. G., 2353, Susskind, B. M., 1386 Tamaki, T., 566 S6derkvist, P., 2624 4942, 4548, 5845, 6020 Sutherland, R. L., 2236 Tammilehto, L., 2610 Soderquist, A. M., 4526 Stetson, P. L., 3698 Sutter, A., 121 Tamura, K., 5042 Sokoloski, J. A., 949 Steuer, M., 1123 Sutter, C., 6400 Tan, K. B., 231 Solares, G. R., 4672 Steven, K., 726 Suyama, M., 734 Tanaka, H., 1675 Soma, M. R., 4348 Stewart, B. C., 4144 Suzaki, A., 3011 Tanaka, H., 5178 Somers, K. D., 5997 Stewart, P. A., 5501s Suzuki, H., 734 Tanaka, J., 416, 803 Somlo, G., 2408 Stewart, W., 301 Suzuki, M., 912 Tanaka, K., 3801, 3965 Somlyo, A. P., 5391 Stinson, S. F., 3029 Suzuki, T., 4335 Tanaka, M., 3372 Sommers, C. L., 5190 Stitz, R., 285 Swaminathan, S., 1606, 1615, Tanaka, O., 5744 Somogyi, A., 2124s St. John, M., 3577 3286 Tanaka, S., 2802 Song, S. U., 2771 Stokke, T., 5007 Swanson, C. A., 3865 Tanaka, T., 3052 Soper, J. T., 1622 Stoler, D. L., 4372 Swanson, S. M., 5732 Tanda, S., 912 Sordat, B., 3705 Stoler, M. H., 1561 Sweatman, T. W., 3409 Tandon, A. K., 3636 Soula, G., 3629 Stolfi, R. L., 4074 Swenberg, J. A., 2008, 2866, Tang, D., 3558 Soussi, T., 6380 Stoner, G. D., 1757, 3547 3851, 4320, 4328, 6984 Tang, F-M., 6848 Sozzi, G., 6079 Stoof, J. C., 3994 Swensen, J., 1643 Taniguchi, T., 6961 Spampinato, G., 1891 Stoopen, G. M., 1291 Swerdlow, P. S., 6270 Tanio, Y., 3310 Spang-Thomsen, M., 3089 Storer, B. E., 5610 Swerdlow, S. H., 5541s Taniwaki, M., 2590 Spears, C. P., 108 Storer, R. D., 3347 Swiderski, C., 5250 Tanizawa, A., 1848 Speder, A., 71 Storkson, J., 1754 Sykes, H. R., 4000 Tanizawa, O., 4420, 5323, 6823 Speeg, K. V., Jr., 3539 Storm, G., 646 Szakal, A. K., 5554s Tannock, I. F., 4441 Speicher, L. A., 4433 Stranahan, P. L., 2923 Szepeshazi, K., 2538 Tansey, W. P., 2489 Speicher, M. R., 2590 Strand, M., 5818 Sznol, M., 2394 Tanzer, L. R., 4663 Spiegel, A. M., 6804 Strassburg, C. P., 815 Sz6116si, J., 6782 Tapiero, H., 6385 Spina, A. M., 4372 Strauss, B. S., 249 Tapscott, S. J., 6431 Spinardi, L., 3918 Strebel, F. R., 4096 T Tarin, D., 1737, 2174 Spinowitz, A., 4227 Streeper, R. T., 1416 Taehibana, I., 3310 Tashiro, K., 3739 Spoettl, G., 1520 Strickland, J. E., 1439 Tada, T., 5641 Tatro, J. B., 2545 Sporn, L. A., 3443 Strickland, P. T., 6400 Taddei, F., 1342 Tatsuka, M., 4232 Sporn, M. B., 4261 Stromberg, K., 341, 3467 Taddei-Peters, W. C., 2603 Tatsumoto, T., 6501 Sprague, M., 1750 Strong, L. C., 6117 Tagawa, M., 24 Taub, R. N., 5244 Spruck, C. H., III, 4787 Stroud, M. R., 3739 Taghian, A., 6292 Tauchi, T., 6598 Squire, R. A., 5818 Studzinski, G. P., 3384 Tagliafieo, E., 11 Tavitian, A., 3083 Sreenath, T., 4942 Stukel, T. A., 6949 Tagra, K. K., 6768 Taylor, D. D., 829 Sridhara, R., 6525 Stulp, R. P., 6705 Tahara, E., 295, 3467 Taylor, J. M., 2413 Srinivasan, S., 4106 Suardet, L., 3705 Taira, M., 6671 Taylor, S. M., 701 Srivastava, B. I. S., 4391 Subar, A. F., 2060s Takada, N., 2419 Taylor-Papadimitriou, J., 1954 Srivastava, S., 4121 Subbarao, V., 2977 Takada, Y., 2191 Teicher, B. A., 6702 Staal, G. E. J., 4773 Suda, T., 444 Takagi, H., 5171 Telang, N. T., 1477 Stadlbauer, T. H. W., 108, 797 Suda, T., 4017 Takahashi, H., 121 Telzerow, P. E., 3094 Stadnicka, A., 1699 Sudaka, P., 3622 Takahashi, H., 5178 Temponi, M., 2497 Stahel, R. A., 5264, 6121 Sugano, H., 2478, 2575 Takahashi, M., 154 Tennant, B. C., 4139 Stahlman, M. T., 5342 Sugarbaker, D. J., 6224 Takahashi, M., 1542, 2995 Tennenbaum, T., 2966 Stambrook, P. J., 983 Sugawara, I., 4408 Takahashi, N., 444 Tepper, C. G., 3384 Stampfer, M. R., 3924 Sugg, N. K., 5198 Takahashi, R., 6297 Terada, M., 1393, 1695, 3099, Stanbridge, E. J., 616, 1297, Sugimachi, K., 775, 2903, 3306 Takahashi, R-i., 978 3367, 3372, 4837 6297, 6956 Sugimoto, Y., 328 Takahashi, T., 734, 2340, 3506, Terao, T., 3610 Stancovski, I., 2580 Sugimura, H., 6712 4168 Terashima, Y., 328, 1205 Stanek, J., 4712 Sugimura, M., 3610 Takahashi, T., 734, 2340, 3506, Testa, J. E., 5597 Staniunas, R. J., 3067 Sugimura, T., 1393, 2092s, 6083 Testa, J. R., 1322, 2702s Stanley, J. S., 58 2124s, 3099, 3367, 3372, 4837 Takahashi, T., 1948 Testard, P., 3629 Stapleton, G. E., 515 Sugio, K., 2903 Takahashi, T., 5400, 6323 T6tu, B., 2325 Staroselsky, A. N., 5808 Sugita, K., 168 Takakura, Y., 4396 Teule, G. J. J., 2569 Starzec, A., 843 Sugiyama, T., 1881 Takamatsu, K., 416, 803 Tew, J. G., 5554s

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7014

Tew, K. D., 4433 Tory, K., 1451 Tu, S-M., 6940 Vande Woude, G., 450 Tezapsidis, N., 1786 Tosi, P., 4069 Tullous, M. W., 674 van Dongen, G. A. M. S., 2569 Thacker, J. D., 3931 Toth, B., 2279 Tung, E., 4484 van Dun, J., 2841 Thaete, L. G., 6797 Toth, C. A., 1775 Tuo, X-H., 5744 Van Ginckel, R. F., 1240 Thampoe, I. J., 4948 Totpal, K., 2557 Turner, A. J., 6270 Vang Nielsen, K., 1210 Than, T. T., 6168 Toupadaki, N., 5364 Turner, M. J., Jr., 4320 Van Horn, L. V., 578 Thangavelu, M., 4678 Tourani, J-M., 3317 Turteltaub, K. W., 2103s, 4682 van Leeuwen, F. E., 2344 Theillet, C., 3918 Toy, B. J., 71 Tuttle, T. M., 548 van Lingen, A., 2569 Thibodeau, S. N., 1974 Toyama, K., 6598 Twentyman, P. R., 5674 Van Meir, E., 4297 Thiel, E., 3498 Traganos, F., 470, 1530, 6200 Twiggs, L., 2248 van Moorselaar, R. J. A., 2916 Thiele, C. J., 4402 Trahan, E., 348 Tyler, G., 1278 van Muijen, G. N. P., 1291 Thierau, D., 1149 Trail, P. A., 5693 Tyler, R. D., 3733 van Nagell, J. R., Jr., 4106 Thomas, F., 843, 4872 Traver, R. D., 797 Tyring, S. K., 3804 Vannais, D., 6305 Thomas, P., 1775 Travis, E. L., 1096 Tzehoval, E., 3679 van Oosterhout, Y. V. J. M., Thomas, T., 1840 Traxler, P., 4492 Tzonou, A., 5364 5921 Thomas, T. J., 1840 Traylor, R. S., 6270 van Osdol, W., 2747s, 5144 Thompson, A. D., 3094 Tremblay, G., 4613 U van Putten, W. L. J., 1107, 6101 Thompson, E. W., 4540, 5190 Tremblay, R., 6329 U, H. S., 1933, 1938 van Staveren, I. L., 1036, 1107 Thompson, W. C., 262 Trentin, L., 5223 Ubukata, K., 758 VanSteveninck, J., 117 Thordarson, G., 4413 Trepel, J., 4306 Uchida, K., 5178 van Tinteren, H., 5229 Thoresen, G. H., 3598 Treskes, M., 2257 Uchida, T., 4335 van Vugt, M. J. H., 1252 Thorgeirsson, S. S., 1044, 1796, Treurniet, H. F., 2344 Uchino, S., 3099 van Zwieten, M. J., 3347 2099s Tribby, I. I., 5853 Uckun, F. M., 406 Varma, M., 2482 Thorgeirsson, U. P., 2099s Trichopoulos, D., 5364 Ueda, M., 1439 Varma, R. S., 2482 Thorlacius, S., 3234 Tridente, G., 623 Ueda, R., 734, 2340, 3506, 6083 Vaupel, P., 2167 Thorpe, P. E., 5954 Triebel, F., 4649 Uehara, H., 5971 Veber, N., 843 Thorson, J. A., 4144 Trinchieri, G., 2530 Uejima, T., 6153, 6158 Vecchio, G., 4582 Thraves, P., 3478 Trinks, U. P., 4492 Uemura, M., 6153, 6158 Vedantham, S., 1056 Thunnissen, F. B. J. M., 5229 Trippett, T. M., 1434 Ullman, B., 2389 Veigl, M. L., 4688 Thurman, R. G., 1639 Tritscher, A. M., 3436 Ullrich, A., 2580, 6139 Venkatesan, P., 2907 Thurneyssen, O., 1352 Tritton, T. R., 4135 Umbas, R., 5104 Vente, P., 2603 Thybaud, V., 5213 Troalen, F., 3901 Umeda, M., 5046 Venzon, D., 1750, 6561 Thyss, A., 2899 Troll, W., 4969 Umemiya-Okada, T., 6961 Verhagen, A. P. M., 6182 Tidefelt, U., 3281 Troncoso, P., 6940 Uneyama, C., 1542 Verhoeven, E., 5229 Tilups, A., 3131 Troonen, H., 5364 Upadhya, P., 515 Vermorken, J. B., 963 Timmer-Bosscha, H., 6885 Troost, D., 1568 Upadhyaya, P., 1176, 2402, Vernier, F., 6353 Timpane, R., 1201 Troutman-Worden, K., 1087 5635 Vernier, P., 5089 Tindall, D. J., 1525 Trowsdale, J., 5416 Upton, P. B., 4328 Verrijk, R., 6653 Tishler, R. B., 3495 Trucco, M., 5913 Urba, W. J., 2394, 3005 Versantvoort, C. H. M., 17 Titus-Ernstoff, L., 851 Trudel, L. J., 267 Urist, M., 4342 Verschueren, R. C. J., 3552 Tj~ilve, H., 1267 Trujillo, J., 4587 Ursin, G., 2060s Verstovsek, S., 3880 Tobinai, K., 3367 Trump, B. F., 6092, 6712 Utsugi, T., 1155 Vertino, P., 4712 Tobler, A., 6121 Trump, D. L., 2456 Utsunomiya, J., 643, 4055 Vervaert, C. E., 394 Tochner, Z., 1750 Tryggvason, K., 1336 Vial, C., 4935 Tockman, M. S., 271 Is, 2766s Tsai, S. J., 2209 V Viallet, J., 3340 Todderud, G., 4526 Tsai, W-Y., 3558 Vachula, E. J., 4175 Vichi, P., 4135 Toft, D. O., 3648 Tsai, Y. C., 4787 Vadai, E., 3679 Vick, J., 3566 Toguchida, J., 2419, 6194, 6588 Tsao, S-W., 5119 Vainikka, S., 2004 Viel, S., 4649 Tohma, Y., 1981 Tsao, Y-P., 1823 Vainio, H., 2357 Vigneri, R., 3924 Toi, M., 275 Tsioulias, G., 3449 Valdez, B. C., 428, 5681 Vihko, P., 6110 Tokino, T., 2984 Tsokos, M., 2243 Valentino, L. A., 810 Vihko, R., 290 Tokuda, H., 6583 Tsongalis, G. J., 3807 Valenzuela, R., 5299 Vijayakumar, S., 5299 Tokudome, S., 2620 Tsonis, P. A., 4858 Valeriote, F. A., 1515 Villaret, D. B., 983 Tolcsvai, L., 4973 Tsuehiya, E., 873, 2478, 5368, Vallera, D. A., 1314 Visek, W. J., 857, 2082s Tolley, R., 24 6696 Vamps, E., 6646 Vishwanatha, J. K., 163 Tomasovic, S. P., 4096, 5271 Tsuchiya, S., 2478 van Agthoven, T., 5082 Visser, G. W. M., 2569 Tomatis, L., 2357 Tsuda, H., 1504, 3099, 3674, van Agthoven, T. L. A., 5082 Vistica, D. T., 2191 Tomita, J. T., 4175 5368, 6358 van Beurden, E. A. C. M., 4773 Vitols, S., 6244 Tomita, N., 2980, 6840 Tsuji, N., 5278, 6258 Van Beusichem, M., 5065 Vizoso, F., 95 Tompkins, R. G., 357, 367 Tsuji, Y., 5278, 6258 Van Cauteren, M., 6025 Vlodavsky, I., 5656 Tone, T., 3110 Tsukamoto, T., 3506 Vandamme, B., 6646 Voeller, D., 6860 Tong, J., 3796 Tsukazaki, K., 803, 1205 van den Berg, A., 1536 Vogel, J. S., 4682 Tong, W. P., 64, 1434, 3908, Tsukita, S., 5770 van den Brekel, M. W. M., 2569 Vogelstein, B., 643, 1780, 2984, 5775, 6619 Tsumuraya, M., 4042 van der Eb, A. J., 53 4530 Tong, Y., 741, 6525 Tsunoda, A., 696 van der Jagt, R. H. C., 89 Vogelzang, N. J., 1573 Too, C. K. L., 2186 Tsunoda, Y., 696 van der Veen, A. Y., 1536 Vokes, E., 4832 Torelli, G., 11 Tsurumi, H., 6323 Van Der Ven, L. T. M., 6516 Volk, T., 6209 Torelli, U., l 1 Tsuruo, T., 3768 van der Vijgh, W. J. F., 2257 Volkenandt, M., 108 Torri, J. A., 5190 Tsuruta, K., 5368 van der Vlist, M., 1252 Vollmer, G., 4642 Torta, M., 1791 Tsutsumi, K., 4254 Van der Wilt, C. L., 4922 von Ammon, K., 2987, 4277 Tortora, G., 2504 Tsuyama, N., 1369 van de Vijver, M. J., 5229 Voncken, J. W., 4534

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7015

Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1992 American Association for Cancer Research. AUTHOR INDEX TO VOLUME 52* von Deimling, A., 2987, 3760, Watanabe, N., 5278, 6258 Wickstrom, E., 6741 Wu, L., 2791, 3029 4277 Watanabe, Y., 5954 Wickstrom, E. L., 6741 Wu, N. Z., 4265 yon der Maase, H., 726 Watatani, M., 3914 Wiegand, R. A., 1660 Wu, R-T., 4696 yon Eschenbach, A. C., 1155, Watkins, J. B., III, 1149 Wiegant, J., 4361 Wu, S., 6279 1598 Watson, T., 2394 Wiehle, S. A., 4914 Wu, S-Q., 688, 1631 Vonk, R. J., 3552 Wattenberg, L. W., 2085s Wieman, T. J., 4914 Wu, Z., 32, 1804 von Kleist, S., 2329 Waud, W., 3604 Wiener, J. S., 5018 Wyllie, F. S., 2938 yon Marschall, Z., 3498 Waxman, D. J., 540, 5797 Wiestler, O. D., 2987, 3760, Wynder, E. L., 5386 yon Wronski, M. A., 1144 Ways, D. K., 5604 4277 Wynford-Thomas, D., 2938 Vooijs, G. P., 4929 Wazer, D. E., 4672 Wike, J. L., 6348 Vos, H. L., 2318 Weber, E., 5264 Wikenheiser, K. A., 5342 X Votaw, M. L., 3871 Weber, G., 258 Wikstrand, C. J., 1144 Xiao, L., 5359 Weber, G. F., 540 Wiibourn, J., 2357 Xing, P-x., 2310 W Weckbecker, G., 4973 Wilchek, M., 4448 Xu, B. H., 6666 Weeks, C. E., 3528 Wilding, G., 5115, 6953 Xu, H-J., 4587, 6297 Wada, C., 307 Wei, H., 2298 Wilke, A. V., 4965 Wada, K., 4335 Xu, Y., 3875 Wei, W-Z., 5183 Wilkins, T. D., 5096 Xu, Y-h., 955 Wada, S., 787 Weich, H. A., 4821 Wilkinson, D. S., 1304 Xu, Y-Z., 533 Wagener, C., 2329 Weichselbaum, R. R., 878, 1445, Will, C. L., 558 Wagner, B. A., 6045 1451, 4832, 5299, 6194 Willems, G., 6025 Y Wagner, H. E., 1775 Willett, C. G., 2677s Weidman, D., 2603 Yachi, A., 737 Wagner, R. F., Jr., 3804 Weidmann, E., 5913, 5963 Williams, B. R. G., 6125 Wahl, R. L., 637, 6476 Yaginuma, Y., 4196 Weinberg, A. G., 6708 Williams, L. J., Jr., 3980 Yagita, H., 4890 Waibel, R., 5264 Weinel, R. J., 2616 Williams, M. E., 5541s Wainfan, E., 2071s Yagura, H., 566 Weiner, L. M., 5713 Williams, P. J., 5395 Wakabayashi, K., 2092s Yaich, L., 77 Weiner, M. W., 71 Willingham, M. C., 181, 3189 Wakefield, L. M., 4261 Yajima, M., 1205 Weinstein, I. B., 2980, 4514, Willner, D., 5693 Yamada, H., 4408 Walczak, J., 6746 Wilson, C. B. J. H., 1592 Waldman, F. M., 3474 6840 Yamada, K., 3655 Wilson, D. F., 3988 Waldren, C. A., 3615, 6305 Weinstein, J. N., 2747s, 5144 Yamada, Y., 1393 Wilson, L., 1750 Walker, C., 301, 6113 Weisberg, H. Z., 5808 Yamada, Y., 2966 Walker, T., 3718 Weisenburger, D. D., 5456s Wilson, P., 2894 Yamaguchi, K., 2620 Walker, V. E., 4320, 4328 Weiss, L., 5482s Wilson, W. R., 138 Yamaguchi, K., 3011 Wallace, H. J., 6270 Weiss, S. W., 3746 Wiltrout, R. H., 4082 Yamaguchi, S., 787 Wallace, P. M., 5759 Weissman, B. E., 6487 Winchell, L. F., 422 Yamaguchi, T., 2419, 6194 Wallace, T. L., 4904 Weitman, S. D., 3396, 6708 Winegar, R. A., 5126 Yamaguchi, T., 6323 Walsh, P. C., 3323 Welch, W. J., 3648 Winer, E. P., 2456 Yamakawa, K., 873 Walsh, T., 2743s Wells, R. J., 521 Wing, K. R., 3572 Yamakawa, Y., 444 Walther, P. J., 5018 Wells, S. A., 770 Winick, N. J., 2243 Yamamori, S., 1187 Walz, A., 4297 Weis, W., 6310 Winkles, J. A., 1040 Yamamoto, A., 1675 Wands, J., 3901 Welsch, C. W., 2040s Winograd, B., 5940 Yamamoto, K., 6083 Waneck, G. L., 4036 Welsh, J. A., 2610, 6092 Winter, B. K., 6279 Yamamoto, M., 5329 Wang, B., 4102 Welt, S., 5663 Winter, S. F., 4168 Yamamoto, M., 6676 Wang, H., 5183 Welty, D., 3145 Wirth, P. J., 1044 Yamamoto, T., 3972 Wang, J., 4473 Wen, P., 1018 Wiseman, R. W., 2624 Yamamuro, T., 2419, 6194 Wang, J. C., 4467 Wen, Z., 2545 Witiak, D. T., 3035 Yamanishi, D. T., 5024 Wang, J-T., 6098 Weng, S-Y., 2478 Wogan, G. N., 45, 267, 2114s Yamaoka, N., 6323 Wang, L., 4824 Wernicke, D., 6447 Wolcott, R. M., 4149 Yamashima, T., 1981 Wang, M., 3776 Wessels, H. M. C., 5921 Wolf, C. R., 4379 Yamashita, J., 1981 Wang, S-M., 4484 West, S., 3048 Wolf, H., 5030 Yamashita, J-i., 4046 Wang, T-H., 6098 Westermark, B., 3213 Wolf, R. F., 3845 Yamashita, S-i., 4046 Wang, Y., 508 Westerveld, A., 1568 Wolff, L., 1032, 5317 Yamashita, Y., 2818 Wang, Y., 3131 Weston, A., 1499, 6712 Wolmark, N., 6371 Yamauchi, N., 5278, 6258 Wang, Y-Y., 5391 Westphal, H., 4196 Wolthers, B. G., 3552 Yan, L., 5803 Wang, Z., 4766 Weterman, M. A. J., 129 l Wolverton, J. S., 4248 Yanagihara, K., 4042 Wang, Z. Y., 1162, 1943, 6657 Wetterhahn, K. E., 4058 Wong, C-Q., 1162 Yanagisawa, A., 3231, 6696 Warburton, D., 3558, 5244, Wetzler, M., 1087 Wong, D. T. W., 389 Yandeil, D. W., 4832, 6194, 6840 Wheeler, R. H., 4342 Wong, G. Y., 6036 6588 Ward, M., 285 Wheelhouse, R. T., 4190 Wong, P. T. T., 84 Yang, A. S., 4787 Ward, U., 5765 Whelan, R. D. H., 3110 Woo, D. V., 4728 Yang, C. S., 1162, 1757, 1943, Warden, H. E., 4828 White, D., 2938 Wood, C., 1643 6657 Warrell, R. P., Jr., 2138, 6619 White, D., 6561 Wood, G. S., 6890 Yang, D., 2549 Warren, L., 3241 White, P. S., 770, 1780 Wood, J. F., 6413 Yang, J-H., 3478 Warrington, R. C., 3796 Whitehead, R. H., 917 Wood, S. G., 3615 Yang, P-M., 6098 Warters, R. L., 883 Whitesell, L., 1721 Woodworth, C. D., 456, 940, Yang, X., 6407 Wasmuth, J., 746 Whiteside, T. L., 85 l, 5913, 5865 Yano, H., 3972 Wasserman, R., 4467 5963 Worland, P., 5190 Yano, T., 775 Wassermann, K., 6853 Whitfieid, J. F., 6329 Wouters, W., 2841 Yano, T., 4545 Watanabe, H., 1948 Whitfield, L., 6746 Wright, K. A., 5674 Yarden, Y., 2580 Watanabe, H., 4878 Whitlow, M., 3402, 6413 Wright, M. A., 6335 Yarmush, M. L., 357, 367, 377 Watanabe, M., 3310 Whitsett, J. A., 5342 Wu, H-C., 1598 Yarosh, D., 4227 Watanabe, M., 5178 Wick, M. R., 3768 Wu, H. H., 5329 Yasuda, N., 696

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7016

Yasui, A., 6690 Yoshida, M., 6671 Z Zhang, W., 4587 Yasui, H., 6810 Yoshida, M., 6676 Zaborniak, C. L. F., 3796 Zhang, W-W., 428, 5681 Yasui, W., 295 Yoshida, O., 1881 Zhang, Y., 1770 Yasukawa-Barnes, J., 4102 Zaharko, D., 3604 Yoshida, T., 4634 Zahm, S. H., 5485s Zhang, Y-J., 2980 Yasumitsu, H., 5046 Yoshii, A., 3201 Zhang, Z-g., 5900 Yasumura, S., 5963 Zaidi, S. I. A., 3582, 6106 Yoshiji, H., 5042 Zain, S., 1073 Zheng, T., 5443s Yatani, R., 5991 Zheng, W., 3865 Yoshimoto, K., 5061 Zaleski, J., 1639 Yayon, A., 5656 Yoshimura, S., 1309 Zhou, B-S., 4280 Yeargin, J., 222 Zaloudik, J., 815 Zhou, F., 6287 Yoshino, I., 775 Zalutsky, M. R., 5054 Yee, J-K., 222 Yoshizawa, H., 1129 Zhou, W., 6905 Yee, V., 4227 Zambello, R., 5223 Zhou, Y-Z., 1635 Young, C. W., 2138, 6619 Zamenhof, R. G., 4672 Yeh, G. C., 6692 Young, C. Y-F., 1525 Zhu, C., 5681 Yeh, M-Y., 4484 Zamore, R., 5663 Zhu, D., 4208 Yeldandi, A. V., 2977 Young, D., 138 Zappler, K., 4791 Young, J., 285 Zhu, S-m., 6092 Yerokun, T., 4779 Zavitsanos, X., 5364 Ziegler, R. G., 2060s Yin, J., 741, 6525 Young, M. R. I., 6335 Zbar, B., 348 Yu, D., 6052 Zilakos, N. P., 4858 Yin, M-b., 5900 Zehnbauer, B., 2984 Zilberstein, A., 3636 Yokota, J., 1695, 3099, 4837 Yu, M. C., 254, 4787 Zelenetz, A. D., 5547s Yu, M. T., 5244 Zimniski, S. J., 235 Yokota, T., 3402, 6413 Zeniya, M., 5178 Zinkewich-P/~otti, K., 1902 Yu, W. C. Y., 6848 Yokoyama, H., 2903 Zetterer, G., 487 Zinn, A. B., 6125 Yokoyama, S., 328, 873 Yuan, F., 5838, 6553 Zeuthen, J., 726 Zoeckler, M. E., 5693 Yokozaki, H., 295, 2504 Yun, C-H., 1868 Zha, X., 5219 Zorrilla, A., 1245 Yoneda, T., 3636, 5395 Yung, B. Y-M., 3593 Zhang, J-Y., 6682 Zucali, J. R., 1770 Yonezawa, T., 566 Yunis, A. A., 413, 5123 Zhang, L., 4634 Zucchini, P., 11 Yong, M. A., 1810 Yuspa, S. H., 1439, 2966, 3145, Zhang, L-X., 5707 Zunino, F., 1666 York, J. L., 58 6487 Zhang, Q-H., 912 Zurawski, V. R., Jr., 3396, 6708 Yoshida, H., 168 Yutsudo, M., 4420 Zhang, Q-X., 2261 Zweibaum, A., 4655 Yoshida, M., 464, 6926 Yuzuki, D. H., 6059 Zhang, Q-X., 2991 Zwelling, L. A., 209

* For title of article and coauthors, see listing in Contents of Volume 52 beginning on page i at the end of this index issue. 7017

Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1992 American Association for Cancer Research. SUBJECT INDEX Volume 52 nant colon tissues, 84 resonance spectroscopy, 71 Accelerator mass spectrometry methotrexate resistance, mucins, 4655 S-Adenosylmethionine fate and distribution ductal pancreatic turnover in Jurkat T-cells 2-amino-l-methyl-6-phenylimidazo[4, frequent loss of expression, tumor sup- induction of interleukin 2 production, 5-b]pyridine, human dietary equiva- pressor gene DCC, 2616 3361 lent dose, 4682 Dunning model S-Adenosyl-D-methionine A431 cells cancer cell motility-inhibitory protein, chemoprevention extracellular control of transition 2349 rat liver carcinogenesis, 4979 phosphatidic acid, epidermal growth endometrial S-Adenosylmethione decarboxylase factor, 5627 estrogen and antiestrogen, transform- inhibitors N-Acetoxy-4-acetylaminobiphenyl ing growth factor gene expression, potent antitumor activity, 4712 metabolism and nucleic acid binding 1704 Adhesion human uroepithelial cells, 3286 human cancer cells 2-Acetylaminofluorene early growth and angiogenesis, SCID up-regulated biosynthesis and expres- -induced hepatocarcinogenesis mice, 6553 sion, vitronectin receptor, 2202 rat liver aryl sulfotransferase IV, com- experimentally manipulable model, diminished leukocyte-endothelium inter- plementary DNA, 4779 primary lung tumors in mice, 2670s action N-Acetylgalactosamine lung tumor microvessels, 4265 -specific lectin expression deletion mapping, short arm of chro- ganglioside and HLA antigen expression mosome 3, 873 tumor progression in vivo, liver metas- basal cell carcinoma lesions, 3201 preferential expression, immunoreac- tasis potential, 5235 tumor cells to platelets tive fucosylceramide, 4408 thrombin treatment, tumor metastasis, Acidification SV40 large T-antigen, surfactant pro- intracellular 3267 tein C gene, 5342 Adipose tissue morphological transformation, Syrian ras gene mutations, prognostic reduction of lipoprotein lipase activity hamster embryo cells, 144 marker, 2903 interleukin 6, cancer cachexia, 4113 Acquired immunodeficiency syndrome mammary Adozelesin immunosuppressive therapy hyperthermia effects, blood flow and lethality and DNA alkylation acquired immunological disorders, cisplatin pharmacokinetics, 4965 cell cycle effects, 5687 5474s induction of apoptosis, tumor necrosis Adrenal gland lymphoma field, 5431 s factor-a, 1342 dehydroepiandrosterone and dehydroepi- -related lymphoma transcriptional and posttranscriptional androsterone sulfate County of Los Angeles, 5482s activation, urokinase plasminogen prediagnostic serum levels, risk of pre- 4'-(9-Acridinylamino)methane-sulfon-m-an- activator gene expression, 2489 menopausal breast cancer, 1 isidide tumor blood flow, 2H-nuclear mag- inhibition of estrogen formation and ac- phosphorylation of topoisomerase II netic resonance, 6010 tion casein kinase II, 2156 mutation of thymidylate synthase gene novel compounds, 610 Acrolein attenuation by exogenous folates, 558 Adriamycin initiation of rat urinary bladder carcino- prostatic cell cycle-dependent cytotoxicity genesis, 3577 dissemination to bone, adherence to modulation by novobiocin, 3515 Acrylophenone bone marrow-derived endothelial daunomycin and antineoplastic molecule cells, 4613 interaction with sphinganine, HL-60 low-density lipoprotein for delivery high-intensity ultrasound, 6353 cell differentiation, 3593 into malignant cells, 3629 hormonal effects, 4663 human glucocorticoid receptor gene dele- Actin tumor-promoting phorbol ester, down- tion, 6612 actin-binding proteins and regulation of androgen induction, -induced modulation of host defenses changes, HL-60 cell differentiation, 1525 tumor-bearing mice, 3572 3063 renal mitoxantrone and Adenocarcinoma epidermal growth factor, transforming biochemical characterization of resist- aUelotype growth factor-o~, 4356 ance, colon adenocarcinoma, 1886 non-small cell lung carcinoma, 2478 systemic liposomes, CGP 31362 or protection from cell death Barrett's esophagus CGP 19835A, 1155 removal of extracellular drug, 4135 persistent clonal areas, clonal expan- uterine endometrial resistance sion, 2946 sulfoglycosphingolipids, 803 drug transport mechanisms, HL-60 breast Adenoma cells, 3157 tumor cell surface-associated binding colonic -resistant human breast cancer cell lines site, Mr 72,000 type IV collagenase, marker for dysplasia, sialyl Lewis x an- loss of epithelial markers, vimentin 5845 tigen, 3138 expression, 5190 cancer induction in mice colorectal reversal of in vivo resistance of tumor Gyromitra esculenta, 2279 genetic changes, p53 alleles, 3965 cells colonic Adenosine 3':5'-monophosphate dihydropyridine analogue, 3655 alterations, protein kinase C, 2216 unhydrolyzable analogues tumor necrosis factor and cell growth inhibition and cell cycle ar- growth inhibition and differentiation, sensitivity, resistant human tumor cell rest, dehydroepiandrosterone, 1372 human cancer cells, 2504 lines, 6630 characterization of resistance, mitox- Adenosine monophosphate, cyclic Aerodigestive tract neoplasms antrone and Adriamycin, 1886 transforming growth factor-/3~ and lung neoplasms and differentiation, mitochondrial DNA inhibition, hepatocyte DNA synthesis, chemoprevention strategies, 2758s expression, 3718 3598 Aflatoxin Bj induction by 6-nitrochrysene, species Adenosine triphosphate binding of metabolites differences, 1542 selective depletion in tumor extrahepatic tissues, depleted glutathi- infrared spectroscopic features, malig- 2-deoxyglucose and insulin, magnetic one levels, 1267

7019

-DNA adducts phocholine normal and malignant bone marrow molecular dosimetry, China, 45 perturbations of cellular acylation hemopoietic cells, 5007 -induced mutations processes, MCF7 and T84 cell lines, 3-Aminobenzamide sequence specificity, xeroderma pig- 2806 cocarcinogen for ultraviolet light-induced mentosum, 5668 Alleles carcinogenesis -induced tumors in nonhuman primates allelotype analysis in osteosarcomas, mouse skin, 4053 low frequency, p53 gene mutation, 2419 4-Aminobiphenyl 1044 chromosomal loss exposure of uroepithelial cells -transformed C3H/10Tl/2 cells different pattern, multiple hepatocellu- tumorigenic transformation, neoplastic protein kinase C overexpression, phor- lar carcinoma, 1504 progression, 1606 bol ester treatments, 990 Harvey-ras-1 inhibition of thioguanine-resistant muta- Aflatoxin-N%guanine nonrandom abnormalities, mammary tions molecular dosimetry in rat urine tumor progression, 4791 uroepithelial cells, 1615 multiple monoclonal antibody affinity loss 2-Amino-3-methylimidazo[4,5-J]quinoline chromatography, 267 chromosome 3p deletions, statistical mutagenic activation of liver Aflatoxins ascertainment, 1451 new form of cytochrome P-450, 758 risk factors for hepatocellular carcinoma, short arms of chromosomes 11 and 2-Amino-l-methyl-6-phenylimidazo[4,5-b] 2114s 17, breast cancer metastasis, 3914 pyridine Aging losses at chromosome 17p fate and distribution pathogenetic mechanisms human renal cell carcinoma, 1881 human dietary equivalent dose, 4682 B-cell non-Hodgkin's lymphoma, p53 and 17p loss Amlodipine 5522s colorectal carcinoma, 1974 inhibition of cancer cell growth AIDS: see Acquired immunodeficiency syn- p53 genetic changes athymic mouse, 2413 drome conversion from colorectal adenoma to Ammine/amine platinum(IV) dicarboxylates Albumin early carcinoma, 3965 acquired cis-diamminedichloropla- no loss of expression Ailografts tinum(II) resistance ras transformation, SV40-immortal- intrapancreatic mechanism-related circumvention, ized hepatocyte cell line, 940 enhanced levels of annexins, pan- ovarian carcinoma, 3857 Alcohol creatic carcinoma, 163 cisplatin-resistant human ovarian carci- cancer and, 2119s Alopecia noma cell lines, 822 Aldehyde dehydrogenase 1-~-o-arabinofuranosylcytosine-induced Amminedibutyratodichloro- protection of hematopoietic progenitor epidermal growth factor and fibroblast (cyclohexylamine)platinum(IV) cells growth factor, rat model, 413 cisplatin and tetraplatin 4-hydroperoxycyclophosphamide, in- chemotherapy-induced cellular accumulation and cytotoxicity, terleukin 1/3 and tumor necrosis fac- protection by 1,25-dihydroxyvitamin ovarian carcinoma, 6188 tor, 1770 D3, 5123 Ammonia Alkaline phosphatase Aluminum nitrogen-stimulated orotic acid synthesis intestinal electron probe microanalytical identifica- nucleotide imbalance, 2082s oncogenic potential, tumor-associated tion Ammonium antigen, 616 postvaccinal sarcomas, cat, 5391 cancer-associated sialosyl-Tn antigen placental-like gene Alveolar nodules mucins, natural killer cell cytotoxicity, induction by sodium butyrate, tran- adoptive transfer of V~2-deleting activ- 4741 scriptional regulation, 3378 ity, 5183 Amphiregulin Alkylating agents Alveolar type II cells activation of/~-hydroxyalkylnitrosamine cripto and development and progression of pulmo- differential immunohistochemical de- involvement of sulfotransferase, 3300 nary tumors tection, normal colon and colorectal carcinogenic potency induction by 4-(methylnitrosamino)-1- tumors, 3467 rodents and humans, 2464 (3-pyridyl)- 1-butanone, 3164 messenger RNA elevation environmental Amines psoriatic epidermis, gastrointestinal repair protein O6-alkylguanine-DNA heterocyclic carcinoma, 3224 alkyltransferase, 1801 chemical analysis, cooked foods, 2103s O6-methylguanine-DNA methyltransfer- food-derived mutagens, carcinogens, Amsacrine ase expression 2092s analogues DNA repair-deficient Chinese hamster P450 activation, flavonoids, 2108s computer simulations in new drug de- ovary cell line, 32 2-Amino-3,4-dimethylimidazo[4,5-flquino- velopment, leukemia cell lines, 209 O-Aikylguanine-DNA alkyltransferase line epipodophyllotoxins and efficient repair of O6-ethylguanine, 6984 induction and inhibition of cytochrome topoisomerase II cleavage, c-myc, nucleotide excision repair activities, hu- P450 3125 man cells, 2008 IA subfamily, chick and rat hepato- etoposide hypersensitivity -mediated carmustine resistance cytes, 3615 overexpression of DNA topoisomerase streptozotocin, Phase I trial, 2456 Amino acid II, yeast cells, 4467 modulation of ethylnitrosourea-induced chemotherapeutic Androgen toxicity high affinity transport across blood- down-regulation of induction mutagenicity, O6-benzylguanine, 3851 brain barrier, 2191 tumor-promoting phorbol ester, pros- nucleotide excision repair, 6983 -lowering diet tate-specific antigen, 1525 relevance of environmental alkylating rate of meiphalan entry, brain and -independent prostate cancer agents, 1801 xenotransplanted glioma, 5590 protooncogene bcl-2 expression, 6940 Alkyl-lysophospholipid neutral -independent prostatic carcinoma growth-inhibitory effects of ET- 18-OCH3 melphalan penetration, blood-brain epidermal growth factor receptor differential susceptibility, A427 and barrier, 138 monoclonal antibody, 5887 A549 cell lines, 2813 7-Aminoactinomycin D Angiogenesis l-O-octadecyl-2-O-methylglycero-3-phos- chromatin structure-dependent binding antiangiogenic agents

7020

potentiation of cytotoxic cancer thera- hormonal effects antagonist SB-75 pies, primary and metastatic disease, prostatic adenocarcinoma, 4663 sustained release formulations, pros- 6702 Antifolates tatic carcinoma, 2538 antiangiogenic effects on endothelial mechanism of natural resistance potentiation of activity by bryostatin-1 cells human soft tissue sarcoma, 1434 1-~-D-arabinofuranosylcytosine, HL- acidic fibroblast growth factor-Pseudo- Antigen-binding proteins 60 cells, 6270 monas exotoxin chimeric protein, single-chain radiation-induced 4995 rapid tumor penetration, other immu- murine T-cell hybridoma, 883 early growth noglobulin forms, 3402 transforming growth factor-/~ human adenocarcinoma, SCID mice, Antiidiotypic antibodies human gastric carcinoma cells, 4042 6553 murine/human chimeric tumor cells inhibition by suramin, 5073 mimicry, ganglioside, 1681 formation of apoptotic bodies, micro- role of cytokines quantitation of tumor-reactive monoclo- filament-disrupting agents, 997 regulation of cell function, pathogen- nal antibody 16.88 l-B-D-Arabinofuranosylcytosine esis of disease, 6129 colorectal metastatic tumor tissue, 1-~-D-arabinofuranosyluracil and Angiotensin II 2603 pharmacokinetics, plasma and cerebro- -induced hypertension Anti-immunoglobulinantibody spinal fluid, 3818 circadian variation, tumor blood flow, surface immunoglobulin-mediated signal cis-diamminedichioroplatinum and 912 transduction pathways drug synergism, 4558 Anionic compounds activation of Raf-l, B-cells, 566 improved sustained release system aromatic Antimicrotubule Stealth liposomes, 2431 reversal of autocrine transformation, combined activity of estramustine and -induced alopecia basic fibroblast growth factor, 5656 taxol epidermal growth factor and fibroblast Aniridia human prostatic carcinoma cell lines, growth factor, rat model, 413 high levels of enhanced reactivation 4433 potentiation of activity by bryostatin-1 herpes simplex virus, skin fibroblasts, Antimitotic agents HL-60 cells, 6270 53 action at tubulin level resistance in human T-lymphoblasts Annexin II computer-assisted evaluation, differen- mediation by mutations, deoxycytidine developmental regulation tial cytotoxicity data, 3892 kinase gene, 2389 human brain, expression in high-grade Antineoplastic agents -resistant CHO cell mutant glioma, 6871 ether lipid class X-ray sensitivity, ataxia telangiectasia Annexins membrane peroxidative damage en- cells, 319 enhanced levels hancement, 6045 thioether-lipid conjugate pancreatic carcinoma cells, 163 Antioxidants colorectal cancer xenografts, 1865 Anoxia inhibition by green tea l-~-D-Arabinofuranosylcytosine-diphos- -inducible endonuclease activity tobacco-specific nitrosamine-induced phate-choline genomic instability, cancer cells, 4372 lung tumorigenesis, 3875 formation Ansamycins phase II enzymes and reversal of cholinephosphotransferasc, benzoquinonoid cancer chemoprevention, green tea, 3886 selective tumoricidal activity, 1721 4050 Arabinosylcytosine Anthracycline Antiprogestins metabolism in lymphocytes resistance down-regulation of tenascin expression fludarabine, chronic lymphocytic leu- circumvention by cinchonine, 2797 mammary neoplasms, 4642 kemia, 897 -resistant HL-60/AR cells Antisense Arachidonate MDR1 amplification, 5244 -mediated specific inhibition in vivo efficacy of novel inhibitor tumor localization and improved thera- P 120 protein expression, prevention of selected signal transduction pathways, peutic index GI to S-phase transition, 5250 3208 encapsulation, long-circulating lipo- Antisense oligonucleotide transformation of cultured cells somes, 891 inhibition of interleukin 1~ gene irradiation and transfection, fatty Anthrapyrazole generation, LAK cells, 4954 acids, 154 CI-941 Apolipoprotein D Arachidonic acid clinical pharmacokinetics, 603 identification of major protein compo- aspirin and potential role of prostaglan- Antibiotics nents dins benzoquinonoid ansamycins breast secretions, benign and malig- colon cancer, 5575 selective tumoricidal activity, 172 l nant breast diseases, 95 Arachnoid villi Antibody Apoptosis immunohistochemical localization -directed targeting of vascular endothe- acquisition of growth-inhibitory response cell adhesion molecule epithelial cad- lial cells phorbol ester, DNA damage, 1907 herin, 1981 murine model, solid tumors, 5954 estrogen-independent breast cancer cell Archival tissue Anticancer drugs line, 3418 applications of experimental studies model system for testing growth and cell cycle progression epidemiological studies, non-Hodg- wap-ras transgenic mouse, 3733 effects of genistein, normal lympho- kin's lymphoma, 5561s Phase II preclinical drug screening cytes and leukemic cells, 6200 Aromatase human tumor xenografts, 5940 hormone-regulated inhibitor exemestane Antidepressant drugs reentry of differentiated prostate cells, Phase I and endocrine study, 5933 stimulation of malignant growth defective cell cycle, 4313 steroid and growth factor modulation clinically relevant doses, 3796 induction by transforming growth factor- MCF-7 and T47D cell lines, 1411 Antiestrogens Arterioles estrogen and human hepatoma cell line, 385 role of microvascular damage transforming growth factor gene induction by tumor necrosis factor-a photodynamic therapy, 4914 expression, endometrial adenocarci- mammary adenocarcinoma cells, 1342 Arylamine N-acetyltransferases noma, 1704 luteinizing hormone-releasing hormone expression in Salmonella typhimurium,

7021

3961 ity, chromosomes 17 and 10, 674 transduction pathways Arylamines sensitization of cells by taxol activation, Raf-l, 566 exposure of textile industry workers radiation, 3495 Beef urinary mutagenicity, N-acetylation tumor suppressor gene cooked phenotype, 4885 chromosome 19q, 4277 human exposure to carcinogens, 6216 heterocyclic Ataxia telangiectasia cells Benzo[a]pyrene metabolic activation and genotoxicity, 1-~-D-arabinofuranosylcytosine-resistant 3-hydroxylation 2099s CHO mutant human liver cytochrome P4502C and Aryl hydrocarbon hydroxylase X-ray sensitivity, 319 3A, 1868 induction of colon adenocarcinoma mAt-Methylene blue -induced malignant tumors 6-nitrochrysene, species differences, targeted radiotherapy autoantiphosphatidylinositol immune 1542 human melanoma xenografts, 4385 response, 2862 Aryl sulfotransferase IV Autoantiphosphatidylinositol -induced mouse forestomach neoplasia liver immune response inhibition, Japanese-style fermented complementary DNA, 4779 benzo[a]pyrene-induced malignant tu- soy sauce, 1754 Asbestos mors, 2862 P-glycoprotein as effiux pump -induced rat mesothelioma Autoimmune diseases MCF-7 cells, 6692 platelet-derived growth factor, receptor increasing incidence of non-Hodgkin's -treated Syrian hamster embryo cells expression, 301 lymphoma, 5496s immortalization, indirect induction, Ascites Antoradiography 2253 hepatoma cells intratumoral and whole-body distribu- Benzo[a]pyrene 7,8-dihydrodiol-9,10-epox- putrescine-dependent invasive capac- tions ide ity, 5313 anti-carcinoembryonic antigen ra- conjugation immunoreactive human chorionic gonad- dioimmunotoxin, 1961 infant Swiss-Webster mice, 1639 otropin 5-Azacytidine Benzola]pyrene diol-epoxide free/3 subunit, malignant tumors, 1520 alteration of DNA methylation pattern -DNA adducts Ascitic fluid flow cytometric detection, 5213 dosimetry, fluorometric assay, 6248 ovarian epithelial cancer cells Azaserine Benzopyranones interleukin I a and ~/gene expression, -induced neoplasms of the pancreas benzothiopyranones and 2248 cholecystokinin receptor overexpres- selectivity, v-abl kinase, 4492 D-Ascorbic acid sion, 3295 Benzoquinonoid growth modulation of colony-forming -induced rat pancreatic carcinoma ansamycins cells gastrin receptors, 6905 selective tumoricidal activity, 1721 bone marrow, myelodysplastic syn- Azathioprine N-Benzyladriamycin- 14-valerate dromes, 4458 immunosuppressive therapy resistance in mouse J774.2 cells AS30-D tumor cells acquired immunological disorders, P-glycoprotein expression, 3409 low mitochondrial proton leak 5474s O6-Benzylguanine deviant bioenergetics, 4935 Azatoxin modulation of ethylnitrosourea-induced Aspirin topoisomerase II inhibition, 4478 toxicity potential role of prostaglandins and Azatyrosine mutagenicity, 3851 colon cancer, 5575 inhibition of chemical carcinogenesis, sensitivity of human tumor xenografts Assays 1628 1,3-bis(2-chloroethyl)-l-nitrosourea, chemical cross-linking Azidothymidine DNA interstrand cross-link forma- somatostatin analogue BIM-23014C -induced cytotoxicity tion, 1171 receptors, breast carcinoma, 843 methotrexate and, HCT-8 cells, 4069 5-Benzyloxybenzyloxyacyclouridine enzymatic Azoxymethane enhancement of 5-fluoro-2'-deoxyuridine cathepsin D as prognostic indicator, -induced intestinal and renal carcinogen- antineoplastic activity node-negative breast cancer, 5198 esis colon carcinoma, 1729 fluorometric dietary fat, protein and energy intake, Bile acids dosimetry of benzo[a]pyrene diol- 857 dietary fiber-mediated mechanisms epoxide-DNA adducts, smokers' carcinogenesis, 2055s lungs, 6248 B intestinal HPLC subtotal colectomy, familial adenoma- molecular dosimetry, aflatoxin-N7- Baculovirus tous polyposis, 3552 guanine, 267 recombinant expressing secreted form meal frequency immunological quantitation transmembrane carcinoma-associated risk of colorectal cancer, 3589 thymidylate synthase, cancer cell lines, antigen, 815 Biliary disease 4306 BALB/c 3T3 cells free ~/subunit of human choriogonado- Astrocytoma platelet-derived growth factor-independ- tropin childhood ent phenotypes core/3 fragment, 4628 parental occupation, 782 pathway for transformation suscepti- BIM-23014C expression pattern of a-protein kinase C bility, 4232 receptors role in malignant progression, 2951 B-cells chemical cross-linking assay, breast grades II and III Epstein-Barr virus-immortalized carcinoma, 843 17p allelic loss, p53 mutations, 2987 tumor-associated epitopes, epithelial Biotinyl malignant mucin complementary DNA, 5985 -ricin molecular analysis, low grade tumor or malignant immunotargeting, streptavidin, 4448 satellitosis, 1568 intracellular catabolism, radiolabeled 2,6-Bis-benzylidenecyclohexanones second tumor suppressor gene, chro- anti-u antibodies, 207 nuclear type II sites and malignant cell mosome 17, 6716 proliferation and maturation proliferation, 2482 progression follicular dendritic cells, 5554s Bischloroethylnitrosourea p53 mutation and loss of heterozygos- surface immunoglobulin-mediated signal combination with o-histidinol

7022

preclinical therapeutic studies, 3604 tumor normal and malignant hemopoietic cells 1,3-Bis-(2-chioroethyl)-l-nitrosourea circadian variation, angiotensin II-in- chromatin structure-dependent bind- mutational specificity duced hypertension, 912 ing, 7-aminoactinomycin D, 5007 Chinese hamster ovary cells, 4688 2H-nuclear magnetic resonance imag- syngeneic transplantation sensitivity of human tumor xenografts ing, 6010 tumor resistance, interleukin 2, 4117 effect of O6-benzylguanine, 1171 Blood group antigens Boron N,N'-Bis( 2-chloroethyl)-N-nitrosourea determination of biomarkers accumulation of l~ in central degenera- E-interferon and intermediate end points, chemopreventive areas simvastatin synergism, human glioma tion trials, 2707s glioma and colon carcinoma spher- cells, 4348 Lea-X oligosaccharides oids, sulfhydryl boron hydride, 1587 AP,N~ Z-Bis(ethyl)spermine formation of mucin gel, tumorigenic quantitative imaging of radiotherapeutic sensitivity squamous lung carcinoma, 2923 drug steady-state messenger RNA, major Blood vessels subcellular resolution, ion microscopy, forms of lung cancer, 5359 microvascular pressure 5219 N,N'-Bis(ethyl)spermine homologues interstitial hypertension, solid tumors, Boron neutron capture antitumor activity 5110 therapy for malignant gliomas, 4672 MALME-3 melanoma xenografts, role of microvascular damage Bovine papillomavirus 2424 photodynamic therapy, 4914 type 2 BK virus Bloom's syndrome bracken fern and, bladder cancer in -transformed mouse cells high levels of enhanced reactivation cattle, 6898 anchorage-independent growth, herpes simplex virus, skin fibroblasts, Bovine seminal ribonuclease suppression of tumorigenicity, 1297 53 growth-inhibitory effect Bladder neoplasms B-lymphoblastoid cells rat thyroid epithelial transformed cells advanced up-regulation of interleukin 4 receptors and tumors, 4582 interleukin 2 and LAK cell treatment, tat gene, HIV-1, 3787 B3-PE 726 B-lymphoblasts B3-LysPE40 and bovine papillomavirus type 2 human hypoxanthine guanine phosphori- antitumor effects, nude mouse model bracken fern association, cattle, 6898 bosyltransferase gene of human breast cancer, 3189 invasive mutational specificity, cisplatin, 2866 BR64 frequent association, p53 gene muta- BM 41.440 -doxorubicin conjugates tions, 1393 membrane lipid modification antigen-specific activity, human tumor superficial sensitivity of leukemic cells, 6263 xenograft models, 5693 antibody drug carrier, immunotherapy, BMY 25282 Bradykinin 3131 BMY 25067 and inhibition of DNA synthesis and growth Bieomycin cytotoxic activity, buthionine sulfoxi- breast stromal cells, 334 circumvention mine and ethacrynic acid, 6666 sensitivity human colon carcinoma resistance, Bombesin neuropeptide signal transduction, lung 2931 antitumorai activity of analogues cancer, 24 fluorescence-labeled analogue, 709 small cell lung cancer xenografts, 4872 Brain human glucocorticoid receptor gene dele- glucocortico!ds and blocking effect of human serum tion, 6612 stimulation of breast cancer cells, en- ricin A chain immunotoxin potentia- Blood dothelin production, 1786 tion, monensin, 623 cell growth factors -like peptides cerebral capillary endothelial cells use in hematology and oncology, Bei- urinary levels, asymptomatic cigarette expression and functional activity, P- jing symposium, 2012 smokers, 2727s glycoprotein, 6969 peripheral multiple neuropeptides developmental regulation of annexin II analysis of PvuII RFLP, breast cancer, growth, small cell lung cancer cells, expression in high-grade glioma, 6871 77 2737s disseminating tumor cells young donors stimulation of growth interactions with leukocytes, 1018 accelerated declining tendency, human breast cancer cell lines, 4545 fetal HTLV-I carrier rates, 2620 Bone transplants, oncogene complementa- Blood-brain barrier osteolytic metastases tion, 3760 high affinity transport synthetic antagonist to laminin, hu- formation of PC12 tumors after trans- chemotherapeutic amino acid, 2191 man melanoma cells in nude mice, plantation melphalan penetration 5395 time course, host age, 1933 neutral amino acid transporter, tumor- sarcoma in vivo growth of C6 glioma cells bearing brain, 138 p53 gene mutation spectrum, 6194 transfection, connexin43 complemen- Blood flow Bone marrow tary DNA, 4208 acute effects -derived endothelial cells melphalan entry tumor necrosis factor-a or lympho- rat prostate adenocarcinoma cells, dis- amino acid-lowering diet, 5590 toxin, subcutaneous rodent tumors, semination to bone, 4613 molecular cloning 2167 expansion cultures Wilms' tumor complementary DNA, cisplatin pharmacokinetics and ex vivo differentiation therapy, method 6407 hyperthermia effects, murine mam- of leukemic cell purging, 6576 neonatal rat mary adenocarcinoma, 4965 growth modulation of colony-forming transplantation, migratory behavior of exchanging water space and cells PC12 cells, 1938 PET measurements, breast tumors, D-ascorbic acid, myeiodysplastic syn- tumor-bearing 1592 dromes, 4458 melphalan penetration, blood-brain human melanoma xenograft lines myelopoiesis-associated immune sup- barrier, 138 different growth characteristics, 584 pressor cells Brain neoplasms lowering of tumor interstitial pressure mice bearing metastatic Lewis lung distribution of glucose transporters, nicotinamide, 3237 carcinoma tumors, 6335 3972

7023

interleukin 8 production, 4297 heterogeneity of progesterone receptor receptor, 63 l0 malignant gliomas content response to heat shock boron neutron capture therapy, 4672 remodeling by tamoxifen, 593 chemotherapeutic drugs, 3648 platelet-derived growth factor-stimulated human mammary epithelial cells retinoblastoma gene, 2991 a-difluoromethylornithine, altered cal- genotoxicity, environmental agents, risk factors and relapse rate cium signaling, 6782 5617 association of cyst type, gross cystic Breast 17B-hydroxysteroid dehydrogenase gene disease, 1791 immortalized HMT-3522 cell line expression risk of altered gene expression, c-myc, 1210 regulation by progestin, 290 hormone levels, vegetarian and nonve- normal immune response to p53 getarian teenage girls, 578 c-myc/c-erbB-2/Ki-67 expression, immunodominant epitopes, muta- screening for germ line TP53 mutations, 2597 tional hot spot, 6380 3234 preneoplastic cell proliferation induction of transforming growth factor- second generation anti-MUCl peptide effect of tamoxifen, mammary carcino- monoclonal antibodies, 2310 genesis, 1477 tamoxifen treatment, 4261 sporadic preneoplastic lesions, 501 influence of tamoxifen mutated human prohibitin gene, chro- stromal cells plasma levels, insulin-like growth fac- mosome 17q21, 1643 inhibition of DNA synthesis, bradyki- tor I, 4719 sporadic amplification nin, 334 inherited p53 gene mutations, 2984 insulin-like growth factor I receptor Breast neoplasms inhibition of cancer cell growth gene, 1036 Adriamycin- and vinblastine-resistant calcium channel antagonists, athymic stimulation of endothelin production cell lines mouse, 2413 bombesin, glucocorticoids, 1786 loss of epithelial markers, vimentin inhibition of cell growth stimulation of growth by bombesin expression, 5190 tyrosine kinase inhibitor, 3636 inhibition by RC-3095, 4545 advanced spontaneous inhibition of estrogen formation and ac- synchronization of cell proliferation regression of, 5-fluorouracil-containing tion hormonal and polyamine manipula- drug combination, 4074 novel compounds, 610 tion, 5720 aggressive inhibitory protein factor systemic adjuvant treatment p53 mutations, 3918 3T3-Ll preadipocytes, 6860 evolving concepts, 2127 analysis of PvulI RFLP insulin-like growth factor binding pro- tissue-specific expression exon structure, estrogen receptor gene, teins, 5204 polymorphic epithelial mucin, trans- 77 insulin receptor expression and function, genie mice, 1954 benign and malignant diseases 3924 vs. mammary epithelial cells identification, major protein compo- interstitial hypertension, 6371 differential display and cloning, mes- nents, 95 management senger RNAs, 6966 blood flow and exchanging water space evolution of paradigms, 2371 ZR-75-1 cells PET measurements, 1592 metastasis antiproliferative effects, octreotide, cell proliferation loss of alleles, chromosomes 11 and 4973 estrogenic potential of progestins, oral 17, 3914 Brequinar contraceptives, 6539 naturally occurring variant potentiation of 5-fluorouracil antitumor clonal analysis inhibition, estrogen receptor, 483 activity polymerase chain reaction, 6594 node-negative uridine nucleotide pools, murine deletion of chromosome 17p cathepsin D as prognostic indicator, model colon 38 tumor, 1660 fluorescence in situ hybridization, 5198 Brequinar sodium 3474 nude mouse model inhibition of dihydroorotate dehydroge- differences in risk factors antitumor effects, B3'PE and B3- nase, 3521 neu protein overexpression, breast tu- LysPE40, 3189 Bromocriptine mor, 2344 operable neoplastic progression differential effects gene amplification, chromosome mouse mammary preneoplastic hyper- bryostatin 1, phorbol ester, 1278 1 lq13 region, 5229 plastic alveolar nodule line C4, differentiation Phase I and endocrine study splenic lymphocyte function, 2209 tumor-inhibitory monoclonal antibod- exemestane, 5933 Bromodeoxyuridine ies, HER-2/neu receptors, 2580 p53 mutations, 5291 potential superiority to iododeoxyuridine disease progression postmenopausal patients radiation sensitizer, colorectal cancer, immunohistochemical staining, trans- tamoxifen adjuvant therapy, low-fat 3698 forming growth factor-E1, 6949 diet, 5386 Bryostatin DNA fingerprinting, 2174 premenopausal preclinical evaluation ectopic epidermal growth factor receptor prediagnostic serum levels, dehydro- murine tumor cell lines, 101 expression, 5082 epiandrosterone, 1 Bryostatin 1 establishment of human BSMZ cell line primary activation and growth overexpression, erbB-2 and c-myc c-m.vc amplification, compared to murine tumor-specific T-cells, 548 genes, 5178 HER2/neu amplification, 1107 decreased murine resistance estrogen-independent prognostic value, urokinase-type plas- Salmonella typhimurium, 2143 programmed cell death, 3418 minogen activator, 6101 phorbol ester and expression and regulation proliferation and cell cycle differential effects, breast cancer cell retinoic acid receptors, 2236 effects of ketoconazole, 6827 lines, 1278 functional role for P-glycoprotein protein tyrosine kinases potentiation of activity effiux pump for benzo[a]pyrene, MCF- c-src oncogene product, 4773 1-fl-D-arabinofuranosylcytosine, HL- 7 cells, 6692 radiolabeled antibody targeting 60 cells, 6270 hepsulfam sensitivity HER-2/neu oncoprotein, 1916 Bufalin glutathione, glutathione S-transferase recombinant single chain antibody-toxin induction of differentiation of HL60/ resistance, 1416 tumor cell growth inhibition, erbB-2 U937/ML1 cells

7024

macrophage/monocyte-like cells, 4634 cell growth tions, autoradiography, 1961 Buthionine sulfoximine endothelin, NRK 49F cells, 3011 specificity and affinity ethacrynic acid and vitamin D and colon cancer, 2067s monoclonal antibodies, 2329 cytotoxic activity, Mitomycin C ana- Calcium channel Carcinogen logues, 6666 antagonists fate and distribution Butylated hydroxyanisole inhibition of cancer cell growth, 2-amino-l-methyl-6-phenylimidazo[4, differential induction athymic mouse, 2413 5-b]pyridine, human dietary equiva- nitroreductases and glutathione trans- indolizine lent dose, 4682 ferases, action on 4-nitroquinoline enhancement, ricin-A chain immuno- food-derived mutagens and, 2092s 1-oxide, 58 toxin activity, 1352 -induced diploid and polyploid hepato- O%Butylguanine Calcyclin cytes urinary excretion abundance of primary transcript biotransformation, separation by cen- N-nitroso-N-butylurea administration, growth-related genes, normal and leu- trifugal elutriation, 1149 rats, 6699 kemic cells, 11 -induced neoplastic progression expression in melanoma cell lines initiated mouse epidermal cells, 3145 C correlation, metastatic behavior, 1291 1,N~-ethenodeoxyadenosine Calmodulin partial purification, DNA glycosylase, CA19-9 antagonists 1377 bispecific antibody targeting nitrosamine-induced lung carcinogene- presence in cooked beef antitumor effects, CD 16, 5713 sis, 2723s human exposure, 6216 CA54/61 Camptothecin -sensitive and -resistant strains of mice marker for epithelial ovarian cancer, cell cycle-related expression growth kinetics, microscopic hepato- 1205 p120 nucleolar antigen, 3491 cellular neoplasms, 280 CA72-4 hypersensitivity of clonal isolates -specific mutational pattern measurement of TAG-72 as serum overexpression of human topoisomer- p53 gene, ultraviolet B radiation-in- marker ase I, baby hamster kidney cells, 525 duced squamous cell carcinoma of management, gastric carcinoma, 1222 -induced G2 arrest skin, 6400 Cachexia active DNA synthesis, 1823 tobacco-specific reduction of lipoprotein lipase activity induction of differentiation metabolic activation, DNA and hemo- interleukin 6, adipose tissue, 4113 stimulation of differentiation-related globin adducts as markers, 2698s systemic hyperinsulinemia genes, U-937 cells, 1245 -treated Syrian hamster embryo cells cancer patients, 3845 inhibition of growth immortalization, 2253 tumor-derived lipolysis-promoting fac- human malignant melanoma, 3980 Carcinogenesis tor, 829 -resistant cell line amplification and expression Cadherin topoisomerase I alteration, Chinese bcl-1 gene, human solid tumor cell dysfunction in human cancer cell line hamster DC3F cells, 1848 lines, 2460 loss of a-catenin, 5770 Camptothecin analogue bronchial and pulmonary E-Cadherin mechanism of cross-resistance focal sites, dogs and hamsters, 2687s decreased expression selection by cisplatin, ovarian cancer carcinogenic potency progression, rat prostatic cancer, 2916 cell line, 328 alkylating agents, rodents and humans, immunohistochemical localization topotecan 2464 human arachnoid villi and meningio- accumulation and cytotoxicity, P-gly- chemical mas, 1981 coprotein expression, 2268 inhibition by azatyrosine, 1628 reduced or absent expression Carbohydrate colon high-grade prostate cancer, 5104 stage-specific antigen expression chemoprevention, 1,4-phenylene- Caicitonin developing pancreas, human embryo, bis(methylene)selenocyanate, 5635 malignancy-associated hypercalcemia 5744 1,2-dimethylhydrazine, alterations in 7-interferon, 444 Carboplatin protein kinase C, 2216 Calcium abdominal hyperthermia and cutaneous chemical broad spectrum neuropeptide antagonists cancers restricted to peritoneal cavity, initiation stage, immunogenetic influ- inhibition of growth, small cell lung 1252 ences, 6106 cancer, 4554 -cyclophosphamide chemotherapy development of liver tumors -calmodulin antagonists DNA strand breaks and cross-links, transforming growth factor-a trans- nitrosamine-induced lung carcinogene- ovarian cancer, 5622 genic mice, 5162 sis, 2723s quantitative ultrastructural effects dietary fiber-mediated mechanisms, induction of apoptosis neurons, Lymnaea stagnalis, 963 2055s tumor necrosis factor-a, mammary ad- Carboxymethylcellulose esophageal enocarcinoma cells, 1342 polyinosine-polycytidylicacid complex p53 mutation, protein accumulation, in vivo efficacy of novel inhibitor combination with interleukin 2, pa- 6092 selected signal transduction pathways, tients with cancer, 3005 frequent somatic mutations 3208 Carcinoembryonic antigen APC gene, pancreatic cancer, 6696 mobilization and stimulation with gas- characterization of new antigenic frag- gastric, 6735 trin ments inhibition by minor dietary constituents, clonal growth, small cell lung cancer adult feces, 4175 2085s cells, 6031 gene expression intestinal and renal multiple neuropeptides recombinant vaccinia virus vaccine, induction by azoxymethane, dietary fat growth, small cell lung cancer cells, nonhuman primate, 6917 and protein, 857 2737s immunoglobulin-like domains in HeLa liposome-entrapped pigments signaling and a-difluoromethylornithine cells polyethylene glycol-mediated delivery, platelet-derived growth factor-stimu- epitope analysis, 5647 fibroblasts, 6638 lated brain tumor cells, 6782 radioimmunotoxin lung stimulation of anchorage-independent intratumoral and whole-body distribu- potential chemopreventive agents, to-

7025

bacco-specific nitrosamine, 2719s ties with and without human papillomavi- mammary monoclonal antibody IMH2, 3739 rus infection, 5323 dietary linoleic acid, mouse skin tumor undifferentiated resistance to tumor necrosis factor promotion, 2049s thyroid gland, p53 mutations, 1369 sensitivity to cisplatin, 4758 effect of tamoxifen, preneoplastic cell Carcinoma, adrenal sensitization to cis-diamminedichloropla- proliferation, 1477 tumor progression tinum(II) metal penultimate cell surface oligosaccha- bryostatin 1, 3119 chemical pathology study section rides, 2222 Carcinoma, colonic workshop, 4058 Carcinoma, anaplastic circumvention of bleomycin resistance, methyl groups loss of keratin expression 2931 effects on DNA methylation, gene posttranslational regulation, 6603 cytotoxicity of Clostridium difficile toxin expression, 2071 s Carcinoma, basal cell A, 5096 multistage, 4837 ganglioside and adhesion molecule effect of tumor size new approaches to treating early lung HLA antigen expression, 3201 radiolabeled F(ab')2 fragments, anticancer, 2652s loss of heterozygosity ICAM-I monoclonal antibodies, newt squamous carcinoma chromosome lq22, 1494 1309 caricature of tissue renewal, 4858 p53 mutations, 3804 enhancement of 5-fluoro-2'-deoxyuridine nitrosamine-induced lung Carcinoma, bladder antineoplastic activity Ca~+/calmodulin antagonists, 2723s antigen presentation 5-benzyloxybenzyloxyacyclouridine, oral BCG-specific CD4 + T-cells, 4286 1729 eosinophil-derived transforming elevated expression ofpp60 ..... , 1457 increased expression growth factor-a, 389 interaction of photodynamic therapy human ribosomal phosphoprotein P0 origin of point mutations hyperthermia or ionizing radiation, messenger RNA, 3067 human tumor cells, 249 cell killing, 117 inhibition of cell growth pancreatic duct retinoblastoma gene product, 1968 interleukin 4, 275 K-ras mutation, Syrian golden ham- Carcinoma, breast intracellular metabolism ster, 4507 -associated DF3-P epitope 5-formyl tetrahydrofolate, 36 pathways that control cell division, 2362 cell surface expression, differentiating marker for dysplasia potent preventative action agents, 6365 sialyl LewisX antigen, 3138 a-carotene, 6583 BIM-23014C receptors microscopic localization rat liver chemical cross-linking assay, 843 sterically stabilized liposomes, 5135 chemoprevention, S-adenosyl-o-methi- DF3-associated antigen NAD(P)H:quinone oxidoreductase gene onine, 4979 tumor selective reactivity, monoclonal expression, 797 rat urinary bladder antibody, 2563 progression and differentiation heat-killed Escherichia coil, 5329 dietary fat and mammary tumorigenesis, S 19 ribosomal protein, laminin-bind- skin 2040s ing protein, 791 dietary energy and fat effects, 2035s estrogen-responsive transforming growth quantitative polymerase chain reaction extracellular matrix receptors, tumor factor-a gastrin and transforming growth fac- progression, 2966 retinoid antagonism, pS2 gene, 3938 tor-a messenger RNA levels, 2261 transformation and chemotherapy identification of major protein compo- spheroids Fourth Charles Heidelberger Confer- nents accumulation of I~ sulfhydryl boron ence, 3821 breast secretions, benign and malig- hydride, 1587 ultraviolet light-induced nant breast diseases, 95 sterically stabilized liposomes 3-aminobenzamide as cocarcinogen, IGFBP-3 gene expression pharmacokinetics, 6774 mouse skin, 4053 estrogen receptor status, 5100 xenografts urinary bladder inhibition of cell growth antitumor effect, 2'-deoxy-5-fluorouri- initiation by acrolein, 3577 interleukin 4, 275 dine conjugates, 132 working group on mechanisms intracellular metabolism Carcinoma, colorectai evaluation, carcinogenic risks, 2357 5-formyl tetrahydrofolate, 36 distribution of cells expressing myc pro- Carcinogenicity invasive and noninvasive teins, 5853 fluoxetine hydrochloride normal breast tissue and, c-myc/c- genetic changes of both p53 alleles rats and mice, 6931 erbB-2/Ki-67 expression, 2597 familial adenomatous polyposis, 3065 induction of colon adenocarcinoma overexpression of human transcription hereditary nonpolyposis 6-nitrochrysene, species differences, factor IID MCC-APC gene region in 5q21, 4530 1542 rapid induction, serum stimulation, p53 and 17p allelic loss, 1974 uracil 307 progression rationale, rats and mice, 1675 regression of skin recurrences loss of expression, DCC gene, 3801 Carcinoma intralesional injections, natural inter- Carcinoma, endometrial advanced ferons a and % 4571 clinical implications locoregional administration, etoposide, sporadic K-ras mutations, 2777 2440 detection of frequent allelic loss, chro- overexpression and mutation of p53, chromatin mosome 17q, 2624 1622 accessibility to DNA, okadaic acid, Carcinoma, cervical Carcinoma, epidermoid 6397 HPV 16-immortalized human endocervi- loss of metastatic phenotype human cell lines cal cells tissue inhibitor of metalloproteinase 2, invasion of connective tissue, uroki- squamous metaplasia, 4254 5597 nase and collagenase, 6754 papillomavirus-immortalized cervical ep- Carcinoma, gastric model of initiated mouse skin, 1439 ithelial cells c-sis/platelet-derived growth factor B -reactive BR64-doxorubicin conjugates down-regulation of keratin 14 gene insulin-like growth factor I, receptor antigen-specific activity, human tumor expression, v-Ha-ras transfection, messenger RNAs, 3453 xenograft models, 5693 5865 growth inhibition specificity and immunobiological proper- p53 gene alterations transforming growth factor-H, 295

7026

interleukin 4 receptor expression overexpression of human transcription epidermal growth factor receptor growth inhibition, 6059 factor liD monoclonal antibody, 5887 management rapid induction, serum stimulation, cell proliferation-inhibiting factor CA 72-4 measurement, TAG-72 as 307 human seminal plasma, similarity to serum marker, 1222 tumorigenic squamous cells transforming growth factor-~, 5821 multiple secretion formation of mucin gel, Le~-X oligo- combined antimicrotubule activity matrix serine proteinases, 5046 saccharides, 2923 estramustine and taxol, 4433 transforming growth factor-t3~ Carcinoma, mammary disruption of mitochondrial function by induction, apoptotic cell death, 4042 limonene-induced regression, 4021 suramin Carcinoma, gastrointestinal N-methyl-N-nitrosourea-induced rhodamine-123 retention, oxygen con- psoriatic epidermis and c-Ki-ras activation, pituitary-isografted sumption, 6953 amphiregulin messenger RNA, 3224 mice, 5732 3,-glutamylcysteine synthetase activity Carcinoma, H59 neu and ras oncogene-induced elevated glutathione levels, 5115 eradication of hepatic metastases early and late ovariectomy, 4102 growth combination chemoimmunotherapy, tumor types derived from epithelial and human prostatic acid phosphatase ac- 6254 myoepithelial cell lines, 1553 tivity, 4600 Carcinoma, hepatocellular Carcinoma, nasopharyngeal ras oncogene mutations aflatoxins as risk factors, 2114s absence of p53 gene mutations, 4787 human papillomavirus DNA, 5991 association with hepatitis C virus risk of receptors for la,25-dihydroxyvitamin assays based on hepatitis C virus pep- herbal medicine use, Epstein-Barr vi- D3, 515 tides, 5364 rus, 3048 sustained release formulations different pattern Carcinoma, non-small cell lung luteinizing hormone-releasing hor- chromosomal allele loss, 1504 allelotype mone antagonist SB-75, 2538 glutaminase and glutamine synthetase, loss of heterozygosity, 2478 Carcinoma, renal cell 1192 elevated DT-diaphorase activity advanced hepatitis B virus-positive messenger RNA content, 4752 Phase II trial, suramin, 5775 p53 mutations cluster at codon 249, p53 aberrations, 4799 allelic losses at chromosome 17p 1635 Carcinoma, ovarian relationship, allelic loss at chromo- HIP gene activation, 5089 abnormal structure and expression some 3p, 1881 increased expression p53 gene, 4196 biosynthesis of nephrocalcin, 1573 human ribosomal phosphoprotein P0 acquired cis-diamminedichloropla- growth regulation messenger RNA, 3067 tinum(II) resistance role, transforming growth factor-a, induction by choline-deficient D-amino mechanism-related circumvention, 3335 acid diet, 5042 3857 metastatic locoregional administration of etoposide ammine/amine platinum(IV) dicarboxy- interferon-3, and -a, 851 active specific immunization, 2440 lates, 822 prognostic factor, serum level of inter- loss of heterozygosity for loci ascitic leukin 6, 3317 chromosome 8p, 5368 targeting, OV-TL 3 immunolipo- molecular and cellular characterization, multiple somes, 646 348 p53 gene mutation pattern, diagnostic autocrine growth factor natural killer cells and marker, 3674 transforming growth factor-a, 341 rat model, 6279 p53 mutations cellular accumulation and cytotoxicity guanidinobenzoatase as marker Germany, 3220 cisplatin, tetraplatin and amminedi- characterization, purification, 3622 spectrum, 6358 butyratodichloro(cyclohexylamine) somatostatin receptors, 6074 Taiwan, 6098 platinum(IV), 6188 Carcinoma, small cell lung T-cell receptor V~ gene usage cisplatin-resistant antitumor activity tumor-infiltrating lymphocytes, 5913 cross-resistance to 5-fluorouracil, col- magainin analogues, 3534 tumor-associated antigen lateral sensitivity to methotrexate, induction of ICAM- 1 serodiagnosis, monoclonal antibody 3110 -r-interferon, specific targeting, 4890 KM-2, 4987 dipyridamole and cisplatin synergism, Carcinoma, squamous cell Carcinoma, Lewis lung 3566 allelotype of non-small cell lung carci- inhibition of murine tumor growth fine-scale deletion mapping noma interferon-inducing imidazoquinolina- distal long arm, chromosome 6, 5815 loss of heterozygosity, 2478 mine, 3528 loss of cis-diamminedichloroplatinum(II) caricature of tissue renewal, 4858 interleukin 6 gene transfection resistance head and neck suppression, malignant phenotype, selection for rhodamine- 123 resist- frequent p53 mutations, 5997 3679 ance, 1902 interstitial hypertension, 1993 metastatic mitochondrial defects radioimmunoscintigraphy, 99mTc-la- myelopoiesis-associated immune sup- cis-diammindichloroplatinum(l l)-re- beled monoclonal antibody E48 pressor cells, 6335 sistant cells, 1895 F(ab')2, 2569 tumor rejection Carcinoma, pancreatic inhibition of DNA interstrand cross-link T-cell subset analysis, metastasis, 6507 acinar removal Carcinoma, lung growth effects, gastrin-releasing pep- 5-fluorouracil, cisplatin, 6501 growth inhibition by cholera toxin tide, 3726 interleukin 2 receptors, 5963 correlation, GM, ganglioside expres- cytotoxicity of Clostridium difficile toxin lung sion, 3340 A, 5096 deletion mapping, short arm of chro- inhibition of outgrowth enhanced levels of annexins mosome 3, 873 unmodified anticarcinoma antibody Syrian hamsters, intrapancreatic allo- metastatic BR96, 3262 grafts, 163 quantitative mapping, 4'-iododeoxy- mediation of tissue invasion gastrin receptors, 6905 rubicin, 974 endogenous receptor-bound urokinase, Carcinoma, prostatic nasal 3043 androgen-independent formaldehyde-induced, p53 mutations,

7027

6113 neoplastic drugs, 2156 cells, 1195 oncogenic human papillomavirus type 16 Catechoi Cell culture male urethra, 5018 -induced glandular stomach lesions mammary epithelial cell lines phosphorus metabolite and cell cycle ki- reversibility, 787 in vivo properties, 1924 netic response a-Catenin Cell cycle radiation, 5299 loss of adozelesin radiation-sensitive and -resistant cells cadherin dysfunction, human cancer lethality, DNA alkylation, 5687 mutations, p53 gene, 6390 cell line, 5770 arrest in colonic adenocarcinoma skin Cathepsin B mechanisms of cell growth inhibition, carcinogen-specific mutational pattern, urokinase-type plasminogen activator dehydroepiandrosterone, 1372 p53 gene, 6400 and camptothecin-induced G2 arrest tumorigenic suppression inhibition, ovarian cancer cell inva- active DNA synthesis, 1823 nude mouse skin graft assay, 6487 sion, 3610 cellular kinetics Carcinoma, thyroid Cathepsin D rat mammary gland terminal end bud neutrophil chemotactic factors, 464 prognostic indicator epithelium, N-methyl-N-nitrosourea Carcinoma, transitional cell node-negative breast cancer, 5198 exposure, 5076 bladder Cathepsin L cellular mechanisms structural chromosome 1 aberrations, protease gene expression and regulation lack of chronic thermotolerance, HeLa 4929 fibroblast transformation, ras onco- $3 cells, 1101 carcinogenicity of uracil gene, 6682 chromatin structure and rationale, rats and mice, 1675 Cations staurosporine effects, normal and leu- Carcinoma, transmembrane simple organic kemic lymphocytes, 470 -associated antigen structural requirements, recognition by defective expression of secreted form, baculovi- multidrug-resistant cells, 6385 hormone-regulated apoptosis, differen- rus recombinant, 815 CD3 tiated prostate cells, 4313 Carcinoma, urinary bladder anti-CD3/interleukin 2-activated tumor- -dependent cytotoxicity T-antigens, 5030 draining lymph node cells Adriamycin and 4-hydroperoxycyclo- Carcinoma, Walker 256 cellular interactions, effector cell gen- phosphamide, modulation by novo- disposition characteristics of macromole- eration, 1129 biocin, 3515 cules -negative tumors effects of bioactive and cytotoxic agents perfused tissue-isolated tumor prepara- anti-CD3 monoclonal antibodies, multiparameter assessment, 4090 tion, 4396 Phase IA/B study, 2394 effects of 17~-estradiol metabolites Carcinomatosis -ricin A chain immunotoxins MCF-7 cells, 5926 VX2 leptomeningeal relation to cellular uptake, degradation effects of quercetin neurotoxicity, intrathecal 4-hydrope- kinetics, 5921 human leukemic T cells, 6676 roxycyclophosphamide, 6168 CIM induction of sister chromatid exchanges Cardiolipin BCG-specific extremely low doses, a-particles, 6394 multidrug-resistant cells induced by lipo- antigen presentation, bladder cancer inhibition of p34 cdc2 kinase activation somes cells, 4286 mitotic progression, Chinese hamster increased accumulation of drugs, 3241 CD7 ovary cells exposed to etoposide, Cardiotoxicity anti-CD7-ricin A chain immunoconju- 1817 animal model gate kinetic response and phosphorus metab- doxorubicin and mitoxantrone, epirub- efficacy, murine model of human T- olite icin and ICRF-187, 194 cell leukemia, 3056 radiation, squamous cell carcinoma, Cardiovascular disease CDI6 5299 aspirin and potential role of prostaglan- CA 19-9 antigen and many growth factors may not be growth dins antitumor effects, bispecific antibody factors, 501 colon cancer, 5575 targeting, 5713 pathways that control cell division, 2362 Carmustine CD24 p26-BCL-2 protein levels O6-alkylguanine-DNA alkyltransferase- major surface antigen proliferating lymphoma and leukemia mediated resistance small cell lung carcinoma, 5264 cell lines, 2802 streptozotocin, Phase I trial, 2456 CD33 prevention of G~- to S-phase transition a-Carotene humanized M 195 monoclonal antibodies antisense-mediated specific inhibition, preventive action against carcinogenesis, biological and immunological features, P120 protein, 5250 6583 6761 progression B-Carotene CD45 effects of genistein, normal lympho- keynote address anti-CD45 antibody cytes and leukemic MOLT-4 and Nutrition and Cancer Conference, selective radiation, hematolymphoid HL-60 cells, 6200 2024s tissue, 1228 radiation-induced apoptosis natural history differentiation-induced changes murine T-cell hybridoma, 883 intraepithelial neoplasia, chemopre- protein-tyrosine phosphatase, human -regulatory genes vention, 1651 leukemia cell lines, 4027 differentiation and retrodifferentiation, reduced cancer risk CD56 myeloid leukemia, 1445 vegetable and fruit intake, 2060s -LAK cell precursor -related expression of p120 nucleolar an- Carotenoids cancer patients receiving interleukin 2, tigen up-regulation of Connexin43 gene 6318 normal human lymphocytes, HL-60 expression, 5707 Cell adhesion and MOLT-4 cells, 3491 Carzelesin homotypic synchronization and growth inhibition cytotoxicity and antitumor activity, 4904 greatly reduced levels, metastatic tu- 3-hydroxypyridin-4-one iron chelators, Casein kinase II mor cell line, 1546 leukemia cell lines, 4591 phosphorylation of topoisomerase II inhibition of metastasis transition from G2 phase to mitosis enzyme-mediated DNA cleavage, anti- protein kinase C, B16FI melanoma phosphatidic acid and extracellular

7028

control, epidermal growth factor in c-Ha-ras antitumor effect, interferon and cyclo- A431 cells, 5627 8-hydroxyguanine at codon 12 sporine A, 6482 tumor cell kinetics point mutations, 3483 enhancement of 5-fluoro-2'-deoxyuridine antineoplastic ether phospholipid Chelating agent antineoplastic activity treatment, 2509 macrocyclic 5-benzyloxybenzyloxycyclouridine,co- tumor suppressor genes, 3246 humoral immune response, radioim- lon carcinoma, 1729 Cell death munoconjugates, 904 expression of O6-methylguanine-DNA protection by removal of extracellular Chelation methyltransferase drug anticarcinoma single-chain Fv molecules human medulloblastoma cell lines, Adriamycin, 4135 iodination, differential metabolic pat- 1144 Cell membrane terns, 6413 fludarabine suppression of cellular aggregates Chemoimmunotherapy arabinosylcytosine metabolism, high levels of episialin, 2318 combination chronic lymphocytic leukemia, 897 CEM cells eradication, hepatic metastases of car- glucuronide prodrugs human glucocorticoid receptor gene dele- cinoma H59, 6254 targeted enzyme activation, 4484 tion long-term growth suppression heat shock and exposure to cancer chemotherapeutic glioma xenografts, 3838 response of breast cancer cells, 3648 drugs, mutagens, 6612 Chemoprevention high-affinity transport of amino acid Central nervous system S-adenosyl-D-methionine across blood-brain barrier, 2191 interleukin 8 production rat liver carcinogenesis, 4979 immunohistochemical identification of neoplastic and infectious diseases, antioxidants and phase II enzymes P-glycoprotein 4297 green tea, 4050 large cell and immunoblastic lym- neoplasms bronchial and pulmonary carcinogenesis phoma, 3768 class VI intermediate filament nestin, focal sites, dogs and hamsters, 2687s -induced alopecia 5334 clinical evaluation of cancer agents, protection by 1,25-dihydroxyvitamin c-erbB-2: see also Oncogenes 2752s D3, 5123 overexpression colon carcinogenesis -induced death cell line establishment, human BSMZ 1,4-phenylenebis(methylene)seleno- prevention of, human interleukin 1, cell line, 5178 cyanate, 5635 4082 recognition by bispecific antibody 2B1 inhibition of carcinogenesis inhibitors of polyamine biosynthesis in vitro cytotoxic targeting, mononu- minor dietary constituents, 2085s block, TNF-induced macrophage acti- clear cells, 6832 inhibition of skin tumor promotion vation, 1891 Cerebrospinal fluid green tea, 6890 locoregional administration of etoposide blocking effect of human serum natural history of intraepithelial neopla- active specific immunization, advanced ricin A chain immunotoxin potentia- sia, 1651 carcinoma, 2440 tion, monensin, 623 new approaches to treating early lung microscopic localization interleukin 8 production cancer, 2652s sterically stabilized liposomes, colon neoplastic and infectious diseases, potential new agents carcinoma-bearing mice, 5135 4297 tobacco-specific nitrosamine, lung car- proliferation-linked regulation pharmacokinetics cinogenesis, 2719s type II IMP dehydrogenase gene, lym- intrathecal 4-hydroperoxycyclophos- potent preventative action phocytes and HL-60 cells, 258 phamide, VX2 leptomeningeal carci- a-carotene, 6583 site-dependent differences in sensitivity nomatosis, 6168 strategies LOX human melanoma tumors, nude pharmacokinetics of 1-13-D-arabinofura- lung and upper aerodigestive tract can- rats, 1347 nosylcytosine cer, 2758s systemic adjuvant treatment 1-~-o-arabinofuranosyluracil, 3818 tamoxifen evolving concepts, breast cancer, 2127 Cervical neoplasms preneoplastic cell proliferation, mam- transformation and human papillomavirus type 16 mary carcinogenesis, 1477 Fourth Charles Heidelberger Confer- E6/E7 genes, induction in mice, 4420 trials ence, 3821 gene expression, stimulation by ta- determination of biomarkers, interme- Chemoprevention moxifen, 6848 diate end points, 2707s methods and strategies inhibited gene transcription, leukore- xyleneselenocyanate lung cancer control, 2641s gulin and -r-interferon, 456 mammary cancer, 2402 China immortalized endocervical cells, squa- Chemosensitizers molecular dosimetry mous metaplasia, 4254 SR33557 aflatoxin-DNA adducts, 45 human papillomavirus-associated subcellular doxorubicin distribution, p53 mutations cluster at codon 249 HLA class II antigen expression, 4009 P388/ADR mouse leukemia cells, hepatitis B virus-positive hepatocellu- laminin receptor messenger RNA, 6440 lar carcinoma, 1635 1561 Chemotactic factors relation of obesity and body fat distribu- ~52Cf neutrophil tion relative biological effectiveness cell line from thyroid carcinoma, 464 endometrial cancer, 3865 inheritable effect of fission neutrons, Chemotherapy Chinese hamster ovary cells liver tumorigenesis, 1948 bcl-2 gene transfer 1-/3-D-arabinofuranosylcytosine-resistant c-fo$ resistance of lymphoid cells, cell death mutant mechanism of induction and DNA fragmentation, 5407 X-ray sensitivity, 319 active oxygen, 3952 clinical significance DNA repair-deficient CGP 31362 ras oncogene activation, human lung O6-methylguanine-DNA methyltrans- immunotherapy of renal adenocarcinoma cancer, 2665s ferase, alkylating agents, 32 systemic liposomes, interleukin 2 or 3'- cyclophosphamide/carboplatin exposure to etoposide interferon, 1155 DNA strand breaks and cross-links, inhibition, p34 cdc2 kinase, 1817 CGP 41251 ovarian cancer, 5622 gene- and strand-specific damage and re- inhibition of signal transduction, 5353 disseminated melanoma pair

7029

4-nitroquinoline 1-oxide, 4183 induction of hepatocellular carcinoma, upstream from c-myc, 6547 interaction of photodynamic therapy 5042 t(8;21) translocation hyperthermia or ionizing radiation, Cholinephosphotransferase disruption ofAML1 gene, single in- cell killing, 117 reversal of tron, 6945 metallothionein overexpression formation, I -~-D-arabinofuranosylcy- translocations nitrogen mustard-induced cytotoxicity, tosine-diphosphate-choline, 3886 cloning of ALL-l, leukemia, 2999 6853 Choriocarcinoma YAC clones mutational specificity differentiation of cell line, 3713 metaphase and interphase cytogenet- 1,3-bis-(2-chloroethyl)-l-nitrosourea, Chromaffin ics, 2590 4688 induction of differentiation in neuro- Chromosome 1 procainamide uptake blastoma cells chromosome 14 and multidrug resistance, 3539 distinct molecular and cellular pheno- loss of heterozygosity, subsets of ad- protection from spontaneous GC to AT types, 4402 vanced neuroblastoma, 1780 transitions Chromatin Harvey-ras-1 alleles and O6-methylguanine-DNA-methyltrans- carcinoma nonrandom abnormalities, mammary ferase, 6471 accessibility to DNA, okadaic acid, tumor progression, 4791 structure-activity study and design 6397 structural aberrations multidrug-resistant reversal com- radon-induced deletions in human cells, transitional cell carcinoma, bladder, pounds, computers, 4121 5126 4929 UV-sensitive excision repair-defective ro- structure Chromosome lp dent mutants induction of DNA double strand loss of heterozygosity eleventh complementation group, breaks, ionizing radiation, 1580 pheochromocytoma, multiple endo- 6690 structure and cell cycle crine neoplasia type 2 syndrome, Chloramphenicol acetyi transferase staurosporine effects, normal and leu- 770 O6-methylguanine-DNA methyltransfer- kemic lymphocytes, 470 Chromosome 1q22 use promoter activity structure-dependent binding of 7-ami- loss of heterozygosity Mer § and Mer- cells, 6404 noactinomycin D basal cell carcinoma, 1494 ChlorambucU normal and malignant bone marrow Chromosome 3 carcinogenic potency hematopoietic cells, 5007 mapping rodents and humans, 2464 topoisomerase II-targeted drugs topoisomerase lib genes, 231 -estrogen conjugate development of monomyelocytic leu- molecular and cellular characterization growth-inhibitory action, MCF-7 cells, kemia cell line, novobiocin, 2782 renal cell carcinoma, 348 1187 Chromosome short arm human glucocorticoid receptor gene dele- abnormalities deletion mapping, squamous cell carci- tion, 6612 adult T-cell leukemia/lymphoma, kar- noma and adenocarcinoma of lung, Chlorin 06 yotype review, 1481 873 lysyl chlorin 06 mixture human non-small cell lung cancer, Chromosome 30 photodynamic therapy, glioma, 1235 2702s allelic losses at chromosome 17p 8-Chloroadenosine allelotype analysis in osteosarcomas, human renal cell carcinoma, 1881 induction of human glioma cells 2419 deletions in head and neck carcinomas growth inhibition, 3994 different pattern of allele loss statistical ascertainment, allelic loss, Chloroethylnitrosourea multiple hepatocellular carcinoma, 1451 -treated DNA 1504 Chromosome 3013 O6-methylguanine-DNA methyltrans- inherited WT1 mutations tumorigenic reversion ferase and, cross-link, 6052 Denys-Drash syndrome, 6125 isogeneic nontumorigenic and tumori- Chlorophenols loss of heterozygosity genic uroepithelial cells, 1631 occupational exposure multiple tumor suppressor genes, Chromosome 3021 non-Hodgkin's lymphoma, 5503s esophageal cancer, 6525 reduced gene expression Chioroquinoxaline suifonamide polymorphic sites within MCC and small cell lung cancer, 1536 Phase I trial, 6619 APC, small cell lung cancer, 1996 Chromosome 5q Cholecystokinin molecular basis of lymphomagenesis, alterations in small cell lung cancer, receptor overexpression 5529s 1322 azaserine-induced neoplasms, pan- multidrug resistance Chromosome 5q33-qter creas, 3295 cytogenetic alterations, lung tumor cell FLT4 Cholecystokinin-B lines, 4361 novel receptor tyrosine kinase, 746 gastrin receptors nonlinkage of 16q markers Chromosome 6 pancreatic carcinoma, 6905 familial predisposition, Wilms' tumor, fine-scale deletion mapping Cholera toxin 6117 distal long arm, ovarian cancers, 5815 growth inhibition of human lung carci- 17p allelic loss Chromosome 6021 noma p53 mutations, grades II and Ill astro- clonal rearrangement correlation, GM~ ganglioside expres- cytoma, 2987 mesenchymal component, pulmonary sion, 3340 pathogenetic mechanisms chondroid hamartoma, 6224 Cholesterol B-cell non-Hodgkin's lymphoma, Chromosome 80 inhibitor simvastatin 5522s loss of heterozygosity for loci N,N'-bis(2-chloroethyl)-N-nitrosourea SR 4233-induced breaks hepatocellular carcinoma, colorectal and B-interferon, human glioma hypoxia and ionizing radiation, repair, cancer and lung cancer, 5368 cells, 4348 4473 Chromosome 9 low mitochondrial proton leak t(4; 1 l)(q21 ;q23) translocation short arm deviant bioenergetics, Ehrlich and altered 1 l-kilobase transcript, leu- molecular analysis of deletions, human AS30-D tumor cells, 4935 kemic cell lines, 3811 gliomas, 2523 Choline t(8; 14) translocation Chromosome 11 -deficient D-amino acid diet breakpoints in Burkitt's lymphoma, 17 and

7030

loss of alleles, breast cancer metasta- aflatoxin Brtransformed immunofluorescence, 2957 sis, 3914 protein kinase C overexpression, phor- liver oncogenesis allelic loss bol ester treatments, 990 molecular and genetic analysis, trans- parathyroid tumors, 6804 genomic rearrangements forming growth factor-o~ transgenic anchorage-independent growth DNA fingerprint assay, 5788 mice, 5171 suppression of tumorigenicity, BK vi- CI-941 mapping chromosomal breakpoints of rus-transformed mouse cells, 1297 clinical pharmacokinetics, 603 Burkitt's lymphoma nude mouse skin graft assay CI-973 t(8; 14) translocations, 6547 tumorigenic suppression, squamous Phase I pharmacokinetics, 6746 messenger RNA cell carcinoma, 6487 potential antileukemic activity, 4130 altered steady-state levels, L 1210 cells short arm Cigarette smoking resistant to deoxyadenosine, 2000 metastasis suppressor gene, prostatic asymptomatic smokers modulation by 4-hydroxynonenal cancer, 3486 urinary levels, bombesin-like peptides, globin gene expression, K562 cells, translocation breakpoint 2727s 4866 bcl-1 and PRAD1 loci, centrocytic lym- cancers of renal pelvis and ureter, 254 overexpression phoma, 5541s fluorometric assay cell line establishment, human BSMZ Chromosome 1 lp13 benzo[a]pyrene diol-epoxide-DNA ad- cell line, 5178 -1 lp15.5 sequences ducts, 6248 topoisomerase II cleavage invasive ovarian cancer, subclonal pro- genetic predisposition and differential effects, amsacrine and epi- gression factor, 6646 lung cancer detection and prevention, podophyllotoxins, 3125 Chromosome 1 lq13 2694s Coke oven workers amplification of genes Cinchonine detection of PAH-DNA adducts poor prognosis, operable breast cancer, circumvention of anthracycline resist- white blood cells, 1510 5229 ance, 2797 Colectomy Chromosome 13 Circadian rhythm subtotal microcell transfer variation of tumor blood flow familial adenomatous polyposis, 3552 reconstitution, retinoblastoma gene angiotensin II-induced hypertension, Colitis function, 6297 rat subcutaneous tumors, 912 dysplastic and cancerous ulcerative Chromosome 16q Cirrhosis loss of heterozygosity, p53/Rb/mcc/ third Wilms' tumor locus, 3094 glutaminase and glutamine synthetase, apc, 741 Chromosome 17 1192 Collagen chromosome 10 and liver nodules -induced activation p53 mutation, human astrocytoma clonal growth, hepatitis B virus-inte- Mr 72,000 type IV collagenase, fibro- progression, 674 grated hepatocytes, 6810 blastoid cells, 4540 mapping Cisplatin: see cis-Diamminedichioropla- Coilagenase topoisomerase IIa genes, 231 tinum(lI) invasion of connective tissue 17p tumor-related locus c-jun human carcinoma cell lines, 6754 pediatric primitive neuroectodermal induction by cis-diamminedichloropla- Mr 72,000 type IV tumors, 3391 tinum(II) tumor cell surface-associated binding second tumor suppressor gene myeloid leukemia, 878 site, 5845 malignant astrocytoma, 6716 Ciorambucil Mr 72,000 and 92,000 type IV Chromosome 17p -spermidine conjugate messenger RNA, human skin cancers, allelic losses targeting of tumor cells and DNA, 1336 human renal cell carcinoma, 1881 4190 matrix metalloproteinase enzyme proseg- deletion of loci in breast cancer cells Clostridium difficile ment fluorescence in situ hybridization, cytotoxicity of toxin A inhibition of tumor cell invasion, 3474 human colonic and pancreatic carci- highly conserved peptide sequence, frequent p53 gene mutations in blast cri- noma cell lines, 5096 2353 sis c-myb Colon chronic myelogenous leukemia, 6588 antisense RNA carcinogenesis p53 mutations oligodeoxynucleotides, proliferation of chemoprevention, 1,4-phenylene- deletions, preneoplastic lung lesions, neuroblastoma cells, 4221 bis(methylene)selenocyanate, 5635 6079 c-myc dietary fiber-mediated mechanisms loss of heterozygosity, malignant abundance of primary transcript carcinogenesis, 2055s glioma, 1427 growth-related genes, normal and leu- dysplastic crypt foci, 4291 Chromosome 17q kemic cells, 11 epithelial cell proliferation detection of frequent allelic loss altered gene expression modulation by dietary fiber, 5906 sporadic breast carcinoma, 2624 immortalized human breast epithelial loss of HLA antigens Chromosome 17q21 cell line, 1210 familial adenomatous polyposis, 3449 human prohibitin gene amplification neoplasia mutations in sporadic breast cancer, compared to HER2/neu amplification, folate deficiency, dimethylhydrazine- 1643 primary breast cancer, 1107 treated rats, 5002 Chromosome 19q deregulated tissues and cell lines tumor suppressor gene infrequent p53 mutation, mouse tu- mucin gene expression, 5971 human astrocytomas, oligodendrocytes mors, 1032 Colonic mucosa and mixed gliomas, 4277 down-regulation of antigen expression alterations in protein kinase C Chronic fatigue syndrome antisense DNA therapy, transgenic 1,2-dimethylhydrazine-induced colonic non-Hodgkin's lymphoma, 5516s mice, 6741 carcinogenesis, 2216 Chrysotile fiber expression Colonic neoplasms strong mutagen in mammalian cells, normal breast tissue, invasive and non- aspirin and potential role of prostaglan- 6305 invasive breast carcinoma, 2597 dins, 5575 C3H/I 0TI/2 cells expression in neuroblastoma cell lines azidothymidine-induced cytotoxicity

7031

methotrexate, 4069 malignant variant of SW480, 6840 camptothecin-induced G2 arrest calcium and vitamin D, 2067s metastases active DNA synthesis, 1823 dimethylhydrazine-induced sialyltransferase activity, hepatic tu- Cyclin D reduced growth rate, rats, 696 mor growth, 1775 gene amplification and expression disruption ofAPC gene metastatic esophageal cancer, 2980 retrotransposal insertion, L1 sequence, quantitation, tumor-reactive monoclo- Cyclin D1 643 nal antibody 16.88, 2603 messenger RNA DNA fingerprinting, 2174 perioperative immunotherapy platelet-derived growth factor, cultured elevation of thymidylate synthase recombinant interleukin 2, 5765 fibroblasts, 4522 5-fluorouracil treatment, addition of radiation sensitizer ~-Cyclodextrin leucovorin, 4922 potential superiority of hromodeoxy- antiangiogenic agents enhanced sensitivity uridine, 3698 potentiation of cytotoxic cancer thera- thermochemoimmunotherapy, 5271 reduction of local recurrence pies, primary and metastatic disease, functional receptors for gastrointestinal monoclonal antibody-drug conjugate, 6702 hormones, 1114 6323 Cyclooxygenase hepatic metastases responsiveness inhibition of skin tumor promotion inhibitory effect of RC-160, growth, transforming growth factors ~1 and ~2, green tea, 6890 6025 3705 role of microvascular damage highly malignant variant SW480 risk of photodynamic therapy, 4914 characterization, 6840 meal frequency, 3589 Cyclopentenylcytosine inhibition of growth by SMS 201.995, xenografts modulation of cytotoxic effect by pri- 917 thioether-lipid conjugate, l-~-o-arabi- mary metabolite, 3503 micrometastases nofuranosylcytosine, 1865 Cyclophosphamide targeted therapy, ~3~I-labeled monoclo- Colorectal polyps -carboplatin chemotherapy nal antibodies, 6036 natural history DNA strand breaks and cross-links, mouse and human intraepithelial neoplasia, chemopre- ovarian cancer, 5622 Phase I and Phase I! drug-metaboliz- vention, 1651 carcinogenic potency ing enzyme systems, 6567 Complementation groups rodents and humans, 2464 mutated ~2-microglobulin gene eleventh combination with D-histidinol HLA class I antigens, 1201 UV-sensitive excision repair-defective preclinical therapeutic studies, 3604 novel mechanisms of resistance rodent mutants, 6690 model system for testing anticancer 5-fluorouracil, different clinically rele- Computer drugs vant dose schedules, 1855 -assisted evaluation wap-ras transgenic mouse, 3733 potentiation of 5-fluorouracil antitumor novel antimitotic agents, action at tub- resistance in medulloblastoma, 5373 activity ulin level, 3892 single dose brequinar, 1660 automated structure evaluation method- no change in repair capacity, mouse proliferation and cell cycle ology lung irradiated three months, 1096 effects of ketoconazole, 6827 structure-activity study, multidrug-re- Cyciopropylpyrroloindole vaccine efficacy sistant reversal compounds, 4121 cytotoxicity and antitumor activity class II major histocompatibility com- simulations in new drug development carzelesin, 4904 plex molecules, 3460 amsacrine analogues, leukemia cell Cyciosporin xenografts lines, 209 immunosuppressive therapy increased tumor hypoxic fractions, Connective tissue acquired immunological disorders, preirradiation of transplantation identification of aluminum 5474s site, 2162 postvaccinal sarcomas, cat, 5391 Cyclosporine A Colony-forming units invasion by human carcinoma cell lines interferon and granulocyte/monocyte urokinase, urokinase receptor and in- antitumor effect, chemotherapy for acquired radioresistance, chronic ra- terstitial collagenase, 6754 disseminated melanoma, 6482 diation leukemogenesis, 1469 Connexin43 CYPIA1 Colony-stimulating factor complementary DNA dose-response relationships for chronic granulocyte transfection, C6 glioma cells, 4208 exposure receptors, human acute leukemia, CPT-11 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3052 mechanism of cross-resistance rat tumor model, 3436 macrophage ovarian cancer cell line, 328 Cyst enhanced invasiveness, carcinoma cell c-ras type lines, 3661 aflatoxin Brinduced mutations risk factors for breast cancer, gross Colorectal neoplasms sequence specificity, xeroderma pig- cystic disease of the breast, 1791 differential immunohistochemical detec- mentosum, 5668 Cystadenocarcinoma tion Creatine kinase various ovarian tumors amphiregulin and cripto, 3467 low mitochondrial proton leak glycosphingolipids, 416 distribution of cells expressing myc pro- deviant bioenergetics, Ehrlich and Cytidylyltransferase teins, 5853 AS30-D tumor cells, 4935 reversal of cholinephosphotransferase DNA polymerase B mutations, 4824 Cripto formation, 1-B-D-arabino furanosylcy- human RAP1A/Krev-1 locus amphiregulin and tosine-diphosphate-choline, 3886 loss of heterozygosity, 285 differential immunohistochemical de- Cytochrome P450 immunization with modified ovine sub- tection, normal colon and colorectal activation of heterocyclic amines maxilllary gland mucin tumors, 3467 presence of flavonoids, 2108s adjuvants, lgM and IgG antibodies to CSF-1 induction and inhibition sialylated Tn, 5663 receptor-positive carcinoma cell lines 2-amino-3,4-dimethylimidazo[4,5-f] interstitial hypertension, 6371 enhanced invasiveness, macrophage quinoline, chick and rat hepatocytes, loss of heterozygosity for loci colony-stimulating factor, 3661 3615 chromosome 8p, 5368 Cyclin B messenger RNA levels

7032

platinum anticancer drugs, hepatic mor growth in mice, 2628 Dendritic cells drug and steroid hormone metabo- Cytoplasm follicular lism, 540 resistance to N-benzyladriamycin-14-val- B-cell proliferation, maturation, 5554s metabolism of 4-(methylnitrosamino)-l- erate Denys-Drash syndrome (3-pyridyl)- l-butanone mouse J774.2 cells, 3409 inherited WT1 mutation, 6125 lung and liver microsomes, hepatoma transcriptional and posttranscriptional 2'-Deoxy-5-azacytidine cells, 1757 activation topotecan and new form responsible for mutagenic acti- urokinase plasminogen activator gene synergistic cytotoxicity, 2180 vation expression, 2489 Deoxycytidine kinase 2-amino-3-methylimidazo[4,5-j]quino- Cytosine mutations within gene line, liver, 758 epigenetic silencing resistance to 1-~-D-arabinofuranosylcy- Phase I and Phase II drug-metabolizing O6-methylguanine-DNA methyltrans- tosine, T-lymphoblasts, 2389 enzyme systems ferase, Mex- cells, 5257 2'-Deoxy-5-fluorouridine mouse and human colon tumors, 6567 Cytosine arabinoside conjugates potentiation of morpholino doxorubicin effects of bioactive and cytotoxic agents antitumor effect, thymoma and colon human liver microsomes, 4379 cell cycle, multiparameter assessment, carcinoma xenografts, 132 proliferation and cell cycle 4090 2-Deoxyglucose effects of ketoconazole, human cancer Cytostatic factor insulin and cell lines, 6827 generation of small cell lung cancer var- depletion of tumor ATP, magnetic res- resistance of murine lung tumors iant onance spectroscopy, 71 xenobiotic-induced cytotoxicity, 6797 resistance to LAK cells, 3310 2-Deoxy-D-glucose Cytochrome P450 2C Cytotoxic T lymphocytes inhibitory effect 3A enzymes and Adriamycin-induced modulation liver tumor growth, rats, 5794 3-hydroxylation of benzo[a]pyrene, host defenses, tumor-bearing mice, 4'-Deoxy-4'-iododoxorubicin 1868 3572 tumor cell resistance Cytochrome P450 3A4 human melanoma-specific Ehrlich ascites cells, 5701 C-oxidative metabolism human xenograft-nude mouse model, 4-Desacetylvinblastine-3-carboxyhydrazide 1-nitropyrene, human liver micro- adoptive immunotherapy, 394 long-term growth suppression somes, 6237 tumor-specific responses glioma xenografts, 3838 Cytochrome P450 IIEI inhibition by transforming growth fac- CZ-Desamino-C2-methyl-ApO-propargyl-5,8- genetic polymorphisms tor-B~, 1386 dideaz afolic acid racial variation, lung cancer risk, 6712 Cytotrophoblasts acquired resistance stable expression in mammalian cells transformation of human placental cells human lymphoblastoid cells, 1137 metabolic activation, nitrosodimethyl- temperature-sensitive Simian virus 40, 2-Desamino-2-methylaminopterin amine, 1796 6001 mode of action, 2148 Cytogenetics Desferrioxamine analysis D cell cycle synchronization and growth in- prospectively ascertained male germ hibition cell tumors, 2285 Dacarbazine 3-hydroxypyridin-4-one iron chelators, metaphase and interphase site-dependent differences in sensitivity 4591 YAC clones, 2590 LOX human melanoma tumors, 1347 cis-Diammine-l,l-cyclobutane dicarboxylate structural chromosome 1 aberrations Daunomycin platinum(II) transitional cell carcinoma, bladder, Adriamycin and tumor necrosis factor-a and 4929 interaction with sphinganine, HL-60 whole-body hyperthermia, 4096 Cytokeratins cell differentiation, 3593 Diamminecyclobutanedicarboxylato- basal and luminal cell type Daunorubicin platinum(II) colocalization, human prostate cancer, small unilamellar vesicles persistence of platinum-ammine-DNA 6182 selective in vivo localization, solid tu- adducts epithelial mors, 3255 gonads and kidneys, rats and tissues Harvey ras gene alterations, mouse ep- DC3F cells from cancer patients, 149 idermal keratinocytes, 680 camptothecin-resistant cell line cis-Diamminedichloroplatinum(II) Cytokines topoisomerase I alteration, 1848 acquired and inherent resistance gene expression DDT~ cells sensitivity to platinum compounds, transcription factors, Hodgkin and selective loss lung cancer cell lines, 5674 Reed-Sternberg cells, 3353 glucocorticoid-dependent responses, acquired resistance local availability 2516 mechanism-related circumvention, tumor rejection and systemic immu- 5-Deazaacyclotetrahydrofolate ovarian carcinoma, 3857 nity, granulocyte-T-cell cross-talk, metabolic effects and kill testicular nonseminomatous germ cell 4853 human T-cell leukemia, 4895 line, 1710 production of interleukin 7 Dehydroepiandrosterone l-/~-D-arabinofuranosylcytosineand genetic modification, murine fibrosar- cell growth inhibition and cell cycle ar- drug synergism, 4558 coma, 3931 rest binding of human single-stranded DNA regulation of cell function colonic adenocarcinoma, 1372 binding protein pathogenesis and disease, 6129 dehydroepiandrosterone sulfate and damaged DNA, 6375 responses to intraventricular injection of prediagnostic serum levels, risk of pre- cellular accumulation and cytotoxicity interleukin 2 menopausal breast cancer, 1 tetraplatin and amminedibutyratodi- leptomeningeal carcinomatosis, 1123 hepatocarcinogenicity in the rat, 2977 chloro(cyclohexylamine) secondary hematopoietic Dehydroepiandrosterone sulfate platinum(IV), ovarian carcinoma, tumor necrosis factor-a, acute myelo- potential implications for breast cancer 6188 genous leukemia blasts, 2197 risk combination with D-histidinol soluble ICAM-1 vegetarian and nonvegetarian teenage preclinical therapeutic studies, 3604 release by human melanoma cells, tu- girls, 578 dipyridamole and

7033

synergism, ovarian carcinoma, 3566 5,10-Dideazatetrahydrofolic acid ex vivo 5-fluorouracil and cellular localization of folate receptor method of leukemic cell purging, bone inhibition of DNA interstrand cross- drug toxicity, folate homeostasis, 6708 marrow expansion cultures, 6576 link removal, squamous cell carci- Diet 2',2'-Difluorodeoxycytidine 5'-triphosphate noma, 6501 amino acid-lowering cellular elimination -induced nephrotoxicity rate of melphalan entry, brain and mechanism of self-potentiation, 533 time dependence and selective modula- xenotransplanted glioma, 5590 a-Difluoromethylornithine tion, WR2721, 2257 2-amino-l-methyl-6-phenylimidazo[4,5- alteration in calcium signaling induction of c-jun expression b]pyridine platelet-derived growth factor-stimu- myeloid leukemia cells, 878 fate and distribution, 4682 lated brain tumor cells, 6782 lipophilic analogues entrapped in lipo- carbohydrates DL-a-Difluoromethylornithine somes, 6341 dysplastic crypt foci, 4291 -mediated inhibition of malignant cell loss of resistance choline-deficient D-amino acid growth selection for rhodamine-123 resist- induction of hepatocellular carcinoma, prevention, polyamine homologues, ance, ovarian carcinoma cells, 1902 5042 1840 modulation of P-450 messenger RNA cooked foods Digestive system levels chemical analysis, heterocyclic amines, neuroendocrine tumors hepatic drug and steroid hormone me- 2103s platelet-derived growth factor, recep- tabolism, 540 food-derived heterocyclic amines tors, 106 modulation of resistance P4503A proteins, flavonoids, 2108s Dihydrofolate reductase human malignant melanoma cells, food-derived mutagens and carcinogens, thymidylate synthase and DT-diaphorase 6790 2092s quantitation of gene expression, po- mutational specificity low-fat lymerase chain reaction, 108 human hypoxanthine guanine phos- tamoxifen adjuvant therapy, postmen- Dihydroorotate dehydrogenase phoribosyltransferase gene, 2866 opausal breast cancer patients, 5386 inhibition of activity by brequinar so- ovarian cancer cell line meal frequency and risk of colorectal dium, 3521 mechanism of cross-resistance, CPT- cancer, 3589 Dihydropyridine analogue 11,328 minor constituents reversal of in vivo resistance of tumor persistence of platinum-ammine-DNA inhibition of carcinogenesis, 2085s cells adducts nutritional factors Adriamycin, 3655 gonads and kidneys, rats and tissues development, non-Hodgkin's lym- Dihydropyrimidine dehydrogenase from cancer patients, 149 phoma, 5492s activity in peripheral mononuclear cells pharmacokinetics and blood flow vegetable and fruit intake systemic clearance, fluorouracil, 2899 hyperthermia effects, murine mam- reduced cancer risk,/~-carotene, 2060s 1,25-Dihydroxyvitamin 1)3 mary adenocarcinoma, 4965 vegetarian and nonvegetarian teenage protection from chemotherapy-induced quantitative ultrastructural effects girls alopecia, 5123 neurons, Lymnaea stagnalis, 963 hormone levels, risk of breast cancer, 1a,25-Dihydroxyvitamin D3 reduction of systemic exposure and tox- 578 receptors icity Dietary fat prostatic carcinoma cell line, 515 encapsulation, poly-lactide-co-glycol- w3 and w6 fatty acids Dilazep ide, 6653 irradiation and transfection, transfor- nitrobenzylthioinosine and dipyridamole resistance of human cervical carcinoma mation of cultured cells, 154 protection from 7-deazaadenosine, hu- cells dietary energy and fat effects man hematopoietic cells, 5879 sensitivity to cisplatin, tumor necrosis tumor promotion, 2035s Diltiazem factor, 4758 keynote address inhibition of cancer cell growth -resistant human ovarian carcinoma cell Nutrition and Cancer Conference, athymic mouse, 2413 lines 2024s 7,12-Dimethylbenz[a]anthracene ammine/amine platinum(IV) dicarbox- mammary tumorigenesis and, 2040s -induced mammary tumors ylates, 822 nutrition and cancer antitumor and endocrine effects, voro- cross-resistance to 5-fluorouracil, col- role of intervention trials, 2030s zole, 1240 lateral sensitivity to methotrexate, protein and energy intake antitumor effects, SMANCS, 1013 3110 azoxymethane-induced intestinal and rapid development, dietary fat, 662 -resistant ovarian carcinoma cells renal carcinogenesis, 857 -induced skin mitochondrial defects, 1895 rapid development of mammary tumors 12-O-tetradecanoylphorbol-13-acetate- sensitization of human cervical carci- 7,12-dimethylbenz[a]anthracene, SEN- caused promotion, green tea poly- noma cells CAR mice, 662 phenols, 6890 bryostatin 1, 3119 Dietary fiber -induced tumors and DNA adduct for- site-dependent differences in sensitivity -mediated mechanisms in carcinogenesis, mation LOX human melanoma tumors, 1347 2055s inhibition by 1,4-phenylene- tumor necrosis factor-a and modulation of colonic epithelial cell pro- bis(methylene)selenocyanate, mam- whole-body hyperthermia, 4096 liferation mary glands, 2402 Dibutyryl cyclic AMP histone acetylation, luminal short Dimethylhydrazine induction of differentiation in neuro- chain fatty acids, 5906 -induced colon tumors in rats blastoma cells N-2-(Diethylaminoethyl)-9-hydroxyellipti- reduced growth rate, 696 distinct molecular and cellular pheno- cinium chloride -treated rats types, 4402 DNA damage and cytoxicity in L1210 folate deficiency, development of co- Dicumarol cells, 1515 lonic neoplasia, 5002 xanthine dehydrogenase-mediated Mito- Differentiation-inhibitingprotein 1,2-Dimethylhydrazine mycin C metabolism, 6936 erythropoiesis inhibitor dysplastic crypt loci, 4291 5,10-Dideazatetrahydrofolate inhibition of activation, membrane -induced colonic carcinogenesis quantitation of folic acid enhancement protein kinase C, 6329 alterations, protein kinase C, 2216 antifolate synergism, 2228 Differentiation therapy Diphtheria

7034

amelanocyte-stimulating hormone-diph- synthetic c-Ha-ras, hypoxanthine, DNA adducts theria toxin fusion protein 1836 aflatoxin B~ interaction with melanotropin recep- interstrand cross-link formation molecular dosimetry, China, 45 tors, melanoma metastases, 2545 effect of O-benzylguanine, sensitivity benzo[a]pyrene diol-epoxide Dipyridamole of human tumor xenografts, l 17 l dosimetry, fluorometric assay, 6248 cisplatin and inhibition by 5-fluorouracil and cispla- covalent synergism, ovarian carcinoma, 3566 tin, squamous cell carcinoma, 6501 induction by tamoxifen, rodents, 1360 nitrobenzylthioinosine and dilazep lesions and growth inhibition by ICI 7,12-dimethylbenz[a]anthracene-induced protection from 7-deazaadenosine, hu- D1694 tumors man hematopoietic cells, 5879 time dependence, 5900 inhibition by 1,4-phenylene- DNA mitochondrial bis(methylene)selenocyanate, mam- accessibility in carcinoma chromatin differentiation, HT-29 colonic adeno- mary gland, 2402 nanomolar okadaic acid, 6397 carcinoma cells, 3718 metabolic activation and genotoxicity alkylation molecular probe for repetitive sequences heterocyclic arylamines, 2099s lethality and cell cycle effects, adozele- metastatic human tumor burden, nude metabolic activation of nitrosodimethyla- sin, 5687 mouse xenograft model, 2791 mine amplification nuclear and mitochondrial stable expression, cytochrome new approach for detection, restriction degradation, induction by teniposide, P450IIE 1, 1796 landmark genomic scanning, 3642 3384 misonidazole antisense origin of point mutations oxygen distribution, 9L gliosarcoma down-regulation of c-myc antigen human tumor cells, 249 tumors and spheroids, 3831 expression, transgenic mice, 6741 papillomavirus type 16 platinum-ammine -binding and nervous system-specific sensitivity of keratinocytes, growth persistence in gonads and kidneys, 149 transcription factor control by retinoids, 187 polycyclic aromatic hydrocarbons small cell lung cancer, 6121 plasmid detection in white blood cells, coke binding of 2-nitropyrene hepatitis B virus replication, well-dif- oven workers, 1510 metabolism in the rat, 1176 ferentiated hepatocyte cell line, 1329 determinants, human placenta, 1499 cellular transformation ploidy alteration DNA damage human papillomavirus type 11, 5872 hepatocarcinogens, nuclear enlarge- acquisition of growth-inhibitory response changes in ploidy and specific karyotypic ment, 1304 phorbol ester, 1907 changes potentiation of activity by bryostatin-1 activation of gadd153 promoter promotion with phenobarbital, rat l-fl-D-arabinofuranosylcytosine, HL- genotoxic agents, 5 liver, 955 60 cells, 6270 cytotoxicity and chemical analysis of heterocyclic amines radon-induced deletions in human cells, ellipticine and a structural analogue, cooked foods, 2103s 5126 L1210 cells, 1515 chloroethylnitrosourea-treated sensitive and specific detection molecular basis of lymphomagenesis, O6-methylguanine-DNA methyltrans- O6-methylguanine, various tests, 5307 5529s ferase and, cross-link, 6052 single-stranded binding protein protection from cell death CpG methylation binding to damaged DNA, cis-diammi- removal of extracellular drug, Adria- insulin-like growth factor II gene, hu- nedichloroplatinum(II), 6375 mycin, 4135 man smooth muscle tumors, 6516 SR 4233-induced chromosome breaks radiation-induced apoptosis double strand breaks hypoxia and ionizing radiation, repair, murine T-cell hybridoma, 883 chromatin structure, ionizing radia- 4473 subcellular distribution of mitoxantrone tion, 1580 strand breaks and cross-links human and drug-resistant murine cells, estrogen responsive elements chemotherapy, ovarian cancer, 5622 flow cytometry, 4000 cooperative estrogen receptor interac- structural chromosome 1 aberrations tumor promoter-induced oxidative events tion, 1073 transitional cell carcinoma, bladder, suppression, sarcophytol A, 2298 fibroblast 4929 DNA fingerprinting nuclear matrix attachment regions, targeting of tumor cells and assay Alu-polymerase chain reaction, 3807 chlorambucil-spermidine conjugate, genomic rearrangements, C3H/10TI/2 food-derived mutagens and carcinogens, 4190 cells, 5788 2092s tumor promoter-induced hydrogen per- histogenetic analysis formation of 7-(2-hydroxyethyl)guanine oxide formation ovarian germ cell tumors, 6823 molecular dosimetry, ethylene oxide, suppression by tamoxifen, human neu- survey of various human tumors 4328 trophils, 4969 metastases, 2174 fragmentation DNA, complementary DNA methylation resistance of lymphoid cells, bcl-2 gene cloning and messenger RNA expression alteration of pattern transfer, 5407 a-class glutathione S-transferases, flow cytometric detection, 5213 fragmentation and induction of apopto- mouse tissues, 314 methyl groups and carcinogenesis, 2071 s sis cloning for galactosyltransferase, 6158 T-cell receptor B-chain gene re- tumor necrosis factor-a, mammary ad- epithelial mucin arrangement enocarcinoma cells, 1342 tumor-associated epitopes, Epstein- acute myeloid leukemia, 6598 genotoxicity of environmental agents Barr virus-immortalized B-cells, DNA polymerase human mammary epithelial cells, 5617 5985 mutations in human colorectal cancer, glycosylase FLT4 4824 partial purification, cyclic carcinogen chromosome 5q33-qter, 746 DNA repair adduct 1,N6-ethenodeoxyadenosine, molecular cloning of Wilms' tumor collateral sensitivity to nitrosoureas 1377 urogenital system and brain, 6407 multidrug-resistant cells, verapamil, hemoglobin adducts as markers p120 5013 metabolic activation, tobacco-specific increased growth of NIH/3T3 cells, -deficient Chinese hamster ovary cell line carcinogens, 2698s transfection, 428 O6-methylguanine-DNA methyltrans- induction of mutation rat liver aryl sulfotransferase IV, 4779 ferase, alkylating agents, 32

7035

gene- and strand-specific damage phosphamide, Novobiocin, 3515 modulation of trenimon-induced cyto- 4-nitroquinoline 1-oxide, Chinese multidrug sensitivity phenotype toxicity hamster ovary cells, 4183 human lung cancer cells, 1666 rat hepatocytes, 3015 intracellular localization by antibodies overexpression NAD(P)H:quinone oxidoreductase gene methylguanine-DNA methyltransfer- amsacrine and etoposide hypersensitiv- expression ase, 6423 ity, yeast cells, 4467 colon carcinoma, 797 liposomes phosphorylation by casein kinase II thymidylate synthase and dihydrofolate pyrimidine dimer removal, UV skin protein kinase C, antineoplastic drugs, reductase cancer, 4227 2156 quantitation of gene expression, po- O6-methylguanine-DNA methyltransfer- -targeted drugs lymerase chain reaction, 108 ase development of monomyelocytic leu- Dysplasia epigenetic silencing, Mex- human kemia cell line, novobiocin, 2782 colonic adenoma-carcinoma sequence cells, 5257 tumor cell resistance sialyl Lewis~ antigen, marker for dys- protection of Chinese hamster ovary 4'-deoxy-4'-iododoxorubicin, Ehrlich plasia, 3138 cells, GC to AT transitions, 6471 ascites cells, 5701 natural history nucleotide excision repair DNA topoisomerase IIa intraepithelial neoplasia, chemopre- O6-alkylguanine-DNA alkyltransferase, II~ and vention, 1651 6983 mapping to human chromosomes 17 Dysplastic nevus syndrome efficient repair of O6-ethylguanine, and 3, 231 high levels of enhanced reactivation 6984 Doppler herpes simplex virus, skin fibroblasts, tumor necrosis factor resistance acute effects of tumor necrosis factor-a 53 increased cisplatin sensitivity, cervical lymphotoxin, subcutaneous rodent tu- carcinoma, 4758 mors, 2167 E urinary excretion of O6-butylguanine Doxorubicin N-nitroso-N-butylurea administration, -BR64 conjugates Eel rats, 6699 antigen-specific activity, human tumor nephroblastomas, 2575 DNA synthesis xenograft models, 5693 Effector cells camptothecin-induced G~ arrest, 1823 chronic cardiotoxicity animal model, 194 generation and tumor regression effects of bioactive and cytotoxic agents liposome-entrapped anti-CD3/interleukin 2-activated tu- cell cycle, multiparameter assessment, antibody-specific binding, lung cancer mor-draining lymph node cells, 4090 cells, 4817 1129 inhibition by bradykinin modulation of subcellular distribution Ehrlich tumor cells breast stromal cells, 334 SR33557, P388/ADR mouse leukemia low mitochondrial proton leak inhibition of hepatocytes cells, 6440 deviant bioenergetics, 4935 transforming growth factor-/~, cyclic response of breast cancer cells tumor cell resistance AMP, 3598 heat shock, chemotherapeutic drugs, 4'-deoxy-4'-iododoxorubicin, 5701 novel mechanisms of resistance to 5- 3648 Eicosanoids fluorouracil site-dependent differences in sensitivity aspirin and potential role of prostaglan- different clinically relevant dose sched- LOX human melanoma tumors, 1347 dins ules, colon cancer, 1855 Drug delivery colon cancer, 5575 prolonged inhibition by X-rays rapid tumor penetration production by human gastric cancer cell H-ras and v-myc oncogene transforma- single-chain Fv, other immunoglobulin line tion, rat embryo fibroblasts, 508 forms, 3402 relation to cell growth, 1744 DNA topoisomerase I Drug-metabolizing enzymes Ellipticine alteration in camptothecin-resistant cell Phase I and Phase II structural analogue and line mouse and human colon tumors, 6567 DNA damage and cytotoxicity, L 1210 Chinese hamster DC3F cells, 1848 Drug resistance: see also Multidrug resist- cells, 1515 overexpression in baby hamster kidney ance Elsamitrucin cells bcl-2 gene transfer Phase I trial and clinical pharmacology, hypersensitivity of clonal isolates, resistance of lymphoid cells, cell death 1406 camptothecin, 525 and DNA fragmentation, 5407 Embryo pseudogene cytotoxic activity of Mitomycin C ana- developing pancreas antisense RNA transcripts, 4280 logues stage-specific carbohydrate antigen DNA topoisomerase II buthionine sulfoximine, ethacrynic expression, 5744 amsacrine-sensitive and -resistant forms acid, 6666 Embryo cells computer simulations, new drug devel- ~,-glutamylcysteine synthetase activity Syrian hamster opment, 209 elevated glutathione levels, prostate carcinogen treatment, immortaliza- cleavage in human c-myc carcinoma cells, 5115 tion, 2253 differential effects, amsacrine and epi- reversal by PAK-2000, 3659 intracellular acidification, morphologi- podophyllotoxins, 3125 selenite cytotoxicity cal transformation, 144 growth and cell cycle progression ovarian tumor cells, 4812 regulation of c-jun andjun-B messen- effects of genistein, normal lympho- sensitivity of resistant human tumor cell ger RNA, prostaglandin E2, 6912 cytes and leukemic cells, 6200 lines Endocervical cells immunostaining in human leukemia tumor necrosis factor, Adriamycin, HPV 16-immortalized rhabdomyosarcoma cell lines, topoi- 6630 squamous metaplasia, 4254 somerase II inhibitors, 4248 Drug screening Endometrial neoplasms inhibition by azatoxin, 4478 smooth muscle a-actin promoter, ras- endothelin-1 gene expression and biosyn- -mediated DNA cleavage activity transformed cells, 6877 thesis, 554 antitumor quinolones, 2818 DT-diaphorase obesity and body fat distribution modulation of cell cycle-dependent cyto- elevated activity and messenger RNA China, 3865 toxicity content Endometrium Adriamycin and 4-hydroperoxycyclo- non-small cell lung carcinoma, 4752 malignant epithelial tumors

7036

clinical implications, K-ras mutations, lines, 3089 tary DNA, 5985 2777 platelet-derived growth factor receptor Epoxide hydrolase Endonuclease and, human glial tumors, 4550 Phase I and Phase II drug-metabolizing anoxia-inducible activity transforming growth factor-a and enzyme systems genomic instability, cancer cells, 4372 renal adenocarcinoma cell growth, mouse and human colon tumors, 6567 Endothelial cells 4356 Epstein-Barr virus acidic fibroblast growth factor-Pseudo- Epidermis herbal medicine use monas exotoxin chimeric protein psoriatic risk of nasopharyngeal carcinoma, antiangiogenic effects, 4995 gastrointestinal carcinoma, amphire- 3048 bone marrow-derived gulin messenger RNA, 3224 -immortalized B-cells rat prostate adenocarcinoma cells, dis- Epipodophyilotoxins tumor-associated epitopes, epithelial semination to bone, 4613 amsacrine and mucin complementary DNA, 5985 cerebral capillary topoisomerase II cleavage, c-myc, -induced B-cell lymphomas expression and functional activity, P- 3125 human peripheral blood leukocytes, glycoprotein, 6969 Epirubicin SCID mice, 5552s microtubule depolymerization chronic cardiotoxicity animal model, 194 molecular basis of lymphomagenesis, photofrin and light, 3443 Episialin 5529s vascular high levels National Cancer Institute Workshop murine model for antibody-directed suppression, cellular aggregation, 2318 etiological factors, non-Hodgkin's targeting, solid tumors, 5954 Epithelial cells lymphoma, 5430s vitronectin receptor altered p53 gene structure -positive donors and SCID mice up-regulated biosynthesis and expres- nickel exposure, 218 B-cell lymphoma, cytogenetic charac- sion, cancer cell adhesion, 2202 breast terization, 4678 Endothelin altered gene expression, immortalized primary immunodeficiencies stimulation of anchorage-independent HMT-3522 cells, 1210 genetic risk factors for lymphoma, cell growth cell lines of R3230AC rat mammary car- 5465s NRK 49F cells, 3011 cinoma -seropositive donors Endothelin-1 tumor types, 1553 heterogeneity, generation of immuno- gene expression and biosynthesis colonic blastic B-cell lymphomas, 2468 endometrial cancer cells, 554 modulation of proliferation, variation viruses other than HIV immunoreactive of dietary fiber, 5906 non-Hodgkin's lymphoma, 5479s mammary phyllode tumors, 4046 mammary Erythroleukemia cells Endothelium cloning of messenger RNAs, human differentiation -leukocyte interaction breast cancer, 6966 differential expression, ras protoonco- tumor microvessels, 4265 development, mammary preneoplasias, genes, 5979 Environment 1924 erythropoiesis inhibitor alkylating agents genotoxicity, environmental agents, inhibition of activation, membrane relevance, repair protein O6-alkylguan- 5617 protein kinase C, 6329 ine-DNA alkyltransferase, 1801 ovarian cancer Erythropoiesis origin of non-Hodgkin's lymphoma, interleukin la and ~ gene expression, inhibitor 5501s 2248 inhibition of activation, membrane Eosinophils prostatic protein kinase C, 6329 transforming growth factor-a acquisition of tumorigenic phenotype, Escherichia coli hamster oral carcinogenesis, 389 neu oncogene, 3174 adaptive response to alkylation damage rectal Epicateehins oxidation of methylhydrazines, muta- inhibition of skin tumor promoter- subtotal colectomy, familial adenoma- genic methylating derivatives, 3693 caused induction tous polyposis, 3552 thyroid heat-killed ornithine decarboxylase, green tea, rat urinary bladder carcinogenesis, 3582 growth-inhibitory effect, bovine sem- Epidermal cells inal ribonuclease, 4582 5329 regulatory elements initiated transformation Ha-ras-mediated mammalian cell carcinogen-induced neoplastic progres- altered expression, wild-type p53, 749 transformation, 983 sion, 3145 Epithelial neoplasms model of initiated mouse skin, 1439 endometrium Esophageal neoplasms Epidermal growth factor clinical implications, K-ras mutations, amplification and expression ectopic receptor expression 2777 human cyclin D gene, 2980 ZR-75-1 human breast cancer cells, Epithelium elevated expression 5082 intraepitheliai neoplasia ornithine decarboxylase gene, 6671 elevated membrane association natural history of, chemoprevention, loss of heterozygosity phospholipase C'rl, MDA-468 mam- 1651 multiple tumor suppressor genes, 6525 mary tumor cells, 4526 tracheal Esophagus extracellular control of transition squamous metaplasia, retinoid status Barrett's G2 phase to mitosis, phosphatidic acid, and keratin expression, 6144 persistent clonal areas, clonal expan- 5627 Epitopes sion, 2946 inhibition of signal transduction carcinoembryonic antigen expression carcinogenesis CGP 41251, 5353 immunoglobulin-like domains, HeLa p53 mutation, protein accumulation, protection from 1-/3-D-arabinofuranosyl- cells, 5647 6092 cytosine-induced alopecia monoclonal antibodies human and rat fibroblast growth factor, rat model, myogenic regulatory protein, 6431 metabolism of N-nitrosomethyl-n-amyl- 413 tumor-associated amine, microsomes, 3547 receptor Epstein-Barr virus-immortalized B- Estradiol human small cell lung cancer cell cells, epithelial mucin complemen- hormone levels

7037

vegetarian and nonvegetarian teenage selective inhibition, phosphatidylinosi- loss of colonic HLA antigens, 3449 girls, 578 tol phospholipase C, 2835 loss of expression of DCC gene tamoxifen adjuvant therapy and low-fat Ether phospholipid progression, colorectal cancer, 3801 diet antineoplastic treatment subtotal colectomy postmenopausal breast cancer patients, tumor cell kinetics, 2509 rectal epithelial cell proliferation, in- 5386 Ethylene oxide testinal bile acids, 3552 17B-Estradiol molecular dosimetry, 4320, 4328 Farming metabolites O6-Ethylguanine increasing incidence of non-Hodgkin's cell cycle events, MCF-7 cells, 5926 efficient repair, 6984 lymphoma, 5496s Estramustine dependence upon O6-alkylguanine-DNA non-Hodgkin's lymphoma and, 2447 taxol and alkyltransferase, human cells, 2008 pesticides and non-Hodgkin's lym- combined antimicrotubule activity, Ethylnitrosourea phoma, 5485s prostatic carcinoma, 4433 -induced toxicity Fat, body Estrogen mutagenicity and, O6-benzylguanine, obesity and antiestrogen and 3851 endometrial cancer, China, 3865 transforming growth factor gene O4-Ethylthymine Fatty acids expression, endometrial adenocarci- sensitive and specific detection ~3 and ~6 noma cells, 1704 HPLC prefractionation, other tests, transformation of cultured cells, irra- -chlorambucil conjugate 5307 diation and transfection, 154 growth-inhibitory action, MCF-7 cells, ET-18-OCHa dietary fiber-mediated mechanisms 1187 growth-inhibitory effects carcinogenesis, 2055s formation and action differential susceptibility, A427 and free polyunsaturated inhibition, novel compounds, 610 A549 cell lines, 2813 anticancer effects, rabbit bearing VX-2 hormonal effects Etoposide tumor, 400 prostatic adenocarcinoma, 4663 amsacrine hypersensitivity growth-inhibitory effects of ET- 18-OCH3 123I_labeled overexpression of DNA topoisomerase differential susceptibility, A427 and estrogen receptor-directed radiotoxic- II, yeast cells, 4467 A549 cell lines, 2813 ity, 5752 exposure of Chinese hamster ovary cells luminal short chain -independent breast cancer cell line inhibition, p34 cdc2, 1817 modulation of colonic epithelial cell programmed cell death, 3418 induction of differentiation by bufalin proliferation, variation of dietary fi- neu and ms oncogene-induced mammary human leukemia cells, 4634 ber, 5906 carcinomas locoregional administration Feces early and late ovariectomy, 4102 active specific immunization, advanced adult persisting sensitivity carcinoma, 2440 new antigenic fragments, carcinoem- resistance to tamoxifen, antiestrogen phosphorylation of topoisomerase II bryonic antigen, 4175 binding site activity, 4106 casein kinase II, 2156 Fern, bracken progestins in oral contraceptives relationship to classical multidrug resist- association of bovine papillomavirus type breast cancer cell proliferation, 6539 ance phenotype, 2874 2 responsive elements Exemestane bladder cancer in cattle, 6898 interaction, cooperative estrogen re- Phase I and endocrine study a-Fetoprotein ceptor, 1073 postmenopausal women, 5933 plasma urokinase-type plasminogen acti- -responsive transforming growth factor- Exotoxin A vator antigen ~/pS2 gene recombinant single chain antibody-toxin primary liver cancer, 1717 retinoid antagonism, breast carcinoma, tumor cell growth inhibition, erbB-2 Fetus 3938 receptor, 6310 brain transplants steroid and growth factor modulation Extracellular matrix oncogene complementation, 3760 aromatase activity, MCF-7 and T47D receptors Fibroblast growth factor cell lines, 1411 mouse skin carcinogenesis, tumor pro- basic -stimulated estrogen receptor gression, 2966 human prostate cancer cells, 571 transcriptional repression, neu proto- Eye reversal of autocrine transformation, oncogene, 6624 inhibition of ocular melanoma aromatic anionic compounds, 5656 tamoxifen-sensitive and -resistant sub- MuUerian inhibiting substance, 1182 RNA and protein levels, melanocytes lines and metastatic melanoma cells, MCF-7 cells, responses to retinoic 5024 acid, 6164 saporin mitotoxin, antitumor activity, Ethacrynic acid Fab' fragments 227 buthionine sulfoximine and whole immunoglobulin and gene expression in dermal fibroblasts cytotoxic activity, Mitomycin C ana- monoclonal antibodies, high molecular induction by tumor promoters, 1040 logues, 6666 weight-melanoma associated anti- protection from 1-~-o-arabinofuranosyl- Ethanol gen, 2497 cytosine-induced alopecia cancer and, 2119s F(ab')2 fragments epidermal growth factor, rat model, isopropyl alcohol or radiolabeled 413 reduced blood clearance, N-nitrosodi- effect of tumor size, anti-ICAM-I -Pseudomonas exotoxin chimeric protein methylamine, 1463 monoclonal antibodies, 1309 antiangiogenic effects, endothelial l,N6-Ethenodeoxyadenosine Familial adenomatous polyposis cells, 4995 partial purification of DNA glycosylase, APC gene receptor 1377 mutation in human gastric cancer, human leukemia cells, 2004 Ether lipid 3231 N-sam gene, T-lymphocytic tumors, membrane peroxidative damage en- genetic changes in both p53 alleles 3367 hancement, 6045 early carcinoma, 3065 Fibroblastoid cells Ether lipid analogues location of germ-line mutations normal and malignant cytotoxic APC gene, 4055 collagen-induced activation, Mr 72,000

7038

type IV collagenase, 4540 effects of genistein, normal lympho- dihydropyrimidine dehydrogenase ac- Fihroblast(s) cytes and leukemic cells, 6200 tivity, peripheral mononuclear cells, anoxia-inducible endonuclease activity progesterone receptor content 2899 genomic instability, cancer cells, 4372 remodeling by tamoxifen, breast can- Fluoxetine hydrochloride breast stromal cells cer, 593 carcinogenicity studies inhibition of DNA synthesis, bradyki- subcellular distribution of mitoxantrone rats and mice, 6931 nin, 334 human and drug-resistant murine cells, Folate cyclin D 1 messenger RNA 40O0 -based thymidylate synthase inhibitor platelet-derived growth factor, 4522 Fludarabine acquired resistance, lymphoblastoid DNA nuclear matrix attachment regions potentiation of arabinosylcytosine me- cells, 1137 Alu-polymerase chain reaction, 3807 tabolism deficiency -HeLa cell hybrids lymphocytes, chronic lymphocytic leu- development of colonic neoplasia, di- oncogenic potential, tumor-associated kemia, 897 methylhydrazine-treated rats, 5002 antigen, 616 Fluid pressure 2-desamino-2-methylaminopterin hsp70 expression interstitial mode of action, 2148 enhanced cell survival, RNA and pro- human adenocarcinoma, SCID mice, exogenous tein synthesis, 3667 6553 thymidylate synthase gene mutation, interaction of photodynamic therapy Fluorescence adenocarcinoma, 558 hyperthermia or ionizing radiation, photobleaching receptor GP38 cell killing, 117 bivalent interaction, apparent affinity, normal and malignant cell lines and long-term cell culture of NIH 3T3 cells 4157 tissues, 3396 individual transforming events, epige- Fluorescence in situ hybridization Folic acid netic induction, 667 structural chromosome 1 aberrations cellular localization of folate receptor normal human transitional cell carcinoma, bladder, drug toxicity, folate homeostasis, 6708 intrinsic radiosensitivity, 6348 4929 enhancement of antifolate synergism potent and specific inhibition by Radici- Fluorine-18 quantitation, 2228 col -labeled Mel-14 monoclonal antibody (6S)-Folinic acid p60 ..... protein kinase, 6926 F(ab')2 fragment 5-fluorouracil and prolonged inhibition of DNA synthesis localization, subcutaneous xenograft pharmacokinetics and toxicity, ad- X-rays, transformation by H-ras and v- model, 5054 vanced cancer, 2408 myc, 508 Fluorodeoxyuridine Food transformation by ras oncogenes radiosensitization cooked beef protease gene expression, regulation, thymidylate synthase inhibition, cell human exposure to carcinogens, 6216 6682 synchronization, 1687 Forestomach Fibroneetin 5-Fiuoro-2'-deoxyuridine benzo[a]pyrene-induced mouse neoplasia aS~l integrin receptor enhancement of antineoplastic activity inhibition, Japanese-style fermented proliferative response, quiescent hu- 5-benzyloxybenzyloxybenzylacyclouri- soy sauce, 1754 man melanoma cells, 4499 dine, colon carcinoma, 1729 Formaldehyde Fibrosarcoma Fluoromycin -induced nasal squamous cell carcinoma cells transduced with IL-6 gene synthesis and evaluation, 709 p53 mutations, 6113 reduced tumorigenicity, decreased 5-Fluorouracil 5-Formyi tetrahydrofolate metastatic potential, 6020 combination chemoimmunotherapy intracellular metabolism genetic modification eradication, hepatic metastases of car- human breast and colon cell lines, 36 production of interleukin 7, host cell cinoma H59, 6254 Fostriecin infiltration and tumor immunity, combination with D-histidinol cytostatic and cytotoxic effects 3931 preclinical therapeutic studies, 3604 HL-60 and MOLT-4 cells, 1530 growth-regulatory effects -containing drug combination Friend leukemia cells phosphatase inhibitors and tumor ne- regression, advanced breast tumors, inhibition of visceral metastases crosis factor, tumor and normal 4074 monoclonal antibody, role of immune cells, 2557 cross-resistance system, 2880 postvaccinal sarcomas in the cat, 5391 cisplatin-resistant human ovarian car- Fucosylceramide radiation-induced cinoma, 3110 immunoreactive nonglycolytic acidification, nuclear cis-diamminedichloroplatinum(II) and preferential expression, lung adenocar- magnetic resonance spectroscopy, inhibition of DNA interstrand cross- cinoma, 4408 1259 link removal, squamous cell carci- Fv molecules retinoic acid inhibition noma, 6501 single chain serum-induced c-los transcription, elevation of thymidylate synthase iodinated vs. radiometal chelated mol- 2384 prevention by addition of leucovorin, ecules, differential metabolic pat- Flavone acetic acid murine colon tumors, 4922 terns, 6413 antitumor effect of hyperthermia in (6S)-folinic acid and mice, 3306 pharmacokinetics and toxicity, ad- Flavonoids vanced cancer, 2408 food-derived heterocyclic amines model system for testing anticancer gadd153 promoter P4503A proteins, 2108s drugs activation by genotoxic agents Flow cytometry wap-ras transgenic mouse, 3733 response to DNA damage, 5 detection of drugs novel mechanisms of resistance B-Galactosyltransferase alteration, DNA methylation pattern, different clinically relevant dose sched- body fluids 5213 ules, colon cancer, 1855 mouse monoclonal antibodies, 6153 expression of N-myc, c-myc, and MDR-1 potentiation by brequinar complementary DNA cloning, 6158 proteins uridine nucleotide pools, routine 4~-Galactosyltransferase immunofluorescence, 2957 model colon 38 tumor, 1660 elevation of activity for paragloboside growth and cell cycle progression systemic clearance sera, patients with cancer, 1875

7039

Gangliosides tion, L1 sequence in colon cancer, E6/E7 adhesion molecule and HLA antigen 643 induction of uterine cervical neopla- expression familial adenomatous polyposis, muta- sias, human papillomavirus type 16, basal cell carcinoma lesions, 3201 tion in human gastric cancer, 3231 4420 GMI frequent somatic mutations, human encoding components of respiratory growth inhibition of lung carcinoma, pancreatic cancer, 6696 burst oxidase cholera toxin, 3340 location of germ-line mutations, famil- tumor necrosis factor and 7-interferon, cell surface accessibility ial adenomatous polyposis, 4055 differentiation of myeloid cell lines, malignant melanoma cells, 4948 -based assay system for drug screening 2530 glycosylation pathways in biosynthesis smooth muscle a-actin promoter, ras- erbA-a2 melanoma and neuroblastoma cells, transformed cells, 6877 increased messenger RNA levels, neo- 5725 bcl- l plastic rodent cells, 2186 hepatoma amplification and expression, human erbB-2 novel I-type glycolipid, NeuAca2-6 solid tumor cell lines, 2460 animal model of human gastric cancer, Gal structure, 4805 BCL-2 anti-erbB-2 monoclonal antibodies, mimicry cell cycle analysis, proliferating lym- 2771 murine/human chimeric anti-idiotype phoma and leukemia, 2802 estrogen receptor antibody, 1681 glucocorticoid-induced apoptosis, pre- analysis of Pvull RFLP, breast cancer, shed from tumor B leukemia, 491 77 localization, serum lipoproteins, 810 resistance of lymphoid cells, cell death expression and DNA methylation Gastric neoplasms and DNA fragmentation, 5407 methyl groups, carcinogenesis, 2071s carcinogenesis, 6735 BCR Fli-1 eicosanoid production metaphase and interphase cytogenet- structure and expression, 5833 relation to cell growth, 1744 ics, YAC clones, 2590 Gadd45 and Gadd153 messenger RNA frequent loss of heterozygosity cancer cells of plasmids levels DCC locus, 3099 antisense RNA, human papillomavirus hypoxia, glucose-regulated proteins, mutation ofAPC gene type 18, 4706 3814 familial adenomatous polyposis, 3231 cell cycle-regulatory genetic predisposition and smoking p53 gene mutations, 4335 differentiation and retrodifferentiation, lung cancer detection and prevention, preferential gene expression myeloid leukemia, 1445 2694s embryo stomach, 3372 c-fos growth-related therapy of an animal model induction by static magnetic field ex- abundance of primary transcript, nor- anti-erbB-2 monoclonal antibodies, posure, HeLaS3 cells, 6522 mal and leukemic cells, 11 2771 chromosome region 3p21 Ha-/Ki-/N-ras activation Gastrin reduced expression, small cell lung chemically induced liver tumors, CD-1 stimulation of Ca 2+ mobilization cancer, 1536 mice, 3347 clonal growth, small cell lung cancer c-myc and globin expression HIP cells, 6031 modulation by 4-hydroxynonenal, activation, human primary liver can- transforming growth factor-a messenger K562 cells, 4866 cer, 5089 RNA levels Connexin43 H-2Kb quantitative polymerase chain reac- up-regulation by carotenoids, 5707 expression in B16 cells, liver metas- tion, colonic carcinoma, 2261 CYP3A tases suppression, 4036 Gastrin-releasing peptide potentiation of morpholino doxorubi- human glucocorticoid receptor antagonist RC-3095 cin, human liver microsomes, 4379 deletion, exposure to cancer chemo- bombesin, human breast cancer cell DCC therapeutic drugs and mutagens, lines, 4545 frequent loss of expression, ductal 6612 anti-growth factor therapy pancreatic adenocarcinoma, 2616 human hypoxanthine guanine phosphori- pharmacologically guided end point, frequent loss of heterozygosity, gastric bosyltransferase 2743s cancer, 3099 mutational specificity, cisplatin, 2866 growth effects on acinar pancreatic carci- loss of expression, progression of colo- human prohibitin noma, 3726 rectal carcinoma, 3801 location on chromosome 17q21, muta- Gastrointestinal hormones defective organ microenvironments tion in sporadic breast cancer, 1643 functional receptors metastases incidence and distribution, IGFBP-3 colon cancer cells, 1114 mutant mice, 2304 estrogen receptor status, human breast Gastrointestinal tract neoplasms deoxycytidine kinase carcinoma, 5100 cytotoxicity of Clostridium difficile toxin resistance to l-~-D-arabinofuranosylcy- IL-6 A, 5096 tosine, T-lymphoblasts, 2389 reduced tumorigenicity, transduced fi- Geldanamycin determination of biomarkers brosarcoma cells, 6020 selective tumoricidal activity, 1721 intermediate end points, chemopreven- incorporated marker Gene tion trials, 2707s fate of clonal lineages, neoplasia and AML1 D-factor metastasis, 1737 disruption within a single intron, regulation, HTLV-I T-cell lines, 6961 inosine-5'-phosphate dehydrogenase t(8;21) chromosomal translocation, differentiation-related solid tumor tissues, tumor cell lines, 6945 induction by camptothecin, U-937 5826 amplification cells, 1245 interferon-stimulated chromosome 11 q 13 region, operable dissociation of sensitivities chronic myelogenous leukemia, 1087 breast cancer, 5229 tumor promotion and progression, interleukin 1/~ amplification in cancer DNA outbred and inbred SENCAR mice, inhibition by antisense oligonucleotide, new approach for detection, restriction 3432 LAK cells, 4954 landmark genomic scanning, 3642 early response loss of heterozygosity APC parathyroid hormone-like peptide, chromosomes 1 and 14, subsets of ad- disruption by retrotransposal inser- 3103 vanced neuroblastoma, 1780

7040

Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1992 American Association for Cancer Research. SUBJECT INDEX TO VOLUME 52 mapping chromosomal breakpoints of RB1 and TP53 p53 mutations Burkitt's lymphoma metastasizing testicular mixed gonadal screen for, based on transcriptional ac- t(8;14) translocations, 6547 stromal tumor, 6705 tivation, 6976 matrix metalloproteinases RCK Glial neoplasms metastasis, transformed rat cell lines, t(l 1; 14) translocation, distinction from amplification/overexpression 4942 MLL/AII-1 gene, 6083 platelet-derived growth factor and epi- MCC-APC retinoblastoma dermal growth factor receptors, hereditary nonpolyposis colorectal car- breast cancer, 2991 4550 cinoma, 4530 reconstitution of function, microcell Glioblastoma MDR-1 transfer of chromosome 13, 6297 stimulation of growth by stem cell factor expression in neuroblastoma cell lines, retroviral vector-mediated transfer c-kit expression, 3498 immunofluorescence, 2957 human renal cancer cells, 6229 Glioblastoma mnltiforme O-methylguanine-DNA methyltransfer- S14 putrescine and spermidine depletion ase promoter activity abundance of primary transcript, nor- calcium signaling, 6782 Mer + and Mer- cells, 6404 mal and leukemic cells, 11 Giioma modification of murine fibrosarcoma SAS amplification accumulation of I~ production of interleukin 7, host cell soft tissue sarcomas, 3746 central degenerative areas, sulfhydryl infiltration and tumor immunity, second tumor suppressor boron hydride, 1587 3931 chromosome 17, malignant astrocy- cell transfection with connexin43 com- MUC1 toma, 6716 plementary DNA, 4208 tissue-specific expression, transgenic selective loss high-grade mice, 1954 glucocorticoid-dependent responses, developmental regulation of annexin mucin DDT~ cell variant, 2516 II, human brain, 6871 expression, colonic tissues and cell -specific oligonucleotide probes measurement of thymidine replace- lines, 5971 a/u/~r and microsomal rat glutathione ment, 5-iododeoxyuridine, 719 myc S-transferases, 5797 induced by 8-chloroadenosine distribution in colorectal epithelium, surfactant protein C growth inhibition, 3994 polyps and malignant tumors, 5853 SV40 large T antigen, pulmonary ade- malignant nm23 nocarcinoma, 5342 boron neutron capture therapy, 4672 clonal populations, metastatic murine tat p53 mutations, loss of heterozygosity, and human neoplasms, 5808 up-regulation of interleukin 4 recep- 1427 messenger RNA, metastatic malignant tors, HIV-1, 3787 mixed melanoma disease progression, 6088 T-cell receptor ~-chain tumor suppressor gene, chromosome N -sam rearrangement, acute myeloid leuke- 19q, 4277 fibroblast growth factor receptor, T- mia, 6598 molecular analysis of deletions lymphocytic tumors, 3367 transformation and chemotherapy short arm of chromosome 9, 2523 p53 Fourth Charles Heidelberger Confer- photodynamic therapy deletions and human papillomavirus ence, 3821 lysyl chlorin p6/chlorin p6 mixture, infection, human head and neck can- tumor suppressor 1235 cer, 4832 loss of heterozygosity, esophageal can- platelet-derived growth factor and its re- mutations, endocrine tumorigenesis, cer, 6525 ceptors, 3213 5061 tumor suppressor genes simvastatin synergism mutations, human gastric cancer, 4335 Third Annual Pezcoller Symposium, N,N'-bis(2-chloroethyl)-N-nitrosourea, mutation spectrum, bone and soft tis- 3246 B-interferon, 4348 sue sarcoma, 6194 vascular endothelial growth factor xenograft immunotherapy mutation spectrum, hepatocellular car- PDGF-induced transcription, protein labeled monoclonal antibody 425, epi- cinoma, 6358 kinase C, 4821 dermal growth factor receptor, 121 pathways that control cell division, 2362 WTI mutations xenografts placental-like alkaline phosphatase inheritance, Denys-Drash syndrome, long-term growth suppression, che- transcriptional regulation, induction 6125 moimmunotherapy, 3838 by sodium butyrate, 3378 Genetics xenotransplanted PML-RARa chimeric product molecular melphalan entry, amino acid-lowering acute promyelocytic leukemia-specific early diagnosis and screening, lung diet, 5590 t(15; 17) translocation, 3687 cancer, 2658s Gliosarcoma polymorphisms Genistein 9L tumors and spheroids racial variation and lung cancer risk, growth and cell cycle progression misonidazole adducts, oxygen distribu- cytochrome P450IIE 1, 6712 normal human lymphocytes, leukemic tion, 3831 preferential expression in embryo stom- MOLT-4 and HL-60 cells, 6200 Globin ach Genotoxic agents gene expression gastric cancer, 3372 activation of gaddl53 promoter modulation by 4-hydroxynonenal, pS2 response to DNA damage, 5 K562 cells, 4866 estrogen-responsive TGF-a and reti- Genotoxicity Glucocorticoid noid antagonism, breast carcinoma, environmental agents bcl-2 gene transfer 3938 human mammary epithelial cells, 5617 resistance of lymphoid cells, cell death p53: see p53 Germany and DNA fragmentation, 5407 tab2 p53 mutations bombesin and peripheral blood mononuclear cells, hepatocellular carcinoma, 3220 stimulation of breast cancer cells, en- hematological and solid tumors, Germ cell neoplasms dothelin production, 1786 3083 cytogenetic analysis, 2285 -dependent responses RB1 multiple biological markers selective loss, DDTI cell variant, 2516 failure to reverse malignant pheno- platinum-based therapy, 3558 -induced apoptosis type, human tumor cell lines, 654 Germ line BCL-2 involvement, human pre-B leu-

7041

kemia, 491 mouse and human colon tumors, 6567 association of cyst type receptor gene deletion Glutathione transferase risk factors for breast cancer, relapse exposure to cancer chemotherapeutic nitroreductases and rate, 1791 drugs, mutagens, 6612 action on 4-nitroquinoline l-oxide, in- Gross cystic disease fluid protein-15 Glucosamine duction by butylated hydroxyanisole, identification of major protein compo- modulation of UDP~ 58 nents small cell lung cancer, 3~p nuclear Glutathione transferase z- breast secretions, benign and malig- magnetic resonance, 3782 predictor for treatment nant breast diseases, 95 Glucose different stages, acute nonlymphoblas- Growth factor B -regulated proteins tic leukemia, 3281 c-sis/platelet-derived Gadd45 and Gadd153 messenger Glycerophospholipids receptor messenger RNAs, primary RNA, hypoxia, 3814 ether lipid class of antineoplastic agents human gastric carcinoma, 3453 systemic hyperinsulinemia membrane peroxidative damage en- Growth factors cancer patients, 3845 hancement, 6045 altered gene expression transporters Glycineamide ribonucleotide transformylase c-myc, immortalized human breast epi- distribution, human brain tumors, 5-deazaacyclotetrahydrofolate inhibitor thelial cell line, 1210 3972 metabolic effects and kill, human T- anti-growth factor therapy Glucosinolates cell leukemia, 4895 pharmacologically guided end point, minor dietary constituents Glycolipids 2743s inhibition of carcinogenesis, 2085s I-type autocrine ~-Glucuronidase hepatoma gangliosides, 4805 transforming growth factor-a, ovarian urinary mutagenicity and N-acetylation Glycoproteins carcinoma, 341 phenotype breast carcinoma-associated DF3-P epi- tumor necrosis factor, neuroblastoma, exposure to arylamines, textile indus- tope 3194 try workers, 4885 cell surface expression, differentiating early response gene family Glucuronide agents, 6365 parathyroid hormone-like peptide, prodrugs Mr 32,000 and Mr 34,000 3103 targeted enzyme activation, cancer serine phosphorylation, bovine leuke- inhibition of breast cancer cell growth therapy, 4484 mia virus-induced lymphosarcoma tyrosine kinase inhibitor, 3636 Giutaminase cells, 6463 inhibition of cellular proliferation glutamine synthetase and T-antigens in human urinary bladder tu~ peptide analogues, insulin-like growth human cirrhotic liver, hepatocellular mors, 5030 factor I, 6447 carcinoma, 1192 Glycosphingolipids mechanism of interferon action "y-Glutamylcysteine synthetase elevation of 4~-galactosyltransferase ac- hairy cell leukemia, 1056 drug resistance tivity mitosis and tissue growth, 501 elevated glutathione levels, prostate sera, patients with cancer, 1875 modulation and steroids carcinoma cells, 5115 Leb/Lea aromatase activity, MCF-7 and T47D Glutathione specificity and immunobiological cell lines, 1411 cellular properties, monoclonal antibody pregnancy-dependent to ovarian-inde- cytotoxicity and resistance, seven plati- IMH2, 3739 pendent progression num compounds, 6885 sulfoglycolipid mammary tumors, primary culture, cytotoxic activity of Mitomycin C ana- first establishment, human monoclonal 6531 logues antibody, 2292 tumor volume and buthionine sulfoximine, ethacrynic various human ovarian tumors, 416 serum levels, prostate-specific antigen acid, 6666 Glycosylphosphatidylinositoi levels, 1598 depletion cellular localization of folate receptor Guanidinobenzoatase extrahepatic tissues, binding of afla- drug toxicity, folate homeostasis, 6708 characterization and purification toxin B~ metabolites, 1267 Gonadal neoplasms marker, human renal carcinoma, 3622 treatment duration, mitomycin C cyto- free human chorionic gonadotropin Gynecological neoplasms toxicity, 4608 subunit, 3901 human uterine endometrial adenocarci- elevated levels Gonads noma ~-glutamylcysteine synthetase activity, persistence of platinum-ammine-DNA sulfoglycosphingolipids, 803 prostate carcinoma cells, 5115 adducts resistance to cytolysis glutathione S-transferase resistance and rats and tissues from cancer patients, tumor necrosis factor-a, 866 hepsulfam sensitivity, breast cancer 149 Gyromitra esculenta cell lines, 1416 G proteins cancer induction in mice, 2279 intracellular epidermal growth factor and transform- selenite-mediated growth inhibition, ing growth factor-a H mammary tumor cells, 1091 renal adenocarcinoma cell growth, Glutathione S-transferases 4356 Hair dyes biochemical characterization of resist- limonene-induced regression increasing incidence of non-Hodgkin's ance mammary carcinoma, 4021 lymphoma, 5496s mitoxantrone and Adriamycin, colonic Grafts Hamartoma adenocarcinoma, 1886 human peripheral blood leukocyte pulmonary chondroid a-class Epstein-Barr virus-seropositive donors, clonal rearrangement, chromosome complementary DNA cloning, messen- generation of immunoblastic B-cell band 6p21, 6224 ger RNA expression, 314 lymphoma, 2468 Haptens microsomal versus leukemia reaction bifunctional antibodies and gene-specific oligonucleotide probes, syngeneic bone marrow transplanta- perivascular distribution, pharmacoki- al~lTr, 5797 tion, tumor resistance, interleukin 2, netic analysis, 5838 Phase I and Phase II drug-metabolizing 4117 H-2 complex enzyme systems Gross cystic disease expression of transfected H-2K b gene

7042

B 16 cells, liver metastases suppres- risk of non-Hodgkin's lymphoma, sor genes sion, 4036 5468s hepatitis B virus transgenic mice, 2823 HCT-8 cells Hematopoietic cells rat liver aryl sulfotransferase IV azidothymidine-induced cytotoxicity protection from 7-deazaadenosine complementary DNA, 4779 HCT-8 cells, 4069 nitrobenzylthioinosine, dilazep and di- reactivation of insulin-like growth factor Head and neck neoplasms pyridamole, 5879 II chromosome 3p deletions restricted oncogenicity role in malignant growth, transgenic statistical ascertainment, allelic loss, BCR/ABL p190, transgenic mice, mice, 2549 1451 4534 Hepatocarcinogenicity frequent p53 mutations, 5997 Hematopoietic neoplasms alteration of ploidy interstitial hypertension RCK gene associated with t(11;14) trans- nuclear enlargement, 1304 correlation with tumor size, 1993 location, 6083 dehydroepiandrosterone in the rat, 2977 measurement of thymidine replacement Hematopoietic progenitors Hepatocellular neoplasms 5-iododeoxyuridine, 719 acquired radioresistance microscopic p53 gene deletions chronic radiation leukemogenesis, growth kinetics, carcinogen-sensitive human papillomavirus infection, 4832 1469 and -resistant strains of mice, 280 radioimmunoscintigraphy role of aldehyde dehydrogenase in pro- Hepatocytes 99mTc-labeled monoclonal antibody tection chick and rat E48 F(ab')2, 2569 4-hydroperoxycyclophosphamide, in- cytochrome P450 induction and inhi- Heat terleukin 1~ and tumor necrosis fac- bition, 2-amino-3,4-dimethylimi- -killed Escherichia coli tor, 1770 dazo[4,5-j']quinoline, 3615 rat urinary bladder carcinogenesis, Hemoglobin diploid and polyploid 5329 DNA adducts as markers biotransformation, separation by cen- Heat shock factor metabolic activation, tobacco-specific trifugal elutriation, 1149 activation and binding carcinogens, 2698s hepatitis B virus-integrated HSP-70A messenger RNA turnover, formation of N-(2-hydroxyethyl)valine clonal growth, cirrhotic liver nodules, heat-sensitive human leukemias, molecular dosimetry, ethylene oxide, 6810 6815 4320 inhibition of DNA synthesis Heat shock protein Hemopoietic cells transforming growth factor-B~, cyclic absence of normal and malignant bone marrow AMP, 3598 thermotolerance, murine lymphoma, chromatin structure-dependent bind- mitoinhibitory effects 2854 ing, 7-aminoactinomycin D, 5007 orotic acid, nucleotide pool imbalance absence of HSP28 synthesis and phos- Hemopoietic stem cells and liver tumor promotion, 2078s phorylation immunotherapy modulation of trenimon-induced cyto- chronic thermotolerance, murine L929 indomethacin and interleukin 2, 6452 toxicity cells, 5780 HEp-3 DT-diaphorase, 3015 chemotherapeutic drugs and loss of metastatic phenotype nitrite and nitrosamine synthesis response of breast cancer cells, 3648 tissue inhibitor of metalloproteinase 2, normal woodchucks and those with HSP-27 5597 hepatitis virus, 4139 prognostic influence, malignant fi- Hepatitis B virus Simian virus 40-immortalized brous histiocytoma, 2325 aflatoxins as risk factors ras transformation, hepatocarcinoge- hsp70 expression in fibroblasts hepatocellular carcinoma, 2114s nesis model, 173 enhanced cell survival, RNA and pro- -integrated hepatocytes ras transformation, no loss of albumin tein synthesis, 3667 clonal growth, cirrhotic liver nodules, expression, 940 HeLa cells 6810 well-differentiated cell line -fibroblast cell hybrids normal woodchucks and those with hepatitis B virus replication, immortal- oncogenic potential, tumor-associated WHV ization by plasmid DNA, 1329 antigen, 616 nitrite and nitrosamine synthesis, 4139 Hepatoma immunoglobulin-like domains -positive hepatocellular carcinoma ascites carcinoembryonic antigen expression, p53 mutations cluster at codon 249, putrescine-dependent invasive capac- epitope analysis, 5647 China, 1635 ity, 5313 inhibition of cell attachment by selenite, replication cancer induction in mice 5803 well-differentiated hepatocyte cell Gyromitra esculenta, 2279 HeLaS3 cells lines, immortalized by plasmid gangliosides induction of c-fos gene expression DNA, 1329 novel I-type glycolipid, NeuAca2-6 static magnetic field, 6522 transgenic mice Gal structure, 4805 lack of chronic thermotolerance oncogenes and tumor suppressor induction of apoptosis cellular mechanisms, 1101 genes, hepatocarcinogenesis, 2823 transforming growth factor-~, 385 Hemangioma Hepatitis C virus metabolism of 4-(methylnitrosamino)-1- bovine papillomavirus type 2 hepatocellular carcinoma association (3-pyridyl)-l-butanone bracken fern and, bladder cancer in assays based on hepatitis C virus pep- lung and liver microsomes, cyto- cattle, 6898 tides, 5364 chromes P-450, 1757 Hemangiosarcoma Hepatocarcinogenesis transplanted cells cancer induction in mice activation of Ha-/Ki-/N-ras genes synthetic hepatic peptides, 1218 Gyromitra esculenta, 2279 chemically induced liver tumors, CD-1 Hepsulfam Hematology mice, 3347 sensitivity in breast cancer cell lines use of blood cell growth factors, 2012 in vitro model glutathione, glutathione S-transferase Hematolymphoid tissue ras transformation, SV40-immortal- resistance, 1416 selective radiation ized hepatocytes, 173 Herbal medicine delivery by anti-CD45 antibody, 1228 metabolic activation and genotoxicity use and Epstein-Barr virus Hematolymphoproliferative neoplasms heterocyclic arylamines, 2099s risk of nasopharyngeal carcinoma, familial aggregation multiple oncogenes and tumor suppres- 3048

7043

Herbicides type II IMP dehydrogenase gene, 258 -immortalized cervical epithelial cells pesticides and non-Hodgkin's lym- HMT-3522 down-regulation of keratin 14 gene phoma, 5485s immortalized cells expression, v-Ha-ras transfection, Herbimycin A altered gene expression, c-myc, 1210 5865 prolongation of survival Hodgkin's disease infection in human head and neck cancer myeloid leukemia C1 cells, mice, 4017 active nodular sclerosing p53 gene deletions, 4832 selective tumoricidal activity, 1721 urinary excretion, high molecular p53 gene alterations Herpes simplex virus weight transforming growth factor- human primary cervical carcinoma, high levels in skin fibroblasts ~, 6768 5323 various hereditary cancer-prone syn- Reed-Sternberg cells and type 11 dromes, 53 cytokine genes and cytokine receptor cellular transformation, 5872 Heterocyclic amines genes, transcription factors, 3353 type 16 human exposure to carcinogens interleukin 9 expression, 1026 association with squamous cell cancer, presence in cooked beef, 6216 Hormone male urethra, 5018 L-Histidinol levels in vegetarian and nonvegetarian E6/E7, induction of uterine cervical preclinical therapeutic studies teenage girls neoplasias, 4420 combination with antitumor agents, potential implications, breast cancer gene transcription inhibition, leukore- pharmacokinetic studies, 3604 risk, 578 gulin and -r-interferon, 456 Histiocytoma polyamine manipulation and sensitivity of keratinocytes, growth malignant fibrous synchronization, breast cancer cell control by retinoids, 187 prognostic influence, HSP-27, 2325 proliferation, 5720 squamous metaplasia, human endocer- Histone HT29 cells vical cells, 4254 acetylation tumor cell kinetics stimulation by tamoxifen, cervical can- modulation of colonic epithelial cell antineoplastic ether phospholipid cer cell line, 6848 proliferation, variation of dietary fi- treatment, 2509 type 18 ber, 5906 HT29-D4 cells antisense RNA, cancer cells of plas- HIV: see Human immunodeficiency virus suramin-induced differentiation mids, 4706 HLA complex potential autocrine role, insulin-like Hybridoma, T-cell class I antigen expression growth factor II, 3182 radiation-induced apoptosis, 883 mutated B2-microglobulin gene, colon HTLV-I Hydrocarbons, polycyclic aromatic cancer cell line, 1201 carrier rates -DNA adducts class II antigen expression accelerated declining tendency, detection in white blood cells, coke human papillomavirus-associated cer- younger blood donors in Japan, oven workers, 1510 vical cancer, 4009 2620 determinants, human placenta, 1499 ganglioside and adhesion molecule molecular basis of lymphomagenesis, 1,2,3,4-tetrahydro-7,12-dimethylbenz[a]- basal cell carcinoma lesions, 3201 5529s anthracene loss of antigens mycosis fungoides/S6zary syndrome regioisomeric B-ring analogues and, familial adenomatous polyposis, 3449 Kaposi's sarcoma, 4391 comparative metabolism, 3035 response and toxicity in melanoma National Cancer Institute Workshop Hydrogen peroxide interleukin 2-based immunotherapy, etiological factors, non-Hodgkin's photoexcited TiO2 particles 6561 lymphoma, 5430s induction of cytotoxicity, 2346 HL-60/AR cells T-cell lines tumor promoter-produced formation anthracycline-resistant regulation, leukemia inhibitory factor/ suppression by tamoxifen, human neu- MDRI amplification, 5244 D-factor gene, 6961 trophils, 4969 HL-60 cells Human chorionic gonadotropin 4-Hydroperoxycyclophosphamide abundance of primary transcript free B subunit cell cycle-dependent cytotoxicity growth-related genes, normal and leu- core/~ fragment, malignant pancreatic modulation by novobiocin, 3515 kemic cells, 11 and biliary disease, 4628 intrathecal cell cycle-related expression immunoreactive neurotoxicity, VX2 leptomeningeal p120 nucleolar antigen, 3491 free/3 subunit, serum and ascites of carcinomatosis, 6168 cytostatic and cytotoxic effects patients with malignant tumors, protection of hematopoietic progenitor fostriecin, 1530 1520 cells differentiation subunit aldehyde debydrogenase, interleukin changes in actin and actin-binding pro- gonadal and nongonadal neoplasms, 1~ and tumor necrosis factor, 1770 teins, 3063 3901 N-Hydroxy-4-acetylaminobiphenyl changes in microtubules, intermediate Human immunodeficiency virus metabolism and nucleic acid binding filaments, 949 AIDS-related lymphoma human uroepithelial cells, 3286 interaction of antileukemia agents, County of Los Angeles, 5482s ~-Hydroxyaikylnitrosamine sphinganine, 3593 other viruses and non-Hodgkin's lym- activation to alkylating agents drug transport mechanisms phoma, 5479s involvement of sulfotransferase, 3300 resistance to Adriamycin, 3157 type 1 tat gene 7-(2-Hydroxyethyl)guanine effects of genistein up-regulation, interleukin 4 receptors, formation and persistence in DNA growth and cell cycle progression, 3787 molecular dosimetry, ethylene oxide, 6200 Human papiilomavirus 4328 induction of differentiation by bufalin -associated cervical cancer N-(2-Hydroxyethyl)valine macrophage/monocyte-like cells, 4634 HLA class II antigen expression, 4009 formation and persistence in hemoglobin novel nontoxic inducer -associated cervical neoplasms molecular dosimetry, ethylene oxide, phenylacetate, tumor cell differentia- high-affinity laminin receptor messen- 4320 tion, 1988 ger RNA, 1561 8-Hydroxyguanine potentiation of activity by bryostatin-I DNA codon 12 1-/~-D-arabinofuranosylcytosine, 6270 ras oncogene mutations, prostate car- c-Ha-ras, point mutations, 3483 proliferation-linked regulation cinoma, 5991 4-Hydroxynonenal

7044

modulation of c-myc and globin gene ogical oxygenation status postradia- B-cell non-Hodgkin's lymphoma, expression tion, 4620 5522s K562 cells, 4866 primary 3-Hydroxypyridin-4-one I genetic risk factors for lymphoma, iron chelators 5465s cell cycle synchronization and growth ICAM-1 lmmunofluorescence inhibition, leukemia cell lines, 459 l enhancement by retinoic acid expression of N-myc, c-myc, and MDR-1 17B-Hydroxysteroid dehydrogenase differential susceptibility, cultured proteins gene expression in breast cancer cells melanoma cell lines, 4766 flow cytometry, neuroblastoma, 2957 regulation by progestin, 290 induction on small cell lung carcinoma Immunogiobulin G inhibition of estrogen formation and ac- ,y-interferon, specific targeting, 4890 antibodies to sialylated Tn tion soluble immunization of colorectal cancer pa- novel compounds, 610 tumor growth in mice, human mela- tients, modified ovine submaxillary Hypercaicemia noma cells, 2628 gland mucin and adjuvants, 5663 malignancy-associated ICI D1694 whole immunoglobulin and Fab' frag- murine -r-interferon, 444 growth inhibition ments Hyperinsulinemia time dependence, DNA lesions, 5900 monoclonal antibodies, high molecular systemic ICRF-187 weight-melanoma associated anticancer patients, 3845 chronic cardiotoxicity animal model, 194 gen, 2497 Hypertension Idarubicin Immunogiobulin M angiotensin ll-induced Phase II study antibodies to sialylated Tn circadian variation, tumor blood flow, unfavorable non-Hodgkin's lym- immunization of colorectal cancer pa- 912 phoma, 3871 tients, modified ovine submaxillary interstitial Imidazoquinolinamine gland mucin and adjuvants, 5663 human breast and colorectal tumors, interferon-inducing Immunoglobulin(s) 6371 inhibition, murine tumor growth, 3528 anti-mouse microvascular pressure, solid tumors, Immune response preexisting reactivity, lack of T-cell 5110 autoantiphosphatidylinositol immunity in, 6979 tumor size, head and neck tumors, benzo[a]pyrene-induced malignant tu- humanized M 195 monoclonal antibodies 1993 mors, 2862 biological and immunological features, Hyperthermia L-a-difluoromethylornithine-mediated 6761 abdominal inhibition -like domains in HeLa cells carboplatin and, cancers restricted to prevention by polyamine homologues, carcinoembryonic antigen expression, peritoneal cavity, 1252 1840 epitope analysis, 5647 antitumor effect humoral -like loops flavone acetic acid, mice, 3306 macrocyclic chelating agent, radioim- FLT4 receptor tyrosine kinase, multi- blood flow and cisplatin pharmacoki- munoconjugates, 904 ple human tissues and cell lines, netics p53 in breast cancer patients 5738 murine mammary adenocarcinoma, immunodominant epitopes, muta- mapping chromosomal breakpoints of 4965 tional hot spot, 6380 Burkitt's lymphoma cytotoxicity Immune suppression t(8; 14) translocations, 6547 endogenous tumor necrosis factor aspirin and potential role of prostaglan- rapid tumor penetration functions, 6258 dins single-chain Fv, 3402 induction of c-fos gene expression colon cancer, 5575 Immunohistochemistry static magnetic field, HeLaS3 cells, Immunity localization of cell adhesion molecule 6522 T-cell epithelial cadherin, human arachnoid interstitial fluid pressure lack of, preexisting anti-mouse immu- villi and meningiomas, 1981 solid tumors, 487 noglobulin reactivity, 6979 staining for transforming growth factor- ionizing radiation of production of interleukin 7 interaction with photodynamic ther- genetic modification, murine fibrosar- disease progression, human breast can- apy, cell killing, 117 coma, 3931 cer, 6949 structural damage in biological tissues Immunization Immunoliposomes magnetic resonance diffusion imaging, active specific OV-TL 3 6066 locoregional administration of etopo- targeting to ascitic ovarian carcinoma whole-body side, advanced carcinoma, 2440 cells, 646 tumor necrosis factor-a combined with liposome-entrapped soluble protein anti- Immunology platinum complexes, 4096 gen new approaches to treating early lung Hypoxanthine prolonged survival, thymoma-bearing cancer, 2652s synthetic c-Ha-ras mice, 6287 lmmunosuppressivetherapy induction of mutation, 1836 Immunoassays acquired immunological disorders and, Hypoxia cathepsin D as prognostic indicator 5474s Gadd45 and Gadd153 messenger RNA node-negative breast cancer, 5198 Immunotherapy levels Immunoconjugates adoptive glucose-regulated proteins, 3814 high-affinity anticarcinoma radioimmu- human xenograft-nude mouse model, increased tumor hypoxic fractions noconjugates melanoma-specific cytotoxic T-cells, preirradiation of transplantation site, therapeutic advantage, 1067 394 colon tumor xenografts, 2162 monoclonal antibody-drug conjugate antibody drug carrier SR 4233-induced DNA and chromosome reduction of local recurrence, colorec- superficial bladder cancer, 3131 breaks tal cancer, 6323 antigen presentation by bladder cancer repair, 4473 novel maytansinoids, 127 cells tumor metabolism lmmunodeficiency BCG-specific CD4 § T-cells, 4286 partial pressure of oxygen, radiobiol- pathogenetic mechanisms fate of antibodies

7045

bound to surface of tumor cells, 835 Insecticides glioma cells, 4348 human glioma xenografts pesticides and other agricultural risk fac- 3,-Interferon labeled monoclonal antibody 425, epi- tors effect of tumor size dermal growth factor receptor, 121 non-Hodgkin's lymphoma, 2447 radiolabeled F(ab')2 fragments, anti- indomethacin and interleukin 2 Insulin ICAM-1 monoclonal antibodies, murine hemopoietic stem cells, 6452 2-deoxyglucose and 1309 interleukin 2-based depletion of tumor ATP, magnetic res- immunotherapy of renal adenocarcinoma HLA association, response and toxic- onance spectroscopy, 71 CGP 31362 or CGP 19835A, systemic ity in melanoma, 6561 pH in human tumor xenografis liposomes, 1155 perioperative transplanted rat tumors, 6209 -induced increase in sensitivity recombinant interleukin 2, colorectal receptor expression and function ovarian cancer targets, lysis by LAK cancer, 5765 breast cancer cell lines, 3924 cells, 764 presence of monoclonal antibody K1 systemic hyperinsulinemia induction of differentiation by bufalin characterization of antigen, ovarian cancer patients, 3845 human leukemia cells, 4634 cancer, 181 Insulin-like growth factor induction of ICAM- 1 renal adenocarcinoma binding proteins specific targeting, small cell lung carci- systemic liposomes, CGP 31362 or human breast cancer tissue, 5204 noma, 4890 CGP 19835A, 1155 Insulin-like growth factor I leukoregulin and suppression of malignant phenotype influence of tamoxifen inhibition, human papillomavirus type interleukin 6 gene transfection, Lewis plasma levels, breast cancer, 4719 16 gene transcription, 456 lung carcinoma, 3679 peptide analogues intralesional injection Immunotoxin inhibition of ceUular proliferation, regression of skin recurrences, breast anti-B4-blocked ricin 6447 carcinomas, 4571 in vivo toxicity, preclinical in vitro pa- receptor gene malignancy-associated hypercalcemia, rameters, 4200 sporadic amplification, human breast 444 anti-CD 19-pokeweed antiviral protein tumors. 1036 metaiodobenzylguanine incorporation human t(4;11) leukemia, SCID mice, receptor messenger RNAs and retention 406 primary human gastric carcinoma, human neuroblastoma cells, 4960 B3-PE and B3-LysPE40 3453 metastatic renal cell carcinoma antitumor effects, nude mouse model Insulin-like growth factor II Phase I trial, 851 of human breast cancer, 3189 CpG methylation myelopoiesis-associated immune sup- CD3-ricin A chain human smooth muscle tumors, 6516 pressor cells relation to cellular uptake, degradation interruption of autocrine growth loop mice bearing metastatic Lewis lung kinetics, 5921 inhibition of growth by suramin, rhab- carcinoma tumors, 6335 monovalent domyosarcoma, 1830 retroviral vector-mediated lymphokine truncated form, Pseudomonas exo- potential autocrine role gene transfer toxin, 5379 suramin-induced differentiation, human renal cancer cells, 6229 recombinant single chain antibody-toxin HT29-D4 cells, 3182 tumor necrosis factor and erbB-2 receptor, inhibition of tumor reactivation during hepatocarcinogenesis NADPH oxidase gene expression, differentiation of myeloid cell lines, growth, 6310 role in malignant growth, transgenic 2530 ricin-A chain activity mice. 2549 rapid differentiation, human neuro- enhancement, indolizine calcium chan- Integrins nel blockers, 1352 blastoma cells, 931 a5/3~ receptor IMP dehydrogenase Interleukin 1 proliferative response to fibronectin, type II prevention of chemotherapy-induced quiescent human melanoma cells, proliferation-linked regulation, lym- death, 4082 phocytes and HL-60 cells, 258 4499 Interleukin la Indole Interferon gene expression and derivatives cyclosporine A and ovarian epithelial cancer cells, 2248 reversal of multidrug resistance, 4735 antitumor effect, chemotherapy for Interleukin IB lndolizine disseminated melanoma, 6482 cytokine responses calcium channel blockers molecular analysis of deletions interleukin 2 injection, leptomeningeal enhancement, ricin-A chain immuno- short arm of chromosome 9, human carcinomatosis, 1123 toxin activity, 1352 gliomas. 2523 inhibition of gene expression lndomethacin a-lnterferon antisense oligonucleotide, LAK cells, interleukin 2 and effects of bioactive and cytotoxic agents 4954 immunotherapy, murine hemopoietic cell cycle, muitiparameter assessment, tumor necrosis factor and stem cells, 6452 4090 protection of hematopoietic progenitor Infrared spectroscopy -inducing imidazoquinolinamine cells, aldehyde dehydrogenase, 1770 features of malignant colon tissues inhibition, murine tumor growth, 3528 Interleukin 2 colon adenocarcinoma, 84 interleukin 2 and -activated tumor-draining lymph node Ingenol hepatic drug metabolism, 262 cells specific binding to protein kinase C intralesional injection cellular interactions, effector cell gen- induction, biological responses, 202 regression of skin recurrences, breast eration, 1129 Inosine-5'-phosphate dehydrogenase carcinomas. 457 I -based immunotherapy gene expression mechanism of action HLA association, response and toxic- solid tumor tissues, tumor cell lines, hairy cell leukemia. 1056 ity in melanoma, 6561 5826 -stimulated genes cancer patients lnositol phosphates chronic myelogenous leukemia, 1087 CD56-LAK cell precursor, 6318 in vivo efficacy of novel inhibitor ~-interferon immunotherapy of renal adenocarcinoma selected signal transduction pathways, N.N'-bis( 2-chloroethyl)-N-nitrosourea CGP 31362 or CGP 19835A, systemic 3208 and simvastatin synergism, human liposomes, 1155

7046

indomethacin and expression 5-Iododeoxyuridine immunotherapy, murine hemopoietic cultured Hodgkin and Reed-Sternberg high grade glioma stem cells, 6452 cells, 1026 measurement of thymidine replace- a-interferon and Interleukin 12 ment, 719 hepatic drug metabolism, 262 role of cytokines Ion microscopy LAK cell treatment and regulation of cell function, pathogen- subcellular resolution in tissue cultures advanced bladder cancer, 726 esis of disease, 6129 quantitative imaging, radiotherapeutic locoregional administration of etoposide Intermediate filament drug, 5219 active specific immunization, advanced changes during HL-60 cell differentia- Iowa carcinoma, 2440 tion, 949 pesticides and other agricultural risk fac- perioperative immunotherapy nestin tors colorectal cancer, 5765 central nervous system tumors, 5334 non-Hodgkin's lymphoma, 2447 platelet and neutrophil-endothelial ad- Interstitial fluid Iproplatin herence pressure quantitative ultrastructural effects macromolecular leakage, 3425 after hyperthermia, solid tumors, 487 neurons, Lymnaea stagnalis, 963 polyinosine-polycytidylicacid complex tumor Iron carboxymethylcellulose, patients with lowering of pressure, nicotinamide, GGT to GTT transversions in codon 12 cancer, 3005 3237 K-ras, renal sarcomas, 4747 production Interstitial matrix 3-hydroxypyridin-4-one chelators methionine adenosyltransferase activ- collagen-induced activation cell cycle synchronization and growth ity, Jurkat T-cells, 3361 Mr 72,000 type IV collagenase, fibro- inhibition, leukemia cell lines, 4591 receptors on human squamous cell carci- blastoid cells, 4540 release noma Intestine xanthine oxidase in oxidative stress, cell lines and tumor, 5963 alkaline phosphatase hyperthermic rat liver perfusion, retroviral vector-mediated lymphokine oncogenic potential, tumor-associated 1699 gene transfer antigen, 616 Irradiation human renal cancer cells, 6229 bile acids -induced expression tumor necrosis factor-a and subtotal colectomy, familial adenoma- O6-methylguanine-DNA methyltrans- tumoricidal activation, peritoneal mac- tous polyposis, 3552 ferase, mammalian cells, 1804 rophages, 3880 dietary fiber-mediated mechanisms influence of H-ras oncogene tumor resistance carcinogenesis, 2055s rat rhabdomyosarcoma cell line, 3073 syngeneic bone marrow transplanta- Invasion mouse lung tion, 4117 human papillomavirus-associated cervi- single dose of cyclophosphamide, no Interleukin 3 cal neoplasms change in repair capacity, 1096 tumor necrosis factor-a and laminin receptor messenger RNA, preirradiation of transplantation site clonal growth, acute myelogenous leu- 1561 increased tumor hypoxic fractions, co- kemia blasts, 2197 -inhibiting factor 2 lon tumor xenografts, 2162 Interleukin 4 primary structure, pulmonary metasta- transfection and inhibition of colon and breast carcinoma sis, 1422 transformation of cultured cells, fatty cell growth, 275 Invasiveness acids, 154 interleukin 4 receptor expression macrophage colony-stimulating factor 3,-Irradiation growth inhibition, gastric carcinoma, CSF-1 receptor-positive carcinoma cell induction of p53 mutations 6059 lines, 3661 thymic lymphomas, 3791 up-regulation of receptors Iodination Isoprenoids tat gene, HIV-1, 3787 anticarcinoma single-chain Fv molecules cell growth inhibition and cell cycle ar- Interleukin 6 chelation, differential metabolic pat- rest cytokine responses terns, 6413 dehydroepiandrosterone, colonic ade- interleukin 2 injection, leptomeningeal Iodine-125 nocarcinoma, 1372 carcinomatosis, 1123 -labeled monoclonal antibody 425 Isopropyl alcohol gene transfection into Lewis lung carci- epidermal growth factor receptor, hu- ethanol or noma cells man glioma xenograft immunother- reduced blood clearance, N-nitrosodi- suppression, malignant phenotype, apy, 121 methylamine, 1463 3679 radioimmunotherapy Isothiocyanates IL-6 gene affinity, two monoclonal antibodies, minor dietary constituents reduced tumorigenicity, transduced fi- 4728 inhibition of carcinogenesis, 2085s brosarcoma cells, 6020 Iodine-131 interleukin 1a and ~ gene expression -labeled monoclonal antibodies J ovarian epithelial cancer cells, 2248 targeted therapy, colonic cancer micro- Japan reduction in lipoprotein lipase activity metastases, 6036 adipose tissue, cancer cachexia, 4113 m-Iodobenzylguanidine accelerated declining tendency serum level as prognostic factor pH in human tumor xenografts HTLV-I carrier rates, young blood donors, 2620 metastatic renal cell carcinoma, 3317 transplanted rat tumors, effect of insu- p53 mutations -transfected B16 melanoma cells, 5412 lin, 6209 Interleukin 7 4'-Iododeoxyrubicin non-small cell lung cancer, 734 production quantitative mapping K genetic modification, murine fibrosar- metastatic squamous cell carcinoma, coma, 3931 974 K562 cells Interleukin 8 Iododeoxyuridine modulation of c-myc and globin gene production in neoplastic and infectious potential superiority of bromodeoxyuri- expression diseases dine 4-hydroxynonenal, 4866 human central nervous system, 4297 radiation sensitizer, colorectal cancer, Keratin Interleukin 9 3698 expression and adhesion

7047

retinoid status, histogenesis of squa- differences in breast cancer risk factors cytokine responses mous metaplasia of tracheal epithe- neu overexpression, breast tumor, intraventricular injection, interleukin lium, 6144 2344 2, 1123 loss of expression Lactoferrin Leucovorin posttranslational regulation, anaplastic identification of major protein compo- combination chemoimmunotherapy carcinoma, 6603 nents eradication, hepatic metastases of car- Keratin 14 breast secretions, benign and malig- cinoma H59, 6254 down-regulation of gene expression nant breast diseases, 95 elevation of thymidylate synthase v-Ha-ras transfection, papillomavirus- LAK cells 5-fluorouracil treatment, murine colon immortalized cervical epithelial Adriamycin-induced modulation tumors, 4922 cells, 5865 host defenses, tumor-bearing mice, inability to rescue a naturally methotrex- Keratinocytes 3572 ate resistant cell line epidermal CD56-LAK cell precursor trimetrexate cytotoxicity, 6866 simple epithelial cytokeratins, Harvey cancer patients receiving interleukin 2, Leukemia ras gene alterations, 680 6318 acute immortalization by papillomavirus type immunotherapy granulocyte colony-stimulating factor 16 DNA indomethacin and interleukin 2, hemo- receptors, 3052 growth control, retinoids, 187 poietic stem cells, 6452 carcinogenic potency immortalized inhibition of interleukin 1B gene alkylating agents, rodents and humans, neoplastic transformation, 2,3,7,8-te- antisense oligonucleotide, 4954 2464 trachlorodibenzo-p-dioxin, 3478 y-interferon enhancement of specific tar- cell cycle synchronization and growth in- Ketoconazole geting hibition proliferation and cell cycle induction of ICAM-1, small cell lung 3-hydroxypyridin-4-one iron chelators, human cancer cell lines, 6827 carcinoma, 4890 4591 Ki-67 interleukin 2 and cloning of ALL-1 overexpression advanced bladder cancer, 726 chromosome translocations, 2999 normal breast tissue, invasive and non- lysis computer simulation in new drug devel- invasive breast carcinoma, 2597 interferon-induced increase in sensitiv- opment Kidney ity, ovarian cancer targets, 764 structural analogues, amsacrine, 209 epithelial cells natural killer cells and renal cell carci- differentiation-induced changes altered p53 gene structure, nickel ex- noma protein-tyrosine phosphatase, CD45, posure, 218 rat model, 6279 4027 molecular cloning resistance DNA topoisomerase II immunostaining Wilms' tumor complementary DNA, generation, small cell lung cancer var- rhabdomyosarcoma cell lines, topoi- 6407 iant, 3310 somerase II inhibitors, 4248 nephroblastomas in the Japanese eel, Laminin-binding protein expression of fibroblast growth factor re- 2575 S 19 ribosomal protein ceptors, 2004 overexpression of human topoisomerase colon carcinoma progression and dif- heat-sensitive I ferentiation, 791 lower heat shock factor activation, hypersensitivity of clonal isolates, Laminins binding, 6815 camptothecin, 525 A and C human t(4; l 1) persistence of platinum-ammine-DNA expression, human myeloid leukemia, anti-CD 19-pokeweed antiviral protein adducts 2847 immunotoxin, SCID mice, 406 rats and tissues from cancer patients, synthetic antagonist induction of differentiation by bufalin 149 formation of osteolytic metastases, hu- macrophage/monocyte-like cells, 4634 Kidney neoplasms man melanoma cells in nude mice, merocyanine 540-sensitized photoperoxi- nephroblastomas in the Japanese eel, 5395 dation 2575 L929 cells selenoperoxidase-mediated cytoprotec- renal pelvis and ureter absence of HSP28 synthesis and phos- tion, 5282 cigarette smoking, 254 phorylation murine retroviral vector-mediated lymphokine chronic thermotolerance, 5780 a-particle-mediated radioimmunother- gene transfer, 6229 LI210 cells apy, 5818 K-ras activation of trans geometry plasmacytoid activation in non-small cell lung cancer, platinum antitumor complexes, 5065 retrovirus and etiology of disease, Chi- 4724 DNA damage and cytotoxicity nook salmon, 6496 GGT to GTT transversions in codon 12 ellipticine and a structural analogue, potential antileukemic activity rat renal sarcomas, nickel subsulfide, 1515 CI-973, 4130 4747 resistance to deoxyadenosine proliferating lymphoma and mutation altered steady-state levels, messenger cell cycle analysis, p26-BCL-2 protein pancreatic duct carcinogenesis, Syrian RNA for c-myc and p53, 2000 levels, 2802 golden hamster, 4507 Lectin Leukemia, hairy cell p53 and N-acetylgalactosamine-specific expres- expression and functional role human mesothelioma cell lines, 2610 sion p75 interleukin 2 receptor chain, 5223 tumor progression in vivo, liver metas- mechanism of interferon action, 1056 Leukemia, lymphoblastic L tasis potential, 5235 novel gene activation acute a-Lactalbumin human primary liver cancer, 5089 suppression, wild-type p53 gene, 222 identification of major protein compo- Leiomyoma Leukemia, lymphocytic nents human smooth muscle tumors chronic breast secretions, benign and malig- CpG methylation, insulin-like growth fludarabine, arabinosylcytosine metab- nant breast diseases, 95 factor II gene, 6516 olism, 897 Lactation Leptomeningeal carcinomatosis NZB mouse model, 437

7048

Leukemia, monomyelocytic Leukemia virus microtubule depolymerization, human cell line development Abelson murine endothelial cells, 3443 resistance to novobiocin, topoisomer- benzopyranones and benzothiopyra- Limonene ase II-targeted drugs, 2782 nones, selectivity for v-abl kinase, -induced regression Leukemia, myelogenous 4492 mammary carcinoma, 4021 acute bovine Linoleic acid clonal growth, tumor necrosis factor-a phosphoproteins, lymphosarcoma, dietary and interleukin 3, 2197 6463 mouse skin tumor promotion, mam- decreased retinoblastoma protein Leukemic cells mary carcinogenesis, 2049s expression, 4587 altered 11-kilobase transcript Linomide chronic t(4; 1 l)(q21 ;q23) chromosome translo- antitumor effects frequent p53 gene mutations, blast cri- cation, 3811 Dunning R-3327 rat prostatic cancers, sis, 6588 interaction 3022 interferon-stimulated genes, 1087 product of Steel locus, 5208 Lipid effects of bioactive and cytotoxic agents method of purging modification and sensitivity of leukemic cell cycle, multiparameter assessment, ex vivo differentiation therapy, murine cells 4090 bone marrow expansion cultures, thioether lipid analogue BM 41.440, humanized M 195 monoclonal antibodies 6576 6263 biological and immunological features, mutagenic specificity of oxygen radicals, Lipidosis 6761 1082 induction Leukemia, myeloid sensitivity to BM 41.440 ricin-A chain immunotoxin activity, acute membrane lipid modification, 6263 1352 radiolabeled antimyeloid antibodies, Leukemogenesis Lipid peroxidation xenograft tumor models, 89 chronic radiation c-myc and globin gene expression T-cell receptor ~-chain gene re- acquired radioresistance, hemato- modulation by 4-hydroxynonenal, arrangement, 6598 poietic progenitors, 1469 K562 cells, 4866 differentiation and retrodifferentiation Leukocyte(s) Lipocortin 2 reversible induction, cell cycle-regula- adhesion developmental regulation tory genes, 1445 role of microvascular damage, photo- human brain, expression in high-grade expression of nuclear envelope laminins dynamic therapy, 4914 glioma, 6871 A and C, 2847 cytokine-activated tumor inhibition, Lipolysis induction of c-jun expression 4853 -promoting factor cis-diamminedichloroplatinum(II), 878 disseminating tumor cells and their in- tumor-derived, 829 prolongation of survival teractions Lipoprotein lipase herbimycin A, mice, 4017 visualization in brain, 1018 reduction of activity in adipose tissue Leukemia, nonlymphoblastic -endothelium interaction interleukin 6, cancer cachexia, 4113 acute tumor microvessels, 4265 Lipoproteins predictor for treatment, glutathione human peripheral blood low density transferase ~r, 3281 EBV-induced B-cell iymphomas, delivery of acrylophenone antineoplas- Leukemia, pre-B SCID mice, 5552s tic molecule, malignant cells, 3629 glucocorticoid-induced apoptosis Leukoplakia elevated uptake, human lung cancer BCL-2 involvement, 491 oral tissue, 6244 Leukemia, promonocytic natural history, intraepithelial neopla- serum retrovirus-induced sia, 1651 localization, shed human tumor gan- involvement of spleen, preleukemic de- Leukoregulin gliosides, 810 velopment, 5317 induction of myeloma cells Liposome(s) Leukemia, promyelocytic decreased P-glycoprotein expression, daunorubicin small unilamellar vesicles acute 5893 selective in vivo localization, solid tu- clinical pharmacology, all-trans-reti- -r-interferon and mors, 3255 noic acid, 2138 inhibition, human papillomavirus type -entrapped doxorubicin retinoic acid-binding protein, normal 16 gene transcription, 456 antibody-specific binding, lung cancer and malignant myeloid cells, 3329 Levamisole cells, 4817 t(l 5; 17) translocation, PML-RARa radiosensitization -entrapped lipophilic cisplatin analogues, chimeric product, 3687 human tumor cells, 3228 6341 Leukemia, T-cell Lewis antigen -entrapped pigments acute glycosphingolipids polyethylene glycol-mediated delivery, anti-CD7-deglycosylated ricin A-chain various ovarian tumors, 416 fibroblasts, 6638 immunotoxin DA7, 1314 Liarozole -entrapped soluble protein antigen adult retinoic acid-induced inhibition prolonged survival, thymoma-bearing chromosome abnormalities, karyotype cell growth, MCF-7 cells, 2841 mice, 6287 review, 1481 Li-Fraumeni syndrome increased accumulation of drugs human inherited p53 gene mutations multidrug-resistance cells, 3241 efficacy of murine model, anti-CD7-ri- breast cancer, 2984 long-circulating cin A chain immunoconjugate, 3056 p53 mutations in breast cancer, 5291 anthracyclines, tumor localization and metabolic effects and kill screening for germ line TP53 mutations therapeutic index, 891 5-deazaacyclotetrahydrofolate, 4895 breast cancer, 3234 muramyl-tripeptide/5-fluorouracil/leuco- N-sam gene Ligands vorin fibroblast growth factor receptor, 3367 biological eradication, hepatic metastases of car- Leukemia inhibitory factor early intervention in cancer, monoclo- cinoma H59, 6254 D-factor gene nal antibodies, 2747s Stealth regulation, HTLV-I infected T-cell Light improved sustained release system, 1- lines, 6961 photofrin and B-D-arabinofuranosylcytosine, 2431

7049

sterically stabilized glutathione S-transferases pulmonary neuroendocrine cell differ- colon carcinoma-bearing mice, 5135 gene-specific oligonucleotide probes, entiation, 2677s pharmacokinetics, colon carcinoma, 5797 preneoplastic lesions 6774 metabolism of 4-(methylnitrosamino)-l- deletions, 17p and p53 mutations, targeting of OV-TL 3 immunoliposomes (3-pyridyl)-l-butanone 6079 ascitic ovarian carcinoma, 646 cytochromes P-450, hepatoma cells, radon-induced deletions in human cells, Lipotropes 1757 5126 methyl groups in carcinogenesis role of cytochrome P-450 tobacco-specific nitrosamine-induced tu- DNA methylation, gene expression, potentiation of morpholino doxorubi- morigenesis 2071s cin, 4379 inhibition by green tea, antioxidants, Lipoxygenase Liver neoplasms 3875 inhibition of skin tumor promotion aflatoxins as risk factors upper aerodigestive tract cancer and green tea, 6890 hepatocellular carcinoma, 2114s chemoprevention strategies, 2758s Liver chemically induced Lung neoplasms aryl sulfotransferase IV complementary activation, Ha-/Ki-/N-ras genes, 3347 accumulation of p53 protein DNA, 4779 development poor prognosis, 4828 carcinogenesis transforming growth factor-a trans- antibody-specific binding chemoprevention, S-adenosyl-L-methi- genic mice, 5162 liposome-entrapped doxorubicin, 48 ! 7 onine, 4979 encapsulation of cisplatin antitumor activity potent preventative action, a-carotene, poly-lactide-co-glycolide, reduction of magainin analogues, 3534 6583 systemic exposure and toxicity, clinical significance changes in ploidy and specific karyotypic 6653 ras oncogene activation, 2665s changes growth control promotion with phenobarbital, 955 inhibitory effect, 2-deoxy-o-glucose, methods and strategies, 2641 s cirrhotic 5794 cytogenetic alterations clonal growth, hepatitis B virus-inte- orotic acid and nucleotide pool imbal- multidrug resistance, 4361 grated hepatocytes, 6810 ance detection and prevention glutaminase and glutamine synthetase, mitoinhibitory effects, hepatocytes, interaction, smoking and genetic pre- 1192 2078s disposition, 2694s cytochrome P4502C and 3A enzymes plasma urokinase-type plasminogen acti- development and progression 3-hydroxylation of benzo[a]pyrene, vator antigen role of alveolar type II cells, 3164 1868 tumor-associated antigen, a-fetopro- development of antibodies against p53 dose-response relationships for chronic tein, 1717 type of p53 mutation, 4168 exposure primary diagnostic research, 2766s 2,3,7,8-tetrachlorodibenzo-p-dioxin, novel gene activation, 5089 DNA fingerprinting, 2174 rat tumor model, 3436 sialyltransferase activity early drug metabolism in mice nude mouse model, colorectal cancer considerations, cancer biomarker in effects, interleukin 2 and a-interferon, metastases, 1775 clinical application, 2711 s 262 Locus intervention approaches, premalignant extrahepatic tissue DCC disease, 2767s binding of aflatoxin BI metabolites, frequent loss of heterozygosity, gastric investigational strategies, detection depleted glutathione levels, 1267 cancer, 3099 and intervention, 2639s hyperthermic perfusion RAP1A/Krev-1 locus new approaches, 2652s xanthine oxidase in oxidative stress, loss of heterozygosity, colorectal tu- preclinical research, 2764s iron release, 1699 mors, 285 early diagnosis and screening metastases suppression Lung application, molecular genetics, 2658s transfected H-21(~ gene, B 16 cells, adenocarcinoma elevated uptake of low density lipopro- 4036 ras gene mutations, prognostic teins, 6244 metastasis potential marker, 2903 first establishment of human monoclonal tumor progression in vivo, soybean ag- bronchial and pulmonary carcinogenesis antibody glutinin lectin binding, 5235 focal sites, dogs and hamsters, 2687s sulfoglycolipid, 2292 mutagenic activation carcinogenesis growth suppression 2-amino-3-methylimidazo[4,5-J]quino- potential chemopreventive agents, to- transfection of p53, 6956 line, new form of cytochrome P-450, bacco-specific nitrosamine, 2719s histopathological grading and survival 758 potent preventative action, a-carotene, queuine content, 4696 oncogenesis 6583 loss of heterozygosity for loci molecular and genetic analysis, trans- chondroid hamartoma chromosome 8p, 5368 forming growth factor-a transgenic clonal rearrangement, chromosome metastasis and response to therapy mice, 5171 band 6p21, 6224 correlation, serum metalloproteinase preneoplastic lesions, 501 metabolism of 4-(methylnitrosamino)-l- levels, 4548 rat (3-pyridyl)-l-butanone molecular analysis P-glycoprotein expression, tumor pro- cytochromes P-450, hepatoma cells, protein tyrosine phosphatase 3' gene, gression, 5154 1757 3506 -specific genes metastasis multidrug-resistant ras transformation, SV40-immortal- primary structure, tumor invasion-in- energy-dependent processes, reduced ized hepatocyte cell line, 940 hibiting factor 2, 1422 drug accumulation, 17 tumorigenesis nitrosamine-induced lung carcinogenesis multidrug sensitivity phenotype 2s2Cf relative biological effectiveness, Ca2+/calmodulin antagonists, 2723s topoisomerase II expression, 1666 fission neutrons, 1948 no change in repair capacity multiple genetic lesions Liver microsomes single dose of cyclosphosphamide, suppression of growth, wild-type but C-oxidative metabolism of 1-nitropyrene 1096 not mutant p53, 2340 cytochrome P450 3A4, 6237 preneoplastic injury neuropeptide signal transduction

7050

bradykinin sensitivity, overall hetero- absence of metastasis in lung adenocarci- immunohistochemical identification, geneity, 24 noma P-glycoprotein, 3768 non-small cell ras gene mutations, prognostic morphology link with etiology, 5431 s chromosome abnormalities, 2702s marker, 2903 murine model system deletion mapping, short arm of chro- breast cancer metastasis natural killer and tumor cell interac- mosome 3, 873 loss of alleles, chromosomes 11 and tions, 4149 K-ras activation, 4724 17, 3914 non-Hodgkin's p53 mutations, Japan, 734 tumor-draining cells pesticides, other agricultural risk fac- p53 mutations, 1695 anti-CD3/interleukin 2 activation, tors, 2447 presence of neuromedin B in cell lines, cellular interactions, 1129 Phase II study, idarubicin, 3871 2732s Lymphoblastoid cells preclinical evaluation of bry0statin primary acquired resistance murine tumor cell lines, 101 experimentally manipulable model, folate-based thymidylate synthase in- proliferating human adenocarcinoma, 2670s hibitor, 1137 cell cycle analysis, p26-BCL-2 protein reduced cancer risk Lymphocytes levels, 2802 E-carotene, vegetable and fruit intake, antigen class I messenger RNA risks in populations with altered immu- 2060s S19 ribosomal protein, colon carci- nity, 5477s resistance to xenobiotic-induced cytotox- noma progression and differentia- thermotolerance icity, 6797 tion, 791 absence of induced heat shock pro- risk of arabinosylcytosine metabolism teins, 2854 genetic polymorphisms and racial vari- fludarabine, chronic lymphocytic leu- xenografts ation, cytochrome P450IIE 1, 6712 kemia, 897 improved delivery, radiolabeled anti- sensitivity to N~,Nle-bis(ethyl)spermine cell cycle-related expression B1 monoclonal antibody, 637 steady-state messenger RNA, 5359 p 120 nucleolar antigen, HL-60 and Lymphoma, B-cell sensitivity to platinum compounds MOLT-4 cells, 3491 cytogenetic characterization acquired and inherent resistance to cis- down-regulation of c-myc antigen SCID mice, EBV-positive donors, platin, 5674 expression 4678 small cell antisense DNA therapy, transgenic generation bombesin analogues, antitumoral ac- mice, 6741 heterogeneity, Epstein-Barr virus-sero- tivity in xenografis, 4872 normal positive donors, 2468 broad spectrum neuropeptide antago- effects of genistein, growth and cell Lymphoma, Burkitt's nists, inhibition of growth, 4554 cycle progression, 6200 antilymphoma activity of-y~ T-cells Ca 2+ mobilization, stimulation by gas- normal and leukemic severe combined immune deficiency, trin, 6031 staurosporine effects, cell cycle and mice, 5610 CD24 as major surface antigen, 5264 chromatin structure, 470 mapping chromosomal breakpoints cellular glutathione, cytotoxicity and normal human fibroblasts and t(8;14) translocations, upstream from resistance of platinum compounds, intrinsic radiosensitivity, 6348 c-myc, 6547 6885 proliferation-linked regulation pattern of p53 mutations, 4273 chromosome alterations, 1322 type II IMP dehydrogenase gene, 258 tumor-associated epitopes epidermal growth factor receptor, splenic epithelial mucin complementary DNA, 3089 bromocriptine effects, neoplastic pro- 5985 growth, stimulation by neuropeptides, gression, 2209 unlabeled and 131I-labeled pan B-cell 2737s T-cell receptor a/~ variability monoclonal antibodies, 6476 loss of heterozygosity, polymorphic melanoma metastasis, 4649 Lymphoma, non-Hodgkin's sites within MCC and APC, 1996 T-cell subset analysis B-cell modulation of UDP-N-acetylhexosa- Lewis lung carcinoma tumor rejection, pathogenetic mechanisms, 5522s mine, glucosamine and uridine, metastasis, 6507 changes in descriptive epidemiology 3782 tumor-infiltrating Great Britain, 5441 s octamer DNA-binding and nervous HLA association, interleukin 2-based changes in diagnosis over time, 5453s system-specific transcription factor, immunotherapy for melanoma, 6561 chronic fatigue syndrome, 5516s 6121 T-cell receptor V~ gene usage, hepato- current knowledge of etiological factors, reduced expression, gene from chro- cellular carcinoma, 5913 5573s, 5574s mosome region 3p21, 1536 tumor-reactive T-cells, lung cancer tis- development of small cell variant sues, 775 nutritional factors, 5492s resistance to LAK cells, cytostatic fac- Lymphoid cells epidemiological studies tor, 3310 bcl-2 gene transfer applications, experimental techniques, tumor-reactive T-cells resistance to cell death and fragmenta- 5561s failure to respond to tumor cell-de- tion, 5407 incidence rived factor, 775 Lymphokines time trends, impact of known risk fac- Luteinizing hormone-releasing hormone modulation of HPV gene expression, tors, 5566s antagonist SB-75 456 increasing incidence, 5496s sustained release formulations, pros- Lymphoma molecular and immunoregulatory mecha- tatic carcinoma, 2538 AIDS-related nisms, 5572s LYl17018 County of Los Angeles, 5482s National Cancer Institute Workshop hormonal effects centrocytic etiological factors, 5430s, 5431 s prostatic adenocarcinoma, 4663 chromosome 11 translocation break- occupational exposure and, 5503s L ymnaea stagnalis points, 5541s origin of quantitative ultrastructural effects on chromosome abnormalities occupational and environmental fac- neurons karyotype review, 1481 tors, 5501s cisplatin, carboplatin and iproplatin, genetic risks overview of classification, 5447s 963 primary immunodeficiencies, 5465s pathological classification Lymph node large cell and immunoblastic epidemiological studies, 5456s

7051

pesticides and, 5485s Magainin analogues development of preneoplasias radiation and, 5489s antitumor activity epithelial cell lines, 1924 research directions and general discus- human lung cancer cell lines, 3534 inhibition of 7,12-dimethylbenz[a]an- sion, 5571s Magnetic field thracene-induced tumors risk factors static 1,4-phenylene- prior medication use, health history, induction of c-los gene expression, bis(methylene)selenocyanate, 2402 5510s HeLaS3 cells, 6522 terminal end bud epithelium risk of Magnetic resonance spectroscopy cellular kinetics, N-methyl-N-nitrosou- familial aggregation, hemopoietic ma- 3~p rea exposure, 5076 lignancies, 5468s depletion of ATP, 2-deoxyglucose and Mammary neoplasms time trends, 5443s insulin, 7 l 7,12-dimethylbenz[a]anthracene-induced United States and international data, Major histocompatibility complex antitumor effects, SMANCS, 1013 5432s class I dimethylbenzanthracene-induced time trends and pathological classifica- mutated/32-microglobulin gene, colon antitumor and endocrine effects, voro- tion, 5570s cancer cell line, 1201 zole, 1240 viruses other than HIV, 5479s class II down-regulation of tenascin expression Lymphoma, T-cell human colon tumor vaccine efficacy, antiprogestins, 4642 tumor progression in vivo 3460 elevated membrane association soybean agglutinin lectin binding, liver Malignancy phospholipase C71, 4526 metastasis potential, 5235 B-cells hormone-independent Lymphoma, thymic intracellular catabolism, radiolabeled role of tamoxifen, rats, 235 p53 mutations anti-u antibodies, 2907 induction by N-methyl-N-nitrosourea induction, 7-irradiation and N-methyl- distribution of cells expressing myc pro- genetically resistant Copenhagen rats, nitrosourea, 3791 teins, 5853 5037 Lymphomagenesis elevated uptake of low density lipopro- mono-L-aspartyl chlorin e6 antigen selection, 5547s teins metabolic properties, mouse model, measure of genomic instability, 5545s human lung cancer tissue, 6244 2890 molecular basis, 5529s glioma phyllodes tumors Lymphosarcoma p53 mutations, loss of heterozygosity, immunoreactive endothelin 1, 4046 bovine leukemia virus-induced 1427 preneoplastic hyperplastic alveolar nod- glycoproteins, serine phosphorylation, growth inhibition and differentiation ule line C4 6463 phosphorothioate analogues of cyclic neoplastic progression, bromocriptine carcinogenic potency AMP, 2504 effects, 2209 alkylating agents, rodents and humans, hemopoietic rapid development and dietary fat 2464 familial aggregation, risk of non- 7,12-dimethylbenz[a]anthracene, SEN- Lymphotoxin Hodgkin's lymphoma, 5468s CAR mice, 662 tumor necrosis factor-a or human papillomavirus-associated cervi- selenite-mediated growth inhibition acute effects, subcutaneous rodent tu- cal neoplasms influence, intracellular glutathione, mors, 2167 laminin receptor messenger RNA, 1091 Lysozyme 1561 subpopulations identification of major protein compo- immunoreactive human chorionic gonad- sequential dissemination, metastatic nents otropin process, 1399 breast secretions, benign and malig- free ~ subunit, ascites and serum, 1520 tumor progression nant breast diseases, 95 low-density lipoprotein nonrandom abnormalities, chromo- Lysyl chlorin p6 delivery of acrylophenone antineoplas- some 1 and Harvey-ras-1 alleles, chlorin p6 mixture tic molecule, 3629 4791 photodynamic therapy, glioma, 1235 stimulation of growth Mammography antidepressant drugs, clinically rele- management of breast cancer M vant doses, 3796 evolution of paradigms, 2371 suppression of malignant phenotype Mass spectrometry microscopy Macromolecules interleukin 6 gene transfection, Lewis secondary ion disposition characteristics lung carcinoma, 3679 4'-iododeoxyrubicin, metastatic squa- perfused tissue-isolated tumor prepara- Malignant progression mous cell carcinoma, 974 tion, 4396 expression pattern of a-protein kinase C Mast cells suppression of cellular aggregates human astrocyoma, 2951 role of cytokines high levels of episialin, 2318 Mammalian cells regulation of cell function, pathogen- Macrophages chrysotile fiber as a strong mutagen, esis of disease, 6129 Adriamycin-induced modulation 6305 Matrix serine proteinases host defenses, tumor-bearing mice, irradiation-induced expression multiple secretion 3572 O6-methylguanine-DNA methyltrans- human gastric carcinoma cell lines, induction of differentiation of leukemia ferase, 1804 5046 cells protection of Chinese hamster ovary Maytansinoids bufalin, 4634 cells immunoconjugates, 127 milky spot GC to AT transitions, O6-methylguan- MCF-7 cells activation of omental milky spots, OK- ine-DNA-methyitransferase, 647 l cell growth and retinoic acid metabolism 432, 5400 stable expression of cytochrome effects of liarozole, 2841 peritoneal P4501IEl effects of 17/3-estradiol metabolites tumoricidal activation, interleukin 2 metabolic activation, nitrosodimethyi- cell cycle events, 5926 and tumor necrosis factor-a, 3880 amine, 1796 elevated level of nuclear protein kinase tumor necrosis factor-induced activation Mammary gland C, 3750 block, inhibitors of polyamine biosyn- development of hyperplasia functional role for P-glycoprotein thesis, 1891 Writ- l transgenic mice, 4413 efflux pump, benzo[a]pyrene, 6692

7052

growth-inhibitory action modulation, cisplatin resistance, 6790 hormone levels, risk of breast cancer, estrogen-chlorambucil conjugate, 1187 radiation sensitivity, primary tumors 578 inhibitory protein factor, 6860 and metastatic lesions, 4453 Mer § cells mitoxantrone-resistant metastases Mer- cells and absence of P-glycoprotein overexpres- a-melanocyte-stimulating-diphtheria O6-methylguanine-DNA methyltrans- sion, reduced intracellular drug ac- toxin fusion protein, 2545 ferase promoter activity, 6404 cumulation, 6175 T-cell receptor a/fl variability, lym- Merocyanine 540 perturbations of cellular acylation proc- phocytes, 4649 -sensitized photoperoxidation and photo- esses metastatic killing 1-O-octadecyl-2-O-methylglycero-3- basic fibroblast growth factor, RNA selenoperoxidase-mediated cytoprotec- phosphocholine, 2806 and protein levels, 5024 tion, leukemia cells, 5282 steroid and growth factor modulation Phase I trial, murine monoclonal anti- Mesenchymal neoplasms aromatase activity, 1411 GD2 antibody 14G2a, 4342 soft tissue sarcomas tamoxifen-sensitive and -resistant sub- metastatic malignant SAS amplification, 3746 lines nm23 messenger RNA, disease pro- Mesothelioma responses to retinoic acid, 6164 gression, 6088 asbestos-induced Medication ocular platelet-derived growth factor, receptor prior use inhibition by Mullerian inhibiting sub- expression, 301 health history, risk factors for non- stance, 1182 p53 and Kirsten-ras mutations, 2610 Hodgkin's lymphoma, 5510s quiescent cells Mesothelium Medulloblastoma as/~l integrin receptor, fibronectin, presence of monoclonal antibody K1 cyclophosphamide resistance, 5373 4499 characterization of antigen, ovarian expression of O6-methylguanine-DNA site-dependent differences in sensitivity cancer, 181 methyltransferase, 1144 dacarbazine and mitozolomide, 1347 Metaiodobenzyiguanine pediatric primitive neuroectodermal tu- -specific cytotoxic T-cells accumulation mors human xenograft-nude mouse model, T-interferon-induced neuroblastoma 17p tumor-related locus, 3391 adoptive immunotherapy, 394 cells, 4960 Melanins surgical specimens Metal liposome-entrapped pigments retention, cellular radiation sensitivity carcinogenesis polyethylene glycol-mediated delivery, in cell and xenograft lines, 1764 chemical pathology study section fibroblasts, 6638 xenografts workshop, 4058 Melanocyte antitumor activity, N,N'- differential metabolic patterns growth of cultures bis(ethyl)spermine homologues, iodinated vs. radiometal chelated anti- 12-O-tetradecanoylphorbol-13-acetate, 2424 carcinoma single-chain Fv mole- protein kinase C activation, 4514 different growth characteristics, blood cules, 6413 a-Melanocyte-stimulating hormone flow, 584 Metalloprotein -diphtheria toxin fusion protein spatial distribution, tumor-specific overexpression in Chinese hamster ovary interaction with melanotropin recep- monoclonal antibodies, 367 cells tors, melanoma metastases, 2545 targeted radiotherapy, 21~At_methylene nitrogen mustard-induced cytotoxicity, Melanoma blue, 4385 6853 -associated antigen tumor-specific monoclonal antibody Metalloproteinase whole immunoglobulin and Fab' frag- uptake, 357 enzyme prosegment ments, monoclonal antibody, 2497 Melanoma, B16 inhibition of tumor cell invasion, calcyclin expression B16F1 highly conserved peptide sequence, correlation, metastatic behavior, 1291 inhibition of metastasis and cell adhe- 2353 cell motility factor receptor expression sion, protein kinase C, 1195 gene expression suppression by retinoic acid, 4878 interleukin 6-transfected, 5412 metastasis, transformed rat cell lines, cultured cell lines transfected H-2I(~ gene 4942 differential susceptibility, ICAM-1 suppression, liver metastases, 4036 inhibitor modulation by retinoic acid, 4766 Melphalan inhibition of invasion, metastasis in disseminated carcinogenic potency cells, 701 antitumor effect, interferon and cyclo- rodents and humans, 2464 serum levels sporine A, 6482 entry into brain and xenotransplanted lung cancer metastasis, response to glycosylation pathways glioma therapy, 4548 biosynthesis of gangliosides, 5725 amino acid-lowering diet, 5590 tumor cell surface-associated binding site HLA association with response and tox- penetration of blood-brain barrier Mr 72,000 type IV collagenase, 5845 icity neutral amino acid transporter, tumor- Metalloproteinase 2 interleukin 2-based immunotherapy, bearing brain, 138 collagen-induced activation 6561 -resistant prostate carcinoma cells human fibroblastoid cells, 4540 human cells -r-glutamylcysteine synthetase activity, tissue inhibitor soluble ICAM-I, tumor growth in 5115 loss of metastatic phenotype, epider- mice, 2628 Meningioma moid carcinoma, 5597 human cells in nude mice immunohistochemical localization Metallothionein synthetic antagonist to laminin, osteo- cell adhesion molecule epithelial cad- acquired resistance to cisplatin lytic metastases, 5395 herin, 1981 testicular nonseminomatous germ cell immunogenic human antigens Meningoencephalitides line, 1710 polyvalent melanoma vaccine, 5948 interleukin 8 production Metaplasia inhibition of growth by campothecins, neoplastic and infectious diseases, squamous 3980 4297 tracheal epithelium, retinoid status malignant Menstruation and keratin expression, 6144 cell surface accessibility, gangliosides, vegetarian and nonvegetarian teenage Metastasis 4948 girls allelotype analysis in osteosarcomas,

7053

2419 synthetic antagonist to laminin, hu- O6-Methylgnanine aspirin and potential role of prostaglan- man melanoma cells in nude mice, sensitive and specific detection dins 5395 HPLC prefractionation, 32p postlabel- colon cancer, 5575 potentiation of cytotoxic cancer thera- ing and immunoprecipitation, 5307 behavior pies Methylguanine-DNA methyltransferase calcyclin expression, melanoma, 1291 antiangiogenic agents, 6702 intracellular localization by antibodies, breast cancer protease gene expression and regulation 6423 loss of alleles, chromosomes 11 and fibroblast transformation, ras onco- O6-Methylguanine-DNA methyltransferase 17, 3914 gene, 6682 chloroethylnitrosourea-treated DNA and dietary fat and mammary tumorigenesis, pulmonary identification of cross-link, 6052 2040s primary structure, tumor invasion-in- DNA repair-deficient Chinese hamster hepatic hibiting factor 2, 1422 ovary cell line eradication by combination chemoim- renal cell carcinoma response to alkylating agents, 32 munotherapy, 6254 guanidinobenzoatase as marker, 3622 epigenetic silencing in Mex- human hepatic tumor growth prognostic factor, serum level of inter- cells, 5257 sialyltransferase activity, colorectal leukin 6, 3317 expression in human medulloblastoma cancer, 1775 selective events in process cell lines, 1144 human tumor burden and response to sequential dissemination, subpopula- irradiation-induced expression therapy tions of mammary tumor, 1399 mammalian cells, 1804 nude mouse xenograft model, repeti- suppression of malignant phenotype promoter activity in Mer § and Mer- tive human DNA sequences, 2791 interleukin 6 gene transfection, Lewis cells, 6404 incidence and distribution lung carcinoma, 3679 protection of Chinese hamster ovary defective organ microenvironments, survey of various human tumors cells mutant mice, 2304 DNA fingerprinting, 2174 spontaneous GC to AT transitions, inhibition by protein kinase C thrombin treatment 6471 cell adhesion, B16FI melanoma cells, adhesion of tumor cells to platelets, Methylhydrazines 1195 3267 oxidation to mutagenic methylating de- inhibition of cell attachment by selenite, transcriptional and posttranscriptional rivatives 5803 urokinase plasminogen activator gene alkylation damage, adaptive response inhibition of invasion expression, 2489 of Escherichia coli, 3693 inhibitor of metalloproteinases, 701 tumor cell line 6-Methylmercaptopurine riboside inhibition of tumor cell invasion greatly reduced levels, homotypic cell 5-fluorouracil-containing drug combina- highly conserved peptide sequence, adhesion molecule activity, 1546 tion matrix metalloproteinase enzyme visceral regression, advanced breast tumors, prosegment, 2353 Friend leukemia cells, inhibition by 4074 Lewis lung carcinoma tumor rejection monoclonal antibody, 2880 4-(Methylnitrosamine)-l-(3-pyridyl)-l-bu- T-cell subset analysis, 6507 Metastasis suppressor gene tanone liver localization to short arm of chromosome development and progression of pulmo- inhibitory effect of RC- 160, colon can- I1 nary tumors cer, 6025 prostatic cancer, 3486 role of alveolar type II cells, 3164 transfected H-2K b gene, B 16 cells, Metastatic potential -induced tumorigenesis 4036 decreased with IL-6 gene inhibition, green and black teas, 1943 tumor progression in vivo, soybean ag- transduction, fibrosarcoma cells, 6020 metabolism in human lung and liver mi- glutinin lectin binding, 5235 Methionine adenosyitransferase crosomes loss of phenotype induction of interleukin 2 production cytochromes P-450, hepatoma cells, epidermoid carcinoma, tissue inhibitor Jurkat T-cells, 3361 1757 of metalloproteinase 2, 5597 Methotrexate placental transfer lung cancer azidothymidine-induced cytotoxicity intrathecal instillation, Syrian golden response to therapy, serum metallo- HCT-8 cells, 4069 hamsters, 3273 proteinase levels, 4548 cell cycle-related expression N-Methyl-N-nitrosourea lymph node p120 nucleolar antigen, 3491 cellular kinetics ras gene mutations, lung adenocarci- cellular localization of folate receptor mammary gland terminal end bud epi- noma, 2903 drug toxicity, folate homeostasis, 6708 thelium, 5076 malignant melanoma collateral sensitivity -induced mammary carcinoma radiation sensitivity, 4453 cisplatin-resistant human ovarian car- c-Ki-ras activation, pituitary-isografted matrix rnetalloproteinase genes cinoma, 3110 mice, 5732 transformed rat cell lines, 4942 intrinsic induction of p53 mutations melanoma human soft tissue sarcoma cell lines, thymic lymphomas, 3791 basic fibroblast growth factor, RNA 3908 mammary tumor induction and protein levels, 5024 model system for testing anticancer genetically resistant Copenhagen rats, a-melanocyte-stimulating-diphtheria drugs 5037 toxin fusion protein, 2545 wap-ras transgenic mouse, 3733 Methyl-P-hydroxyphenyllactate T-cell receptor a/~ variability, lym- resistance nuclear type II sites phocytes, 4649 mucins, colonic adenocarcinoma, 4655 malignant cell proliferation, inhibition multistage carcinogenesis, 4837 3-Methyicholanthrene by 2,6-bis-benzylidenecyclohexan- murine and human neoplasms genomic rearrangements ones, 2482 clonal populations, nm23 gene expres- DNA fingerprint assay, C3H/10TI/2 O4-Methylthymine sion, 5808 cells, 5788 sensitive and specific detection neoplasia and Methylglyoxal bis(guanylhydrazone) HPLC prefractionation, other tests, fate of clonal lineages, incorporated S-adenosylmethionine decarboxylase in- 5307 genetic marker, 1737 hibitors Mex- cells osteolytic potent antitumor activity, 4712 epigenetic silencing

7054

O6-methylguanine-DNA methyltrans- 2384 mouse tumor model, 2890 ferase, 5257 Mitogens Monoclonal antibody(ies) Microcell transfer endothelin production 9.2.27 chromosome 13 stimulation of breast cancer cells, long-term growth suppression, glioma reconstitution, retinoblastoma gene bombesin and glucocorticoids, 1786 xenografts, 3838 function, 6297 Mitomycin C affinity chromatography Microcirculation cytotoxicity molecular dosimetry, aflatoxin-N% angiogenesis treatment duration, glutathione deple- guanine, 267 early growth, human adenocarcinoma tion, 4608 AM-3 in SCID mice, 6553 disposition characteristics of macromole- sialyl Lewis x antigen, marker for dys- Microfilament cules plasia in colonic adenoma-carci- -disrupting agents perfused tissue-isolated tumor prepara- noma sequence, 3138 formation of apoptic bodies, tumor tion, 4396 antibody binding assays cells undergoing apoptosis, 997 elevated DT-diaphorase activity affinity, bivalent interaction, 4157 Bz-Microglobulin messenger RNA content, non-small antibody drug carrier gene mutation cell lung carcinoma, 4752 immunotherapy, superficial bladder HLA class I antigen expression, colon NAD(P)H:quinone oxidoreductase gene cancer, 3131 cancer cell line, 1201 expression anti-CD3 Micrometastasis colon carcinoma, 797 CD3-negative tumors, Phase IA/B hematogenous xanthine dehydrogenase-mediated me- study, 2394 prostate cancer, 6110 tabolism anti-CD45 Microsomes dicumarol, 6936 selective radiation, hematolymphoid metabolism of N-nitrosomethyl-n-amy- Mitomycin C analogues tissue, 1228 lamine cytotoxic activity anti-erbB-2 human and rat esophagus, 3547 buthionine sulfoximine and ethacrynic therapy of an animal model, human Microspheres acid, 6666 gastric cancer, 2771 encapsulation of cisplatin Mitosis anti-growth factor therapy poly-lactide-co-glycolide, reduction of inhibition of p34 cdcz kinase activation pharmacologically guided end point, systemic exposure and toxicity, p34 cdez tyrosine dephosphorylation, 2743s 6653 Chinese hamster ovary cells exposed anti-ICAM-1 Microtubules to etoposide, 1817 effect of tumor size, radiolabeled changes during HL-60 cell differentia- tissue growth and F(ab')2 fragments, 1309 tion, 949 relationship to growth factors, 501 anti-MUC1 peptide depolymerization transition from G2 phase second generation, 2310 photofrin and light, human endothelial phosphatidic acid and extracellular anti-P-glycoprotein cells, 3443 control, epidermal growth factor in reversal of Vinca alkaloid resistance, Milk A431 cells, 5627 human tumor xenograft, 1810 nitrogen-stimulated orotic acid synthesis Mitoxantrone binding to same antigen nucleotide imbalance, 2082s Adriamycin and differing affinities, multicell spheroids, Minnesota biochemical characterization of resist- 4728 pesticides and other agricultural risk fac- ance, colon adenocarcinoma, 1886 bispecific antibodies and haptens tors chronic cardiotoxicity animal model, 194 perivascular distribution, pharmacoki- non-Hodgkin's lymphoma, 2447 -resistant MCF-7 cells netic analysis, 5838 Minocycline absence of P-glycoprotein overexpres- bispecific antibody 2B1 antiangiogenic agents sion, reduced intracellular drug ac- cytotoxie targeting, mononuclear cells, potentiation of cytotoxic cancer thera- cumulation, 6175 6832 pies, primary and metastatic disease, subcellular distribution bispecific antibody targeting 6702 human and drug-resistant murine cells, CA19-9 antigen and CD16, antitumor Mirex flow cytometry, 4000 effects, 5713 novel nonphorbol ester-type tumor pro- Mitozolomide bound to surface of tumor cells moter site-dependent differences in sensitivity fate of, 835 mouse skin, 631 LOX human melanoma tumors, 1347 B3-PE and B3-LysPE40 Misonidazole ML1 cells antitumor effects, nude mouse model distribution of adducts induction of differentiation by bufalin of human breast cancer, 3189 oxygen distribution, 9L gliosarcoma macrophage/monocyte-like cells, 4634 CD3-ricin A chain immunotoxins tumors and spheroids, 3831 Molecules relation to cellular uptake, degradation Mitochondria carcinogenic processes, 2362 kinetics, 5921 defects in cis-diamminedichloropla- MOLT-4 cells cell surface accessibility tinum(lI)-resistant cells cell cycle-related expression total ganglioside composition, malig- ovarian carcinoma, 1895 p120 nucleolar antigen, 349 ! nant melanoma cells, 4948 disruption of function by suramin cytostatic and cytotoxic effects complementary DNA cloning rhodamine-123 retention, prostate car- fostriecin, ! 530 galactosyltransferase, 6158 cinoma, 6953 effects of genistein detection of nuclear matrix proteins in DNA expression growth and cell cycle progression, serum differentiation, HT-29 colonic adeno- 6200 cancer patients, 422 carcinoma cells, 3718 Monensin DF3-P epitope proton leak blocking effect of human serum cell surface expression, differentiating deviant bioenergetics, Ehrlich and ricin A chain immunotoxin potentia- agents, 6365 AS30-D tumor cells, 4935 tion, 623 distribution to solid tumors Mitogenesis Mono-L-aspartyl chlorin e6 effects, target antigen competition, retinoic acid inhibition metabolic properties 1284 serum-induced c-fos transcription, photosensitizing responsiveness, -drug conjugate

7055

reduction of local recurrence, colorec- specificity and affinity carcinoma tal cancer, 6323 carcinoembryonic antigen, 2329 Le~-X oligosaccharides, 2923 E48 T-antigens in human urinary bladder tu- gene expression radioimmunoscintigraphy, head and mors, 5030 colonic tissues and cell lines, 597 l neck cancer, 2569 TS 106 modified ovine submaxillary gland early intervention in cancer quantitation of thymidylate synthase, immunization of colorectal cancer pa- biological ligands, 2747s cancer cell lines, 4306 tients, 5663 epidermal growth factor receptor tumor-inhibitory polymorphic epithelial androgen-independent prostatic carci- HER-2/neu receptor, breast cancer cell tissue-specific expression, transgenic noma, 5887 differentiation, 2580 mice, 1954 F-18-1abeled F(ab')2 fragment tumor-reactive 16.88 second generation anti-MUC1 peptide localization, subcutaneous xenograft quantitation, colorectal metastatic tu- monoclonal antibodies, 2310 model, 5054 mor tissue, 2603 Miillerian inhibiting substance 14G2a tumor selective reactivity inhibition of ocular melanoma, 1182 Phase I trial, metastatic melanoma, recombinant peptide, DF3 breast car- Multidrug resistance: see also Drug resist- 4342 cinoma-associated antigen, 2563 ance high-affinity anticarcinoma radioimmu- tumor-specific circumvention of anthracycline resist- noconjugates spatial distribution, human melanoma ance therapeutic advantage, 1067 xenografis, 367 cinchonine, 2797 human uptake, human melanoma xenografts, circumvention of bleomycin resistance sulfogylcolipid, 2292 357 human colon carcinoma, 2931 humanized M 195 unlabeled and ~31I-labcledpan B-cell decreased P-glycoprotein expression biological and immunological features, nude mice bearing Raji Burkitt lym- myeloma cells induced by cytokine leu- 6761 phoma xenografts, 6476 koregulin, 5893 IMH2 unmodified anticarcinoma antibody elevated levels of nuclear protein kinase specificity, immunobiological proper- BR96 C ties, 3739 inhibition of outgrowth, human tu- MCF-7 cells, 3750 inhibition of Friend leukemia cell vis- mors in nude mice, 3262 increased accumulation of drugs ceral metastases, 2880 uptake in solid tumors cells induced by liposomes, 3241 7-interferon enhancement of specific tar- antibody affinity and antigen density, lung cancer cell lines without P-glyco- geting predicted and observed effects, 377 protein expression induction of ICAM-I, small cell lung whole immunoglobulin and Fab' frag- energy-dependent processes, reduced carcinoma, 4890 ments drug accumulation, 17 intracellular localization determinants, high molecular weight- MDR1 amplification methylguanine-DNA methyltransfer- melanoma associated antigen, 2497 anthracycline-resistant HL-60/AR ase, 6423 Monocyte cells, 5244 1311- or 12SI-labeled -like cells modulation of subcellular doxorubicin epidermal growth factor receptor, hu- induction of differentiation, bufalin, distribution man glioma xenograft immunother- 4634 SR33557, P388/ADR mouse leukemia apy, 121 Mononuclear cells cells, 6440 KM-2 in vitro cytotoxic targeting multidrug sensitivity phenotype serodiagnosis, hepatocellular carci- bispecific antibody 2B1, 6832 human lung cancer cells, 1666 noma, 4987 peripheral new approaches to treating early lung K 1 presence on ovarian cancer and me- dihydropyrimidine dehydrogenase ac- cancer, 2652s sothelium tivity, fluorouracil systemic clear- P-glycoprotein- and non-P-glycoprotein- characterization of antigen, 181 ance, 2899 mediated micropharmacology peripheral blood cytogenetic alterations, lung tumor cell solid tumors, binding site barrier, 5144 ras-related rab2 gene product, hemato- lines, 4361 mouse logical and solid neoplasms, 3083 phenotype ~-galactosyltransferase in body fluids, Monoterpenes relationship to VP-16, 2874 6153 minor dietary constituents phenotype of disease-oriented panels MRK16 inhibition of carcinogenesis, 2085s anticancer drug screening, tumor cell reversal of multidrug resistance, trans- Morpholino doxorubicin lines, 3029 genic mice, 4427 role of cytochrome P-450 in potentiation predictor for treatment myogenic regulatory protein human liver microsomes, 4379 glutathione transferase x, acute non- epitope mapping, diagnostic utility, Motility-inhibitoryprotein lymphoblastic leukemia, 3281 6431 cancer cell procainamide uptake -penicillin G amidase conjugate Dunning adenocarcinoma model, 2349 Chinese hamster ovary model, 3539 activation, N-(4'-hydroxyphenylace- Mouse mammary tumor virus resistance to Adriamycin tyl)palytoxin, 5759 adoptive transfer of V/~2-deleting activity drug transport mechanisms, HL-60 radiolabeled anti-# antibodies C4 preneoplastic hyperplastic alveolar cells, 3157 intracellular catabolism, malignant B- nodules, 5183 response of breast cancer cells cells, 2907 Mucin heat shock, chemotherapeutic drugs, radiolabeled anti-B1 cancer-associated sialosyl-Tn antigen 3648 Raji lymphoma xenografts, improved inhibition, natural killer cell cytotoxic- reversal delivery, 637 ity, 4741 monoclonal antibody MRK16, trans- radiolabeled antimyeloid antibodies complementary DNA genic mice, 4427 acute leukemia xenograft tumor tumor-associated epitopes, 5985 two novel indole derivatives, 4735 model, 89 expression and characterization reversal compounds ricin A chain immunotoxin potentiation resistance to methotrexate, colonic ad- structure-activity study and design, blocking effect of human serum, mo- enocarcinoma, 4655 computer automated structure evalu- nensin, 623 gel formed by tumorgenic squamous lung ation methodology, 4121

7056

structural requirements for recognition human tumor cells, 249 inhibition, Japanese-style fermented simple organic cations, 6385 Mutations soy sauce, 1754 verapamil germ line p53 intraepithelial collateral sensitivity to nitrosoureas, based on transcriptional activation, natural history of, 1651 5013 6976 metastasis and Multiple endocrine neoplasia p53 and 17p alellic loss fate of clonal lineages, incorporated high levels of enhanced reactivation colorectal carcinoma, 1974 genetic marker, 1737 herpes simplex virus, skin fibroblasts, Mycosis fungoides Neoplastic progression 53 HTLV-I or a related retrovirus, 4391 bromocriptine effects type 1 Myelodysplastic syndromes mammary preneoplastic hyperplastic allelic loss from chromosome l 1, para- growth modulation of colony-forming alveolar nodule line C4, 2209 thyroid tumors, 6804 cells carcinogen-induced type 2 L-ascorbic acid, 4458 initiated mouse epidermal cells, 3145 I p loss of heterozygosity, pheochro- Myeloid cells tumorigenic transformation and mocytoma, 770 differentiation 4-aminobiphenyl exposure, uroepithe- transgenic c-mos mouse model, 450 NADPH oxidase gene expression, tu- lial cells, 1606 Muramyl-tripeptide mor necrosis factor and 7-inter- Neoplastic transformation liposomal feron, 2530 immortalized keratinocytes combination chemoimmunotherapy, normal and malignant 2,3,7,8-tetrachlorodibenzo-p-dioxin, eradication of hepatic metastases, retinoic acid-binding protein, acute 3478 6254 promyelocytic leukemia, 3329 platelet-derived growth factor-independ- Muscle, skeletal Myeloma cells ent phenotypes platelet and neutrophil-endothelial ad- induction by cytokine leukoregulin pathway for transformation suscepti- herence decreased P-glycoprotein expression, bility, 4232 induction by interleukin 2, macromo- 5893 Neovasculature lecular leakage, 3425 Myelopoiesis vascular permeability and Muscle, smooth -associated immune suppressor cells tumor retention, photodynamic agents, a-actin promoter mice bearing metastatic Lewis lung 924 ras-transformed cells, drug screening, carcinoma, 6335 Nephroblastoma 6877 Myoepithelial cells Japanese eel, 2575 human tumors cell lines of R3230AC rat mammary car- Nephrocalcin CpG methylation, insulin-like growth cinoma biosynthesis in human renal carcinoma, factor II gene, 6516 tumor types, 1553 1573 Mushroom Myogenic regulatory protein Nephrotoxicity Gyromitra esculenta MyoD1 cisplatin-induced cancer induction in mice, 2279 monoclonal antibodies, 6431 time dependence and selective modula- Mutagen Myometrium tion, WR2721, 2257 UV-sensitive excision repair-defective ro- human smooth muscle tumors Nerve growth factor dent mutants CpG methylation, insulin-like growth low affinity receptor eleventh complementation group, factor II gene, 6516 reduced expression, prostatic tissue, 6690 5403 Mutagenesis N Nestin human glucocorticoid receptor gene dele- class VI intermediate filament tion NADPH oxidase human central nervous system tumors, exposure to cancer chemotherapeutic gene expression during differentiation 5334 drugs, mutagens, 6612 tumor necrosis factor and ~,-interferon, Neuroblastoma induction of mutation myeloid cell lines, 2530 expression of N-myc, c-myc, and MDR- synthetic c-Ha-ras, hypoxanthine, NAD(P)H:quinone oxidoreductase 1 proteins 1836 gene expression immunofluorescence staining, flow cy- O6-methylguanine-DNA-methyltransfer- human colon carcinoma, 797 tometry, 2957 ase Na+/H + exchange glycosylation pathways protection of Chinese hamster ovary regulation of intracellular pH biosynthesis of gangliosides, 5725 cells, GC to AT transitions, 6471 microenvironmental conditions, tumor induction of differentiation specificity of oxygen radicals cell lines, 4441 distinct molecular and cellular pheno- human leukemia cells, 1082 NALM-6 cells types, 4402 Mutagenicity protein-tyrosine phosphatase expression, inverse relationship chrysotile fiber 737 trk expression, N-myc amplification, mammalian cells, 6305 Natural killer cells 1364 human N-acetyltransferases cytotoxicity metaiodobenzyiguanine accumulation expression in Salmonella, 3961 mucins, cancer-associated sialosyl-Tn ~,-interferon-induced cells, 4960 modulation of ethylnitrosourea-induced antigen, 4741 proliferation and differentiation toxicity polyinosine-polycytidylicacid complex c-myb antisense RNA, oligodeoxynu- O6-benzylguanine, 3851 carboxymethylcellulose, patients with cleotides, 4221 urinary cancer, 3005 rapid differentiation exposure to arylamines, textile indus- renal cell carcinoma ,y-interferon, tumor necrosis factor, try workers, 4885 rat model, 6279 931 Mutagens tumor cell interactions rare circulating cells chemical analysis of heterocyclic amines development, murine lymphoma sensitive detection, reverse transcrip- cooked foods, 2103s model system, 4149 tase-polymerase chain reaction, food-derived Neoplasia 4701 carcinogens and, 2092s benzo[a]pyrene-induced mouse forestom- subsets origin of point mutations ach loss of heterozygosity, chromosomes 1

7057

and 14, 1780 p 120 antisense RNA, 568 l tumorigenesis, green and black teas, tumor necrosis factor as autocrine interclonal heterogeneity 1943 growth factor, 3194 focus-forming phenotype, 1047 N-Nitrosodimethylamine Neuroectodermal neoplasms long-term cell culture metabolic activation pediatric primitive individual transforming events, epige- cytochrome P450IIEI stable expres- 17p tumor-related locus, 3391 netic induction, 667 sion, mammalian cells, 1796 peripheral sis-transformed reduced blood clearance chondrocytic differentiation, nude morphological reversion, trichostatin increased urinary excretion, exposure mouse xenograft, 4214 A, 168 to ethanol or isopropyl alcohol, Neuroendocrine cells Nitrite 1463 pulmonary nitrosamine synthesis and N-Nitrosomethyl-n-amylamine differentiation, preneoplastic lung in- hepatocytes, normal woodchucks and metabolism by microsomes jury, 2677s those with hepatitis virus, 4139 human and rat esophagus, 3547 Neuroendocrine neoplasms p-Nitro-benzyl-DOTA N-Nitroso-N-butylurea digestive system macrocyclic chelating agent administration in rats platelet-derived growth factor, recep- humoral immune response, radioim- urinary excretion, O6-butylguanine, tors, 106 munoconjugates, 904 6699 Neurofibromatosis Nitrobenzylthioinosine Nitrosoureas high levels of enhanced reactivation dilazep and dipyridamole collateral sensitivity herpes simplex virus, skin fibroblasts, protection from 7-deazaadenosine, hu- multidrug-resistant cells, selection 53 man hematopoietic cells, 5879 with verapamil, 5013 Neuromedin B 6-Nitrochrysene N-myc presence in lung cancer cell lines, 2732s induction of colon adenocarcinoma inverse relationship to trk expression Neurons species differences, 1542 neuroblastoma, 1364 quantitative ultrastructural effects Nitrogen N-Oct-3 cisplatin/carboplatin/iproplatin,L ym- -stimulated orotic acid synthesis expression by small cell lung cancer, naea stagnalis, 963 nucleotide imbalance, 2082s 6121 Neuropeptides Nitrogen mustard Nonlymphoid tissues broad spectrum antagonists -induced cytoxicity normal and transformed small cell lung cancer, 4554 metallothionein overexpression, c-kit receptor, 6139 new approaches to treating early lung Chinese hamster ovary cells, 6853 Notophthalmus viridescens cancer, 2652s l-Nitropyrene squamous carcinoma signal transduction in lung cancer C-oxidative metabolism caricature of tissue renewal, 4858 bradykinin sensitivity, 24 cytochrome P450 3A4, human liver Novobiocin stimulation microsomes, 6237 modulation of cell cycle-dependent cyto- growth, small cell lung cancer cells, 2-Nitropyrene toxicity 2737s DNA binding Adriamycin, 4-hydroperoxycyclophos- Neutrons metabolism in the rat, 1176 phamide, 3515 fission 4-Nitroquinoline 1-oxide monomyelocytic leukemia cell line 252Cf relative biological effectiveness, action of nitroreductases and glutathione resistance, topoisomerase II-targeted liver tumorigenesis, 1948 transferases drugs, 2782 Neutrophii(s) induction by butylated hydroxyanisole, N-ras chemotactic factors 58 mutation cell line from thyroid carcinoma, 464 gene- and strand-specific damage and re- ultraviolet radiation-induced skin can- -endothelial adherence pair cers, 3946 induction by interleukin 2, macromo- Chinese hamster ovary cells, 4183 NRK 49F cells lecular leakage, 3425 Nitroreductases stimulation of anchorage-independent tumor promoter-induced hydrogen per- glutathione transferases and cell growth oxide formation action on 4-nitroquinoline J-oxide, in- endothelin, 3011 suppression by tamoxifen, 4969 duction by butylated hydroxyanisole, Nuclear envelope N-(4'-Hydroxyphenylacetyl)palytoxin 58 laminins A and C activation Nitrosamine expression, human myeloid leukemia, monoclonal antibody-penicillin G ami- -induced lung carcinogenesis 2847 dase conjugate, 5759 Ca2+/calmodulin antagonists, 2723s Nuclear magnetic resonance Nickel -induced lung tumorigenesis diffusion imaging exposure inhibition by green tea, 3875 structural damage and hyperthermia, altered p53 gene structure, human epi- synthesis biological tissues, 6066 thelial cells, 218 normal woodchucks and those with inhibitory effect of RC-160 on growth Nickel suhsulfide hepatitis virus, 4139 hepatic metastases, colon cancer, 6025 GGT to GTT transversions in codon 12 tobacco-specific modulation of UDP-N-acetylhexosamine K-ras, renal sarcomas, 4747 potential chemopreventive agents, lung glucosamine and uridine, small cell Nicotinamide carcinogenesis, 2719s lung cancer, 3782 lowering of tumor interstitial fluid pres- tobacco-specific carcinogens tumor blood flow sure metabolic activation, DNA and hemo- mammary adenocarcinoma, 6010 mechanistic and therapeutic implica- globin adducts as markers, 2698s Nuclear magnetic resonance spectroscopy tions, 3237 N-Nitroso compounds radiation-induced fibrosarcoma 1 tumor NIH/3T3 cells alkylating nonglycolytic acidification, 1259 increased growth by transfection mutations of codons 204 and 213, p53 radiobiological oxygenation status pos- human p120 complementary DNA, in- gene, 2995 tradiation hibition by p120 antisense construct, N-Nitrosodiethylamine tumor metabolism, partial pressure of 428 4-(methylnitrosoamino)-l-(3-pyridyl)-l- oxygen, 4620 inhibited proliferation butanone and Nuclear matrix

7058

nuclear type II sites tumor suppressor gene loma, transgenic mice, 978 malignant cell proliferation, inhibition chromosome 19q, 4277 neu by 2,6-bis-benzylidenecyclohexan- Oligodeoxynucleotides acquisition of tumorigenic phenotype, ones, 2482 inhibition of proliferation ventral prostate epithelial cell line, Nuclear matrix proteins c-myb antisense RNA, transformed 3174 detection in serum neuroectodermal cell lines, 4221 transformation, protein tyrosine phos- cancer patients, 422 Oligonucleotide probes phatase 1B expression, 478 Nucleic acid gene-specific neu and ras binding of N-hydroxy-4-acetylaminobi- a/~/rr and microsomal rat glutathione mammary carcinomas, early and late phenyl S-transferases, 5797 ovariectomy, 4102 N-acetoxy-4-acetylaminobiphenyl,uro- Oligosaccharides neu overexpression epithelial cells, 3286 Lea-X differences, breast cancer risk factors, Nucleotide formation of mucin gel, tumorigenic 2344 excision repair activities squamous lung carcinoma, 2923 pathways that control cell division, 2362 efficient repair of O6-ethylguanine, hu- penultimate cell surface ras man cells, 2008 adrenal carcinoma tumor progression, transformation, reversal of divergent imbalance 2222 differentiation, 4269 nitrogen-stimulated orotic acid synthe- Omentum ras mutations sis, 2082s milky spots and milky spot macrophages human papillomavirus DNA, prostate pool imbalance and orotic acid activation by OK-432, 5400 carcinoma, 5991 mitoinhibitory effects, hepatocytes, Oncogenes restricted oncogenicity 2078s application of molecular genetics BCR/ABL pl90, transgenic mice, Nucleus early diagnosis and screening, lung 4534 transcriptional and posttranscriptional cancer, 2658s sis-transformed NIH3T3 cells activation c-erb-B2: see also c-erb-B2 morphological reversion, trichostatin urokinase plasminogen activator gene altered gene expression, immortalized A, 168 expression, 2489 human breast epithelial cell line, tumor suppressor genes and Nutrition 1210 hepatocarcinogenesis, hepatitis B virus cancer and c-fos transgenic mice, 2823 role of intervention trials, 2030s induction by static magnetic field ex- Oncogenesis cancer conference and, 2124s posure, HeLaS3 cells, 6522 liver Nutrition and Cancer Conference serum-induced transcription, retinoic molecular and genetic analysis, trans- keynote address, 2024s acid inhibition, 2384 forming growth factor-a transgenic clinical application of biomarkers, 2711 s mice, 5171 O c-mos Oncogenicity pheochromocytoma and C-cell thyroid cellular transformation Obesity neoplasms, transgenic mouse model, human papillomavirus type 11, 5872 body fat distribution and 450 Oncology endometrial cancer, China, 3865 complementation in fetal brain trans- use of blood cell growth factors, 2012 Occupational risks plants, 3760 Oral contraceptives coke oven workers c-src estrogenic potential of progestins detection of PAH-DNA adducts, white protein tyrosine kinases, breast cancer, breast cancer cell proliferation, 6539 blood cells, 1510 4773 Orange oil exposure of textile industry workers to expression of N-myc, c-myc, and MDR-I minor dietary constituents arylamines immunofluorescence, neuroblastoma, inhibition of carcinogenesis, 2085s urinary mutagenicity, N-acetylation 2957 Organoselenium compound phenotype, 4885 Ha-ras 1,4-phenylenebis(methylene)- non-Hodgkin's lymphoma, 5503s mammalian cell transformation, Esch- selenocyanate origin of non-Hodgkin's lymphoma, erichia coil, 983 chemoprevention, colon carcinogene- 5501s HER2/neu sis, 5635 parental occupation c-myc amplification, primary breast inhibition of 7,12-dimethylbenz[a]an- childhood astrocytoma, 782 cancer, 1107 thracene-induced tumors, mammary relevance of environmental alkylating interferon-induced increase in sensitiv- gland, 2402 agents ity, ovarian cancer targets, 764 Organosulfur compounds repair protein O6-alkylguanine-DNA radiolabeled antibody targeting, 1916 minor dietary constituents alkyltransferase, 1801 tumor-inhibitory monoclonal antibod- inhibition of carcinogenesis, 2085s 1-O-Octadecyl-2-O-methylglycero-3-phos- ies, breast cancer cell differentiation, Ornithine decarhoxylase phocholine 2580 elevated gene expression perturbations of cellular acylation proc- H-ras human esophageal cancer, 6671 esses influence, rat rhabdomyosarcoma cell skin tumor promoter-caused induction MCF7 and T84 cell lines, 2806 line, 3073 inhibition by epicatechins, green tea, Octreotide H-ras and v-myc 3582 antiproliferative effects prolonged inhibition of DNA synthesis Orotic acid ZR-75-1 human breast cancer cells, by X-rays, rat embryo fibroblasts, nitrogen-stimulated synthesis 4973 508 nucleotide imbalance, 2082s OK-432 K-ras mutation nucleotide pool imbalance and liver tu- activation of omental milky spots pancreatic duct carcinogenesis, Syrian mor promotion milky spot macrophages, 5400 golden hamster, 4507 mitoinhibitory effects, hepatocytes, Okadaic acid mechanism of interferon action 2078s accessibility to DNA hairy cell leukemia, 1056 Osteosarcoma carcinoma chromatin, 6397 mutant human c-Ha-ras allelotype analysis, 2419 Oligodendrocytes chemically induced forestomach papil- failure of RBI to reverse malignant phe-

7059

notype p52 3674 human tumor cell lines, 654 genetic changes in alleles mutations metastasizing testicular mixed gonadal conversion from colorectal adenoma to aggressive breast cancer, 3918 stromal tumor, 6705 early carcinoma, 3965 basal cell carcinoma, 3804 Ovarian neoplasms p53 breast cancer, 5291 advanced human epithelial aberrations deletions, preneoplastic lung lesions, unifocal origin, 5119 human non-small cell lung carcinoma, 6079 DNA strand breaks and cross-links 4799 endocrine tumorigenesis, 5061 chemotherapy, 5622 abnormal structure and gene expression formaldehyde-induced nasal squamous drug resistant and nonresistant human ovarian carcinoma cell lines, cell carcinoma, 6113 selenite cytotoxicity, 4812 4196 hepatocellular carcinoma, Taiwan, epithelial absence of mutations 6098 CA54/61 as marker, 1205 primary nasopharyngeal carcinoma, human hepatocellular carcinoma, Ger- epithelial cells 4787 many, 3220 interleukin 1a and/3 gene expression, accumulation human lung tumors, 1695 2248 poor prognosis, human lung cancer, human malignant gliomas, loss of het- fine-scale deletion mapping 4828 erozygosity, 1427 distal long arm, chromosome 6, 5815 aflatoxin Brinduced mutations non-small cell lung cancer, Japan, 734 germ cell tumors sequence specificity, xeroderma pig- 17p allelic loss, grades II and IIl astro- histogenetic analysis, DNA finger- mentosum, 5668 cytoma, 2987 printing, 6823 altered gene structure radiation-sensitive and -resistant squa- glycosphingolipids, 416 nickel exposure, human epithelial mous carcinoma cells, 6390 inhibition of invasion cells, 218 unique association, undifferentiated modulation, urokinase-type plasmino- development of antibodies carcinomas of thyroid gland, 1369 gen activator and cathepsin B, 3610 type of mutation, lung cancer, 4168 mutations cluster at codon 249 interferon-induced increase in sensitivity frequency and diversity of mutations hepatitis B virus-positive hepatocellu- lysis by LAK cells, 764 childhood rhabdomyosarcoma, 2243 lar carcinoma, China, 1635 marker with homology to vaccinia virus frequent gene mutations in blast crisis mutations in thymic lymphomas IgV-like region, multiple transmem- chronic myelogenous leukemia, 6588 induction, ~,-irradiation and N-methyl- brane domains, 5416 frequent mutations nitrosourea, 3791 presence of monoclonal antibody K1 head and neck cancer, 5997 mutation spectrum characterization of antigen, 18 l gene alterations bone and soft tissue sarcomas, 6194 radiolabeled antibody targeting papillomavirus infection, human pri- overexpression and mutation HER-2/neu oncoprotein, 1916 mary cervical carcinoma, 5323 endometrial carcinoma, 1622 recombinant single chain antibody-toxin gene deletions pattern of mutations tumor cell growth inhibition, erbB-2 human papillomavirus infection, hu- Burkitt's lymphoma, 4273 receptor, 6310 man head and neck cancer, 4832 second tumor suppressor gene selection by cisplatin gene mutations chromosome 17, malignant astrocy- mechanism of cross-resistance, CPT- frequent association, invasive bladder toma, 6716 I l, 328 cancer, 1393 selective mutation of codons 204 and subclonal progression factor human gastric cancer, 4335 213 deletion of chromosome 11 p 13- gene mutation spectrum alkylating N-nitroso compounds, rat l lpl 5.5 sequences, 6646 hepatocellular carcinoma, 6358 tumors, 2995 Ovariectomy immune response in breast cancer pa- transfection early and late tients growth suppression, lung cancer cells, neu and ras oncogene-induced mam- immunodominant epitopes, muta- 6956 mary carcinomas, 4102 tional hot spot, 6380 tumor suppressor genes Ovary infrequent mutation in mouse tumors Third Annual Pezcoller Symposium, -independent progression deregulated myc, 1032 3246 growth control, mammary tumors, inherited gene mutations ultraviolet B radiation-induced squamous 6531 breast cancer, 2984 cell carcinoma Oxygen Kirsten-ras mutations and carcinogen-specific mutational pattern, distribution human mesothelioma cell lines, 2610 skin, 6400 misonidazole adducts, 9L gliosarcoma loss of heterozygosity unifocal origin tumors and spheroids, 3831 dysplastic and cancerous ulcerative co- advanced human epithelial ovarian mechanism of c-fos induction, 3952 litis, 741 cancers, 5119 partial pressure of multiple tumor suppressor genes, wild-type tumor metabolism, radiobiological ox- esophageal cancer, 6525 altered expression, murine epithelial ygenation status postradiation, 4620 low frequency of gene mutation cell transformation, 749 radicals tumors induced by aflatoxin B~, non- suppression, acute lymphoblastic leu- mutagenic specificity, human leukemia human primates, 1044 kemia, 222 cells, 1082 messenger RNA wild-type but not mutant state of oxygenation altered steady-state levels, L 1210 cells suppression of growth, lung cancer, localization of tumors, phosphoresc- resistant to deoxyadenosine, 2000 2340 ence imaging, 3988 mutation and loss of heterozygosity p60 .... protein kinase chromosomes 17 and 10, human astro- potent and specific inhibition cytoma progression, 674 Radicicol, 6926 mutation and protein accumulation p75 p26 multistage human esophageal carcino- interleukin 2 receptor chain -BCL-2 protein levels genesis, 6092 functional role, leukemic hairy cells, cell cycle analysis, proliferating lym- mutation pattern as diagnostic marker 5223 phoma and leukemia cell lines, 2802 multiple hepatocellular carcinoma, low affinity nerve growth factor receptor

7060

reduced expression, prostatic tissue, 1938 rat liver, 5154 5403 p34~CZ/cyclic B complex functional role p120 active DNA synthesis effiux pump for benzo[a]pyrene, MCF- cDNA camptothecin-induced G2 arrest, 1823 7 cells, 6692 antisense RNA, inhibited NIH 3T3 Peanut agglutinin immunohistochemical identification proliferation, 5681 T-antigens in human urinary bladder tu- large cell and immunoblastic lympho- complementary DNA mors, 5030 mas, 3768 increased growth of NIH/3T3 cells, Penclomedine monoclonal antibody transfection, 428 murine pharmacokinetics and metabo- reversal of Vinca alkaloid resistance, p190 lism, 2830 human tumor xenografts, 1810 BCR/ABL Penicillin G amidase multidrug resistance restricted oncogenicity, transgenic -monoclonal antibody conjugate cytogenetic alterations, lung tumor cell mice, 4534 activation, N-(4'-hydroxyphenylace- lines, 4361 P388/ADR cells tyl)palytoxin, 5759 multidrug-resistant phenotype modulation of subcellular distribution Penoxyacetic acid disease-oriented panels, anticancer doxorubicin, SR33557, 6440 pesticides and non-Hodgkin's lym- drug screening, 3029 PAK-200 phoma, 5485s resistance to N-benzyladriamycin-14-val- reversal of drug resistance, 3659 Peptide erate Palytoxin hepatic mouse J774.2 cells, 3409 prodrug transplanted rat hepatoma cells, 1218 reversal of in vivo resistance of tumor activation, monoclonal antibody-peni- highly conserved sequence cells cillin G amidase conjugate, 5759 inhibition of tumor cell invasion, ma- dihydropyridine analogue, Adriamy- Pancreas trix metalloproteinase enzyme pro- cin, 3655 duct carcinogenesis segment, 2353 pH K-ras mutation, Syrian golden ham- Peritoneal cavity human tumor xenografts ster, 4507 cancer transplanted rat tumors, effect of insu- HIP gene activation rationale for carboplatin treatment, ab- lin, 6209 human primary liver cancer, 5089 dominal hyperthermia, 1252 intracellular human embryo Perspectives in Cancer Research regulation in tumor cell lines, mi- stage-specific expression, carbohydrate aspirin and potential role of prostaglan- croenvironmental conditions, 4441 antigens, 5744 dins intracellular acidification Pancreatic neoplasms colon cancer, 5575 morphological transformation, Syrian azaserine-induced cytokine-activated tumor inhibition, hamster embryo cells, 144 cholecystokinin receptor overexpres- 4853 Phagocytes sion, 3295 evolution of paradigms tumor promoter-induced oxidative events free ~ subunit of human choriogonado- management of breast cancer, 2371 suppression, sarcophytol A, 2298 tropin evolving concepts Phenethyl isothiocyanate core ~ fragment, 4628 systemic adjuvant treatment, breast potential chemopreventive agents frequent somatic mutations cancer, 2127 tobacco-specific nitrosamine, lung car- APC gene, 6696 many growth factors may not be growth cinogenesis, 2719s Papilloma factors, 501 Phenobarbital forestomach natural history of intraepithelial neopla- changes in ploidy and specific karyotypic mutant human c-Ha-ras transgenes, sia changes transgenic mice, 978 cancer chemoprevention strategy, 1651 rat liver, 955 growth origin of point mutations Phenoxyacetic acids inhibition effect, green tea, 6657 human tumor cells, 249 occupational exposure model of initiated mouse skin, 1439 Pesticides non-Hodgkin's lymphoma, 5503s Paragloboside mirex Phenylacetate elevation of 4B-galactosyltransferase ac- novel nonphorbol ester-type tumor nontoxic inducer of tumor cell differen- tivity promoter, mouse skin, 631 tiation, 1988 sera, patients with cancer, 1875 non-Hodgkin's lymphoma and, 5485s Phenylalanine mustard Parathyroid other agricultural risk factors and combination with L-histidinol role of p53 mutations non-Hodgkin's lymphoma, men in preclinical therapeutic studies, 3604 endocrine tumorigenesis, 5061 Iowa and Minnesota, 2447 1,4-Phenylenebis(methylene)selenocyanate Parathyroid hormone P-glycoprotein chemoprevention -like peptide absence of overexpression colon carcinogenesis, 5635 early response gene family, 3103 reduced intracellular drug accumula- inhibition of 7,12-dimethylbenz[a]an- Parathyroid neoplasms tion, mitoxantrone-resistant MCF-7 thracene-induced tumors allelic loss from chromosome 11, 6804 cells, 6175 mammary gland, 2402 a-Particles decreased expression Pheochromocytoma extremely low doses myeloma cells induced by cytokine leu- C-cell thyroid neoplasms and induction, sister chromatid exchanges, koregulin, 5893 transgenic c-mos mice, 450 6394 energy-dependent processes I p loss of heterozygosity PC9 cells reduced drug accumulation, multidrug- multiple endocrine neoplasia type 2 cadherin dysfunction resistant lung cancer cell lines, 17 syndromes, 770 loss of a-catenin, 5770 expression Phorbol dibutyrate PCI2 cells accumulation and cytotoxicity, topote- 1,2-dimethylhydrazine-induced colonic formation after transplantation into rat can, 2268 carcinogenesis brains expression and functional activity alterations, protein kinase C, 2216 time course, host age, 1933 cultured cerebral capillary endothelial Phorbol ester migratory behavior cells, 6969 acquisition of growth-inhibitory response transplantation, neonatal rat brain, expression during tumor progression DNA damage, 1907

7061

altered response to treatments metabolite and cell cycle kinetic response -independent phenotypes aflatoxin B~-transformed C3H/10Tl/2 radiation, squamous cell carcinoma, BALB/c 3T3 cell variant, transforma- cells, 990 5299 tion susceptibility, 4232 bryostatin 1 and Photodynamic agents -induced transcription differential effects, breast cancer cell tumor retention vascular endothelial growth factor lines, 1278 role of neovasculature, vascular perme- gene, protein kinase C, 4821 modulation of protein kinase C-~ ability, 924 inhibition of signal transduction U937 cells, 5604 Photodynamic therapy CGP 41251, 5353 tumor-promoting interaction with hyperthermia or ioniz- receptor down-regulation of androgen inducing radiation epidermal growth factor receptor and, tion, prostate-specific antigen, 1525 cell killing, different cell types, 117 human glial tumors, 4550 Phorbol 12-myristate 13-acetate lysyl chlorin p6/chlorin p6 mixture receptor expression and induction of fibroblast growth factor glioma, 1235 asbestos-induced rat mesothelioma, gene expression role of microvascular damage, 4914 301 human dermal fibroblasts, 1040 Photofrin receptors and Phosphatase light and human glioma tissue, 3213 inhibitors microtubule depolymerization, human neuroendocrine tumors, digestive sys- growth-regulatory effects of tumor ne- endothelial cells, 3443 tem, 1006 crosis factor, tumor and normal Photosensitization -stimulated brain tumor cells cells, 2557 mono-L-aspartyl chlorin e6 a-difluoromethylornithine, altered cal- Phosphate metabolic properties, mouse tumor cium signaling, 6782 inorganic model, 2890 Platelet-derived growth factor B pH in human tumor xenografts, trans- Phyllodes neoplasms receptor messenger RNAs planted rat tumors, 6209 immunoreactive endothelin l, 4046 primary human gastric carcinoma, Phosphatidic acid Pigments 3453 extracellular control of transition liposome-entrapped Platelets G2 phase to mitosis, epidermal growth polyethylene glycol-mediated delivery, adhesion of tumor cells factor in A431 cells, 5627 fibroblasts, 6638 thrombin treatment, tumor metastasis, Phosphatidylinositol Piritrexim 3267 phospholipase C pediatric Phase I trial, 521 neutrophil-endothelial adherence selective inhibition, cytotoxic ether p34cdcz kinase induction by interleukin 2, macromo- lipid analogues, 2835 inhibition of activation lecular leakage, 3425 Phosphoglycerokinase mitotic progression, Chinese hamster Platinum clonal analysis of human breast cancer ovary cells exposed to etoposide, anticancer drugs polymerase chain reaction, 6594 1817 modulation of P-450 messenger RNA Phospholipase A2 Placenta levels, hepatic drug and steroid hor- resistance to cytolysis determinants mone metabolism, 540 tumor necrosis factor-a, gynecological polycyclic aromatic hydrocarbon-DNA antitumor complexes cell lines, 866 adducts, 1499 activation, trans geometry, 5065 Phospholipase C human cells -based therapy selective inhibition transformation, temperature-sensitive multiple biological markers, germ cell cytotoxic ether lipid analogues, 2835 Simian virus 40, 6001 tumor, 3558 Phospholipase C71 -like alkaline phosphatase gene Platinum-ammine elevated membrane association induction by sodium butyrate, tran- persistence of DNA adducts MDA-468 mammary tumor cells, scriptional regulation, 3378 gonads and kidneys, rats and tissues 4526 transfer of 4-(methylnitrosamino)-1-(3- from cancer patients, 149 Phospholipids pyridyl)-l-butanone Platinum compounds growth-inhibitory effects of ET- 18-OCH3 intrathecal instillation, Syrian golden cytotoxicity and resistance differential susceptibility, A427 and hamsters, 3273 cellular glutathione, 6885 A549 cell lines, 2813 Plasmids gene-specific oligonucleotide probes hydrolysis antisense RNA a/#/~r and microsomal rat glutathione inhibition of DNA synthesis by brady- human papillomavirus type 18, effect S-transferases, 5797 kinin, breast stromal cells, 334 on cancer cells, 4706 sensitivity of lung cancer cells N-(Phosphonacetyl)-L-aspartate Plasminogen activator acquired and inherent resistance to cis- 5-fluorouracil-containing drug combina- plasma urokinase-type platin, 5674 tion primary liver cancer, tumor-associated Platinum(IV) dicarboxylates regression, advanced breast tumors, antigen, 1717 acquired cis-diamminedichloropla- 4074 type 1 inhibitor tinum(II) resistance Phosphoprotein cytotoxic conjugate and, antitumor ac- mechanism-related circumvention, P0 messenger RNA- tivity, 5829 ovarian carcinoma, 3857 increasedexpression, hepatocellular urokinase p120 nucleolar antigen carcinoma and colon carcinoma, transcriptional and posttranscriptional cell cycle-related expression 3067 activation, metastatic tumor cells, normal human lymphocytes, HL-60 Phosphorescence 2489 and MOLT-4 cells, 3491 imaging urokinase-type Polyamines localization of tumors, state of oxy- inhibition, ovarian cancer cell inva- chlorambucil-spermidine conjugate genation, 3988 sion, 3610 targeting of tumor cells and DNA, Phosphorothioate prognostic value, primary breast can- 4190 analogues of cyclic AMP cer, 6101 homologues growth inhibition and differentiation, Platelet-derived growth factor prevention of OL-a-difluoromethylor- human cancer cells, 2504 cyclin D1 messenger RNA nithine-mediated inhibition, immune Phosphorus cultured fibroblasts, 4522 response, 1840

7062

inhibitors of biosynthesis Polyps Prostatic neoplasms block, tumor necrosis factor-induced distribution of cells expressing myc pro- androgen-independent activation of macrophages, 1891 teins, 5853 protooncogene bcl-2 expression, 6940 manipulation Positron emission tomography antitumor effects synchronization, breast cancer cell measurements of blood flow and ex- quinoline-3-carboxamide linomide, proliferation, 5720 changing water space 3022 putrescine and spermidine depletion breast tumors, 1592 basic fibroblast growth factor, 571 calcium signaling, 6782 pp60 ..... colocalization steady-state messenger RNA elevated expression basal and luminal cell type cytokera- sensitivity to N~,N~2- low grade bladder carcinoma, 1457 tins, 6182 bis(ethyl)spermine, major forms of 32p Postlabeling differentiated lung cancer, 5359 sensitive and specific detection hormone-regulated apoptosis, defec- Polyclonal antibodies C~-methylguanine, O4-methylthymine tive cell cycle, 4313 intracellular localization and CrLethylthymine, 5307 hematogenous micrometastasis, 6110 methylguanine-DNA methyltransfer- P120 protein invasion and metastases ase, 6423 antisense-mediated specific inhibition block by taxol, 3776 Polycythemia vera prevention, Gr to S-phase transition, localization of metastasis suppressor carcinogenic potency 5250 gene alkylating agents, rodents and humans, Preadipocytes short arm of chromosome 11, 3486 2464 secretion of protein factor progression Polyethylene glycol inhibition, MCF-7 cells, 6860 decreased expression of E-cadherin, -mediated delivery of liposome-en- Pregnancy 2916 trapped pigments -dependent to ovarian-independent pro- reduced expression mutator phenotypes, fibroblasts, 6638 gression low affinity nerve growth factor recep- Polyglutamates mammary tumors, primary culture, tor, 5403 2-desamino-2-methylaminopterin 6531 reduced or absent E-cadherin expression, mode of action, 2148 Preneoplasia 5104 intracellular metabolism mammary Protease 5-formyl tetrahydrofolate, breast and development, mouse mammary epithe- gene expression and regulation colon cell lines, 36 lial cell lines, 1924 fibroblast transformation, ras onco- Polyinosine-polycytidylic acid Procainamide gene, 6682 complexed with poly-L-lysine and car- uptake in Chinese hamster ovary model Protein boxymethylcellulose multidrug resistance, 3539 systemic hyperinsulinemia combined with interleukin 2, patients Progestins cancer patients, 3845 with cancer, 3005 estrogenic potential Protein kinase C Poly-lactide-co-glycolide oral contraceptives, breast cancer cell activation encapsulation of cisplatin proliferation, 6539 growth of human melanocyte cultures, reduction, systemic exposure and tox- 17~-hydroxysteroid dehydrogenase gene 12-O-tetradecanoylphorbol-13-ace- icity, 6653 expression tate, 4514 Polylactosamine breast cancer cells, 290 activator bryostatin 1 type 1 and type 2 chain antigens Prolactin decreased murine resistance, Salmo- stage-specific expression, developing bromocriptine effects nella typhimurium, 2143 pancreas of human embryo, 5744 neoplastic progression, mammary pre- alterations Polymerase chain reaction neoplastic hyperplastic alveolar nod- 1,2-dimethylhydrazine-induced colonic Alu- ule line C4, 2209 carcinogenesis, 2216 nuclear matrix attachment regions, fi- 10-propargyl-5,8-dideazafolate Ca2+/calmodulin antagonists broblast DNA, 3807 quantitation of folic acid enhancement nitrosamine-induced lung carcinogene- clonal analysis of human breast cancer, antifolate synergism, 2228 sis, 2723s 6594 Prostaglandin E2 dietary energy and fat effects detection of frequent allelic loss regulation of c-jun and jun-B messenger tumor promotion, 2035s proximal chromosome 17q, sporadic RNA growth inhibition breast carcinoma, 2624 Syrian hamster embryo cells, 6912 transforming growth factor-S, gastric gastrin and transforming growth factor-a Prostaglandins carcinoma cells, 295 messenger RNA aspirin and inhibition of activation levels in colonic carcinoma, 2261 role in colon cancer, 5575 erythropoiesis inhibitor, 6329 quantitation of gene expression Prostate inhibition of metastasis and cell adhesion thymidylate synthase, dihydrofolate re- epithelial cell line B16FI melanoma cells, 1195 ductase and DT-diaphorase, 108 acquisition of tumorigenic phenotype, inhibition of signal transduction reverse transcriptase neu oncogene, 3174 CGP 41251, 5353 sensitive detection, rare circulating Prostate-specific antigen nuclear neuroblastoma cells, 4701 down-regulation of androgen induction elevated level, MCF-7 cells, 3750 -single strand conformation polymor- tumor-promoting phorbol ester, pros- overexpression and phorbol ester treat- phism tatic adenocarcinoma, 1525 ments role of p53 mutations, endocrine tu- estimation of prostatic growth aflatoxin Brtransformed C3H/10TI/2 morigenesis, 5061 men with and without prostate disease, cells, 990 Polyphenols 3323 PDGF-induced transcription green tea serum levels vascular endothelial growth factor 7,12-dimethylbenz[a]anthracene-in- tumor volume, endocrine and growth gene, 4821 duced skin, 6890 factors, 1598 platelet-derived growth factor-independ- skin tumor promoter-caused induction Prostatic acid phosphatase ent phenotypes ornithine decarboxylase, inhibition by activity and growth pathway for transformation suscepti- epicatechins in green tea, 3582 prostate carcinoma cells, 4600 bility, 4232

7063

sensitization of human cervical carci- surface immunoglobulin-mediated sig- -induced fibrosarcoma 1 tumor noma cells nal transduction pathways, B-cells, nonglycolytic acidification, nuclear cis-diamminedichloroplatinum(II), 566 magnetic resonance spectroscopy, bryostatin 1, 3119 ra$ 1259 specific binding by ingenol differential expression, differentiation ionizing induction of biological responses, 202 of human erythroleukemia cells, chromatin structure, induction of Protein kinase C-~ 5979 DNA double strand breaks, 1580 modulation by phorbol esters trk photodynamic therapy and hyperther- U937 cells, 5604 N-myc amplification, neuroblastoma, mia, cell killing, 117 a-Protein kinase C 1364 SR 4233-induced DNA and chromo- expression pattern in human astrocy- Wnt-1 some breaks, repair, 4473 toma development of mammary hyperplasia, murine protector tempol, 1750 role in malignant progression, 2951 transgenic mice, 4413 non-Hodgkin's lymphoma and, 5489s Protein tyrosine kinase Provitamin A phosphorus metabolite and cell cycle ki- human breast cancer carotenoids netic response c-src oncogene product, 4773 up-regulation of Connexin43 gene squamous cell carcinoma, 5299 human prostatic acid phosphatase activ- expression, 5707 radiobiological oxygenation status pos- ity Pseudomonas exotoxin tradiation growth, prostatic carcinoma cells, -acidic fibroblast growth factor chimeric tumor metabolism, partial pressure of 4600 protein oxygen, 4620 p60 .... protein kinase antiangiogenic effects, endothelial selective potent and specific inhibition, Radici- cells, 4995 hematolymphoid tissue, delivery by col, 6926 truncated form anti-CD45 antibody, 1228 Protein-tyrosine phosphatase monovalent immunotoxin, 5379 -sensitive and -resistant squamous carci- differentiation-induced changes Putrescine noma cells CD45 expression, human leukemia -dependent invasive capacity mutations, p53 gene, 6390 cell lines, 4027 rat ascites hepatoma cells, 5313 sensitivity in cell and xenograft lines expression in pre-B cell NALM-6, 737 depletion human melanoma surgical specimens, 7 gene calcium signaling, 6782 1764 molecular analysis, lung cancer, 3506 Pyrimidine sensitivity of primary tumors and met- Protein tyrosine phosphatase 1B dimer removal enhanced by DNA repair astatic lesions transformation by human neu oncogene, liposomes malignant melanoma, 4453 478 reduced incidence, UV skin cancer, sensitization of astrocytoma cells Protooncogenes 4227 taxol, 3495 bcl-2 Pyroglutamylglutamylglycylserylasparagine Radicicol androgen-independent prostate cancer, peptide inhibition potent and specific inhibition 6940 transplanted rat hepatoma cells, 1218 p60 ..... protein kinase, 6926 c-Ha-ras Radioimmunoconjugates 8-hydroxyguanine at codon 12, point Q high-affinity anticarcinoma mutations, 3483 therapeutic advantage, 1067 Quercetin c-jun and jun-B messenger RNA humoral immune response late phase of cell cycle regulation by prostaglandin E2, Syrian macrocyclic chelating agent, 904 arrest of human leukemic T-cells, hamster embryo cells, 6912 Radioimmunoscintigraphy c-Ki-ras activation 6676 99mTc-labeled monoclonal antibody #48 Queuine N-methyl-N-nitrosourea-induced mam- F(ab')2 transfer ribonucleic acids mary carcinoma, pituitary-isografted head and neck cancer, 2569 mice, 5732 histopathological grading and survival, Radioimmunotherapy lung cancer, 4696 c-kit anti-~ antibodies Quinoline-3-carboxamide stimulation of growth by stem cell fac- intracellular catabolism, malignant B- linomide tor, glioblastoma cell line, 3498 cells, 2907 ~intitumor effects, prostatic cancers, c-kit receptor 125 I 3022 normal and transformed nonlymphoid affinity, two monoclonal antibodies, Quinolones tissues, 6139 4728 antitumor c-myb 1311-labeled monoclonal antibodies mammalian topoisomerase If-me- antisense RNA and oligodeoxynucleo- targeted therapy, colonic cancer micro- diated DNA cleavage activity, 2818 tides, proliferation of neuroblastoma metastases, 6036 Quinazoline cells, 4221 a-particle-mediated antifolate thymidylate synthase inhibitor c-myc / c-erb B- 2 /Ki-6 7 murine leukemia, 5818 ICI D 1694 normal breast tissue, invasive and non- quantitation of tumor-reactive monoclo- time dependence, DNA lesions and invasive breast carcinoma, 2597 nal antibody 16.88 growth inhibition, 5900 c-raf-1/c-fms/c-erbB-2 " colorectal metastatic tumor tissue, metaphase and interphase cytogenet- 2603 R ics, YAC clones, 2590 Radioimmunotoxin in vivo properties Race anticarcinoembryonic antigen mammary epithelial cell lines, 1924 variation and lung cancer risk intratumoral and whole-body distribu- K-ras mutations genetic polymorphisms, cytochrome tions, autoradiography, 1961 clinical implications, malignant epithe- P450IIE 1, 6712 Radiolabeling lial tumors of endometrium, 2777 Radiation antimyeloid antibodies neu enhanced sensitivity acute leukemia xenograft tumor transcriptional repression, estrogen- SCID normal tissues, 6292 model, 89 stimulated estrogen receptor, 6624 -induced apoptosis Radionuclides Rafi l murine T-cell hybridoma, 883 rapid tumor penetration

7064

single-chain Fv, other immunoglobulin no loss of albumin expression, 940 tooncogene, 6624 forms, 3402 -transformed cells extracellular matrix Radioresistance smooth muscle a-actin promoter, drug mouse skin carcinogenesis, tumor pro- acquired screening, 6877 gression, 2966 hematopoietic progenitors, chronic ra- RC-160 Fc'r III diation leukemogenesis, 1469 inhibitory effect on growth bispecific antibody 2B1, cytotoxic tar- influence of H-ras oncogene hepatic metastases of colon cancer, geting by mononuclear cells, 6832 rat rhabdomyosarcoma cell line, 3073 magnetic resonance imaging, 6025 fibroblast growth factor Radiosensitivity RC-3095 expression, human leukemia cells, intrinsic inhibition of growth' 2004 normal human fibroblasts and lym- human breast cancer cell lines, 4545 N-sam gene, T-lymphocytic tumors, phocytes, 6348 Receptors 3367 Radiosensitization BI and B2 FLT4 fluorodeoxyuridine inhibition of DNA synthesis by brady- immunoglobulin-like loops, multiple thymidylate synthase inhibition, cell kinin, breast stromal cells, 334 human tissues and cell lines, 5738 synchronization, 1687 basic fibroblast growth factor folate levamisole reversal of autocrine transformation, cellular localization, drug toxicity, human tumor cells, 3228 aromatic anionic compounds, 5656 6708 Radiotherapy BIM-23014C folate GP38 quantitative imaging of Na2BI2HlISH chemical cross-linking assay, breast normal and malignant cell lines and subcellular resolution, ion microscopy, carcinoma, 843 tissues, 3396 5219 bombesin functional targeted antitumoral activity of analogues, gastrointestinal hormones, colon can- 211At_methylene blue, human mela- small cell lung cancer xenografts, cer cells, 1114 noma xenografts, 4385 4872 gastrin Radiotoxicity cholecystokinin pancreatic carcinoma, 6905 estrogen receptor-directed azaserine-induced neoplasms, pan- gastrin-releasing peptide Auger electrons, 5752 creas, 3295 growth effects, acinar pancreatic carci- Radon c-kit noma, 3726 -induced deletions in human cells, 5126 normal and transformed human non- glucocorticoid ras lymphoid tissues, 6139 gene deletion, exposure to cancer clinical signifcance of activation CSF-1 chemotherapeutic drugs, 6612 human lung cancer, 2665s invasiveness of carcinoma cell lines, granulocyte colony-stimulating factor differential expression during differentia- macrophage colony-stimulating fac- human acute leukemia, 3052 tion tor, 3661 HER-2/neu human erythroleukemia cells, 5979 1a,25-dihydroxyvitamin D3 tumor-inhibitory monoclonal antibod- fibroblast transformation prostatic carcinoma cell line, 515 ies, breast cancer cell differentiation, protease gene expression, regulation, epidermal growth factor 2580 6682 altered gene expression, immortalized insulin gene alterations human breast epithelial cell line, expression and function, breast cancer simple epithelial cytokeratins, mouse 1210 cell lines, 3924 epidermal keratinocytes, 680 ectopic expression, ZR-75-1 human insulin-like growth factor I gene mutations as prognostic marker breast cancer cells, 5082 sporadic amplification, human breast lung adenocarcinoma without lymph human small cell lung cancer cell tumors, 1036 node metastasis, 2903 lines, 3089 o~sfll integrin -mediated transformation labeled monoclonal antibody 425, hu- proliferative response to fibronectin, reversal, divergent differentiation, man glioma xenograft immunother- quiescent human melanoma cells, 4269 apy, 121 4499 mutant human c-Ha-ras monoclonal antibody, androgen-inde- interleukin 2 chemically induced forestomach papil- pendent prostatic carcinoma, 5887 human squamous cell carcinoma cell loma, transgenic mice, 978 platelet-derived growth factor receptor lines and tumor, 5963 mutations and, human glial tumors, 4550 interleukin 2 injection, leptomeningeal human papillomavirus DNA, prostate testosterone and growth properties, carcinomatosis, 1123 carcinoma, 5991 1246-3A cells, 4242 p75 functional role, leukemic hairy neoplastic progression by EJ/ras tumor necrosis factor resistance, in- cells, 5223 steps of transformation, uroepithelial creased cisplatin sensitivity, 4758 interleukin 4 cells, 688 erbB-2 expression and growth inhibition, gas- pathways that control cell division, 2362 recombinant single chain antibody- tric carcinoma, 6059 -related rab2 gene product toxin, 6310 tat gene, HIV-1, 3787 peripheral blood mononuclear cells, estrogen laminin hematological and solid neoplasms, estrogen-chlorambucil conjugate, messenger RNA expression, human 3083 MCF-7 cells, 1187 papillomavirus-associated cervical synthetic c-Ha-ras containing hypoxan- IGFBP-3 gene expression, human neoplasms, 1561 thine breast carcinoma, 5100 LDL induction of mutation, 1836 inhibition, naturally occurring variant polyethylene, liposome-entrapped pig- Third Annual Pezcoller Symposium, in human breast tumors, 483 ments into fibroblasts, 6638 3246 interaction, consensus or variant estro- melanotropin transformation of Simian virus 40-im- gen responsive elements, 1073 a-melanocyte-stimulating-diphtheria mortalized hepatocytes PvuIII RFLP, breast cancer and pe- toxin fusion protein, 2545 model of hepatocarcinogenesis, 173 ripheral blood, 77 nerve growth transformation of SV40-immortalized radiotoxicity, Auger electrons, 5752 low affinity, prostate tissue, 5403 hepatocyte cell line transcriptional repression, neu pro- platelet-derived growth factor

7065

asbestos-induced rat mesothelioma, microcell transfer of chromosome 13, fer 301 various human cancer cell types, human renal cancer cells, 6229 epidermal growth factor receptor and, 6297 RG-13022 human glial tumors, 4550 gene product expression inhibition of breast cancer cell growth, human glioma tissue, 3213 bladder carcinoma cells, 1968 3636 neuroendocrine tumors, digestive sys- high levels of enhanced reactivation Rhabdomyosarcoma tem, 1006 herpes simplex virus, skin fibroblasts, childhood progesterone 53 frequency and diversity, p53 muta- remodeling by tamoxifen, breast can- tumor suppressor genes tions, 2243 cer, 593 Third Annual Pezcoller Symposium, DNA topoisomerase II immunostaining retinoic acid 3246 human leukemia, topoisomerase II in- expression and regulation, breast can- Retinoic acid hibitors, 4248 cer cells, 2236 -binding protein in normal and malig- inhibition of growth by suramin somatostatin nant myeloid cells insulin-like growth factor II autocrine human renal cell carcinoma, 6074 acute promyelocytic leukemia, 3329 growth loop, 1830 T-cell a/~ effects of bioactive and cytotoxic agents rat cell line variability in lymphocytes, infiltration cell cycle, multiparameter assessment, influence, H-ras oncogene, 3073 of melanoma metastasis, 4649 4090 spheroids T-cell V~ ICAM-1 modulation central proliferation, differentiation, usage in tumor-infiltrating lympho- differential susceptibility, cultured 474 cytes, hepatocellular carcinoma, melanoma cell lines, 4766 Rhizoxin 5913 -induced inhibition Phase I and pharmacokinetics, 2894 thyroid hormone liarozole, cell growth and metabolism Rhodamine-123 antagonist erbA-a2, increased messen- in MCF-7 cells, 2841 resistance ger RNA levels, 2186 induction of differentiation in neuro- loss of cis-diamminedichloropla- type 1 plasminogen activator inhibitor blastoma cells tinum(II) resistance, ovarian carci- cytotoxic conjugate, antitumor activ- distinct molecular and cellular pheno- noma cells, 1902 ity, 5829 types, 4402 retention and oxygen consumption urokinase inhibition of serum-induced c-fos tran- disruption of mitochondrial function invasion of connective tissue, human scription by suramin, prostate carcinoma, carcinoma cell lines, 6754 fibrosarcoma cell line, 2384 6953 mediation of tissue invasion, lung car- receptor a Ribonucleic acids cinoma, 3043 chromosome 17q, sporadic breast car- queuine content vitronectin cinoma, 2624 histopathological grading and survival, up-regulated biosynthesis and expres- receptor expression and regulation lung cancer, 4696 sion, cancer cell adhesion, 2202 breast cancer cells, 2236 Ribosomal proteins Reed-Sternberg cells suppression P0 messenger RNA active nodular sclerosing Hodgkin's dis- melanoma cell motility factor receptor increased expression, hepatocellular ease expression, 4878 carcinoma and colon carcinoma, urinary excretion, high molecular tamoxifen-sensitive and -resistant sub- 3067 weight transforming growth factor- lines Richter's syndrome ~, 6768 MCF-7 cells, 6164 NZB mouse model cytokine gene expression all-trans-Retinoic acid chronic lymphocytic leukemia, 437 cytokine receptor genes, transcription clinical pharmacology Ricin factors, 3353 acute promyelocytic leukemia, 2138 anti-B4-blocked interleukin 9 expression, 1026 induction of differentiation by bufalin in vitro toxicity, preclinical in vitro pa- Renal neoplasms: see Kidney neoplasms human leukemia cells, 4634 rameters, 4200 Respiratory burst oxidase Retinoid -biotinyl induction of gene expression antagonism immunotargeting, streptavidin, 4448 tumor necrosis factor and 7-interferon, estrogen-responsive transforming Ricin A chain differentiation of myeloid cell lines, growth factor-a/pS2 gene, breast anti-CD7-ricin A chain immunoconju- 2530 carcinoma, 3938 gate Restriction fragment length polymorphism growth control efficacy, murine model of human T- clonal analysis of human breast cancer sensitivity of keratinocytes, immortali- cell leukemia, 3056 polymerase chain reaction, 6594 zation by papiUomavirus type 16 -CD3 immunotoxins histogenetic analysis DNA, 187 relation to cellular uptake, degradation DNA fingerprinting, ovarian germ cell status and control of keratin expression kinetics, 5921 tumors, 6823 histogenesis, squamous metaplasia of immunotoxin activity human glucocorticoid receptor gene dele- tracheal epithelium, 6144 enhancement, indolizine calcium chan- tion Retrovirus nel blockers, 1352 exposure to cancer chemotherapeutic HTLV-I immunotoxin DA7 drugs, mutagens, 6612 mycosis fungoides/S6zary syndrome, treatment of human acute T-cell leuke- PvulI Kaposi's sarcoma, 4391 mia, SCID mice, 1314 estrogen receptor gene, breast cancer increasing incidence of non-Hodgkin's immunotoxin potentiation and peripheral blood, 77 lymphoma, 5496s monensin or carrier protein-monensin Retinoblastoma -induced promonocytic leukemia conjugates, blocking effect of human decreased protein expression involvement of spleen, preleukemic de- serum, 623 acute myelogenous leukemia, 4587 velopment, 5317 RNA failure of RB1 to reverse malignant phe- plasmacytoid leukemia antisense notype etiology of disease, Chinook salmon, cancer cells of plasmids, human papil- human tumor cell lines, 654 6496 lomavirus type lg, 4706 gene function reconstitution vector-mediated lymphokine gene trans- human p120 complementary DNA,

7066

high homology to mouse p120 com- human skin cancers, 1336 renal plementary DNA, 5681 O6-methylguanine-DNA methyltransfer- GGT to GTT transversions in codon transcripts, human DNA topoisomerase promoter activity 12, K-ras, 4747 ase I pseudogene, 4280 Mer + and Mer- cells, 6404 soft tissue c-myb antisense modulation of P-450 levels leucovorin, trimetrexate cytotoxicity, oligodeoxynucleotides, proliferation of platinum anticancer drugs, hepatic 6866 neuroblastoma cells, 4221 drug and steroid hormone metabo- mechanism of natural resistance, 1434 hsp70 expression in fibroblasts lism, 540 SAS amplification, 3746 enhanced cell survival, protein synthe- nm23 Sarcophytol A sis, 3667 metastatic malignant melanoma, dis- suppression protein levels and ease progression, 6088 basic fibroblast growth factor, melano- tumor promoter-induced oxidative nm23 gene expression events, 2298 cytes and metastatic melanoma cells, clonal populations, metastatic murine 5024 and human neoplasms, 5808 SateUitosis transcriptional and posttranscriptional overexpression of human transcription low grade tumor or activation factor lID molecular analysis, malignant astrocy- urokinase plasminogen activator gene serum stimulation, lung and breast toma, 1568 expression, 2489 carcinoma, 307 SB-75 RNA, messenger platelet-derived growth factor and its re- luteinizing hormone-releasing hormone abundance of primary transcript ceptors antagonist growth-related genes, normal and leu- sustained release formulations, pros- kemic cells, 11 human glioma tissue, 3213 tatic carcinoma, 2538 altered steady-state levels sensitivity of resistant human tumor cell c-myc and p53, L 1210 cells resistant lines Selenite to deoxyadenosine, 2000 tumor necrosis factor, Adriamycin, cytotoxicity amphiregulin 6630 drug resistant and nonresistant ovarian psoriatic epidermis, gastrointestinal serum-induced c-fos transcription tumor cells, 4812 carcinoma, 3224 retinoic acid inhibition, 2384 inhibition of cell attachment, 5803 antagonist thyroid hormone receptor S 19 ribosomal protein -mediated growth inhibition erbA-a2 iaminin-binding protein, colon carci- intracellular glutathione, mammary tu- neoplastic rodent cells, 2186 noma progression and differentia- mor cells, 1091 c-jun and jun-B tion, 791 steady-state Selenium regulation by prostaglandin E2, Syrian xyleneselenocyanate hamster embryo cells, 6912 sensitivity to N~,NJ2- complementary DNA cloning and bis(ethyl)spermine, major forms of chemoprevention of mammary cancer, a-class glutathione S-transferases, lung cancer, 5359 2402 mouse tissues, 314 Selenoperoxidase -mediated cytoprotection cyclin DI S platelet-derived growth factor, cultured merocyanine 540-sensitized photope- fibroblasts, 4522 Salmon, Chinook roxidation, photokilling of leukemia differential display and cloning retrovirus cells, 5282 human breast cancer vs. mammary epi- plasmacytoid leukemia, etiology of dis- Seminal plasma thelial cells, 6966 ease, 6496 prostate carcinoma cell proliferation-in- elevated DT-diaphorase activity Salmonella typhimurlum hibiting factor non-small cell lung carcinoma, 4752 decreased murine resistance similarity to transforming growth fac- endogenous tumor necrosis factor func- bryostatin 1, 2143 tor-~3, 5821 tions expression of human arylamine N-acetyl- Serine resistant factor against hyperthermic transferases phosphorylation cytotoxicity, 6258 metabolism, mutagenic activation, glycoproteins, bovine leukemia virus- Gadd45 and Gadd153 3961 induced lymphosarcoma cells, 6463 hypoxia, glucose-regulated proteins, Saporin Serine proteinases 3814 mitotoxin matrix gastrin and transforming growth factor-a basic fibroblast growth factor, antitu- multiple secretion, human gastric car- levels in colonic carcinoma, quantita- mor activity, 227 cinoma cell lines, 5046 tive polymerase chain reaction, 2261 Sapporo Cancer Seminar Serum HIP gene activation eleventh annual, 2362 blocking effect human primary liver cancer, 5089 Sarcoma ricin A chain immunotoxin potentia- HSP-70A bone and soft tissue tion, monensin or carrier protein- lower heat shock factor activation, p53 gene mutation spectrum, 6194 monensin conjugates, 623 heat-sensitive leukemia, 6815 human soft tissue cell lines human ribosomal phosphoprotein P0 intrinsic resistance, 3908 immunoreactive human chorionic gonad- increased expression, hepatocellular inhibition of murine tumor growth otropin carcinoma and colon carcinoma, interferon-inducing imidazoquinolina- free/3 subunit, malignant tumors, 1520 3067 mine, 3528 Serum banks IGFBP-3 gene expression Kaposi's use in cancer research, 5557s estrogen receptor status, human breast HTLV-I or a related retrovirus, 4391 Severe combined immnnodeficiency carcinoma, 5100 malignant fibrous histiocytoma antilymphoma activity laminin receptor prognostic influence, HSP-27, 2325 76 T-cells, mice, 5610 human papillomavirus-associated cer- measurement of thymidine replacement cytogenetic characterization vical neoplasms, 1561 5-iododeoxyuridine, 719 B-cell lymphoma, EBV-positive do- Mr 72,000 and 92,000 type IV collagen- postvaccinal nors, 4678 ases aluminum, cat, 5391 mice

7067

early growth and angiogenesis, human preneoplastic lesions, 501 antitumor activity, 2424 adenocarcinoma, 6553 regression of recurrences of breast carci- Spheroids tumors arising in mice nomas glioma and colon carcinoma enhanced radiation sensitivity, SCID intralesional injections, natural inter- accumulation of ~~ central degenera- normal tissues, 6292 ferons a and 7, 4571 tive areas, 1587 S6zary syndrome tumor promoters 9L gliosarcoma tumors and HTLV-I or a related retrovirus, 4391 induction of epidermal ornithine de- misonidazole adducts, oxygen distribu- Sialosyl-Tn antigen carboxylase, epicatechins in green tion, 3831 cancer-associated tea, 3582 multicell mucins, natural killer cell cytotoxicity, tumor promotion affinity on 251 radioimmunotherapy, 4741 dietary linoleic acid, mammary carci- 4728 Sialyl Lewis x antigen nogenesis, 2049s rhabdomyosarcoma marker of dysplasia ultraviolet light-induced carcinogenesis central proliferation, differentiation, colonic adenoma-carcinoma sequence, 3-aminobenzamide as cocarcinogen, 474 3138 4053 Sphinganine Sialyltransferase Skin neoplasms interaction of antileukemia agents activity and hepatic tumor growth initiation stage HL-60 cell differentiation, 3593 nude mouse model, colorectal cancer immunogenetic influences, cutaneous Spleen metastases, 1775 chemical carcinogenesis pathway, lymphocyte function Simian virus 40 6106 bromocriptine effects, neoplastic pro- -immortalized hepatocyte cell line ultraviolet gression, 2209 ras transformation, no loss of albumin pyrimidine dimer removal, DNA re- preleukemic development expression, 940 pair liposomes, 4227 murine retrovirus-induced promono- -immortalized hepatocytes ultraviolet radiation-induced cytic leukemia, 5317 ras transformation, hepatocarcinoge- N-ras mutation, 3946 Squamous metaplasia nesis model, 173 SMANCS HPV 16-immortalized human endocervi- large T-antigen antitumor effects cal cells, 4254 transcriptional elements of human sur- 7,12-dimethylbenz[a]anthracene, rat SR 4233 factant protein C gene, pulmonary mammary tumor, 1013 -induced DNA and chromosome breaks adenocarcinoma, 5342 SMS 201.995 hypoxia and ionizing radiation, repair, temperature-sensitive inhibition of growth 4473 transformation, human placental cells, human colon cancer, 917 SR 33557 6001 Sodium butyrate modulation of subcellular distribution Simvastatin alteration of DNA methylation pattern doxorubicin, P388/ADR mouse leuke- synergistic effect flow cytometric detection, 5213 mia cells, 6440 N,N'-bis(2-chloroethyl)-N-nitrosourea transcriptional regulation S19 ribosomal protein and #-interferon, glioma cells, 4348 placental-like alkaline phosphatase differential expression Single-chain Fv gene, 3378 colon carcinoma progression and dif- rapid tumor penetration Sodium chloride ferentiation, 791 other immunoglobulin forms, 3402 carcinogenicity of uracil Stathmokinesis Sister chromatids rationale, rats and mice, 1675 growth and cell cycle progression induction of exchanges Somatostatin effects of genistein, normal lympho- extremely low doses, a-particles, 6394 analogue BIM-23014C receptors cytes and leukemic cells, 6200 Skin chemical cross-linking assay, breast Staurosporine carcinogenesis carcinoma, 843 cell cycle and chromatin structure dietary energy and fat effects, tumor analogue octreotide normal and leukemic lymphocytes, promotion, 2035s antiproliferative effects, ZR-75-1 470 extracellular matrix receptors, tumor breast cancer cells, 4973 derivative CGP 41251 progression, 2966 receptors in human renal cell carcinoma, inhibition of signal transduction, 5353 potent preventative action, a-carotene, 6074 Steel locus 6583 SOS responses product of 7,12-dimethylbenz[a]anthracene-induced high levels of enhanced reactivation replacement, leukemic cell interaction, 12-O-tetradecanoylphorbol-13-acetate- herpes simplex virus, skin fibroblasts, 5208 caused promotion, green tea poly- 53 Stein cell factor phenols, 6890 Soybean agglutinin stimulation of growth growth of papillomas lectin binding c-kit expression, glioblastoma cell line, inhibitory effect, green tea, 6657 tumor progression in vivo, liver metas- 3498 inhibitory effect of green tea tasis potential, 5235 Stem cells tumorigenesis, ultraviolet light and 12- SOy sauce basal and luminal cell type cytokeratins O-tetradecanoylphorbol-13-acetate, Japanese-style fermented colocalization, prostatic cancer, 6182 1162 inhibition, benzo[a]pyrene-induced defective organ microenvironment initiated mouse forestomach neoplasia, 1754 metastases incidence and distribution, mouse model, 1439 Species differences mutant mice, 2304 natural history induction of colon adenocarcinoma growth factors, 501 intraepithelial neoplasia, chemopre- 6-nitrochrysene, 1542 newt squamous carcinoma vention, 1651 Spermidine caricature of tissue renewal, 4858 novel nonphorbol ester-type tumor pro- -chlorambucil conjugate Steroids moter targeting of tumor cells and DNA, growth factor modulation and chlorinated pesticide mirex, 631 4190 aromatase activity, MCF-7 cells, 1411 nude mouse depletion hormone metabolism graft assay, tumorigenic suppression of calcium signaling, 6782 platinum anticancer drugs, modulation squamous cell carcinoma, 6487 Spermine analogues of P-450 messenger RNA levels, 540

7068

Stomach like growth factor II autocrine and metastases embryo growth loop, 1830 prostate tumor cells, 3776 preferential gene expression, gastric Phase II trial estramustine and cancer, 3372 advanced renal cell carcinoma, 5775 combined antimicrotubule activity, Stomach lesions Surfactant prostatic carcinoma, 4433 catechol-induced protein C gene sensitization of astrocytoma cells reversibility, 787 SV40 large T-antigen, pulmonary ade- radiation, 3495 Streptavidin nocarcinoma, 5342 T-cells -blocked biotinyl-ricin SV40 large T-antigen 3,6 cytotoxicity, immunotargeting via bio- immortalization antilymphoma activity, severe com- tinyl monoclonal antibody, 4448 phenotypically and karyotypically sta- bined immune deficiency, 5610 Streptozotocin ble thyroid epithelial cell line, 2938 anti-CD3 monoclonal antibodies O~-alkylguanine-DNA alkyltransferase CD3-negative tumors, Phase IA/B carmustine resistance, Phase I trial, T study, 2394 2456 BCG-specific CD4 + Stroma TAG-72 antigen presentation, bladder carci- immunoreactive endothelin 1 serum marker noma, 4286 mammary phyllodes tumor, 4046 CA 72-4 measurement, management cytokine-activated tumor inhibition, Stromal cells of gastric carcinoma, 1222 4853 stimulation of breast cancer cells Taiwan interferon-7 and -a bombesin and glucocorticoids, endo- hepatocellular carcinoma Phase I trial, metastatic renal cell car- thelin production, 1786 p53 gene mutation, 6098 cinoma, 851 Stromal neoplasms Talisomycin S~ob Jurkat metastasizing testicular mixed gonadal synthesis and evaluation of fluoromycin, induction of interleukin 2 production, osteosarcoma components, 6705 709 methionine adenosyltransferase ac- Stromelysin Tamoxifen tivity, 3361 matrix metalloproteinase genes adjuvant therapy and low-fat diet lack of immunity metastatic potential, transformed rat serum binding proteins and estradiol, preexisting anti-mouse immunogiobu- cell lines, 4942 postmenopausal breast cancer pa- lin reactivity, 6979 Sulfhydryl boron hydride tients, 5386 leukemic accumulation of l~ heterogeneity of progesterone receptor effects of quercetin, cell cycle, 6676 central degenerative areas, glioma and content murine tumor-specific colon carcinoma spheroids, 1587 quantitative dual parameter flow cy- activation and growth, bryostatin 1, Sulfoglycolipid tometry, breast cancer, 593 548 first establishment of human monoclonai induction of covalent DNA adducts, subset analysis of Lewis lung carcinoma antibody, 2292 1360 tumor rejection Suifoglycosphingolipids induction of hormone-independent rat metastasis, 6507 human uterine endometrial adenocarci- mammary tumors, 235 tumor-reactive noma, 803 induction of transforming growth factor- lung cancer tissues, 775 Sulfotransferase El VE2-deleting activity activation of E-hydroxyalkylnitrosamine human breast cancer, 4261 adoptive transfer, 5183 alkylating agents, 3300 management of breast cancer "1"84 cells Sulindac evolution of paradigms, 2371 perturbations of cellular acylation proc- aspirin and potential role of prostaglan- modulation of cisplatin resistance esses dins malignant melanoma cells, 6790 1-O-octadecyl-2-O-methylglycero-3- colon cancer, 5575 plasma levels of insulin-like growth fac- phosphocholine, 2806 natural history tor I T47D cells intraepithelial neoplasia, chemopre- insulin-like growth factor binding pro- steroid and growth factor modulation vention, 1651 tein I, breast cancer, 4719 aromatase activity, 1411 Supernatants preneoplastic cell proliferation Tea tumor cell conversion N-nitroso-N-methylurea-induced mam- green and black latent to active form, transforming mary carcinogenesis, 1477 inhibition of tumorigenesis, 1943 growth factor-E, 5641 resistance Tea, green Snperoxide dismutase persisting sensitivity to estrogen, an- antioxidant and phase II enzymes manganous tiestrogen binding site activity, 4106 cancer chemoprevention, 4050 endogenous tumor necrosis factor, -sensitive and -resistant sublines of inhibition protective function intracellularly, MCF-7 cells tobacco-specific nitrosamine-induced 5278 responses to retinoic acid, 6164 lung tumorigenesis, 3875 Suramin stimulation of human papillomavirus inhibitory effect disruption of mitochondriai function type 16 growth of skin papillomas, 6657 rhodamine- 123 retention, prostate car- gene expression, cervical cancer cell inhibitory effect on tumorigenesis cinoma, 6953 line, 6848 ultraviolet light, 12-O-tetradecanoyl- individualized dosing suppression phorbol-13-acetate, 1162 use of adaptive control with feedback, tumor promoter-produced hydrogen skin tumor promoter-caused induction 64 peroxide formation, human neutro- ornithine decarboxylase, inhibition by -induced differentiation of HT29-D4 phils, 4969 epicatechins, 3582 cells systemic adjuvant treatment 12-O-tetradecanoylphorbol-13-acetate- potential autocrine role, insulin-like evolving concepts, breast cancer, 2127 caused promotion growth factor II, 3182 T-antigens 7,12-dimethylbenz[a]anthracene-in- inhibition of angiogenesis, 5073 urinary bladder carcinoma, 5030 duced skin, 6890 inhibition of growth Taxol Technetium-99m human rhabdomyosarcoma, insulin- block of processes essential for invasion labeled monoclonal antibody E48 F(ab'h

7069

radioimmunoscintigraphy, head and chloro(cyclohexylamine) prolonged survival by vaccination, sol- neck cancer, 2569 platinum(IV) uble protein antigen entrapped in li- Temperature cellular accumulation and cytotoxicity, posomes, 6287 -sensitive Simian virus 40 ovarian carcinoma, 6188 Thyroid transformation, human placental cells, Textile industry workers epithelial transformed cells and tumors 6001 exposure to arylamines growth-inhibitory effect, bovine sem- Tempol urinary mutagenicity, N-acetylation inal ribonuclease, 4582 novel murine radiation protector, 1750 phenotype, 4885 hormone receptor antagonist erbA-a2 Tenasein Thermochemoimmunotherapy increased messenger RNA levels, neo- down-regulation by expression enhanced sensitivity plastic rodent cells, 2186 antiprogestins, rat mammary tumors, human colon tumor cell lines, 5271 phenotypically and karyotypically stable 4642 Thermotolerance cell line Teniposide absence of induced heat shock proteins conditionally immortalized, SV40 cell cycle-related expression murine lymphoma, 2854 large T-antigen, 2938 p120 nucleolar antigen, 3491 chronic role of p53 mutations induction of nuclear and mitochondrial absence of HSP28 synthesis, murine endocrine tumorigenesis, 5061 DNA degradation, 3384 L929 cells, 5780 Thyroid hormone Teratoma lack of expression receptor o~ -derived tumorigenic cell line cellular mechanisms, HeLa $3 cells, chromosome 17q, sporadic breast car- testosterone, tumor growth and EGF ll01 cinoma, 2624 receptor expression, 4242 resistant factor against hyperthermic cy- Thyroid neoplasms Testis totoxicity C-cell metastasizing testicular mixed gonadal endogenous tumor necrosis factor pheochromocytoma, transgenic c-mos stromal tumor functions, 6258 mice, 450 osteosarcoma components, 6705 Thioether undifferentiated nonseminomatous germ cell line -lipid conjugate p53 mutations, 1369 acquired resistance to cisplatin, 1710 1-~-o-arabinofuranosylcytosine, colo- TiO2 particles Testosterone rectal cancer xenografts, 1865 photoexcited growth properties Thioguanine induction of cytotoxicity, 2346 epidermal growth factor receptor, tera- -resistant mutations Tissue banks toma-derived tumorigenic cell line, inhibition by 4-aminobiphenyl, uroepi- applications of experimental studies 4242 thelial cells, 1615 epidemiological studies, non-Hodg- platinum anticancer drugs Thrombin kin's lymphoma, 5561s modulation of P-450 messenger RNA effect of treatment on tumor cells T-iymphoblasts levels, 540 adhesion of tumor cells to platelets, resistance to l-~-D-arabinofuranosylcyto- 2,5,2',5'-Tetrachlorobiphenyl tumor metastasis, 3267 sine changes in ploidy and specific karyotypic Thromboxane mediation by mutations, deoxycytidine changes role of microvascular damage kinase gene, 2389 rat liver, 955 photodynamic therapy, 4914 Tn 2,3,7,8-Tetrachiorodibenzo-p-dioxin Thymidine sialylated dose-response relationships for chronic replacement immunization of colorectal cancer pa- exposure high grade glioma, 5-iododeoxyuri- tients, modified ovine submaxillary rat tumor model, 3436 dine, 719 gland mucin and adjuvants, 5663 immortalized keratinocytes Thymidylate synthase Tobacco neoplastic transformation, 3478 dihydrofolate reductase and DT-diaphor- interaction between smoking and genetic 12-O-Tetradecanoylphorbol-13-acetate ase predisposition acquisition of growth-inhibitory response quantitation of gene expression, po- lung cancer detection and prevention, DNA damage, 1907 lymerase chain reaction, 108 2694s -caused tumor promotion elevation following 5-fluorouracil treat- -specific carcinogens 7,12-dimethylhenz[a]anthracene-in- ment metabolic activation, DNA and hemo- duced skin, green tea polyphenols, prevention by addition of leucovorin, globin adducts as markers, 2698s 6890 murine colon tumors, 4922 -specific nitrosamine growth of human melanocyte cultures folate-based inhibitor potential chemopreventive agents, lung protein kinase C activation, 4514 acquired resistance, human lympho- carcinogenesis, 2719s -induced oxidative events and DNA blastoid cells, 1137 -specific nitrosamine-induced lung tu- damage gene mutation morigenesis suppression, sarcophytol A, 2298 attenuation by exogenous folates, ade- inhibition by green tea and major poly- inhibitory effect of green tea on tumori- nocarcinoma, 558 phenol, 3875 genesis immunological quantitation Topotecan skin, SKH- 1 mice, 1162 monoclonal antibody TS 106, cancer accumulation and cytotoxicity 1,2,3,4-Tetrahydro-7,12-dimethylbenz[a]an- cell lines, 4306 effect, P-glycoprotein expression, 2268 thracene inhibition and cell synchronization 2'-deoxy-5-azacytidine and regioisomeric B-ring fluoro analogues radiosensitization, fluorodeoxyuridine, synergistic cytotoxicity, 2180 and 1687 Toxins comparative metabolism, 3035 intracellular metabolism rapid tumor penetration Tetrahydrocortisol 5-formyl tetrahydrofolate, breast and single-chain Fv, other immunoglobulin antiangiogenic agents colon cell lines, 36 forms, 3402 potentiation of cytotoxic cancer thera- Thymoma Trachea pies, primary and metastatic disease, antitumor effect epithelium 6702 2'-deoxy-5-fluorouridine conjugates, squamous metaplasia, retinoid status Tetraplatin 132 and keratin expression, 6144 cisplatin and amminedihutyratodi- -bearing mice Transcription factor liD

7070

overexpression in lung and breast carci- loma, transgenic mice, 978 loss of heterozygosity noma Transplantation multiple tumor suppressor genes, rapid induction, serum stimulation, fetal brain esophageal cancer, 6525 307 oncogene complementation, 3760 mammary Transcription factors formation of PCI 2 tumors dietary fat and, 2040s cytokine genes and cytokine receptor rat brain, time course and host age, model system for testing anticancer genes 1933 drugs Hodgkin's and Reed-Sternberg cells, immunosuppressive therapy wap-ras transgenic mouse, 3733 3353 acquired immunological disorders, role of cytokines N-Oct 3 5474s regulation of cell function, pathogen- expression, small cell lung cancer, neonatal rat brain esis of disease, 6129 6121 migratory behavior, PC12 cells, 1938 tobacco-specific nitrosamine-induced Transforming growth factor preirradiation of site lung gene expression increased tumor hypoxic fractions, co- inhibition by green tea, antioxidants, estrogen and antiestrogen, endometrial lon tumor xenografts, 2162 3875 adenocarcinoma cells, 1704 syngeneic bone marrow Tumorigenicity Transforming growth factor-a tumor resistance, interleukin 2, 4117 reconstitution of retinoblastoma gene altered gene expression Trehalose function immortalized human breast epithelial differentiation of HT-29 cells microcell transfer, chromosome 13, cell line, 1210 mitochondrial DNA expression, 3718 6297 autocrine growth factor Trenimon retinoblastoma gene product ovarian carcinoma cell lines, 341 -induced cytotoxicity bladder carcinoma, 1968 eosinophil-derived modulation by DT-diaphorase, rat he- suppression hamster oral carcinogenesis, 389 patocytes, 3015 anchorage-independent growth, BK vi- epidermal growth factor and Trichostatin A rus-transformed mouse cells, 1297 renal adenocarcinoma cell growth, sis-transformed NIH3T3 cells Tumor invasion-inhibiting factor 2 4356 morphological reversion, 168 primary structure and inhibitory effect estrogen-chlorambucil conjugate Triiodothyronine pulmonary metastasis, tumor cells, growth-inhibitory action, MCF-7 cells, antagonist thyroid hormone receptor 1422 1187 erbA-a2 Tumor necrosis factor gastrin messenger RNA levels increased messenger RNA levels, neo- Adriamycin and quantitative polymerase chain reac- plastic rodent cells, 2186 sensitivity, resistant human tumor cell tion, colonic carcinoma, 2261 Trimetrexate lines, 6630 growth regulation cytotoxicity autocrine growth factor for neuro- human renal carcinoma cells, 3335 leucovorin, methotrexate resistant soft blastoma, 3194 receptor messenger RNAs tissue cell line, 6866 endogenous primary human gastric carcinoma, quantitation of folic acid enhancement 9intracellular protective factor, 5278 3453 antifolate synergism, 2228 -induced activation of macrophages transgenic mice Trophoblasts block, inhibitors of polyamine biosyn- development of liver tumors, 5162 differentiation of choriocarcinoma cell thesis, 1891 Transforming growth factor-B line, 3713 -r-interferon and growth inhibition Tubulin NADPH oxidase gene expression, dif- gastric carcinoma cells, 295 action of novel antimitotic agents ferentiation of myeloid cell lines, high molecular weight computer-assisted evaluation, differen- 2530 urinary excretion, active nodular scle- tial cytotoxicity data, 3892 rapid differentiation, human neuro- rosing Hodgkin's disease, 6768 Tumor-associated antigen blastoma cells, 931 prostate carcinoma cell proliferation-in- bivalent interaction interleukin 18 and hibiting factor apparent antibody affinity, antibody protection of hematopoietic progenitor human seminal plasma, 5821 binding assays, 4157 cells, aldehyde dehydrogenase, 1770 tumor cell conversion membrane glycoproteins resistance of human cervical carcinoma latent to active form, 5641 serine phosphorylation, bovine leuke- cells Transforming growth factor-~l mia virus-induced lymphosarcoma, sensitivity to cisplatin, 4758 cyclic AMP and 6463 resistant factor against hyperthermic cy- inhibition, hepatocyte DNA synthesis, monoclonal antibody KM-2 totoxicity, 6258 3598 serodiagnosis, hepatocellular carci- Tumor necrosis factor-a immunohistochemical staining noma, 4987 combined with platinum complexes disease progression, human breast can- oncogenic potential whole-body hyperthermia, 4096 cer, 6949 HeLa x fibroblast cell hybrids, 616 cytokine responses induction in human breast cancer Tumor-associated leukocytes interleukin 2 injection, leptomeningeal tamoxifen treatment, 4261 cytokine-activated tumor inhibition, carcinomatosis, 1123 induction of apoptosis 4853 epidermal growth factor receptor mono- human hepatoma cell line, 385 Tumorigenesis clonal antibody induction of apoptotic cell death endocrine androgen-independent prostatic carci- human gastric carcinoma cells, 4042 role of p53 mutations, 5061 noma, 5887 inhibition of tumor-specific CTL re- inhibition in A/J mice growth-regulatory effects sponses, 1386 green and black teas, 1943 phosphatase inhibitors, tumor and transforming growth factor-~2 and inhibitory effect of green tea normal cells, 2557 responsiveness, colorectal cancer cell ultraviolet light, 12-O-tetradecanoyl- induction of apoptosis lines, 3705 phorbol-13-acetate, 1162 mammary adenocarcinoma cells, 1342 Transgenes liver induction of differentiation by bufalin mutant human c-Ha-ras 2s2Cf relative biological effectiveness, human leukemia cells, 4634 chemically induced forestomach papil- fission neutrons, 1948 interleukin 2 and

7071

tumoricidal activation, peritoneal mac- amplification and expression, bcl-1 nones, 4492 rophages, 3880 gene, 2460 interleukin 3 and inosine-5'-phosphate dehydrogenase U clonai growth, acute myelogenous leu- gene expression, 5826 kemia blasts, 2197 interstitial fluid pressure, hyperther- U937 cells lymphotoxin or mia, 487 induction of differentiation acute effects, subcutaneous rodent tu- micropharmacology, monoclonal anti- differentiation-related genes, campto- mors, 2167 bodies, 5144 thecin, 1245 myelopoiesis-associated immune sup- microvascular pressure, interstitial hy- induction of differentiation by bufalin pressor cells pertension, 5110 macrophage/monocyte-like cells, 4634 mice bearing metastatic Lewis lung monoclonal antibody uptake, antibody modulation of protein kinase C-~ carcinoma tumors, 6335 affinity and antigen density, 377 phorbol esters, 5604 resistance to cytolysis murine model for antibody-directed UDP-N-acetylhexosamine malignant gynecological cell lines, 866 targeting, vascular endothelial cells, modulation by glucosamine and uridine role of cytokines 5954 small cell lung cancer, 31p nuclear regulation of cell function, pathogen- pattern of p53 mutations, Burkitt's magnetic resonance, 3782 esis of disease, 6129 lymphoma, 4273 Ultrasound tumor-derived lipolysis-promoting fac- Phase II preclinical drug screening, high-intensity tor, 829 human tumor xenografis, 5940 prostatic adenocarcinoma, 6353 Tumor progression 3~p NMR and cell cycle response, ra- Ultraviolet adrenal carcinoma diation, 5299 radiation-induced skin cancers penultimate cell surface oligosaccha- ras-related rab2 gene product, periph- N-ras mutation, 3946 rides, 2222 eral blood mononuclear cells, 3083 -sensitive excision repair-defective rodent development of liver tumors selective in vivo localization, dauno- mutants transforming growth factor-a trans- rubicin small unilamellar vesicles, eleventh complementation group, genic mice, 5162 3255 6690 growth control target antigen competition, distribu- Ultraviolet B mammary tumors, primary culture, tion of monoclonal antibodies, 1284 radiation-induced squamous cell carci- 6531 Tumor suppressor genes noma inhibition of cancer cell growth allelotype carcinogen-specific mutational pattern, calcium channel antagonists, athymic non-small cell lung carcinoma, 2478 p53 gene, 6400 mouse, 2413 chromosome 19q Ultraviolet C loss of keratin expression human astrocytomas, oligodendroglio- genomic rearrangements posttranslational regulation, anaplastic mas and mixed gliomas, 4277 DNA fingerprint assay, C3H/10TV2 carcinoma, 6603 DCC cells, 5788 malignant variant of SW480, 6840 frequent loss of expression, ductal Ultraviolet light multistage carcinogenesis, 4837 pancreatic adenocarcinoma, 2616 -induced carcinogenesis nonrandom abnormalities human prohibitin 3-aminobenzamide as cocarcinogen, chromosome 1 and Harvey-ras-1 al- chromosome 17q21 mutation, spo- mouse skin, 4053 leles, mammary gland, 4791 radic breast cancer, 1643 inhibitory effect of green tea on tumori- normal and transformed nonlymphoid multiple oncogenes and genesis tissues hepatocarcinogenesis, hepatitis B virus skin, SKH-1 mice, 1162 c-kit receptor, 6139 transgenic mice, 2823 reduced incidence of skin cancer P-glycoprotein expression p53/Rb/mcc/apc pyrimidine dimer removal, DNA re- rat liver, 5154 loss of heterozygosity, dysplastic and pair liposomes, 4227 skin carcinogenesis cancerous ulcerative colitis, 741 Uracil extracellular matrix receptors, 2966 pathways that control cell division, 2362 carcinogenicity soybean agglutinin lectin binding RAP1A/Krev-I locus rationale, rats and mice, 1675 N-acetylgalactosamine-specific lectin, loss of heterozygosity, colorectal tu- Ureter liver metastasis potential, 5235 mors, 285 cancer of suppression by retinoic acid Third Annual Pezcoller Symposium, cigarette smoking, 254 melanoma cell motility factor receptor 3246 Urethra expression, 4878 Tyrosine kinase male Tumor promoters FLT4 receptor oncogenic HPV type 16, squamous -caused induction of epidermal ornithine immunoglobulin-like loops, multiple cell cancer, 5018 decarboxylase human tissues and cell lines, 5738 Uridine inhibition by epicatechins, green tea, inhibitor modulation of UDP-N-acetylhexosamine 3582 inhibition, breast cancer cell growth, small cell lung cancer, 3~p nuclear -induced oxidative events 3636 magnetic resonance, 3782 suppression, sarcophytol A, 2298 novel receptor nucleotide pools induction FLT4, chromosome 5q33-qter, 746 brequinar, 5-fluorouracil activity, 1660 basic fibroblast growth factor gene, hu- pathways that control cell division, 2362 Urinary bladder man dermal fibroblasts, 1040 src carcinogenesis mutagenic specificity of oxygen radicals benzoquinonoid ansamycins, selective heat-killed Escherichia coli, 5329 human leukemia cells, 1082 tumoricidal activity, 1721 initiation by acrolein, 3577 Tumor promotion v-abl carcinogenicity of uracil dietary energy and fat effects, 2035s prolongation of survival with herbimy- rationale, rats and mice, 1675 progression and cin A, myeloid leukemia C1 cells, Urine dissociation of sensitivities, outbred 4017 aflatoxin-DNA adducts and inbred SENCAR mice, 3432 Tyrosine protein kinase molecular dosimetry, China, 45 Tumors: see also specific type selectivity for v-abl kinase increased excretion of N-nitrosodimeth- solid benzopyranones and benzothiopyra- ylamine

7072

reduced blood clearance, N-nitrosodi- nonhuman primate, 6917 Woodchuck hepatitis virus methylamine, 1463 Vanadate nitrite and nitrosamine synthesis levels of bombesin-like peptides growth-regulatory effects hepatocytes, 4139 asymptomatic cigarette smokers, phosphatase inhibitors and tumor ne- WR2721 2727s crosis factor, tumor and normal time dependence and selective modula- molecular dosimetry cells, 2557 tion aflatoxin-NT-guanine, multiple mono- Vascular permeability cisplatin-induced nephrotoxicity, 2257 clonal antibody affinity chromatog- role of neovasculature raphy, 267 tumor retention, photodynamic agents, X Uroepithelial cells 924 different steps of transformation Verapamil Xanthine dehydrogenase neoplastic progression, EJ/ras, 688 inhibition of cancer cell growth Mitomycin C metabolism inhibition of thioguanine-resistant muta- athymic mouse, 2413 dicumarol, 6936 tions multidrug-resistant cells Xanthine oxidase 4-aminobiphenyl and its N-hydroxy collateral sensitivity to nitrosoureas, oxidative stress and iron release derivatives, 1615 5013 hyperthermic rat liver perfusion, 1699 isogeneic nontumorigenic and tumori- structure and MDR reversal activity, Xenobiotic resistance genic 4121 induced cytoxicity loss of 3pl 3, tumorigenic reversion, v-Ha-ras resistance of murine lung tumors, 1631 transfection of papillomavirus-immortal- 6797 metabolism and nucleic acid binding ized cervical epithelial cells Xenografts N-hydroxy-4-acetylaminobiphenyl,N- down-regulation, keratin 14 gene colon tumor acetoxy-4-acetylbiphenyl, 3286 expression, 5865 increased tumor hypoxic fractions, tumorigenic transformation and neoplas- Vimentin preirradiation of transplantation tic progression expression in Adriamycin- and vinblas- site, 2162 4-aminobiphenyl and its metabolites, tine-resistant cells colorectal cancer 1606 loss of epithelial markers, breast can- thioether-lipid conjugate, 1-r Urogenital system cer, 5190 nofuranosylcytosine, 1865 molecular cloning induction of differentiation glioma Wilms' tumor complementary DNA, camptothecin, U937 cells, 1245 immunotherapy, labeled monoclonal 6407 loss of keratin expression antibody and epidermal growth fac- Urokinase posttranslational regulation, anaplastic tor receptor, 121 invasion of connective tissue carcinoma, 6603 long-term growth suppression, che- human carcinoma cell lines, 6754 Vinblastine moimmunotherapy, 3838 receptor-bound -resistant human breast cancer cell lines human adenocarcinoma in SCID mice mediation of tissue invasion, lung car- loss of epithelial markers, vimentin angiogenesis, early growth, 6553 cinoma, 3043 expression, 5190 human malignant melanoma -type plasminogen activator Vinca alkaloid inhibition of growth, camptothecins, prognostic value, primary breast can- reversal of resistance 3980 cer, 6101 anti-P-glycoprotein monoclonal anti- human tumor Uterus body, human tumor xenograft, 1810 pH, effect of insulin, 6209 human smooth muscle tumors Vitamin D Phase II preclinical drug screening, CpG methylation, insulin-like growth calcium and colon cancer, 2067s 5940 factor II gene, 6516 Vitronecfin reversal of Vinca alkaloid resistance, induction of cervical neoplasias in mice receptor anti-P-glycoprotein monoclonal an- human papillomavirus type 16 E6/E7 up-regulated biosynthesis and expres- tibody, 1810 genes, 4420 sion, cancer cell adhesion, 2202 sensitivity to 1,3-bis(2-chloroethyl)-l- yon Hippel-Lindau syndrome nitrosourea, effect of O6-benzylguan - V high levels of enhanced reactivation ine, 1171 herpes simplex virus, skin fibroblasts, lung tumor Vaccine 53 elevated DT-diaphorase activity, mes- colon tumor Vorozole senger RNA content, 4752 efficacy, class II major histocompati- antitumoral and endocrine effects melanoma bility complex, 3460 dimethylbenzanthracene-induced antitumor activity, N,N'- immunization of colorectal cancer pa- mammary tumors, 1240 bis(ethyl)spermine homologues, tients VP-16: see Etoposide 2424 modified ovine submaxillary gland VX-2 neoplasms different growth characteristics, blood mucin and adjuvants, 5663 anticancer effects flow, 584 polyvalent melanoma free polyunsaturated fatty acids, 400 spatial distribution, tumor-specific immunogenic human melanoma anti- monoclonal antibodies, 367 gens, 5948 W targeted radiotherapy, Z~lAt-methylene prolonged survival of thymoma-bearing blue, 4385 mice White blood cells tumor-specific monoclonal antibody soluble protein antigen entrapped in li- detection of PAH-DNA adducts uptake, 357 posomes, 6287 coke oven workers, 1510 nude mouse Vaccinia virus Wilms' tumor chondricytic differentiation, peripheral IgV-like region familial predisposition neuroectodermal tumor cell line, multiple transmembrane domains, nonlinkage of 16q markers, 6117 4214 ovarian tumor marker, 5416 molecular cloning of complementary metastatic human tumor burden, re- Vaccinia virus vaccine DNA sponse to therapy, 2791 carcinoembryonic antigen gene expres- urogenital system and brain, 6407 nude mouse model sion third locus on chromosome 16q, 3094 adoptive immunotherapy, human mel-

7073

anoma-specific cytotoxic T-cells, dine conjugates, 132 Xyleneselenocyanate 394 tumor models chemoprevention of mammary cancer, Raji lymphoma antigen-specific activity, carcinoma-re- 2402 improved delivery, radiolabeled anti- active BR64-doxorubicin conjugates, Y B1 monoclonal antibody, 637 5693 Yeast unlabeled and ~31I-labeled pan B-cell Xeroderma pigmentosum artificial chromosome clones monoclonal antibodies, 6476 sequence specificity metaphase and interphase cytogenet- retention of cellular radiation sensitivity aflatoxin Brinduced mutations, 5668 ics, 2590 human melanoma surgical specimens, X-rays Yeast cells 1764 genomic rearrangements amsacrine and etoposide hypersensitivity small cell lung cancer DNA fingerprint assay, C3H/IOTI/2 overexpression, DNA topoisomerase antitumoral activity, bombesin ana- cells, 5788 lI, 4467 logues, 4872 prolonged inhibition of DNA synthesis Z subcutaneous model H-ras and v-myc oncogene transforma- Zinc-a2-glycoprotein localization, F-18-1abeled monoclonal tion, rat embryo fibroblasts, 508 identification of major protein compo- antibody fragment, 5054 sensitivity nents thymoma and colon carcinoma 1-~-D-arabinofuranosylcytosine-resist- breast secretions, benign and malig- antitumor effect, 2'-deoxy-5-fluorouri- ant CHO cell mutant, 319 nant breast diseases, 95

7074

Cancer Res 1992;52:6999-7074.

Updated version Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/52/24_Supplement/6999.citation

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Subscriptions Department at [email protected].

Permissions To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/52/24_Supplement/6999.citation. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.